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Abstract	
In	the	kidney,	unbound	amino	acids	are	freely	filtered	into	the	lumen	of	the	nephron.	
For	 reabsorption	 to	occur,	 they	must	be	 transported	across	 the	phospholipid	bilayers	of	 the	
tubular	epithelium	by	 selective	 transport	 systems.	Mutations	 in	 these	 transport	 systems	can	
lead	 to	 disease	 though	 a	 conferred	 lack	 of	 amino	 acid	 re-absorption.	 One	 such	 disease	 is	
cystinuria,	caused	by	mutations	in	SLC3A1	and	SLC7A9,	which	encode	the	two	protein	subunits	
of	System	b0,+,	 rBAT	and	b0,+AT,	respectively.	 In	healthy	 individuals	System	b0,+	mediates	Na+-
independent	reabsorption	of	dibasic	amino	acids,	and	the	cysteine	dimer,	cystine,	in	exchange	
for	 neutral	 amino	 acids.	 In	 cystinuric	 patients,	 these	 amino	 acids	 are	 not	 sufficiently	 re-
absorbed	causing	a	dibasic	aminoaciduria	and	the	precipitation	of	cystine	crystals,	 leading	to	
the	formation	of	renal	calculi.		
	 A	 cohort	 of	 cystinuric	 patients	 was	 recruited	 to	 the	 study,	 and	 both	 genes	 were	
screened	for	causal	variants.	A	range	of	techniques	was	employed	to	enable	the	detection	of	
small	point	mutations	and	large	genomic	rearrangements.	Four	novel	missense	variants	were	
detected	in	SLC3A1.	These	were	M465K,	N254T,	L416P	and	Y579D.	In	silico	homology	modeling	
of	 rBAT	 against	 the	 crystal	 structure	 of	 B.	 cereus	 oligo-1,6-glucosidase	 (PDB	 code	 1UOK),	
predicted	the	location	of	these	mutations	in	the	extracellular	domain	of	the	protein.		
When	 rBAT	 cRNA	 was	 injected	 into	 Xenopus	 oocytes,	 uptake	 of	 the	 prototypical	
System	b0,+	substrate	[3H]arginine	was	observed,	following	the	association	of	human	rBAT	with	
an	 endogenous	 oocyte	 light	 chain.	 	 A	 series	 of	 techniques	 was	 optimised	 to	 allow	 the	
characterisation	 of	 FLAG-tagged	 rBAT	 function	 and	 expression	 in	 oocytes,	 1-6	 days	 post-
injection	of	cRNA.	
Mutations	in	rBAT	lead	to	a	mis-folding	of	the	protein	and	its	early	degradation	in	the	
ER,	 preventing	 successful	 trafficking	 of	 the	 System	 b0,+	 heterodimer	 to	 the	 renal	 epithelial	
membrane.	This	aberrant	trafficking	leads	to	reduced	rBAT	expression	and	System	b0,+	activity	
in	oocytes.	Functional	characterisation	of	 the	novel	mutant	proteins	 led	to	a	decrease	 in	 the	
Vmax	of	 [3H]arginine	 transport.	Over-expression	of	 rBAT	 in	oocytes	apparently	overcomes	 the	
defect	and	leads	to	a	recovery	of	function	over	time.	However,	[3H]arginine	uptake	in	M465K-
expressing	oocytes	was	still	lower	than	that	observed	with	wild-type	rBAT	even	at	6	days	post-
injection.	These	data	were	supported	by	immunofluorescent	detection	of	rBAT	and	the	mutant	
proteins	 at	 the	 plasma	membrane	of	 oocytes.	Western	 blotting	 of	 total	membrane	proteins	
from	 oocytes	 expressing	 mutated	 rBAT	 showed	 decreased	 total	 protein,	 suggestive	 of	 an	
increased	rate	of	degradation	associated	with	the	pathogenic	variants.		
An	increased	understanding	of	the	effect	of	these	mutations	on	the	biogenesis	of	rBAT	
will	contribute	to	the	identification	of	novel	therapeutic	targets	in	the	treatment	of	cystinuria.	
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Chapter	1 :	Introduction	
1.1	Amino	acid	transport	in	the	renal	epithelium	
The	principal	 function	of	the	kidney	 is	 to	 filter	waste	products	 from	the	bloodstream	
whilst	 retaining	 essential	 molecules.	 Blood	 enters	 the	 glomerulus	 through	 the	 afferent	
arteriole	and	solutes	and	water	are	filtered	from	the	capillaries	across	the	glomerular	barrier.	
The	glomerular	barrier	is	a	complex	membrane	that	allows	sieving	of	small	molecules	(<50kDa)	
that	 can	 pass	 through	 the	 porous	 layers	 (Haraldsson	 et	 al.,	 2008).	 The	 charge	 and	
conformation	of	molecules	are	also	putatively	implicated	in	their	ability	to	freely	pass	into	the	
renal	 filtrate.	 However,	 it	 is	 clear	 that	 molecular	 weight	 plays	 the	 biggest	 role	 in	 filtration	
(Haraldsson	 et	 al.,	 2008).	 Ions	 and	 molecules	 contained	 in	 the	 filtrate	 are	 selectively	
reabsorbed	through	various	transport	pathways.		
Amino	 acids	 are	 small	 molecules	 that	 are	 required	 in	 all	 cells	 of	 the	 body	 for	 the	
synthesis	of	all	proteins,	purines	and	pyrimidines,	and	as	energy	metabolites	(Castagna	et	al.,	
1997;	 Bröer,	 2008).	 Most	 amino	 acids	 exist	 in	 a	 zwitterionic	 form	 at	 neutral	 pH.	 These	
hydrophilic	 molecules	 are	 unable	 to	 pass	 freely	 through	 the	 lipid	 bilayer	 of	 the	 renal	
epithelium	(Christensen,	1979,	1984).	Therefore,	following	their	passage	into	the	renal	filtrate	
they	must	be	selectively	reabsorbed	into	the	bloodstream,	across	the	epithelial	barrier	(Bröer,	
2008).	To	enable	this	process	to	occur,	a	complex	profile	of	transport	proteins	is	located	in	the	
apical	and	basolateral	membranes	of	the	nephron.	
1.2	Renal	proximal	tubular	transport	systems	
Membrane	transport	proteins	can	be	described	as	passive	or	active.	Passive	transport	
systems	move	substrates	along	their	electrochemical	gradients.	Therefore,	a	direct	source	of	
energy	 is	 not	 required	 for	 transport.	 However,	 active	 transport	 systems	 move	 molecules	
against	their	electrochemical	gradient	through	energy	coupling	mechanisms.	Active	transport	
systems	 are	 classified	 as	 primary,	 secondary,	 or	 tertiary,	 based	 upon	 their	 specific	 energy	
source	(Hediger	et	al.,	2004).	Primary	active	transport	systems	directly	utilise	energy	from	the	
hydrolysis	of	ATP	to	create	an	electrochemical	gradient,	and	secondary	active	transporters	use	
this	 gradient	 to	 co-transport	 ions	 and	molecules.	 This	 allows	 the	 desired	movement	 of	 the	
transported	molecules,	creating	a	concentration	gradient	(Hediger	et	al.,	2004).	Tertiary	active	
transport	 systems	 utilise	 this	 concentration	 gradient	 for	 the	 exchange	 of	 other	 molecules.	
Transport	 systems	 can	be	 further	 classified	 according	 to	 the	direction	of	 the	 co-transport	of	
ions	 and	 molecules.	 Symporters	 transport	 the	 substrates	 in	 the	 same	 direction,	 whereas	
antiporters	mediate	the	obligatory	exchange	of	two	or	more	substrates	(Lolkema	et	al.,	1995).	
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The	 expression	 pattern	 of	 transport	 proteins	 varies	 dramatically	 along	 the	 length	 of	 the	
nephron.	 A	 distinct	 expression	 gradient	 in	 expression	 of	 transporters	 can	 be	 seen	 along	 the	
proximal	tubule	alone	(the	principal	site	of	solute	reabsorption),	which	is	often	split	into	three	
segments:	S1,	S2,	and	S3,	with	S3	being	the	most	distal	(Fernandez	et	al.,	2002).	
Half	a	century	on	from	the	first	description	of	human	amino	acid	transport	in	the	liver	
(Van	 Slyke	 and	Meyer,	 1913),	 Oxender	 and	 Christensen	 (1963)	 reported	 that	 two	 different	
“agencies”	were	 responsible	 for	 the	selective	movement	of	amino	acids	 in	Ehrlich	cells.	Two	
distinct	 transport	 systems	 were	 identified:	 System	 A,	 which	 transported	 alanine	 and	 small,	
polar	amino	acids,	and	System	L,	which	preferred	leucine	and	large,	hydrophobic	amino	acids	
(Oxender	&	 Christensen,	 1963).	 A	 further	 15	 amino	 acid	 transport	 systems	 have	 since	 been	
described,	the	nomenclature	of	which	describes	their	respective	substrate	specificities	(Bröer,	
2008).	For	example,	System	ASC	prefers	the	amino	acid	substrates	alanine,	serine,	and	cysteine	
and	 systems	 that	 transport	 anionic,	 cationic,	 and	 neutral	 amino	 acids	 are	 denoted	 by	 the	
letters	x,	y,	and	z,	respectively	(Bröer,	2008).	Additionally,	upper	case	nomenclature	represents	
Na+-dependent	transport	(i.e.	System	B0),	and	lower	case	denotes	Na+-independent	movement	
of	amino	acids	(i.e.	System	b0,+)	(Table	1.1).	The	transport	systems	identified	by	Christensen	et	
al.	 (1984)	 were	 in	 non-epithelial	 cell	 lines,	 and	 largely	 reflect	 the	 systems	 present	 in	 the	
basolateral	 membrane	 of	 polarised	 cells	 (Bröer,	 2008).	 Ultimately,	 work	 following	 the	
discoveries	of	Halvor	Christensen	has	led	to	the	identification	of	17	different	epithelial	amino	
acid	transport	systems,	classified	by	their	selectivity,	and	ion-coupling	mechanism	of	transport	
(Table	 1.1)	 (Christensen,	 1984;	 Bröer,	 2008).	 The	 apical	 and	 basolateral	 transport	 systems	
present	in	the	epithelium	of	the	renal	proximal	tubule	are	displayed	in	Figure	1.1.	
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System	 Protein	 Gene	 Substrates	 Affinity	 Mechanism	 Ion-coupling	 Expression*	
A	
SNAT2	 SLC38A2	
G,	P,	A,	S,	
C,	Q,	N,	H,	
M	
M	 S	 Na+	 Ub	
SNAT4	 SLC38A4	
G,	A,	S,	C,	
Q,	N,	M,	
AA+	
M	 S	 Na+	 K	
ASC	
ASCT1	 SLC1A4	 A,	S,	C	 H	 A	 Na+	 K	
ASCT2	 SLC1A5	 A,	S,	C,	T,	Q	 H	 A	 Na
+	 K,	I	(BM)	
asc	 CD98/	asc1	
SLC3A2/	
SLC7A10	
G,	A,	S,	C,	
T	 H	 A	 	 K	
B0	
	
B0AT1	 SLC6A19	 AA0	 L	 S	 Na+	 K,	I	(AM)	
B0AT2	 SLC6A15	 P,	L,	V,	I,	M	 H	 S	 Na+	 K	
B0,+	 ATB0,+	 SLC6A14	 AA
0,	AA+,		
β-Ala	 H	 S	 Na
+,	Cl-	 I	(AM)	
b0,+	 rBAT/	b0,+AT	
SLC3A1/	
SLC7A9	
R,	K,	O,	
cystine	 H	 A	 	 K,	I	(AM)	
β	 TauT	 SLC6A6	 Tau,	β-Ala	 H	 S	 Na+,	Cl-	 I	(AM,	BM)	
Gly	 XT2	 SLC6A18	 G	 	 	 	 K	(AM)	
IMINO	 IMINO	 SLC6A20	 P,	OH-P	 M	 S	 Na+,	Cl-	 K,	I	(AM)	
L	
CD98/	
LAT1	
SLC3A2/	
SLC7A5	
H,	M,	L,	I,	
V,	F,	Y,	W	 H	 A	 	 	
CD98/	
LAT2	
SLC3A2/	
SLC7A8	
AA0,		
(not	P)	 M	 A	 	 K,	I	(BM)	
LAT3	 SLC43A1	 L,	I,	M,	F	 L	 U	 	 K	
LAT4	 SLC43A2	 L,	I,	M,	F	 L	 U	 	 	
N	
SNAT3	 SLC38A3	 Q,	N,	H	 L	 S	 Na
+(S),	
H+(A)	 K	(BM)	
SNAT5	 SLC38A5	 Q,	N,	H,	S,	G	 L	 S	
Na+(S),	
H+(A)	 K	
PAT	
PAT1	 SLC36A1	
P,	G,	A,	
GABA,		
β-Ala	
L	 S	 H+	 K,	I	(AM)	
PAT2	 SLC36A2	 P,	G,	A	 M	 S	 H+	 K	(AM)	
T	 TAT1	 SLC16A10	 F,	Y,	W	 L	 U	 	 K,	I	(BM)	
X-AG	
EAAT2	 SLC1A2	 E,	D	 H	 S	
Na+(S),	
H+(A)	
K+(A)	
K	(BM)	
EAAT3	 SLC1A1	 E,	D	 H	 S	
Na+(S),	
H+(A),	
K+(A)	
K,	I	(AM)	
x-c	
CD98/	
xCT	
SLC3A2/	
SLC7A11	 E,	cystine	 H	 A	 	 Ub	
y+	 CAT-1	 SLC7A1	 R,	K,	O,	H	 M	 U	 	 Ub	
y+L	
CD98/	
y+LAT1	
SLC3A2/	
SLC7A7	
K,	R,	Q,	H,	
M,	L	 H	 A	 Na
+	 K,	I	(BM)	
CD98/	
y+LAT2	
SLC3A2/	
SLC7A6	
K,	R,	Q,	H,	
M,	L,	A,	C	 H	 A	 Na
+	 K,	I	(BM)	
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Table	1.1:	Renal	and	intestinal	epithelial	transport	systems.	Amino	acids	are	identified	using	
the	one-letter	coding	system;	O,	ornithine;	OH-P,	hydroxyproline.	The	affinity	of	the	transport	
systems	 is	 identified	 as:	 H,	 high	 (<100μM);	 M,	 medium	 (100μM-1mM);	 L,	 low	 (>1mM).	 S,	
symport;	 A,	 antiport;	 U,	 uniport;	 Ub,	 ubiquitous;	 AM,	 apical	 membrane;	 BM,	 basolateral	
membrane.	 *,	Only	 the	expression	 in	 the	 renal	 and	 intestinal	 epithelium	 is	 considered	here.	
Adapted	from	Bröer	(2008).		
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Figure	1.1:	A	schematic	representation	of	renal	proximal	tubule	amino	acid	transporters.	The	
transport	of	amino	acids	across	the	renal	proximal	tubular	epithelium	is	mediated	by	a	range	
of	 different	 transport	 systems.	 The	 disorders	 associated	 with	 mutations	 in	 the	 transport	
proteins	are	denoted	 in	red	next	to	their	respective	transport	systems.	β-Ala,	β-alanine;	Tau,	
taurine;	 AA+,	 dibasic	 amino	 acids;	 CssC,	 cystine;	 AA0,	 neutral	 amino	 acids.	 Modified	 from	
Palacin	et	al.	(2005).	
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1.3	The	function	of	System	b0,+	
One	 renal	 proximal	 tubular	 transport	 system,	 b0,+,	 named	 to	 reflect	 its	 Na+-
independent	(small	“b”)	exchange	of	neutral	(0)	and	dibasic	(+)	amino	acids,	is	responsible	for	
the	 reabsorption	of	dibasic	amino	acids,	and	the	cysteine	dimer,	 cystine	 (Wells	and	Hediger,	
1992).	First	 reported	 in	1988	 in	mouse	blastocysts,	 system	b0,+	was	 identified	due	 to	 its	Na+-
independent	 transport	 of	 amino	 acid	 substrates,	 unlike	 a	 second,	 Na+-dependent	 transport	
system,	B0,+,	also	isolated	in	blastocysts	(Van	Winkle	et	al.,	1988).	 It	has	since	been	identified	
that	System	b0,+	is	an	obligatory	exchange	system	of	neutral	and	dibasic	amino	acids,	with	a	1:1	
stoichiometry	(Coady	et	al.,	1994;	Ahmed	et	al.,	1995;	Chillarón	et	al.,	1996).	
System	b0,+	is	located	on	the	proximal	tubule	epithelium	and	is	the	only	known	apical	
membrane	transporter	of	cystine	in	the	kidney	(Silbernagl,	1988).	Cystine	is	transported	from	
the	 lumen	 of	 the	 nephron	 into	 the	 cytoplasm	 of	 the	 epithelial	 cell	 where	 it	 is	 cleaved	 into	
monomeric	 cysteine	 and	 transported	 into	 the	 bloodstream	 through	 distinct	 basolateral	
transport	systems	(Figure	1.1).	 It	has	been	demonstrated	through	rat	kidney	micro-perfusion	
data	that	>90%	of	cystine	reabsorption	occurs	in	the	early	proximal	tubule	(Volkl	&	Silbernagl,	
1982).	 This	 corresponds	 to	 the	 renal	 localisation	 of	 system	b0,+,	 identified	 through	Northern	
blotting.	 In	 the	 renal	proximal	 tubule,	 the	dibasic	amino	acids	and	cystine	are	 reabsorbed	 in	
exchange	 for	neutral	amino	acids,	which	are	effluxed	 into	 the	 lumen	of	 the	proximal	 tubule.	
These	amino	acids	 can	be,	 in	 turn,	 reabsorbed	via	Na+-dependent	apical	 symporters	 such	as	
B0AT1	 (Figure	 1.1)	 (Chillarón	 et	 al.,	 1996).	 The	 known	 substrates	 of	 System	 b0,+,	 and	 the	
measured	affinities	of	the	transport	system	when	expressed	in	Xenopus	oocytes,	are	listed	in	
Table	1.2.	
	 	
Characteristic	 Amino		acid	 Substrate	 Experimental	determination	
Affinity		
(μM)	
rBAT		
species	 Reference	
Cysteine	
dimer	 Cystine	 Yes	
Uptake	(5-497μM)	 36	 Rabbit	 1	
Uptake	(10-200μM)	 60	 Rabbit	 2	
Uptake	(10-200μM)	 43	 Human	 3	
Uptake	(5-497μM)	 30	 Human	 1	
Uptake	(5-497μM)	 67.3	 Rat	 4	
Dibasic		
(cationic)	
Arginine	 Yes	
Uptake	(15μM)	 --	 Rat	 4	
Uptake	(50μM),		
cis-inhibition	(99%	cystine,	98%	arginine,	90%	leucine;	5mM)	 --	 Human	 3	
Uptake	(10μM-10mM)		
cis-inhibition	(96%	arginine	99%,	cystine	99%	leucine,	99%	alanine;	5mM)	 105	 Rabbit	 2	
Lysine	 Yes	
Uptake	(15μM)	 --	 Human	 1	
cis-inhibition	(90%	phenylalanine;	1mM)	 --	 Rat	 5	
cis-inhibition	(95%	arginine,	97%	cystine,	98%	leucine,	99%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(15μM),		
cis-inhibition	(97%	cystine,	98%	alanine,	97%	leucine;	2mM)	 --	 Rat	 4	
Ornithine	 Yes	
cis-inhibition	(96%	arginine	98%	cystine,	98%	leucine,	99%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(15μM)	 --	 Rat	 4	
Neutral		
(zwitterionic)	 Leucine	 Yes	
Uptake	(15μM)	 --	 Rat	 4	
Uptake	(50μM),		
cis-inhibition	(95%	cystine,	85%	arginine,	98%	leucine;	5mM)	 --	 Human	 3	
Uptake	(10-100μM)	 22	 Rat	 5	
cis-inhibition	(92%	arginine	97%	cystine,	97%	leucine,	99%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(10μM-10mM)	 128	 Rabbit	 2	
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Phenyl-
alanine	 Yes	
Uptake	(10-100μM)	 29	 Rat	 5	
cis-inhibition	(75%	arginine	60%	cystine,	55%	leucine,	80%	alanine;	5mM)	 --	 Rabbit	 2	
Methionine	 Yes	
Uptake	(15μM)	 --	 Human	 1	
Uptake	(10-100μM)	 71	 Rat	 5	
Uptake	(15μM)	 --	 Rat	 4	
Glutamine	 Yes	
Uptake	(50μM)	 --	 Rat	 5	
Uptake	(15μM)	 --	 Rat	 4	
Asparagine	 Yes	 Uptake	(15μM)	 --	 Rat	 4	
Histidine	 Yes	
Uptake	(10-100μM)	 167	 Rat	 5	
cis-inhibition	(52%	arginine,	76%	cystine,	75%	leucine,	85%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(15μM)	 --	 Rat	 4	
Serine	 Yes	
Uptake	(15μM)	 --	 Human	 1	
Uptake	(15μM)	 --	 Rat	 4	
Un-bulky,		
neutral	
Alanine	 Yes	(weak)	
Uptake	(15μM)	 --	 Human	 1	
cis-inhibition	(50%	arginine,	80%	cystine,	80%	leucine,	60%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(10-100μM)	 50	 Rat	 5	
Uptake	(50μM)	 --	 Rabbit	 2	
Uptake	(15μM)	 --	 Rat	 4	
Threonine	 Yes	(weak)	 cis-inhibition	(40%	arginine,	65%	cystine,	75%	leucine,	87%	alanine;	5mM)	 --	 Rabbit	 2	
Cysteine	 Yes	(weak)	 cis-inhibition	(50%	arginine,	80%	leucine,	90%	alanine;	5mM)	 --	 Rabbit	 2	
Valine	 Yes	(weak)	 cis-inhibition	(46%	arginine,	68%	cystine,	60%	leucine,	80%	alanine;	5mM)	 --	 Rabbit	 2	
D-isomer	
Ornithine	 Yes	(weak)	 cis-inhibition	(40%	arginine,	60%	cystine,	45%	leucine,	80%	alanine;	5mM)	 --	 Rabbit	 2	
Lysine	 Yes	(weak)	 cis-inhibition	(75%	arginine	75%	cystine,	60%	leucine,	90%	alanine;	5mM)	 --	 Rabbit	 2	
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cis-inhibition	(80%	cystine;	2mM)	 --	 Rat	 4	
Cyclic	 Proline	 No	
cis-inhibition	(2%	arginine,	1%	cystine,	4%	leucine,	5%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(15μM)	 --	 Rat	 4	
Acidic		
(anionic)	
Aspartic	
acid	 No	 Uptake	(15μM)	 --	 Rat	 4	
Glutamic	
acid	 No	
Uptake	(50μM)	 --	 Rabbit	 2	
Uptake	(50μM)	 --	 Rat	 5	
cis-inhibition	(0%	cystine,	8%	arginine,	4%	leucine;	5mM)	 --	 Human	 3	
Uptake	(15μM)	 --	 Rat	 4	
Branched	at	α-
carbon	
α-AIB	 No	
Uptake	(50μM)	 --	 Rat	 5	
Uptake	(50μM),		
cis-inhibition	(20%	arginine,	25%	cystine,	12%	leucine,	10%	alanine;	5mM)	 --	 Rabbit	 2	
MeAIB	 No	 Uptake	(200μM)	 --	 Rabbit	 2	
	
	
Table	1.2:	The	measured	kinetics	of	System	b0,+	transport	in	Xenopus	oocytes.	System	b0,+	transport	of	amino	acid	substrates	induced	in	Xenopus	oocytes	through	
expression	of	the	rBAT	protein.	1,	Lee	et	al.,	1993;	2,	Bertran	et	al.,	1992;	3,	Bertran	et	al.,	1993;	4,	Wells	and	Hediger,	1992;	5,	Tate	et	al.,	(1992).	
	
	
	 	
11	
1.4	Heterodimeric	amino	acid	transporters:	the	SLC3	proteins	
Of	the	17	distinct	amino	acid	transport	systems	described	in	Table	1.1,	5	of	these	are	
classed	 as	 heterodimeric	 transport	 systems,	 functioning	 via	 the	 interaction	 of	 two	 distinct	
protein	 subunits:	 a	 heavy	 chain	 and	 a	 light	 chain.	 These	 are:	 System	 asc	 (CD98	 and	 asc1),	
System	b0,+	 (rBAT	and	b0,+AT),	System	L	 (CD98	and	LAT1	or	LAT2),	System	xc-	 (CD98	and	xCT),	
and	 System	 y+L	 (CD98	 and	 y+LAT1	 or	 y+LAT2)	 (Table	 1.1).	 The	 “heavy	 chains”	 of	 the	
heterodimeric	 transport	 systems	are	members	of	 the	mammalian	 SLC3	 family	of	 amino	acid	
transporters,	of	which	there	are	only	2:	SLC3A1	(rBAT)	and	SLC3A2	(CD98).	These	glycosylated	
proteins	are	covalently	bonded	to	their	respective	“light	chains”,	members	of	the	SLC7	family	
of	 transporters,	 via	 an	 extracellular	 disulphide	 bond	 (Verrey	 et	 al.,	 2004).	 The	 structure	 of	
these	heterodimeric	transport	systems	was	first	identified	following	the	expression	cloning	of	
rBAT	(SLC3A1)	in	Xenopus	laevis	oocytes.		
In	the	early	1990s,	three	research	groups	isolated	the	mRNA	of	a	protein	that	induced	
b0,+-like	 amino	 acid	 transport	 activity	 when	 expressed	 in	 Xenopus	 oocytes.	 (Bertran	 et	 al.,	
1992b;	Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	et	al.,	1993;	Lee	
et	al.,	1993).	Wells	and	Hediger	(1992)	isolated	a	cDNA	from	rat	kidney	tissue	that	encoded	a	
protein	 that	 induced	high	affinity	 (Km=	63.7µM)	cystine	 transport	 in	 the	oocyte.	They	named	
this	 protein	 D2	 and	 localised	 the	mRNA	 to	 the	 kidney	 and	 intestine	 through	 Northern	 blot	
analysis.	 Following	 estimation	 of	 the	 protein	 topology	 of	 D2,	 the	 group	 predicted	 only	 one	
transmembrane	 domain	 in	 the	 structure,	 therefore	 classifying	 it	 as	 a	 Type-II	 Membrane	
Glycoprotein	(Figure	1.2A).	Since	its	discovery,	hydrophilicity	modelling	has	further	supported	
the	 presence	 of	 only	 one	 TMD,	 reinforcing	 the	 belief	 that	 rBAT	 modulates	 transporter	
function,	 and	 possesses	 no	 transport	 function	 alone	 (Palacin,	 1994).	 The	 DNA	 sequence	 of	
rBAT	 showed	sequence	homology	with	bacterial	 glucosidases,	but	 the	protein	demonstrated	
no	enzymatic	activity,	following	investigation	of	a	range	of	sugars	(Wells	and	Hediger,	1991).		
A	 second	 transporter	 cDNA	 was	 isolated	 from	 a	 pool	 of	 rabbit	 kidney	 cortex	 cDNA	
which	had	79%	homology	at	the	protein	level	to	D2.	This	molecule	was	named	rBAT	(related	to	
b0,+	amino	acid	transporter)	(Bertran	et	al.,	1992b;	Bertran	et	al.,	1992c).	Like	D2,	rBAT	seemed	
to	stimulate	b0,+	activity	in	Xenopus	oocytes.	
Finally,	through	expression	cloning	in	Xenopus	oocytes,	Tate	et	al.	(1992)	discovered	a	
rat	 renal	protein	with	 similar	 functional	properties:	NAA-Tr	 (neutral	 amino	acid	 transporter).	
Sequencing	studies	predicted	a	four	TMD	structure	and	a	shared	structural	motif	with	nicotinic	
ligand-gated	 ion	 channels	 was	 hypothesised	 (Figure	 1.2B).	 They	 used	 the	 deduced	 cDNA	
sequence	to	plot	the	calculated	hydrophilicity	in	different	regions	of	the	protein,	and	identified	
four	putative	 transmembrane	domains,	with	 intracellular	N	and	C	termini	 (Tate	et	al.,	1992).	
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This	 model	 was	 also	 reported	 in	 an	 investigation	 by	 Gasparini	 et	 al.	 (1995).	 A	 schematic	
representation	of	 the	 four	transmembrane	domain	model	of	 rBAT	 is	depicted	 in	Figure	1.2B,	
based	 upon	 the	 findings	 of	 Tate	 et	 al.	 (1992).	 However,	 this	 model	 has	 now	 become	
redundant,	as	the	single	transmembrane	domain	topological	morphology	of	rBAT	has	become	
widely-accepted	(Figure	1.2A).	Despite	the	differences	in	the	predicted	membrane	topology	of	
the	 proteins,	 it	 became	 apparent	 that	 the	 three	 groups	 had	 isolated	 the	 same	 protein	 in	
different	mammalian	species	(Segawa	et	al.,	1997).		
Today,	 this	 protein	 is	 universally	 known	as	 rBAT,	 and	 the	mRNA	has	been	 shown	by	
northern	blot	to	mainly	localise	to	the	kidney	and	small	intestine,	with	low	levels	of	detection	
in	the	brain,	liver,	and	pancreas	(Bertran	et	al.,	1992b;	Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	
Wells	 &	 Hediger,	 1992;	 Bertran	 et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	 Protein	 expression	 has	 been	
localised	 to	 the	 renal	 proximal	 tubular	 and	 small	 intestinal	 epithelium	 through	
immunohistochemical	detection	of	the	protein	in	rat	tissues	(Furriols	et	al.,	1993;	Pickel	et	al.,	
1993;	 Albers	 et	 al.,	 1999).	 Furthermore,	 it	 has	 been	 localised	 to	 the	 apical	 membrane	 of	 a	
human	intestinal	epithelial	cell	line,	Caco-2	(Anderson	et	al.,	2004).		
CD98	was	first	discovered	by	Haynes	et	al.	(1981)	as	a	lymphocytic	surface	antigen	in	a	
hybridoma	 cell	 line.	 The	 identified	 protein	 was,	 in	 fact,	 a	 heterodimeric	 molecule,	 with	 a	
glycosylated	 heavy	 chain	 (80kDa)	 and	 non-glycosylated	 light	 chain	 (38kDa)	 associated	 via	 a	
disulphide	bond	(Luscher	et	al.,	1985).	However,	the	function	of	the	heterodimer	remained	a	
mystery.	 Due	 to	 the	 high	 levels	 of	 CD98	 expression	 in	 malignant	 human	 cells,	 and	 rapidly	
dividing	cell	lines,	it	was	postulated	to	be	a	growth	factor	(Yagita	et	al.,	1986).	Additionally,	it	
was	 discovered	 that	 the	 anti-CD98	 antibody	 inhibited	 the	 exchange	 of	 Na+	 and	 Ca2+	 in	
sarcolemmal	 vesicles,	 which	 led	 to	 the	 hypothesis	 that	 this	 was	 an	 ion	 exchange	 channel	
(Michalak	et	al.,	1986).	Between	1987	and	1989,	the	mouse	and	human	cDNA	encoding	CD98	
were	isolated	(Quackenbush	et	al.,	1987;	Parmacek	et	al.,	1989).	It	was	identified	that	human	
CD98	 was	 a	 529	 amino	 acid	 glycoprotein,	 with	 only	 one	 predicted	 transmembrane	 domain	
(Quackenbush	 et	 al.,	 1987).	 Human	 CD98	 was	 predicted	 to	 have	 4	 sites	 of	 N-glycosylation,	
whilst	 the	 mouse	 protein	 had	 9	 putative	 N-glycosylation	 sites	 (Parmacek	 et	 al.,	 1989).	
However,	 these	 proteins	 were	 found	 to	 have	 77%	 sequence	 identity,	 and	 be	 expressed	
ubiquitously.	The	mRNA	for	CD98	was	detected	in	all	murine	tissues	investigated.	These	were:	
brain,	liver,	kidney,	lung,	heart,	muscle,	and	testis	(Parmacek	et	al.,	1989).	
Following	 the	 identification	 of	 rBAT,	 and	 the	 prediction	 that	 it	 contained	 only	 one	
transmembrane	domain,	with	a	large,	glycosylated	extracellular	domain,	the	sequence	identity	
between	these	 two	proteins	was	 investigated.	 It	was	discovered	 that	 the	 two	proteins,	 rBAT	
and	CD98,	shared	30%	sequence	identity	and	50%	similarity	(Figure	1.3)	(Bertran	et	al.,	1992b).	
As	 the	 function	 of	 CD98	 remained	 unknown,	 the	 cRNA	 for	 this	 protein	 was	 injected	 into	
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Xenopus	 oocytes	 to	 investigate	whether	 amino	 acid	 transport	 function	was	 induced,	 as	 had	
been	observed	with	the	structurally	related	protein,	 rBAT	(Bertran	et	al.,	1992a;	Wells	et	al.,	
1992).	 Upon	 expression	 of	 CD98	 in	 oocytes,	 3-fold	 stimulation	 in	 y+L	 activity	 was	 observed	
(Bertran	et	al.,	1992a;	Wells	et	al.,	1992).	This	transport	of	neutral	and	dibasic	amino	acids	was	
shown	 to	 be	 saturable,	 and	 differed	 from	 the	 System	 b0,+	 activity	 induced	 upon	 rBAT	
expression	 in	 several	ways.	 Firstly	 the	 transport	 of	 neutral	 amino	 acids	was	 observed	 to	 be	
Na+-dependent.	 Additionally,	 no	 transport	 of	 cystine	 was	 induced	 following	 expression	 of	
CD98,	and	pH-dependent	histidine	transport	was	also	measured	(Bertran	et	al.,	1992a;	Wells	
et	al.,	1992).	Through	recognition	of	the	sequence	similarities	between	these	two	proteins,	the	
function	of	CD98	was	identified.	However,	it	was	apparent	that	the	two	heavy	chains	had	the	
capacity	to	harness	different	light	chains	for	amino	acid	transport,	leading	to	the	induction	of	
different	transport	systems.	The	mRNA	expression	patterns	for	these	two	heavy	chains	differ	
greatly.	 Whilst	 the	 expression	 of	 CD98	 appears	 to	 be	 ubiquitous,	 rBAT	 mRNA	 localises	
predominantly	to	the	renal	proximal	tubule	and	 intestinal	epithelium	(Parmacek	et	al.,	1989;	
Bertran	et	al.,	1992a;	Bertran	et	al.,	1992b;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Wells	et	
al.,	 1992;	 Lee	 et	 al.,	 1993).	Additionally,	 studies	 into	 the	expression	of	 these	proteins	 in	 the	
MDCK	 cell	 line	 identified	 that	 CD98	 is	 associated	 with	 basolateral	 membrane	 transport	 in	
polarised	cell	systems,	whilst	rBAT	is	found	only	at	the	apical	membrane	of	epithelia	(Bauch	&	
Verrey,	2002;	Bauch	et	al.,	2003;	Anderson	et	al.,	2004).	This	further	confirmed	the	ability	of	
the	two	proteins	to	harness	distinct	light	chains,	and	mediate	amino	acid	transport	by	different	
systems.			
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Figure	1.2:	Schematic	representation	of	the	proposed	topology	models	of	rBAT.	Two	distinct	
topology	models	 have	been	proposed	 for	 rBAT.	A,	 Single	 transmembrane	domain	model	 for	
rBAT	with	a	 large	extracellular	domain	 showing	homology	 to	B.	 cereus	oligo-1,6-glucosidase.	
The	residue	numbers	at	the	boundary	of	the	different	domains	are	provided.	The	domains	are	
coloured	 according	 to	 the	 structure	 of	 the	 glucosidase	 enzymes,	 discussed	 in	 section	 1.9.	
Based	 upon	 the	 model	 by	 Bertran	 et	 al.	 (1992)	 and	 Rius	 and	 Chillarón	 (2012);	 B,	 Four-
transmembrane	domain	model	of	rBAT.	The	residue	numbers	at	the	N-	and	C-termini	of	each	
transmembrane	 domain	 are	 denoted,	 along	 with	 the	 putative	 sites	 of	 N-glycosylation	 (Y).	
Based	upon	the	model	by	Tate	et	al.,	(1992)	and	Gasparini	et	al.	(1995).				
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rBAT      MAEDKSKRDSIEMSMKGCQTNNGFVHNEDILEQTPDPGSSTDNLKHSTRGI--------- 
CD98      MSQDT------EVDMKEVELNE--------LEPEKQPMNAASGAAMSLAGAEKNGLVKIK 
       *::*.      *:.**  : *:        **   :* .::..   *  *             
 
rBAT      LGSQEPDFKGVQPYAGMPKEVLFQFSGQ---ARYRIPREILFWLTVASVLVLIAATIAII 
CD98      VAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWL---GWLGMLAGAVVII 
       :..:*.:  ..  ::*:.** *::.:*.   .* * .  :****   . * ::*.::.**   
 
rBAT            ALSPKCLD-----WWQEGPMYQIYPRSFKDSNKDGNGDLKGIQDKLDYITALNIKTVWIT  
CD98            VRAPRCRELPAQKWWHTGALYRI--GDLQAFQGHGAGNLAGLKGRLDYLSSLKVKGLVLG                  
                . :*.* :     **: *.:*.*   .::  :  * *:* *::..***:::*::* : :    
 
rBAT            SFYKSSLKDFRYGVEDFREVDPIFGTMEDFENLVAAIHDKGLKLIIDFIPNHTSDKHIWF  
CD98            PIHKNQKDDV--AQTDLLQIDPNFGSKEDFDSLLQSAKKKSIRVILDLTPNYR-------                  
                .::*.. .*.  .  *: ::** **: ***:.*: : :.*.:.:*:*: **:           
 
rBAT            QLSRTRTGKYTDYYIWHDCTHENGKTIPPNNWLSVYGNSSWHFDEVRNQCYFHQFMKEQP  
CD98            ------------------------------------GENSWFFTQV--------------                                                      
                                                    *:.**.* :*                 
 
rBAT            DLNFRNPDVQEEIKEILRFWLTKGVDGFSLDAVKFLLEAKHLRDEIQVNKTQIPDTVTQY  
CD98            ------DTVATKVKDALEFWLQAGVDGFQVRDIENLKDASSFLAEWQ-------------                          
                        *  ::*: * ***  *****.:  :: * :*. :  * *                
 
rBAT            SELYHDFTTTQVGMHDIVRSFRQTMDQYSTEPGRYRFMGTEAYAESIDRTVMYYGLPFIQ  
CD98            ---------------NITKGFSED-----------RLLIAGTNSSDLQQI-----LSLLE                                 
                               :*...* :            *:: : : :..::.      *.:::   
 
rBAT            EAD--FPFNNYLSMLDTVSGNSVYEVITSWMENMPEGKWPNWMIGGPDSSRLTSRLGNQY  
CD98            SNKDLLLTSSYLSDSGS-TGEHTKSLVTQYL-NATGNRWCSWSL--SQARLLTSFLPAQL                  
                . .  :  ..***  .: :*: . .::*.:: * . ..* .* :  .::  *** *  *    
 
rBAT            VNVMNMLLFTLPGTPITYYGEEIGMGNIVAANLNESYDINTLRSKSP-MQWDNSSNAGFS  
CD98            LRLYQLMLFTLPGTPVFSYGDEIGL---------DAAALPGQPMEAPVMLWDESSFPDIP                  
                :.: :::********:  **:***:         ::  :     ::* * **:** ..:.   
 
rBAT            EASNTWLPTNSDYHTVNVDVQKTQPRSALKLYQDLSLLHANELLLNRGWFCHLRNDSHYV  
CD98            GAVSA---------NMTVKGQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGPELF                   
                 * .:         .:.*. *. :* * *.*:. **  .::*  * .* *  :  ..  .   
 
rBAT            VYTRELDGIDRIFIVVLNFGESTL---LNLHNM--ISGLPAKIRIRLSTNSA-DKGSKVD  
CD98            SYIRHWDQNER-FLVVLNFGDVGLSAGLQASDLPASASLPAKADLLLSTQPGREEGSPLE                   
                * *  *  :* *:******:  *   *:  ::   :.****  : ***:.. ::** ::   
 
rBAT            TSGIFLDKGEGLIFEHNTKNLLHRQTAFRDRCFVSNRACYSSVLNILYTSC  
CD98            LERLKLEPHEGLLL----------------------RFPYAA---------                   
                 . : *:  ***::                      *  *::          
	
	
Figure	1.3:	Identification	of	sequence	similarity	between	human	rBAT	and	CD98.	Amino	acid	
sequence	alignment	of	human	rBAT	(NM_000341.3)	and	CD98	(NM_001013251.2).	Consensus	
symbols	 are	 displayed	 below	 aligned	 residues.	 *,	 Fully-conserved	 residues;	 :,	 conservation	
between	groups	with	strongly	similar	properties	(scoring	>0.5	in	the	Gonnet	PAM	250	matrix);	
.,	 conservation	 between	 groups	 with	 weakly	 similar	 properties	 (scoring	 ≤0.5	 in	 the	 Gonnet	
PAM	250	matrix).	
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1.5	Heterodimeric	light	chains:	the	SLC7	family	of	proteins	
The	first	light	chain	of	the	heterodimeric	transport	systems	was	identified	in	rat	glioma	
cells	through	expression	cloning	by	co-expression	of	CD98	and	the	rat	glioma	cell	cDNA	library	
(Kanai	et	al.,	1998).	When	the	cRNA	was	co-injected	into	Xenopus	oocytes	along	with	the	cRNA	
for	CD98,	saturable,	Na+-independent	uptake	of	[14C]leucine	was	observed	(Kanai	et	al.,	1998).	
However,	no	uptake	was	induced	following	the	expression	of	either	protein	alone.	The	mRNA	
isolated	was	 for	 the	protein	LAT1,	shown	to	 induce	classic	System	L	 transport	characteristics	
(Table	 1.1)	when	 co-expressed	with	 CD98	 in	 the	 oocytes	 (Kanai	 et	 al.,	 1998).	 The	 uptake	 of	
[14C]leucine	 was	 strongly	 inhibited	 by	 2mM	 isoleucine,	 phenylalanine,	 and	 the	 System	 L-
specific	 inhibitor	 2-amino-2-norbornanecarboxylic	 acid	 (BCH)	 (Kanai	 et	 al.,	 1998).	 Shortly	
following	this	discovery,	the	human	and	mouse	cDNAs	for	y+LAT1	and	y+LAT2	were	identified	
through	 expression	 cloning	with	 CD98	 in	Xenopus	 oocytes	 and	 shown	 to	 induce	 System	 y+L	
activity	(Torrents	et	al.,	1998;	Pfeiffer	et	al.,	1999b).	Subsequently,	3	additional	light	chains	for	
CD98	 have	 been	 identified	 (Table	 1.1).	 These	 are:	 xCT	 (System	 xc-	 (Sato	 et	 al.,	 1999)),	 LAT2	
(System	L	 (Pineda	 et	al.,	1999;	Segawa	 et	al.,	1999)),	and	asc1	 (System	asc	 (Fukasawa	 et	al.,	
2000)).		
The	 first	 light	chain	to	associate	with	rBAT	was	discovered	 in	1999	from	a	rat	kidney	
cDNA	library,	 isolated	due	to	its	high	sequence	identity	(43%,	Figure	1.4)	with	LAT1	and	LAT2	
(Chairoungdua	 et	 al.,	 1999).	 As	 the	 associated	 transporter	 of	 system	 b0,+,	 this	 light	 chain	 is	
known	as	b0,+AT	(Chairoungdua	et	al.,	1999).	Northern	blot	analysis	detected	expression	of	the	
mRNA	 in	 the	 kidney	 and	 small	 intestine	 of	 rat	 tissue	 samples,	 and	 the	 protein	 was	
immunolocalised	 to	 the	 apical	membrane	 of	 renal	 proximal	 tubules.	 In	 the	 rat	 renal	 tissue,	
expression	of	 the	protein	 appeared	higher	 in	 the	proximal	 convoluted	 tubules	 (S1)	 than	 the	
straight	tubules	(S2>S3)	(Chairoungdua	et	al.,	1999).	When	the	cDNA	for	this	protein	was	co-
transfected	 with	 rBAT	 in	 COS-7	 cells,	 a	 large	 (6-fold)	 induction	 of	 [14C]cystine	 uptake	 was	
observed,	which	was	absent	when	the	proteins	were	expressed	in	 isolation	(Chairoungdua	et	
al.,	1999).	Shortly	following	this	discovery,	the	mouse	and	human	cDNAs	for	b0,+AT	were	also	
isolated	 (Pfeiffer	 et	 al.,	 1999a).	 Northern	 blot	 analysis	 showed	 localisation	 of	 mouse	 b0,+AT	
mRNA	 to	 the	 kidney	 and	 small	 intestine	 with	 an	 expression	 gradient	 in	 the	 renal	 proximal	
tubule	 of	 S1>	 S2>	 S3,	 confirming	 the	 findings	 of	 Chairoungdua	 et	 al.	 (1999).	 This	 reported	
expression	pattern	of	b0,+AT	directly	 contradicts	 that	of	 rBAT.	Northern	blot	analysis	of	 rBAT	
mRNA	expression	detected	 a	 strong	 signal	 in	 the	 S3	 segment	 of	 rat	 proximal	 tubular	 tissue,	
with	only	weak	hybridisation	observed	in	the	S1	and	S2	segments	(Kanai	et	al.,	1992).	Despite	
the	expression	gradient	of	b0,+AT	mRNA	directly	opposing	that	of	rBAT	(S1<	S2<	S3),	it	remains	
the	only	light	chain	known	to	associate	with	rBAT.	All	SLC7	“light	chains”	of	the	heterodimeric	
transport	 systems	have	a	conserved	cystine	 residue	 (Cys144	 in	b0,+AT,	Figure	1.4),	which	can	
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form	 a	 disulphide	 bridge	 with	 the	 respective	 heavy	 chain:	 CD98	 (Cys109)	 or	 rBAT	 (Cys114)	
(Chillarón	et	al.,	2010).	
	 	The	ability	for	CD98	to	interact	with	b0,+AT	remains	ambiguous.	When	b0,+AT	was	first	
identified	by	Chairoungdua	et	al.,	(1999),	a	6-fold	increase	in	[14C]cystine	uptake	was	observed	
in	COS-7	cells	co-transfected	with	rBAT	and	b0,+AT	above	cells	transfected	with	empty	plasmid,	
or	 the	 cDNA	 for	 either	 protein	 alone.	 Cells	 co-transfected	with	CD98	and	b0,+AT,	 showed	no	
induced	 uptake	 of	 [14C]cystine,	 indicating	 that	 b0,+AT	 associated	 specifically	 with	 rBAT	
(Chairoungdua	 et	 al.,	 1999).	 However,	 Rajan	 et	 al.	 (2000)	 demonstrated	 that,	 when	 co-
expressed	in	human	retinal	pigment	epithelial	(HRPE)	cells,	the	association	of	human	CD98	and	
rabbit	or	mouse	b0,+AT	can	induce	System	b0,+	activity.	They	identified	Na+-independent	uptake	
of	1μM	[3H]arginine	via	 rBAT-b0,+AT	and	CD98-b0,+AT,	which	was	 inhibited	 in	 the	presence	of	
2mM	unlabelled	competitor	compounds	in	the	same	profile	(Rajan	et	al.,	2000).	Transport	was	
inhibited	in	the	presence	of	neutral	and	cationic	amino	acids,	and	unaffected	by	the	presence	
of	 glutamate	 or	 MeAIB,	 consistent	 with	 the	 substrate	 specificity	 of	 System	 b0,+	 (Table	 1.1)	
(Rajan	 et	 al.,	 2000).	 When	 concentration-dependent	 uptake	 of	 System	 b0,+	 substrates	 was	
measured,	it	was	identified	that	although	the	two	induced	transport	systems	showed	the	same	
substrate	 selectivity	 profile,	 the	 measured	 affinities	 were	 different.	 The	 affinity	 (Km)	 for	
arginine	 uptake	 via	 CD98-b0,+AT	 was	 12±1μM	 (Rajan	 et	 al.,	 2000).	 However,	 the	 Km	 value	
calculated	for	rBAT-b0,+AT	transport	was	much	higher,	at	88±9μM.	This	suggested	for	the	first	
time	that	the	structure	of	the	heavy	chain	could	influence	the	affinity	of	the	induced	transport	
system,	serving	as	a	modulator	of	transport	and	not	merely	a	“trafficking”	protein	(Rajan	et	al.,	
2000).		
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b0,+AT         MGDTGLRKRR--------------------EDEKSIQSQEPKTTSLQKELGLISGISIIV  
xCT           ----MVRKPVVSTISKGGYLQG--NVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIII 
y+LAT1        -MVDSTEYEVASQPEVET------------SPLGDGASPGPEQVKLKKEISLLNGVCLIV 
y+LAT2        MEAREPGRPTPTYHLVPNTSQS--QVE---EDVSSPPQRSSETMQLKKEISLLNGVSLVV 
LAT1          MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNITLLNGVAIIV 
asc1          -MAGHTQQPSGRGNPRPAPSP---------SPVPGTVPGASERVALKKEIGLLSACTIII 
LAT2          -MEEGARHRNNTEKKHPGGGE---------SDASPEAGSGGGGVALKKEIGLVSACGIIV                                                               
                                                           *:.:: *: .  :::   
b0,+AT         GTIIGSGIFVSPKSVLSNTEAVGPCLIIWAACGVLATLGALCFAELGTMITKSGGEYPYL 
xCT           GTIIGAGIFISPKGVLQNTGSVGMSLTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYI 
y+LAT1        GNMIGSGIFVSPKGVLIYSASFGLSLVIWAVGGLFSVFGALCYAELGTTIKKSGASYAYI                         
y+LAT2        GNMIGSGIFVSPKGVLVHTASYGMSLIVWAIGGLFSVVGALCYAELGTTITKSGASYAYI 
LAT1          GTIIGSGIFVTPTGVLKEAGSPGLALVVWAACGVFSIVGALCYAELGTTISKSGGDYAYM 
asc1          GNIIGSGIFISPKGVLEHSGSVGLALFVWVLGGGVTALGSLCYAELGVAIPKSGGDYAYV 
LAT2          GNIIGSGIFVSPKGVLENAGSVGLALIVWIVTGFITVVGALCYAELGVTIPKSGGDYSYV                  
        *.:**:***::*..**  : : * .* :*   * .: .*:*.:****. * ***. *.*:  
b0,+AT         MEAYGPIPAYLFSWASLIVIKPTSFAIICLSFSEYVCAPFYVGCKPPQIVVKCLAAAAIL 
xCT           LEVFGPLPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLITAVGIT 
y+LAT1        LEAFGGFLAFIRLWTSLLIIEPTSQAIIAITFANYMVQPLFPSCFAPYAASRLLAAACIC 
y+LAT2        LEAFGGFIAFIRLWVSLLVVEPTGQAIIAITFANYIIQPSFPSCDPPYLACRLLAAACIC 
LAT1          LEVYGSLPAFLKLWIELLIIRPSSQYIVALVFATYLLKPLFPTCPVPEEAAKLVACLCVL 
asc1          TEIFGGLAGFLLLWSAVLIMYPTSLAVISMTFSNYVLQPVFPNCIPPTTASRVLSMACLM 
LAT2          KDIFGGLAGFLRLWIAVLVIYPTNQAVIALTFSNYVLQPLFPTCFPPESGLRLLAAICLL                   
         : :* : .::  *  :::: *:   ::.: *. *:  * :  *  *    . ::   :   
b0,+AT         FISTVNSLSVRLGSYVQNIFTAAKLVIVAIIIISGLVLLAQGNTKNFD--NSFEG-AQLS 
xCT           VVMVLNSMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFK--DAFSG-RDSS 
y+LAT1        LLTFINCAYVKWGTLVQDIFTYAKVLALIAVIVAGIVRLGQGASTHFE--NSFEG-SSFA 
y+LAT2        LLTFVNCAYVKWGTRVQDTFTYAKVVALIAIIVMGLVKLCQGHSEHFQ--DAFEG-SSWD 
LAT1          LLTAVNCYSVKAATRVQDAFAAAKLLALALIILLGFVQIGKGDVSNLDPNFSFEG-TKLD 
asc1          LLTWVNSSSVRWATRIQDMFTGGKLLALSLIIGVGLLQIFQGHFEELRPSNAFAFWMTPS 
LAT2          LLTWVNCSSVRWATRVQDIFTAGKLLALALIIIMGIVQICKGEYFWLEPKNAFEDFQEPD                  
        .:  :*.  *  .: :*  ::  *:  :  :*  *.: : :*    :    :*         
b0,+AT         VGAISLAFYNGLWAYDGWNQLNYITEELRNPYRNLPLAIIIGIPLVTACYILMNVSYFTV 
xCT           ITRLPLAFYYGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTT 
y+LAT1        VGDIALALYSALFSYSGWDTLNYVTEEIKNPERNLPLSIGISMPIVTIIYILTNVAYYTV 
y+LAT2        MGNLSLALYSALFSYSGWDTLNFVTEEIKNPERNLPLAIGISMPIVTLIYILTNVAYYTV 
LAT1          VGNIVLALYSGLFAYGGWNYLNFVTEEMINPYRNLPLAIIISLPIVTLVYVLTNLAYFTT 
asc1          VGHLALAFLQGSFAFSGWNFLNYVTEEMVDARKNLPRAIFISIPLVTFVYTFTNIAYFTA 
LAT2          IGLVALAFLQGSFAYGGWNFLNYVTEELVDPYKNLPRAIFISIPLVTFVYVFANVAYVTA                  
        :  : **:  . ::: **  **::***: :. ..:* :* *.:.:**  * : *::* *.  
b0,+AT         MTATELLQSQAVAVTFGDRVLYPASWIVPLFVAFSTIGAANGTCFTAGRLIYVAGREGHM 
xCT           INAEELLLSNAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVFAVSRLFYVASREGHL 
y+LAT1        LDMRDILASDAVAVTFADQIFGIFNWIIPLSVALSCFGGLNASIVAASRLFFVGSREGHL 
y+LAT2        LNISDVLSSDAVAVTFADQTFGMFSWTIPIAVALSCFGGLNASIFASSRLFFVGSREGHL 
LAT1          LSTEQMLSSEAVAVDFGNYHLGVMSWIIPVFVGLSCFGSVNGSLFTSSRLFFVGSREGHL 
asc1          MSPQELLSSNAVAVTFGEKLLGYFSWVMPVSVALSTFGGINGYLFTYSRLCFSGAREGHL 
LAT2          MSPQELLASNAVAVTFGEKLLGVMAWIMPISVALSTFGGVNGSLFTSSRLFFAGAREGHL                  
        :   ::* *:**** *.:  :      :*: *.:* :*. *.  .: .** : ..****:  
b0,+AT         LKVLSYISVRRLTPAPAIIFYGIIATIYIIPGDINSLVNYFSFAAWLFYGLTILGLIVMR 
xCT           PEILSMIHVRKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYLR 
y+LAT1        PDAICMIHVERFTPVPSLLFNGIMALIYLCVEDIFQLINYYSFSYWFFVGLSIVGQLYLR 
y+LAT2        PDLLSMIHIERFTPIPALLFNCTMALIYLIVEDVFQLINYFSFSYWFFVGLSVVGQLYLR 
LAT1          PSILSMIHPQLLTPVPSLVFTCVMTLLYAFSKDIFSVINFFSFFNWLCVALAIIGMIWLR 
asc1          PSLLAMIHVRHCTPIPALLVCCGATAVIMLVGDTYTLINYVSFINYLCYGVTILGLLLLR 
LAT2          PSVLAMIHVKRCTPIPALLFTCISTLLMLVTSDMYTLINYVGFINYLFYGGTVAGQIVLR                   
         . :. *     ** *:::.    : :     *   ::*: .*  ::  . :: * : :*  
b0,+AT         FTRKELERPIKVPVVIPVLMTLISVFLVLAPIISKPTWEYLYCVLFILSGLLFYFLFVHY 
xCT           YKCPDMHRPFKVPLFIPALFSFTCLFMVALSLYSDPF-STGIGFVITLTGVPAYYLFIIW 
y+LAT1        WKEPDRPRPLKLSVFFPIVFCLCTIFLVAVPLYSDTI-NSLIGIAIALSGLPFYFLIIRV 
y+LAT2        WKEPKRPRPLKLSVFFPIVFCICSVFLVIVPLFTDTI-NSLIGIGIALSGVPFYFMGVYL 
LAT1          HRKPELERPIKVNLALPVFFILACLFLIAVSFWKTPV-ECGIGFTIILSGLPVYFFGVWW 
asc1          WRRPALHRPIKVNLLIPVAYLVFWAFLLVFSFISEPM-VCGVGVIIILTGVPIFFLGVFW 
LAT2          WKKPDIPRPIKINLLFPIIYLLFWAFLLVFSLWSEPV-VCGIGLAIMLTGVPVYFLGVYW                         
                **:*: : :*    .   *::  .: . .       . : *:*:  ::: :    
b0,+AT         ----KFGWAQKISKPITMHLQMLMEVVPPE-----------EDPE--------------- 
xCT           --DKKPRWFRIMSEKITRTLQIILEVV-PE-----------EDKL--------------- 
y+LAT1        PEHKRPLYLRRIVGSATRYLQVLCMSVAAE-----------MDLEDGGEMPKQRDPKSN- 
y+LAT2        PESRRPLFIRNVLAAITRGTQQLCFCVLTE-----------LDVAEEKKDERKTD----- 
LAT1          --KNKPKWLLQGIFSTTVLCQKLMQVV----------------PQET------------- 
asc1          --RSKPKCVHRLTESMTHWGQELCFVVYPQ-----------DAPEEEENGPCPPSLLPAT 
LAT           --QHKPKCFSDFIELLTLVSQKMCVVVYPEVERGSGTEEANEDMEEQQQPMYQPTPTKDK                      
            .           *   * :   *                                    
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Figure	1.4:	The	sequence	identity	of	human	SLC7	light	chains.	Multiple	sequence	alignment	of	
human	 b0,+AT	 (NM_001243036.1),	 xCT	 (NM_014331.3),	 y+LAT1	 (NM_001126105.2),	 y+LAT2	
(NM_001076785.2),	LAT1	(NM_003486.5),	asc1	(NM_019849.2),	and	LAT2	(NM_001267037.1).	
Consensus	 symbols	 are	 displayed	 below	 aligned	 residues:	 *,	 fully-conserved	 residues;	 :,	
conservation	between	groups	with	strongly	similar	properties;	.,	conservation	between	groups	
with	weakly	similar	properties.	The	conserved	GXG	and	GWXXL	motifs	that	flank	the	unwound	
regions	 in	 transmembrane	 domains	 1	 and	 6,	 respectively,	 are	 highlighted	 in	 black.	 These	
residues	 are	 discussed	 in	 section	 1.7.	 The	 conserved	 cysteine	 residues	 that	 are	 predicted	 to	
form	the	disulphide	bridge	with	rBAT	or	CD98	are	highlighted	in	yellow.		
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1.6	The	renal	stone	disease,	cystinuria	
Cystinuria	(OMIM	220100)	is	the	most	common	genetic	cause	of	urolithiasis	with	mean	
prevalence	 worldwide	 of	 1:7000	 (Thomas	 et	 al.,	 2014).	 Cystinuria	 was	 first	 reported	 in	 the	
literature	 in	 1810,	 when	 an	 insoluble	 renal	 calculus	 of	 “cystic	 oxide”,	 weighing	 270g,	 and	
coated	in	a	“phosphate	of	lime”	was	removed	from	the	bladder	of	a	5	year	old	boy	(Wollaston,	
1810;	Knox,	1958).	However,	 it	was	a	century	 later	when	Sir	Archibald	Garrod	made	the	 link	
between	the	observations	on	this	chronic	stone-forming	condition,	further	identified	in	other	
patients,	 with	 Mendel’s	 theories	 of	 genetic	 inheritance	 (Garrod,	 1908).	 At	 the	 time,	 the	
pathology	 of	 cystinuria	 was	 attributed	 to	 a	 metabolic	 defect,	 leading	 to	 cystine	 stone	
formation	in	the	bladder	(Knox,	1958).	
By	1958,	several	integral	discoveries	in	determining	the	cause	of	this	disease	had	been	
made.	Firstly,	 in	1947,	microbiologist	Hier	reported	that	cystinuric	patients	also	had	elevated	
urinary	concentrations	of	arginine,	ornithine,	and	lysine,	whilst	only	poorly-soluble	cystine	was	
a	 component	of	 the	 calculi	 (Dent	 et	 al.,	 1954;	Knox,	 1958).	 The	 second	key	breakthrough	 in	
uncovering	 the	 pathophysiology	 of	 cystinuria	 was	 made	 by	 Charles	 Dent	 in	 1951,	 when	 he	
reported	the	presence	of	hexagonal	crystals	that	had	formed	through	cystine	deposition	in	the	
renal	tubules,	not,	as	previously	suspected,	in	the	bladder	(Dent	&	Rose,	1951;	Knox,	1958).	It	
was	 concluded	 that	 the	 basis	 of	 the	 disease	 pathology	 was	 attributable	 to	 a	 lack	 of	
reabsorption	of	 cystine	 (Dent	&	Rose,	1951;	Knox,	1958).	 This	 led	 to	 the	understanding	 that	
the	cause	of	elevated	amino	acids	in	the	urine	was	a	defective	transport	system,	as	opposed	to	
a	metabolic	pathway.		
The	 identification	 of	 System	 b0,+	 by	 Van	 Winkle	 (1988),	 the	 only	 transport	 system	
known	to	reabsorb	cystine	from	the	filtrate	in	the	proximal	tubule,	and	the	expression	cloning	
of	rBAT	in	Xenopus	oocytes	in	the	early	1990s,	led	to	the	identification	of	the	transport	system	
responsible	 for	 the	 pathophysiology	 of	 cystinuria	 (Silbernagl,	 1988;	 Bertran	 et	 al.,	 1992b;	
Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	et	al.,	1993;	Lee	et	al.,	
1993).	 Cystinuria	 is	 caused	 by	 defects	 in	 the	 apical	 proximal	 tubular	 transport	 system,	 b0,+,	
which	 leads	 to	 an	 incomplete	 reabsorption	 of	 dibasic	 amino	 acids	 arginine,	 lysine	 and	
ornithine,	 and	 the	 cysteine	 dimer,	 cystine.	 This	 causes	 precipitation	 of	 cystine	 and	 the	
formation	of	renal	calculi,	along	with	a	dibasic	aminoaciduria.		
Cystinuria	was	originally	thought	to	be	an	autosomal	recessive	condition	(Harris	et	al.,	
1955).	That	 is,	 a	patient	must	have	 inherited	 two	mutated	alleles	 in	order	 to	present	with	a	
disease	 phenotype.	 However,	 it	 soon	 became	 apparent	 that	 some	 obligate	 heterozygote	
carriers	 of	 mutations	 i.e.	 the	 parents	 or	 offspring	 of	 cystinuric	 patients,	 presented	 with	 a	
dibasic	aminoaciduria	(Harris	et	al.,	1955).	Based	on	this,	cystinuria	patients	were	classified	as	
“Type	I”	or	“non-Type	I”	(Harris	et	al.,	1955).	In	Type	I	patients,	the	cystinuria	phenotype	runs	
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as	 a	 purely	 recessive	 trait,	 with	 obligate	 heterozygote	 relatives	 of	 the	 affected	 probands,	
showing	normal	urinary	amino	acid	profiles	(Harris	et	al.,	1955).	Conversely,	non-Type	obligate	
heterozygotes	have	elevated	urinary	levels	of	arginine,	cystine,	lysine	and	ornithine,	indicating	
a	 dominant	 inheritance	pattern	of	mutations	 (Harris	 et	 al.,	 1955).	 In	 one	 attempt	 at	 the	 re-
classification	of	cystinuric	patients,	the	non-Type	I	individuals	were	further	classified	as	Type	II	
and	Type	III	(Rosenberg	et	al.,	1966).	Type	II	cystinuria	displays	a	more	severe	phenotype	than	
Type	 III	 (Rosenberg	 et	 al.,	 1966).	 However,	 it	 became	 apparent	 that	 the	 penetrance	 of	
phenotype	in	some	patients	and	their	obligate	heterozygote	relatives	was	highly	variable	and	it	
was	 difficult	 to	 classify	 patients	 using	 the	 established	 nomenclature	 (Harris	 et	 al.,	 1955;	
Rosenberg	et	al.,	1966;	Dello	Strologo	et	al.,	2002).	 
During	 the	 1990s	 linkage	 analysis	 identified	 the	 two	 genes	 involved	 in	 cystinuria	
through	maximum	LOD	scoring	of	microsatellite	markers	 (Pras	et	al.,	1994;	Yan	et	al.,	1994).	
The	gene	encoding	rBAT	was	 located	to	the	short	arm	of	chromosome	2,	coinciding	with	the	
position	of	 a	 known	 solute	 carrier	 gene	SLC3A1	 (Pras	 et	 al.,	 1994).	 Comprised	of	 ten	 exons,	
SLC3A1	spans	more	than	45kb,	and	is	specifically	located	at	region	2p16.3-21	(Yan	et	al.,	1994).	
A	second	causative	gene,	SLC7A9,	located	at	the	19q31.1	locus,	now	known	to	encode	the	light	
chain	protein	b0,+AT,	was	also	identified	as	a	causal	mutated	allele	in	cystinuria	through	linkage	
analysis	in	cystinuric	patients	(Bisceglia	et	al.,	1997;	Wartenfeld	et	al.,	1997;	Chairoungdua	et	
al.,	 1999).	 Defects	 in	 either	 of	 the	 two	 genes	 encoding	 the	 subunits	 of	 the	 heterodimeric	
transport	system,	can	cause	an	abnormality	in	transport	(Chillarón	et	al.,	2010).		
Following	 the	 identification	 of	 the	 two	 genes	 involved	 in	 this	 disease,	 a	 modern	
classification	system	was	introduced,	which	is	now	widely	used	in	the	literature	(Dello	Strologo	
et	 al.,	 2002).	 Patients	 with	 mutations	 in	 SLC3A1	 are	 classed	 as	 type	 “A”,	 and	 those	 with	
mutations	 in	 SLC7A9,	 type	 “B”.	 Thus,	 patients	 can	 be	 classified	 as	 Type	 AA,	 BB,	 or	 AB,	
depending	 on	 the	 chromosomal	 location	 of	 their	 specific	 mutations	 (Dello	 Strologo	 et	 al.,	
2002;	Gucev	et	al.,	2011).			
1.7	Current	therapies	for	cystinuria	
To	 limit	 the	 formation	 of	 cystine	 calculi	 in	 the	 renal	 filtrate	 and	 urine	 of	 cystinuric	
patients,	treatments	aim	to	increase	the	solubility	of	the	cysteine	dimer	(Figure	1.5A).	Dietary	
modifications	can	be	undertaken	to	reduce	the	recurrence	of	stone	formation	through	limiting	
dietary	 intake	 of	 sodium,	 which	 has	 been	 shown	 to	 increase	 urinary	 cystine	 excretion,	 and	
animal	 proteins,	 due	 to	 their	 high	 cystine	 and	 methionine	 content	 (Goldfarb	 et	 al.,	 2006).	
Despite	the	presence	of	System	b0,+	in	the	apical	membrane	of	the	small	intestine,	patients	do	
not	 suffer	 deficiencies	 in	 the	 dibasic	 amino	 acids	 or	 cystine	 due	 to	 the	 presence	 of	 peptide	
transporters	 such	 as	 PepT1,	 and	 the	 body’s	 ability	 to	 synthesise	 cystine	 from	 methionine	
(Palacin	et	al.,	2004).			
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As	first	reported	by	Wollaston	(1810),	the	solubility	of	cystine	in	water	and,	therefore,	
the	urine,	is	low.	At	pH	7	the	solubility	of	cystine	in	the	urine	is	<1mM,	increasing	to	2mM	at	
pH	7.5	 (Dent	 et	al.,	 1965;	Chillarón	 et	al.,	 2010).	The	 solubility	of	 cystine	 in	water	at	25°C	 is	
only	 460μM	 (O'Neil,	 2006).	 Through	 a	 combination	 of	 hyperdiuresis,	 to	 lower	 the	 absolute	
concentration	of	cystine,	and	alkalinisation	of	the	renal	filtrate,	to	increase	the	solubility	of	the	
filtered	 dimer,	 the	 recurrence	 of	 cystine	 stones	 can	 be	 lowered	 (Chillarón	 et	 al.,	 2010).	
Potassium	 citrate	 is	 the	 preferred	 alkalinising	 agent	 due	 to	 the	 increased	 amount	 of	 cystine	
excretion	associated	with	sodium	bicarbonate	or	sodium	citrate	(Fjellstedt	et	al.,	2001).		
If	hyperdiuresis	and	urinary	alkalinisation	fail	to	adequately	control	stone	formation	in	
cystinuric	patients,	treatment	with	the	cystine-binding	thiol	drugs	(CBTD)	is	considered.	CBTD	
include	captopril,	tiopronin,	and	D-penicillamine	(Figure	1.5D)	(Barbey	et	al.,	2000;	Thomas	et	
al.,	2014).	These	drugs	work	by	breaking	down	cystine	into	monomeric	cysteine	amino	acids,	
through	 conjugation	 via	 disulphide	 bond	 formation	 (Figure	 1.5C-E).	 These	 cysteine-drug	
conjugates	 are	 predicted	 to	 be	 x50	 more	 soluble	 in	 urine	 than	 the	 cystine	 dimer	 (Lotz	 &	
Bartter,	 1965;	 Goldfarb	 et	 al.,	 2006;	 Chillarón	 et	 al.,	 2010).	 Captopril	 is	 an	 Angiotensin	
Converting	Enzyme	 inhibitor	 (ACEi),	commonly	prescribed	 for	 the	treatment	of	hypertension,	
by	 preventing	 the	 conversion	 of	 angiotensin	 I	 to	 angiotensin	 II	 (Goldfarb	 et	 al.,	 2006).	 As	 a	
widely	 prescribed	 drug,	 the	 side	 effect	 profile	 associated	 with	 captopril	 treatment	 is	 low.	
However,	 it	 has	 been	 reported	 that	 the	 efficacy	 of	 captopril	 on	 cystine	 conjugation	 in	
cystinuria	 is	 not	 established	 (Goldfarb	 et	 al.,	 2006).	 This	 is	 because	 concentrations	 in	 the	
plasma,	and	consequently	the	renal	filtrate,	do	not	reach	sufficient	levels	to	provide	adequate	
conjugation	 of	 cystine	 (Goldfarb	 et	 al.,	 2006;	 Chillarón	 et	 al.,	 2010;	 Thomas	 et	 al.,	 2014).	 D-
Penicillamine	and	tiopronin	 (Figure	1.5D)	are	both	 thiol-containing	 immunomodulating	drugs	
associated	 with	 a	 wide	 range	 of	 severe	 adverse	 effects	 including	 hypersensitivity,	
hepatotoxicity,	proteinuria	and	haematuria	 (Pak,	1969;	Goldfarb	et	al.,	2006;	Chillarón	et	al.,	
2010).	Therefore,	despite	an	improvement	in	cystine	conjugation	over	captopril,	many	patients	
cannot	tolerate	treatment	with	tiopronin	or	D-penicillamine	and	therapy	is	discontinued.		
It	 has	 been	 reported	 that	 >50%	 of	 patients	 with	 cystinuria	 will	 pass	 stones	
spontaneously.	 For	 large	 stones	 >5mm	 in	 diameter	 urological	 interventions	 are	 required.	
However,	 Extracorporeal	 Shockwave	 Lithotripsy	 (ESWL)	 is	 not	 thought	 to	 be	 effective	 in	 the	
disintegration	 of	 cystine	 stones	 (Chillarón	 et	 al.,	 2010).	 Open	 surgery	 is	 often	 reported	 to	
remove	cystine	calculi,	and	 in	severe	cases	of	the	disease	patients	can	reach	end	stage	renal	
disease	(ESRD),	requiring	transplantation	(Thomas	et	al.,	2014;	Rhodes	et	al.,	2015).	
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Figure	 1.5:	 The	molecular	 structure	 of	 cystine	 and	 cystine-drug	 conjugates.	 The	molecular	
structure	of	cysteine	(A),	which	can	form	a	dipeptide	via	a	peptide	bond	with	another	amino	
acid	(B),	or	a	dimer	via	a	disulphide	bond	to	form	cystine	(C).	Using	thiol-containing	drugs	(D),	
cystine	 can	 be	 broken	 down	 to	 form	 cysteine-drug	 conjugates,	which	 are	more	 soluble	 and	
prevent	the	formation	of	cystine	calculi	in	the	renal	filtrate.	
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1.8	Inherited	diseases	of	renal	transport	
Mutations	in	other	renal	transport	systems	can	lead	to	disease	associated	with	a	lack	
of	 amino	 acid	 reabsorption	 in	 the	 proximal	 tubule.	 Hartnup	 disorder	 (OMIM	 234500)	 was	
named	 after	 the	 patient	 Eddie	 Hartnup,	 who	 first	 presented	 with	 the	 disease	 in	 1956,	
displaying	symptoms	of	a	“pellagra-like	rash”	and	cerebral	ataxia	(Baron	et	al.,	1956).	Hartnup	
disease	 is	 an	 autosomal	 recessive	 condition	 that	 affects	 around	 1:30,000	 in	 European	
populations	 caused	 by	 mutations	 in	 SLC6A19,	 encoding	 the	 apical	 membrane	 transporter	
B0AT1	 (Figure	 1.1)	 (Bröer,	 2009).	 B0AT1	 is	 an	 apical	 membrane	 protein	 that	 mediates	 Na+-
dependent	 transport	 of	 neutral	 amino	 acids	 (Table	 1.1).	 	 Also	 located	 in	 the	 small	 intestine,	
mutations	in	this	transporter	affects	the	absorption	of	ingested	neutral	amino	acids	from	the	
diet.	 However,	 through	 the	 administration	 of	 a	 high	 protein	 diet,	 most	 patients	 remain	
asymptomatic,	 as	 the	 deficiency	 is	 compensated	 by	 the	 absorption	 of	 oligopeptides	 by	 the	
apical	peptide	transporter,	PepT1	(Bröer,	2009).	Patients	remain	largely	asymptomatic	despite	
the	presence	of	a	neutral	aminoaciduria,	notably	tryptophan	(Bröer,	2008,	2009).	
Lysinuric	 Protein	 Intolerance	 (LPI,	 OMIM:	 222700)	 occurs	 in	 around	 1:60,000	 of	 the	
population	in	Finland,	where	the	prevalence	is	highest	(Torrents	et	al.,	1999).	LPI	is	caused	by	
mutations	 in	the	 light	chain	of	a	basolateral	heterodimeric	transport	system,	y+L	(Figure	1.1),	
namely	 SLC7A7,	 the	 gene	 encoding	 y+LAT1	 (Torrents	 et	 al.,	 1999).	 To	 date,	 no	 pathogenic	
mutations	have	been	reported	in	SLC3A2,	the	gene	encoding	CD98	(Stenson	et	al.,	2014).	It	is	
considered	 that	 due	 to	 the	 ubiquitous	 distribution	 of	 CD98	 in	mammalian	 systems,	 and	 the	
association	 of	 this	 heavy	 chain	 with	 many	 different	 light	 chains,	 mutations	 in	 this	 protein	
would	have	fatal	consequences	 in	foetal	development	(Palacin	et	al.,	2005).	Unlike	cystinuria	
and	 Hartnup	 disorder,	 mutations	 in	 the	 Na+-dependent	 exchanger	 of	 extracellular	 neutral	
amino	acids	and	intracellular	dibasic	amino	acids	cause	a	multi-organ	phenotype	(Palacin	et	al.,	
2004).	LPI	was	first	described	by	Perheentupa	and	Visakorpi	(1965)	as	a	dibasic	aminoaciduria.	
In	LPI	patients,	 lysine	 is	present	 in	the	urine	at	a	concentration	10-fold	greater	than	arginine	
and	 30-fold	 greater	 than	 ornithine,	 respectively	 (Palacin	 et	 al.,	 2004).	 Unlike	 cystinuria,	 no	
renal	 stone	 formation	 is	associated	with	 the	aminoaciduria	as	System	y+L	does	not	 transport	
poorly-soluble	 cystine.	 Plasma	 concentrations	 of	 the	 dibasic	 amino	 acids	 are	 sub-normal	 as	
peptide	 transport	 cannot	 compensate	 for	 a	 lack	 of	 function	 of	 this	 basolateral	 transport	
system,	 as	 it	 can	with	 apical	 transport	 systems	 b0,+	 and	 B0	(Palacin	 et	 al.,	 2004).	 The	 clinical	
presentation	of	LPI	 includes	protein	malnutrition,	which	occurs	 in	 infants	after	weaning.	This	
leads	 to	 a	 failure	 to	 thrive,	 osteoporosis,	 hypotonia,	 and	mental	 retardation	 (Palacin	 et	 al.,	
2004).	Arginine	and	ornithine	are	key	components	in	the	urea	cycle.	Therefore,	a	deficiency	in	
these	amino	acids	 can	 lead	 to	post-prandial	hyperammonemia	when	patients	are	 fed	a	high	
protein	 diet.	 LPI	 patients	 can	 be	 treated	 with	 a	 low-protein	 diet	 and	 the	 urea	 cycle	
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intermediate,	 citrulline.	 This	prevents	hyperammonemia,	which	 can	 induce	 coma	and	death.	
However,	the	lysine	deficiency	remains	and	leads	to	poor	growth	and	osteoporosis	(Palacin	et	
al.,	2004).	
Other	 inherited	 disorders	 of	 amino	 acid	 transport	 include	 iminoglycinuria	 (OMIM:	
242600),	 and	 dicarboxylic	 aminoaciduria	 (OMIM:	 222730)	 (Bröer,	 2008).	 Both	 of	 these	
conditions	are	 caused	by	mutations	 in	 apical	 transport	 systems	of	 the	 renal	proximal	 tubule	
(Figure	1.1),	leading	to	benign	aminoacidurias	of	their	respective	substrates	(Table	1.1).	
1.9	Glycoside	hydrolase	enzyme	structure 
The	glycoside	hydrolases	(GH)	(EC	3.2.1)	are	a	large	group	of	enzymes	that	cleave	the	
glycosidic	 bond	 between	 carbohydrate	 molecules	 and	 are	 found	 across	 archeal,	 bacterial,	
eukaryotic	and	viral	domains	of	life	(Lombard	et	al.,	2014).	The	GH	enzymes	are	divided	into	14	
clans	 (A-N)	based	upon	 their	 secondary	 structure	 (Lombard	 et	 al.,	 2014).	 The	alpha	amylase	
family	is	one	member	of	the	GH-H	clan,	members	of	which	share	the	same	common	ancestor,	
secondary	structural	fold,	and	catalytic	machinery	(Stam	et	al.,	2006).	Their	primary	sequence	
similarity	is	low,	which	is	thought	to	account	for	the	variability	in	substrate	specificity	of	these	
enzymes	 (Pujadas	&	 Palau,	 2001).	 The	 conserved	 secondary	 structure	 is	 composed	 of	 three	
domains,	A-C	(Figure	1.6)	(Ramasubbu	et	al.,	1996).	The	N-terminal	domain,	Domain	A,	of	clan	
GH-H	 consists	 of	 a	 (β/α)8,	 or	 triosephosphate	 isomerase	 (TIM)	 barrel,	 a	 protein	 fold	 first	
identified	in	the	muscle	of	chickens	(Banner	et	al.,	1975;	Brayer	et	al.,	1995).	In	a	TIM	barrel,	
the	 polypeptide	 chain	 consists	 of	 eight	 parallel	 β	 sheets,	 linked	 by	 α	 helices	 (Figure	 1.7)	
(Banner	et	al.,	1975).	Domain	B	is	a	loop-rich	subdomain	inserted	between	β3	and	α3,	which,	
together	with	Domain	A,	forms	the	cleft	of	the	enzyme	active	site	(Janecek	et	al.,	1997).	Within	
this	 cleft,	 exists	 a	 “catalytic	 triad”,	 first	 discovered	 in	 Taka	Amylase	A	 from	Apergillus	 oyzae	
(Matsuura	 et	 al.,	 1984).	 This	 consists	 of	 three	 highly	 conserved	 residues	 that	 act	 as	 a	
nucleophile	 (Asp),	 proton	 donor	 (Glu),	 and	 transition-state	 stabiliser	 (Asp)	 (Matsuura	 et	 al.,	
1984).	 Finally,	 Domain	 C,	 the	 C-terminal	 domain,	 is	 an	 anti-parallel	 β	 sheet	 (Figure	 1.7)	
(Janecek	et	al.,	1997).	It	has	been	suggested	that	the	strict	conservation	of	secondary	structure	
within	 the	 families	 of	 the	 GH-H	 clan	 is	 due	 to	 the	 presence	 of	 seven	 conserved	 sequence	
regions	 (CSR)	 (Table	 1.3),	 which	 are	 distributed	 throughout	 the	 protein	 (Toda	 et	 al.,	 1982;	
Friedberg,	1983;	Rogers,	1985;	Nakajima	et	al.,	1986;	Janecek,	1992,	1994).	
In	 addition	 to	 alpha	 amylases,	 clan	 GH-H	 also	 includes	 oligo-1,6-glucosidases	 and	
neopullulanases	 (Watanabe	 et	 al.,	 1990).	Oligo-1,6-glucosidase	 from	Bacillus	 cereus	 is	 a	 558	
amino	acid	enzyme	(PDB	code	1UOK,	Figure	1.6).	Like	the	other	glycoside	hydrolases	belonging	
to	 clan	GH-H,	 this	 enzyme	 consists	 of	 the	 three	domains	A,	 B	 and	C	with	 an	 insertion	of	 an	
extra	helix	between	β6	and	α6,	 and	 three	 extra	helices	between	β8	and	α8	 (α8’,	α8’’,	α8’’’)	
(Figure	1.7)	(Watanabe	et	al.,	1997).		
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Figure	 1.6:	 The	 characteristic	 structural	 domains	 of	 the	GH-H	 clan	 of	 enzymes.	 The	 crystal	
structure	of	oligo-1,6-glucosidase	(PDB	code	1UOK;	Watanabe	et	al.,	1997).	Domains	A1	(red)	
and	 A2	 (green)	 display	 a	 (β/α)8	 structural	 fold,	 which	 is	 interrupted	 by	 loop-rich	 domain	 B	
(yellow).	The	cleft	formed	by	the	interruption	of	the	(β/α)8	fold	forms	the	enzyme	active	site.	
Domain	 C	 (blue)	 is	 comprised	 of	 a	 β	 sheet.	 The	 N-	 and	 C-termini	 are	 labelled	 N	 and	 C,	
respectively.		
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Figure	1.7:	 The	TIM	barrel	 conserved	 throughout	 the	GH-H	 clan	of	 enzymes.	 	A,	Schematic	
diagram	 of	 the	 top-view	 of	 a	 triosephosphate	 isomerase	 (TIM)	 barrel	 displaying	 the	
characteristic	 (β/α)8	 fold.	Squares	 represent	β	sheets	and	circles	 represent	α	helices;	B,	Top-
view	 of	 the	 TIM	 barrel	 isolated	 from	 the	 crystal	 structure	 of	B.	 cereus	oligo-1,6-glucosidase	
(PDB	 code	1UOK;	Watanabe	et	al.,	1997).	Domains	B	 and	C	have	been	 removed;	β1α1,	 red;	
β2α2,	 orange;	 β3α3,	 yellow;	 β4α4,	 green;	 β5α5,	 blue;	 β6α6,	 indigo;	 β7α7,	 violet;	 β8α8,	
magenta.	
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Table	 1.3:	 The	 seven	 conserved	 sequence	 regions	 of	 the	 GH	 enzyme	 clan.	 The	 seven	
identified	 conserved	 sequence	 regions	 (CSR)	 are	 the	 principal	 sites	 of	 primary	 sequence	
similarity	in	the	GH-H	clan	of	enzymes.	The	conserved	sequence	regions	are	numbered	in	order	
of	 their	 discovery.	 (Toda	 et	 al.,	 1982;	 Friedberg,	 1983;	 Rogers,	 1985;	 Nakajima	 et	 al.,	 1986;	
Janecek,	1992,	1994).	Their	location	in	the	secondary	structure	is	also	stated.	
	 	
CSR	 Sequence	 Location	
1	 NMKLMMDLVVNH	 β3	
2	 GIDGFRMDVINF	 β4	
3	 MTVGEMPG	 β5	
4	 WNSLYWNNHD	 β7	
5	 QPDLN	 Loop	3	(of	Domain	B)	
6	 GIDVIWLSP	 β2	
7	 GTPYIYQGE	 β8	
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1.10	The	structure	of	the	heterodimeric	heavy	chains:	CD98	and	rBAT	
In	 2007,	 the	 extracellular	 domain	 of	 CD98	 was	 crystallised	 and	 the	 structure	
determined	 to	 a	 2.8Å	 resolution	 (Fort	 et	 al.,	 2007)	 (Figure	 1.8A,	 PDB	 code	 2DH2).	 It	 was	
discovered	to	have	a	shared	secondary	structure	with	 the	GH-H	clan	of	enzymes	 (Fort	et	al.,	
2007).	Unlike	the	structurally	related	GH-H	enzymes,	CD98	lacks	the	insertion	of	Domain	B	(the	
subdomain)	in	the	TIM	barrel	of	Domain	A,	removing	the	active	site	cleft	(Figure	1.8A)	(Fort	et	
al.,	2007).	Screening	the	protein	with	a	range	of	sugars	failed	to	detect	any	enzymatic	activity	
(Fort	et	al.,	2007).	Despite	low	primary	sequence	identity	with	1UOK	(27%),	the	A	domains	of	
the	two	proteins	share	83%	structural	identity	(Fort	et	al.,	2007).		
The	 crystal	 structure	 of	 rBAT	 has	 not	 yet	 been	 resolved.	 This	 is	 mainly	 due	 to	 the	
difficulties	 in	 yielding	 large	 quantities	 of	 hydrophobic	 eukaryotic	 membrane	 proteins.	
Additionally,	 the	 hydrophobic	 proteins	 must	 be	 extracted	 from	 the	 membrane	 using	
detergents,	which	disrupt	 the	native	 folding	of	 the	proteins	 (White	&	Wimley,	1999).	Due	to	
this,	 the	 vast	majority	 of	 crystal	 structures	 of	membrane	 proteins	 in	 the	 Protein	 Data	 Bank	
(PDB)	 are	 from	 lower	 prokaryotic	 organisms,	 harvested	 in	 large	 quantities	 of	 the	 proteins	
through	 recombinant	 technology	 (Carpenter	 et	 al.,	 2008).	 It	 is	 not	 possible	 to	 express	many	
eukaryotic	 transport	proteins	 in	bacterial	 expression	 systems	due	 to	 their	 structural	 reliance	
on	 post-translational	 modifications,	 which	 do	 not	 occur	 in	 prokaryotes	 (Vinothkumar	 &	
Henderson,	 2010).	 Although	 no	 crystal	 structure	 of	 the	 extracellular	 domain	 of	 rBAT	 is	
available,	the	structural	and	sequence	similarity	to	other	related	proteins	can	be	investigated	
to	 predict	 the	 topology	 of	 the	molecule.	 Following	 the	 resolution	 of	 the	 crystal	 structure	 of	
CD98,	an	 in	silico	study	considered	the	ancestry	and	structural	relationship	of	rBAT	and	CD98	
with	the	glycoside	hydrolase	(GH)	clan	of	enzymes	(Gabrisko	&	Janecek,	2009).	In	contrast	with	
CD98,	 the	 extracellular	 domain	 of	 rBAT	 appears	 to	 share	 Domain	 B	 (Figure	 1.8B)	 and	 the	
catalytic	triad	of	the	GH-H	enzymes	(Figure	1.9)	(Gabrisko	&	Janecek,	2009).		
The	extracellular	 domain	of	 rBAT	 is	 predicted	 to	 share	many	more	of	 the	 conserved	
structural	 and	 sequential	 alpha-amylase	 features	 than	 CD98,	 potentially	 indicating	 a	 shorter	
evolutionary	distance	between	the	proteins	(Gabrisko	&	Janecek,	2009).	Consequently,	1UOK	
seems	 to	 provide	 a	 more	 accurate	 template	 for	 a	 homology	 model	 of	 rBAT.	 Despite	 the	
similarities,	rBAT	possesses	a	30	amino	acid	C-terminal	tail	that	does	not	model	to	any	known	
structure	 (Rius	 &	 Chillarón,	 2012).	 Alignment	 of	 the	 rBAT	 extracellular	 domain	 amino	 acid	
sequence	 (Asp116-Lys653)	with	 the	extracellular	domain	of	CD98	 (Gln116-Ala528)	and	oligo-
1,6-glucosidase	from	B.	cereus	demonstrates	that	the	rBAT	extracellular	domain	shares	greater	
primary	sequence	similarity	with	the	bacterial	enzyme	than	with	the	only	other	member	of	the	
SLC3	 family,	 CD98	 (Figure	 1.9).	 The	 extracellular	 domain	 of	 rBAT	 also	 shares	 the	 complete	
conservation	of	CSR5	with	the	enzyme	(Figure	1.9)	(Gabrisko	&	Janecek,	2009).	A	high	degree	
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of	conservation	between	all	three	protein	sequences	can	be	observed	in	the	regions	in	which	
CSR	1,	3,	and	7	fall	(Figure	1.9).	Despite	the	low	sequence	identity	between	rBAT	and	CD98,	the	
two	proteins	both	covalently	 link	 to	 their	 respective	 light	 chains	 through	conserved	cysteine	
residues	(Cys114	and	Cys109,	respectively)	(Bröer	&	Wagner,	2002).		
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Figure	1.8:	The	extracellular	domains	of	CD98	and	rBAT.	A,	Side	view	of	the	CD98	extracellular	
domain	(PDB	code	2DH3;	Fort	et	al.,	2007),	which	shows	a	high	level	of	structural	homology	to	
the	GH-H	clan	of	 enzymes,	however	 it	 does	not	possess	domain	B;	B,	 Side	 view	of	 the	 rBAT	
extracellular	 domain	 model	 based	 on	 oligo-1,6-glucoside	 from	 B.	 cereus	 (PDB	 code	 1UOK;	
Watanabe	et	al.,	1997).	Red,	domain	A1;	yellow,	domain	B;	green,	domain	A2;	blue,	domain	C.	
Amino	 acid	 residue	 numbers	 that	 fall	 into	 the	 distinct	 structural	 domains	 are	 denoted	
underneath	the	domain	labels.	The	putative	location	of	the	transmembrane	domain	is	denoted	
with	an	arrow.	
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Figure	1.9:	 Sequence	 similarity	between	 the	extracellular	domains	of	 rBAT,	and	CD98	with	
oligo-1,6-glucosidase	 from	 B.	 cereus. Multiple	 sequence	 alignment	 of	 human	 rBAT	
(NM_000341.3)	and	CD98	(NM_001013251.2)	extracellular	domains	with	oligo-1,6-glucosidase	
from	B.	cereus	(denoted	1UOK,	GI:4558191).	Domain	regions	are	highlighted	above	each	row	
of	sequence.	Domain	A1:	red;	Domain	B:	yellow;	Domain	A2:	green;	Domain	C:	blue.	Residues	
highlighted	 in	 grey	 indicate	 residues	 fully	 conserved	 between	 1UOK	 and	 either	 of	 the	
mammalian	protein	sequences.	Black	boxes	indicate	the	CSR	in	the	GH-H	clan	of	enzymes.	The	
residues	of	the	catalytic	triad	are	highlighted	in	black.	
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1.11	The	APC	superfamily	and	the	LeuT	fold	
The	 Aquifex	 aeolicus	 leucine	 transporter,	 LeuTAa,	 was	 crystallised	 and	 structurally	
resolved	 to	 reveal	 a	12	 transmembrane	domain	 structure,	with	an	 internal	 structural	 repeat	
(Figure	 1.10)	 (Yamashita	 et	 al.,	 2005).	 This	 5+5	 “inverse	 repeat”	 fold	 was	 previously	
unpredictable	 from	 internal	 sequence	 alignments	 of	 LeuTAa,	due	 to	 a	 low	 primary	 sequence	
similarity	between	the	domains	(Yamashita	et	al.,	2005).	Following	a	rotation	of	176.5o,	it	was	
discovered	 that	 the	 first	 five	 domains	 could	 be	 superposed	 over	 the	 following	 five	
transmembrane	domains	(Figure	1.10).	Transmembrane	domains	1	and	6	display	the	greatest	
levels	 of	 conservation,	 followed	by	domains	 3	 and	8	 (Yamashita	 et	 al.,	 2005).	 The	 structural	
organisation	of	the	crystallised	LeuTAa	in	the	occluded	conformation	revealed	an	internal	core	
of	four	helices	(transmembrane	domains	1,	3,	6,	and	8)	surrounded	by	the	additional	domains	
(2,	 4,	 5,	 7,	 9-12)	 (Yamashita	 et	 al.,	 2005).	 Transmembrane	 domains	 1	 and	 6	were	 found	 to	
possess	an	unwound	region	in	the	alpha	helix,	flanked	by	a	series	of	conserved	residues.	These	
are:	 G24,	 L25,	 G26	 in	 transmembrane	 domain	 1,	 and	 G256,	 A257,	 I258,	 I259,	 T260	 in	
transmembrane	domain	6.	The	disruption	to	the	helical	structure	is	thought	to	expose	atoms	
from	 the	 amino	 acid	 spine	 to	 allow	 for	 additional	 substrate	 interaction	 (Yamashita	 et	 al.,	
2005).	Highly	conserved	domains	3	and	8	sit	in	the	membrane	at	a	50°°	angle	(Figure	1.10).	In	
LeuTAa	transmembrane	domains	9	and	12	interact	with	the	equivalent	domains	on	an	adjacent	
molecule	to	form	a	structural	homodimer	(Yamashita	et	al.,	2005).	This	5+5	 inverse	repeat	 is	
universally	known	as	the	LeuT	fold,	due	to	its	discovery	in	the	bacterial	leucine	transporter.	
The	Amino	Acid-Polyamine-Organocation	 (APC)	 superfamily	 of	 transporters	 is	 one	of	
29	 distinct	 superfamilies,	 composed	 of	 600	 different	 families,	 which	 together	 include	more	
than	 5600	 transport	 proteins	 (http://tcdb.org)	 (Chang	 et	 al.,	 2004).	 The	 APC	 superfamily	
consists	of	18	distinct	transporter	families,	 including	the	Neurotransmitter:Sodium	Symporter	
(NSS)	family,	of	which	LeuTAa	is	a	member	(Chang	et	al.,	2004;	Yamashita	et	al.,	2005).	Another	
of	 the	 transporter	 families	belonging	 to	 the	APC	superfamily	 is	 the	APC	 family	 (Chang	 et	al.,	
2004).	 Included	 in	 the	 APC	 family	 of	 transporters	 are	 the	 mammalian	 L-type	 amino	 acid	
transporters	 (LATs)	 (Chang	 et	 al.,	 2004).	 The	 light	 chains	 of	 the	 heterodimeric	 amino	 acid	
transport	systems	are	members	of	the	SLC7	family	of	LATs,	along	with	homologous	membrane	
transporters	identified	in	prokaryotic	systems	(Jack	et	al.,	2000).		
Following	 the	 crystallisation	 of	 LeuTAa,	 and	 identification	 of	 the	 LeuT	 structural	 fold,	
other	prokaryotic	 transport	proteins	belonging	to	 the	APC	superfamily	have	had	their	crystal	
structures	 resolved	 (Gao	 et	 al.,	 2009;	 Shaffer	 et	 al.,	 2009).	 Through	 these	 structures,	 it	 has	
become	 apparent	 that	 many	 functionally	 distinct	 transporters,	 with	 low	 levels	 of	 primary	
sequence	identity	(<10%),	share	the	LeuT	fold	(Forrest,	2013).	In	addition	to	the	inverse	repeat	
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fold,	APC	transporter	structures	have	been	shown	to	contain	the	conserved	GSG	motif	flanking	
the	 unwound	 region	 of	 transmembrane	 domain	 1	 and	 a	 five	 amino	 acid	 GVESA	 motif	 in	
transmembrane	domain	6	(Gao	et	al.,	2009).	Additionally,	 in	a	similar	manner	to	LeuTAa,	 two	
transporters	belonging	to	the	APC	family,	AdiC	(arginine-agmatine	transporter)	 in	E.	coli,	and	
ApcT	(H+-coupled,	broad	specificity	amino	acid	transporter)	 in	M.	jannaschii,	form	membrane	
homodimers	 through	 interactions	 between	C-terminal	 transmembrane	domains.	 In	 this	 case	
via	transmembrane	domains	11	and	12	(Gao	et	al.,	2009;	Shaffer	et	al.,	2009).	 
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Figure	1.10:	Schematic	representation	of	the	LeuT	fold.	The	membrane	topology	of	the	LeuT	
5+5	 inverse	repeat	fold	 in	the	bacterial	transporter,	LeuTAa.	Transmembrane	domains	1-5	and	
6-10	form	an	inverse	structural	repeat	pattern,	highlighted	by	two	triangles.	Transmembrane	
domains	1	(green)	and	6	(orange)	are	 interrupted	by	unwound	regions	of	their	alpha	helices.	
Together	with	transmembrane	domains	3	(blue)	and	8	(purple)	they	form	the	binding	pocket	
for	leucine	(red	circle).	Adapted	from	Yamashita	et	al.,	2005.		
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1.12	The	structure	of	b0,+AT,	the	light	chain	of	System	b0,+	
Although	 the	 crystal	 structures	 of	 the	 heterodimeric	 amino	 acid	 transporter	 light	
chains	 remain	unsolved,	 it	 is	predicted	 that	 they	 share	 the	LeuT	 fold	 (Chillarón	 et	al.,	 2010).	
Gasol	 et	al.	 (2004)	 identified	 the	membrane	 topology	of	 the	CD98	 light	 chain	 xCT	 through	a	
series	of	biochemical	experiments.	It	was	discovered	through	expression	of	System	xc-	in	HeLa	
cells	with	 an	N-terminally	 His-tagged	 and	 C-terminally	myc-tagged	 xCT	 light	 chain	 that	 both	
terminals	of	the	protein	were	intracellular	(Gasol	et	al.,	2004).	Additionally,	cysteine	scanning	
accessibility	studies	confirmed	a	12	transmembrane	domain	topology	of	the	light	chain	(Gasol	
et	al.,	2004).	
HHPRED	 is	 a	 statistical	 method	 for	 detecting	 structural	 homology	 amongst	 proteins	
from	their	primary	sequences	(Sӧding	et	al.,	2005).	Through	the	use	of	this	technique,	the	3D	
structure	of	the	mammalian	LATs	can	be	predicted	(Reig	et	al.,	2007;	Bartoccioni	et	al.,	2010;	
Chillarón	et	al.,	2010;	Fotiadis	et	al.,	2013;	Meury	et	al.,	2014;	Rosell	et	al.,	2014;	Napolitano	et	
al.,	2015).	This	allows	the	creation	of	a	homology	model	of	the	protein	of	interest.	To	date,	the	
prokaryotic	arginine:agmatine	transporter	AdiC	from	E.	coli	(PDB	code	3L1L;	Gao	et	al.,	2010)	
has	 been	 the	 template	 most	 widely	 used	 for	 the	 creation	 of	 homology	 models	 of	 the	 slc7	
family	members	LAT1,	LAT2,	and	b0,+AT	(Chillarón	et	al.,	2010;	Rosell	et	al.,	2014;	Napolitano	et	
al.,	2015).	Additionally,	Reig	et	al.	(2007)	reported	a	prokaryotic	serine:threonine	antiporter	in	
B.	 subtilis	 (SteT)	 which	 has	 the	 highest	 identified	 primary	 sequence	 homology	 to	 the	
mammalian	 light	 chains	 (>30%).	 Despite	 the	 crystal	 structure	 of	 this	 protein	 remaining	
unknown,	 it	 has	 been	 used	 as	 a	 model	 of	 mammalian	 APC	 family	 transporters	 to	 identify	
critical	 binding	 residues	 involved	 in	 the	 transport	 of	 amino	 acids,	 namely	 in	 transmembrane	
domain	8.	The	importance	of	these	residues,	in	relation	to	the	System	b0,+	light	chain,	b0,+AT,	is	
discussed	in	Chapter	7.	
The	 structure	 of	 b0,+AT	 is	 predicted	 to	 consist	 of	 12	 transmembrane	 domains	
(Chairoungdua	 et	 al.,	 1999).	 The	 HHPRED	 algorithm	 predicts	 100%	 probability	 of	 structural	
homology	between	b0,+AT	and	 the	E.	 coli	 transport	protein	AdiC	 (PDB	 code	3L1L;	Gao	et	al.,	
2010).	 Using	 AdiC	 as	 a	 template	 structure,	 a	 homology	 model	 of	 b0,+AT	 predicts	 a	 “LeuT”	
structural	 arrangement	 of	 the	 transmembrane	 domains	 (Figure	 1.12).	 Transmembrane	
domains	1-5	and	6-8	form	the	5+5	inverse	repeat	fold	(Figures	1.11-1.12).	As	observed	in	other	
proteins	sharing	the	LeuT	fold,	transmembrane	domains	1,	3,	6,	and	8	of	b0,+AT	form	the	inner	
core	 of	 the	 protein,	 creating	 the	 substrate	 binding	 pocket	 (Figure	 1.12B),	 whilst	 the	 other	
domains	provide	 structural	 support	 (Figure	1.12A).	 The	unwound	 regions	of	 transmembrane	
domains	 1	 and	 6	 can	 be	 observed	 in	 the	 model	 (Figure	 1.12B),	 which	 are	 flanked	 by	 the	
conserved	residues	GSG	and	GWNQL,	respectively	(Figure	1.4).		
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Figure	 1.11:	 Schematic	 representation	 of	 b0,+AT	 transmembrane	 domains	 based	 upon	 the	
crystal	 structure	of	AdiC.	The	membrane	topology	of	 the	predicted	LeuT	5+5	 inverse	 repeat	
fold	 in	 the	 mammalian	 light	 chain,	 b0,+AT.	 Transmembrane	 domains	 1-5	 and	 6-10	 form	 an	
inverse	 structural	 repeat	 pattern,	 highlighted	 by	 two	 triangles.	 Transmembrane	 domains	 1	
(green)	 and	 6	 (orange)	 are	 interrupted	 by	 unwound	 regions	 of	 their	 alpha	 helices.	 Together	
with	transmembrane	domains	3	(blue)	and	8	(purple)	they	form	the	binding	pocket	for	leucine	
(red	 circle).	 Adapted	 from	 Yamashita	 et	 al.,	 (2005)	 and	 based	 upon	 the	 homology	 model	
displayed	in	Figure	1.12	(Gao	et	al.,	2010).	
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Figure	 1.12:	 Homology	 model	 of	 b0,+AT	 based	 upon	 the	 crystal	 structure	 of	 AdiC.	 A,	 The	
predicted	 structure	 of	 b0,+AT	 based	 upon	 the	 template	 protein	 arginine:agmatine	 antiporter	
(AdiC)	from	E.coli	(PDB	code	3L1L,	Gao	et	al.,	2010).	The	light	chain	of	System	b0,+	is	predicted	
to	 have	 12	 transmembrane	 domains;	 B,	 Transmembrane	 domains	 1	 (green),	 3	 (blue),	 6	
(yellow)	 and	8	 (purple)	 are	predicted	 to	 form	 the	 inner	 core	of	 the	 structure.	 The	unwound	
regions	of	transmembrane	domains	1	and	6	are	expected	to	be	the	site	of	substrate	binding.	
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1.13	The	Endoplasmic	Reticulum-Associated	Degradation	pathway	
The	 Endoplasmic	 Reticulum	 is	 a	 membrane-bound	 organelle	 found	 universally	 in	
eukaryotic	 cells.	 Comprised	 of	 a	 network	 of	 cisternae,	 it	 consists	 of	 two	 structurally	 distinct	
components	 based	 upon	 morphology:	 the	 rough	 (RER)	 and	 smooth	 (SER)	 endoplasmic	
reticulum.	When	a	ribosome	carrying	out	translation	of	the	mRNA	becomes	bound	to	the	RER,	
the	 nascent	 polypeptide	 chains	 of	 membrane	 proteins	 enter	 the	 lumen	 of	 the	 ER	 via	
translocation	 through	 the	heterotrimeric	Sec61	complex	 (Johnson	&	van	Waes,	1999).	There	
they	 are	 stabilised	 by	 the	 Binding	 immunoglobulin	 Protein	 (BiP),	 one	 member	 of	 the	 heat-
shock	protein	70	(Hsp70)	class	of	molecular	chaperones	(Figure	1.13A)	(Palade,	1975;	Johnson	
&	 van	 Waes,	 1999;	 Helenius	 &	 Aebi,	 2001).	 Molecular	 chaperones	 bind	 polypeptides	 and	
stabilise	 them	 in	 their	 unfolded	 state,	 to	 prevent	 aggregation	 of	 the	 molecule	 whilst	 the	
hydrophobic	 regions	 are	 exposed,	 facilitating	 native	 folding.	 (Flynn	 et	 al.,	 1991;	 Buck	 et	 al.,	
2010).	Following	correct	insertion	into	the	ER	membrane,	and	folding	of	the	polypeptide	chain,	
along	with	intermediate	N-linked	glycosylation,	subunit	oligomerisation,	and	the	formation	of	
disulphide	bonds,	 the	proteins	 are	 transferred	 in	 vesicles	 to	 the	Golgi	 apparatus	 (Johnson	&	
van	 Waes,	 1999).	 Here,	 more	 extensive	 post-translational	 modifications	 such	 as	 the	
maturation	and	“trimming”	of	N-glycans	are	carried	out.	Following	correct	cellular	processing	
by	the	Golgi,	the	transport	proteins	are	targeted	to	the	cell	membrane.		
An	estimated	20-30%	of	nascent	polypeptide	chains	are	mis-folded	in	the	lumen	of	the	
ER,	 a	 number	 that	 increases	 dramatically	 upon	 the	 introduction	 of	 mutations	 into	 the	
translated	protein	sequence	(Kopito	&	Ron,	2000;	Schubert	et	al.,	2000;	Romisch,	2005).	The	
ER	contains	many	early	“checkpoints”	to	ensure	that	proteins	that	have	not	folded	into	their	
native	conformation	are	rapidly	degraded	and	removed	from	the	ER	lumen.	These	checkpoints	
collectively	 form	the	ER-Associated	Degradation	pathway	 (ERAD),	which	mediates	 the	export	
of	mis-folded	proteins	from	the	ER	to	the	cytoplasm	for	targeting	by	the	proteasome	(Werner	
et	 al.,	 1996;	 Molinari,	 2007).	 To	 date,	 little	 is	 known	 regarding	 what	 allows	 the	 exact	
recognition	of	mis-folded	proteins	in	the	ER	lumen.	However,	it	has	been	postulated	that,	due	
to	 the	 diversity	 in	 the	 structures	 of	 proteins	 synthesised	 by	 the	 ER,	 this	would	 be	 a	 “global	
structural	 feature”,	such	as	the	exposure	of	 large	hydrophobic	regions	of	the	polypeptide,	as	
opposed	to	a	specific	amino	acid	motif	(Romisch,	2005).	
In	N-glycosylated	proteins,	such	as	rBAT,	the	structure	of	the	carbohydrate	chains	has	
been	shown	to	contribute	 to	 the	degradation	of	 the	protein	by	 the	ER	 following	mis-folding.	
Following	the	co-translational	addition	of	the	monoglucosylated	intermediate	N-linked	glycans	
to	the	newly	synthesised	proteins	(Figure	1.13B),	the	lectin	molecular	chaperones	calnexin	and	
calreticulin	 can	 bind	 (Figure	 1.13C)	 (Molinari	 &	 Helenius,	 2000).	 Whilst	 bound	 to	 the	
calnexin/calreticulin	 chaperones,	 proteins	 are	 stabilised	 in	 order	 to	 achieve	 native	 folding	
	 47	
through	transitioning	through	a	series	of	conformations	(Ruddock	&	Molinari,	2006).	In	native	
proteins,	 following	 the	 release	 of	 the	 protein	 from	 calnexin/calreticulin,	 glucosidase	 II	 trims	
the	innermost	glucose	from	the	glycan	residues	to	prevent	reassociation	of	the	lectins	(Figure	
1.13D)	 (Molinari	 &	 Helenius,	 2000;	 Helenius	 &	 Aebi,	 2001).	 These	 native	 proteins	 are	 then	
exported	 from	the	ER	to	 the	Golgi	 in	vesicles.	However,	proteins	 that	are	recognised	as	mis-
folded	are	 re-glucosylated	by	 the	enzyme	UGT1,	allowing	 the	 repeated	binding	of	molecular	
chaperones	in	the	calnexin/calreticulin	system,	and	a	second	attempt	at	native	folding	(Figure	
1.13E)	(Ellgaard	et	al.,	1999;	Ruddock	&	Molinari,	2006;	Molinari,	2007).	Mutated	proteins	that	
cannot	achieve	the	native	conformation	are	known	to	leave	the	calnexin/calreticulin	cycle	by	
one	of	two	methods.	The	first	of	these	is	to	become	“extensively	mis-folded”,	and	the	second	
is	 by	 exposing	 N-glycans	 that	 cannot	 be	 re-glucosylated	 by	 UGT1	 (Figure	 1.13F)	 (Molinari,	
2007).	 Mis-folded	 proteins	 are	 then	 re-translocated	 into	 the	 cytoplasm	 through	 the	 Sec61	
translocon	complex	by	a	diverse	system	of	lectins	and	molecular	chaperones,	for	proteasomal	
degradation	(Molinari,	2007).	
Although	the	mis-folding	of	proteins	in	the	ER	is	common,	those	that	have	mutations	
in	their	sequence	will	never	achieve	native	folding.	These	proteins	will	be	rapidly	degraded	by	
the	 ERAD	 pathway	 and	 are	 known	 as	 loss-of-function	 mutations	 that	 contribute	 to	 disease	
phenotypes.	 Perhaps	 the	 most	 well-known	 example	 of	 this	 phenomenon	 is	 the	 ΔF508	
mutation	 in	 the	Cystic	Fibrosis	Transmembrane	Conductance	Regulator	 (CFTR),	which	causes	
the	autosomal	recessive	disease	Cystic	Fibrosis	due	to	a	lack	of	trafficking	of	the	Cl-	channel	to	
the	 apical	 membrane	 of	 the	 airway	 and	 intestinal	 epithelium	 (Molinari,	 2007).	 It	 is	 also	
believed	 that	 this	 is	 the	cause	of	a	 lack	of	 trafficking	of	System	b0,+	 to	 the	membrane	of	 the	
renal	epithelium	in	Type	A	cystinuric	patients.	In	order	to	correct	the	loss	of	function	mutation	
in	CFTR	the	use	of	molecular	chaperones	has	been	suggested,	which	stabilise	the	mis-folded,	
yet	 functional	protein,	preventing	 the	activation	of	ERAD,	and	allowing	successful	exit	of	 the	
protein	from	the	ER	(Molinari,	2007).	This	is	discussed	in	detail	in	Chapter	5.	
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Figure	 1.13:	 Schematic	 representation	 of	 the	 ERAD	 pathway.	 A,	 The	 nascent	 polypeptide	
chain	enters	 the	 lumen	of	 the	ER	via	 the	Sec61	 translocon	complex;	B,	 It	 is	 stabilised	by	 the	
binding	 immunoglobulin	 protein	 (BiP,	 green)	 and,	 where	 appropriate,	 glycosylated	 by	
oligosaccharide	 transferase	 (OST,	 purple);	 C,	 Following	 the	 addition	 of	monoglucosylated	N-
glycans,	 the	polypeptide	 is	 stabilised	by	 the	calnexin/calreticulin	 chaperone	system	 (Cnx/Crt,	
grey);	D,	Proteins	that	achieve	native	folding	(orange)	are	de-glucosylated	by	glucosidase	II	and	
exported	 from	 the	 ER	 to	 the	 Golgi	 in	 vesicles;	 E,	mis-folded	 proteins	 are	 re-glucosylated	 by	
UGTI	 and	 reassociate	with	 the	 chaperone	 system	 to	 attempt	 native	 folding;	 F,	 proteins	 that	
achieve	 extreme	 mis-folding	 are	 escorted	 by	 BiP	 (green)	 and	 an	 assortment	 of	 molecular	
chaperones	into	the	cytoplasm	via	the	translocon	(Sec61).	Here	they	will	be	degraded	by	the	
proteasome.	Adapted	from	Meusser	et	al.	(2005).	
	 	
	 50	
1.14	The	biogenesis	of	rBAT	and	assembly	of	System	b0,+	
Several	groups	have	studied	the	biogenesis	and	post-translational	modifications	of	the	
subunits	 of	 System	 b0,+.	 Two	 glycosylated	 forms	 of	 rBAT	 are	 observed	 as	 bands	 of	 90	 and	
84kDa	 when	 electrophoretically	 resolved	 (Tate	 et	 al.,	 1992).	 The	 lower	 band	 is	
Endoglycosidase-H	 (Endo-H)	 sensitive,	 representative	 of	 immature,	 high-mannose	 N-
glycosylated	 protein	 produced	 in	 the	 ER.	 The	 upper	 band	 indicates	 the	 presence	 of	 core	
glycosylated	protein,	 produced	 following	 transfer	 to	 the	Golgi,	 and	 glycan	 trimming	 (Tate	 et	
al.,	1992;	Chillarón	et	al.,	1997;	Bartoccioni	et	al.,	2008;	Sakamoto	et	al.,	2009).	The	light	chain	
of	the	transport	system	is	non-glycosylated,	and	can	be	identified	by	western	blot	as	a	single	
band	of	around	40kDa	(Chairoungdua	et	al.,	1999;	Pfeiffer	et	al.,	1999a;	Bauch	&	Verrey,	2002;	
Bauch	et	al.,	2003).	A	specific	motif	in	the	C-terminal	of	b0,+AT,	namely	a	conserved	Val-Pro-Pro	
motif,	has	been	shown	to	be	essential	for	exit	of	the	heterodimer	from	the	ER	and	subsequent	
mature	glycosylation	state	of	rBAT	(Sakamoto	et	al.,	2009).		
Disulphide	 bonds	 within	 the	 rBAT	 extracellular	 domain	 are	 critical	 for	 the	 native	
folding	 of	 the	 protein	 (Rius	&	 Chillarón,	 2012).	 HeLa	 cells	 were	 transfected	with	 eight	 rBAT	
single	 cysteine	mutants.	 From	 these	 studies,	 three	 disulphide	 bridges	were	 identified	 in	 the	
structure,	which	were	essential	for	function.	These	were:	Cys242-Cys273	in	Domain	A,	Cys751-
Cys666	connecting	Domain	C	with	the	30	amino	acid	tail,	and	Cys673-Cys685	in	the	C-terminal	
tail	 (Rius	 &	 Chillarón,	 2012).	 The	 absence	 of	 any	 of	 these	 bridges	 resulted	 in	 a	 significant	
decrease	in	uptake	of	[3H]cystine	in	HeLa	cells	when	compared	to	wild-type	transport	(Rius	&	
Chillarón,	2012).	Results	also	confirmed	the	involvement	of	Cys114	in	forming	the	heterodimer	
with	b0,+AT	(Rius	&	Chillarón,	2012).	
Bauch	and	Verrey	(2002)	identified	through	the	stable	transfection	of	MDCK	cells	with	
both	 subunits	 of	 System	 b0,+	 that	 a	 band	 representing	 the	 heterodimer	 could	 be	 observed	
following	resolution	of	proteins	under	non-reducing	conditions,	confirming	association	of	the	
two	 subunits	 via	 disulphide	 linkage.	 Through	 co-precipitation	 of	 the	 two	 proteins	 it	 was	
identified	 that	b0,+AT	was	present	 in	 the	cells	 in	great	excess	over	 rBAT,	and	almost	all	 rBAT	
protein	was	 associated	with	 b0,+AT	 (Bauch	&	Verrey,	 2002).	 Through	 a	 series	 of	 pulse-chase	
experiments	in	transfected	MDCKII	and	HeLa	cells,	it	was	identified	that	rBAT	is	unstable	in	the	
absence	of	a	 light	chain	with	which	 it	can	associate,	and	completely	disappears	within	an	8h	
window	(Bauch	&	Verrey,	2002;	Bartoccioni	et	al.,	2008).	Conversely,	b0,+AT	was	not	degraded	
in	 the	 absence	 of	 rBAT,	 and	 remained	 stable	 throughout	 the	 chase	 (Bauch	&	 Verrey,	 2002;	
Bartoccioni	et	al.,	2008).	This	indicated	that	rBAT	is	co-translationally	associated	with	the	light	
chain,	and	 is	rapidly	degraded	 in	the	absence	of	b0,+AT,	by	the	ERAD	pathway	(Bartoccioni	et	
al.,	2008).	It	has	been	reported	that	b0,+AT	remains	functional	in	the	absence	of	rBAT	(Reig	et	
al.,	 2002).	 This	 was	 detected	 by	measurement	 of	 arginine	 and	 cystine	 uptake	 in	 liposomes	
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reconstituted	from	solubilised	HeLa	cells	that	had	been	transfected	with	the	System	b0,+	 light	
chain.	 This	 indicated	 that	 the	 heavy	 chain	 of	 the	 transport	 system	 is	 solely	 required	 for	
trafficking	of	the	light	chain	to	the	plasma	membrane,	contradicting	earlier	proposals	that	the	
heavy	chain	can	influence	the	substrate	specificity	of	the	transport	system	(Section	1.5)	(Reig	
et	al.,	2002).	
It	has	been	identified	that	System	b0,+	sits	in	the	apical	membrane	of	epithelial	cells	as	
a	heterotetramer,	formed	between	stable	interactions	between	two	heterodimers,	which	are	
not	 disrupted	 by	 the	 treatment	 of	 protein	 samples	 with	 5mM	 urea,	 and	 are	 only	 partially	
disrupted	with	 2%	 SDS	 (Fernandez	 et	 al.,	 2006).	 Pfeiffer	 et	 al.	 (1999a)	 reported	 System	 b0,+	
transport	in	HeLa	cells,	induced	by	the	expression	of	a	concatenated	cDNA.	This	cDNA	encoded	
an	rBAT-b0,+AT	fusion	protein,	linked	by	an	intracellular	sequence	of	amino	acids	between	the	
N-termini	 of	 the	 two	 proteins.	 This	 fusion	 protein,	 however,	 is	 structurally	 distinct	 to	 the	
native	heterodimer,	and	does	not	form	a	heterotetrameric	structure	when	expressed	 in	vitro	
(Fernandez	et	al.,	2006).	These	data	indicate	that	the	heterodimer	is	the	functional	unit	of	the	
transport	 system,	 despite	 a	 heterotetrameric	 structural	 assembly	 in	 vivo	 (Fernandez	 et	 al.,	
2006).	 To	 date,	 no	 evidence	 has	 been	 provided	 to	 support	 the	 theory	 that	 CD98-associated	
transport	systems	form	heterotetramers	(Fernandez	et	al.,	2006).	 In	fact,	rBAT	appears	to	be	
the	determining	factor	to	heterotetramer	formation,	as	when	co-expressed	with	the	System	Xc-	
light	chain	 in	HeLa	cells,	an	rBAT-xCT	heterotetramer	was	detected.	However,	when	xCT	was	
co-expressed	with	CD98,	only	the	heterodimeric	 form	could	be	detected	following	SDS-PAGE	
(Fernandez	et	al.,	2006).	
To	date,	the	structural	 interactions	between	the	two	subunits	of	System	b0,+,	beyond	
the	disulphide	bridge	 covalently	bonding	 the	 two	 subunits,	 remain	unknown.	However,	data	
has	 emerged	 regarding	 the	 interaction	 between	 CD98	 and	 its	 light	 chain	 LAT2	 and	 a	
prokaryotic	 light	chain,	SPRM1	(Pfeiffer	et	al.,	1998;	Rosell	et	al.,	2014).	Pfeiffer	et	al.	 (1998)	
demonstrated	 that	 in	 addition	 to	 the	 disulphide	 bond	 between	 heavy	 and	 light	 chains	 of	
heterodimeric	 amino	 acid	 transport	 systems,	 further	 steric	 interactions	 occur.	 CD98	was	 co-
expressed	with	SPRM1	(Schistosoma	mansoni	protein),	a	light	chain	permease	requiring	CD98	
for	plasma	membrane	localisation,	in	Xenopus	oocytes	(Pfeiffer	et	al.,	1998;	Skelly	et	al.,	1999).	
The	cysteine	residue	at	position	109	in	the	CD98	molecule	was	mutated	to	serine,	to	eliminate	
the	disulphide	bridge	between	CD98	and	the	light	chain.	This	resulted	in	the	observation	that	
C109S	in	human	CD98	still	resulted	in	the	presence	of	both	subunits	at	the	plasma	membrane,	
detected	by	immunofluorescent	microscopy	(Pfeiffer	et	al.,	1998).	However,	in	the	absence	of	
the	 disulphide	 bond,	 the	 amount	 of	 protein	 at	 the	 membrane	 was	 reduced,	 and	 SPRM1-
mediated	amino	acid	transport	was	reduced	to	30%	of	that	seen	in	the	presence	of	wild	type	
CD98	 (Pfeiffer	 et	 al.,	 1998).	 This	 indicates	 that	 the	disulphide	bond	 is	 required	 for	 optimum	
	 52	
trafficking	of	a	functional	transport	system	to	the	membrane.	However,	in	the	absence	of	the	
disulphide	bridge,	sufficient	steric	interactions	occur	to	allow	some	trafficking	of	the	transport	
system.		
Through	transmission	electron	microscopy	(TEM)	following	the	reconstitution	of	CD98-
LAT2	in	proteoliposomes,	Rosell	et	al.	(2014)	obtained	a	3D	map	of	the	heterodimer,	revealing	
the	 supramolecular	 architecture.	 This	 revealed	 that	 the	 large	 extracellular	 domain	 of	 CD98	
covered	 most	 of	 the	 extracellular	 face	 of	 the	 light	 chain,	 the	 site	 of	 the	 substrate	 binding	
pocket	 (Rosell	 et	 al.,	 2014).	 However,	 it	 was	 tilted	 at	 an	 angle	 forming	 a	 cleft,	 putatively	
allowing	access	of	the	substrate	to	the	binding	site,	without	the	need	for	it	to	pass	through	the	
heavy	 chain	 molecule	 (Rosell	 et	 al.,	 2014).	 From	 docking	 analyses	 of	 the	 known	 crystal	
structure	 of	 the	 CD98	 ectodomain	with	 a	 homology	model	 of	 LAT2	 from	 the	 known	 crystal	
structure	 of	 AdiC	 (PDB	 code	 3L1L;	 Gao	 et	 al.,	 2010),	 specific	 residues	 were	 identified	 that	
crosslink	the	two	proteins	(Rosell	et	al.,	2014).		These	residues	are	predicted	to	sit	far	from	the	
substrate	binding	pocket,	 and	 form	mainly	hydrophobic	 interactions	with	 the	 lower	external	
residues	of	CD98.	Additionally,	from	the	lowest-energy	docking	model	of	the	two	subunits,	 it	
appears	as	though	further	stabilisation	of	the	heterodimer	 is	achieved	through	interaction	of	
CD98	domain	C	with	the	extracellular	 loop	connecting	transmembrane	domains	11	and	12	 in	
LAT2	(Meury	et	al.,	2014;	Rosell	et	al.,	2014).	Although	it	is	known	that	structural	distinctions	
exist	 between	CD98	and	 the	only	other	member	of	 the	mammalian	 SLC3	 family	of	proteins,	
rBAT,	 these	 data	 provide	 the	 first	 insight	 into	 the	 structural	 interactions	 of	 heavy	 and	 light	
chains	in	heterodimeric	transport	systems.		
The	data	regarding	the	biogenesis	of	System	b0,+	and	the	function	of	the	two	subunits,	
logically	suggests	that	mutations	in	rBAT	lead	to	a	lack	of	trafficking	of	the	transport	system	to	
the	apical	membrane,	and	those	in	b0,+AT	confer	a	change	in	the	substrate	affinity.	Indeed,	this	
appears	 to	 be	 in	 accordance	 with	 functional	 studies	 of	 mutations	 in	 cystinuria	 patients	
(Chillarón	et	al.,	2010).	The	known	effects	of	System	b0,+	mutations	upon	the	transport	system	
are	discussed	in	detail	in	Chapter	5.		
1.15	Aims	and	objectives	
Since	 the	 implication	 of	 System	 b0,+	 in	 the	 underlying	 pathophysiology	 of	 cystinuria,	
many	mutations	have	been	identified	in	the	two	genes	encoding	the	protein	subunits,	SLC3A1	
and	SLC7A9.	The	first	stage	of	this	study	was	to	identify	the	causal	variants	in	these	two	genes	
in	a	cohort	of	UK	cystinuria	patients	(Chapter	3).	We	hoped	to	identify	novel	variants,	or	those	
that	had	not	been	investigated	previously	in	the	literature.		
The	second	aim	of	this	investigation	was	to	optimise	a	range	of	techniques	that	would	
allow	 the	 functional	 characterisation	 of	 rBAT	 expression	 in	 Xenopus	 oocytes,	 through	 the	
	 53	
association	with	 the	endogenous	 light	 chain,	homologous	 to	b0,+AT	 (Chapter	4).	Additionally,	
techniques	 that	 would	 allow	 the	 immunodetection	 of	 rBAT	 expression	 both	 in	 total	 oocyte	
membranes,	and	specifically	at	 the	plasma	membrane	needed	to	be	developed.	Through	the	
addition	 of	 a	 series	 of	 FLAG	 epitopes	 to	 the	 exogenous	 human	 protein,	 we	 were	 able	 to	
establish	a	range	of	techniques	to	allow	the	accurate	expression	and	localisation	of	rBAT	in	the	
oocytes	(Chapter	4).		
Type	 A	 cystinuria	 is	 caused	 by	 mutations	 in	 rBAT,	 which	 are	 believed	 lead	 to	 early	
degradation	 of	 the	 mis-folded	 proteins	 in	 the	 ER,	 and	 prevent	 successful	 trafficking	 of	 the	
transport	 system	 to	 the	apical	plasma	membrane	 (Dello	 Strologo	 et	al.,	 2002;	Bartoccioni	 et	
al.,	2008).	In	turn,	this	prevents	the	reabsorption	of	cystine	and	dibasic	amino	acids	from	the	
renal	 filtrate,	 leading	 to	 the	 formation	 of	 cystine	 calculi.	 To	 date,	 of	 91	 reported	 missense	
mutations	 in	 the	 SLC3A1	 gene,	 only	 6	 have	 been	 functionally	 characterised	 (Stenson	 et	 al.,	
2014).	The	results	of	the	reported	characterisation	experiments	from	other	research	groups	is	
discussed	in	detail	in	Chapter	5.	In	Chapter	5,	the	range	of	techniques	established	in	Chapter	4		
was	used	 to	measure	of	 rBAT	mutant	 function	 in	oocytes.	Additionally,	an	 in	 silico	approach	
was	 employed	 to	 predict	 the	 topological	 location	 of	 the	mutations	 in	 the	 rBAT	 extracellular	
domain	(Chapter	5).		
	 The	final	aim	of	this	study	was	to	investigate	how	modifications	to	rBAT	could	affect	its	
expression.	We	 investigated	how	the	therapies	currently	used	to	solubilise	cystine	can	affect	
the	expression	and	function	of	the	transport	system.	We	also	considered	how	modifications	to	
the	biogenesis	of	rBAT	affect	its	release	from	the	ER	and	targeting	to	the	apical	membrane	in	
Xenopus	oocytes	 and	 the	mammalian	epithelial	 cell	 line,	 Caco-2.	 This	 included	 temperature-
dependent	 inhibition	 of	 the	 ERAD	 pathways,	 use	 of	 the	 proteasomal	 inhibitor	MG-132,	 and	
inhibition	of	rBAT	N-glycosylation	both	globally,	and	at	individual	Asn	residues	in	the	protein.		
Through	furthering	our	understanding	of	 the	effect	 that	 rBAT	mutations	have	on	the	
cellular	 localisation	 of	 the	 transport	 system,	 we	 could	 potentially	 predict	 novel	 therapeutic	
targets	 for	 cystinuria.	 These	 data	 are	 valuable	 in	 the	 determination	 of	 whether	 the	 use	 of	
molecular	chaperones,	such	as	those	therapeutically	implicated	in	Cystic	Fibrosis,	would	be	of	
value	 in	 cystinuria.	 Additionally,	 through	 studies	 into	 the	 biogenesis	 of	 rBAT	 and	 how	
modifications	 to	 the	 native	 protein	 can	 affect	 its	 release	 from	 the	 ER,	 we	 can	 gain	 further	
insight	into	how	loss-of-function	mutations	in	cystinuria	affect	the	protein.		
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Chapter	2 :	Materials	and	Methods	
2.1	Materials	
All	chemicals	were	purchased	from	Sigma-Aldrich	(Poole,	UK)	unless	stated	otherwise.	
All	amino	acids	were	 in	 the	L-isoform.	Cell	culture	and	consumable	plastics	were	supplied	by	
Corning	(Amsterdam,	The	Netherlands)	or	VWR	(Lutterworth,	UK).		
	
2.2	Genetic	analysis	of	a	cohort	of	cystinuria	patients		
	 The	 aim	 of	 this	 study	 was	 to	 identify	 causal	mutations	 in	 a	 cohort	 of	 patients	 with	
cystinuria.	In	addition	to	this,	we	aimed	to	further	our	understanding	of	how	these	mutations	
lead	to	a	disease	phenotype.	For	the	purpose	of	these	investigations,	a	cohort	of	patients	with	
cystinuria	was	employed.	The	patients	were	screened	in	SLC3A1	and	SLC7A9,	both	of	the	genes	
known	 to	 be	 involved	 in	 cystinuria	 (see	 Chapter	 1).	 We	 hoped	 to	 identify	 novel,	
uncharacterised	 mutations	 in	 the	 two	 genes	 and	 investigate	 their	 effects	 on	 the	 proteins	
through	expression	in	the	Xenopus	laevis	oocyte	expression	system.		
2.2.1	Patient	DNA	sample	collection	
Patient	 genomic	 DNA	 (gDNA)	 samples	 were	 collected	 from	 44	 patients	 and	 17	
relatives.	 Samples	were	collected	 through	 the	Freeman	Hospital,	Newcastle	upon	Tyne,	with	
the	exception	of	 patients	 28	 and	29	who	were	 recruited	 remotely	 at	 the	Rare	Kidney	 Stone	
Consortium	 (RKSC)	 international	 patient	 meeting	 (London,	 December	 2012).	 The	 study	 was	
approved	by	the	National	Research	Ethics	Service	(NRES)	Committee	North	East	(11/NE/0259).	
Informed	consent	was	obtained	from	all	participants	or	their	legal	guardians	where	applicable	
by	 Dr.	 John	 Sayer.	 All	 patients	 were	 classified	 as	 cystinuric	 on	 the	 basis	 of	 at	 least	 one	
confirmed	 cystine	 stone	 through	 chemical	 analysis.	 Dr.	 John	 Sayer	 extracted	 patient	 gDNA	
samples	 from	 salival	 swabs	 or	 whole	 blood	 samples	 prior	 to,	 and	 throughout,	 this	
investigation.	Family	member	samples	were	 requested	 following	 the	 initial	genetic	 screening	
of	the	patients.	These	were	obtained	when	it	was	desirable	to	collect	further	genetic	data	to	
inform	 segregation	 analysis	 of	 mutations.	 Dr.	 John	 Sayer	 obtained	 the	 gDNA	 samples	 from	
relatives	of	patients	in	the	same	manner.		
2.2.2	Touchdown	PCR	to	amplify	patient	gDNA	samples	
The	 touchdown	 amplification	 of	 patient	 samples,	 and	 subsequent	 steps	 in	 the	
detection	 of	 mutations	 with	 CEL-I	 endonuclease,	 were	 completed	 by	 myself	 along	 with	 Dr.	
Noel	Edwards.	For	each	gDNA	sample,	amplification	of	the	DNA	by	polymerase	chain	reaction	
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(PCR)	was	employed	to	increase	the	quantity	of	patient	DNA	for	analysis.	Each	of	the	10	exons	
and	flanking	intronic	regions,	including	splice	sites,	of	SLC3A1	and	the	13	exons	of	SLC7A9	was	
amplified	by	PCR	using	 forward	and	reverse	primer	pairs	 (Table	2.1	and	2.2)	designed	by	Dr.	
John	Sayer,	Newcastle	University	(IDT,	Belgium).	This	provided	a	total	of	23	amplified	exons,	or	
“amplicons”,	for	each	patient.	A	schematic	representation	of	the	amplification	of	the	10	exons	
of	SLC3A1	 is	 depicted	 in	 Figure	2.1	 to	 aid	understanding	of	 this	 process.	 The	 same	principle	
was	applied	for	amplification	of	SLC7A9	gDNA.	The	composition	of	the	25μl	reaction	mixture	is	
listed	in	Table	2.4.	
Touchdown	PCR	(BIORAD	DNA	Engine	Dyad	Peltier	Thermal	cycler)	was	employed	for	
amplification	of	gDNA	 (Table	2.4).	 	Touchdown	PCR	 is	a	useful	 tool	 for	amplifying	sequences	
from	complex	genomes	as	it	increases	the	specificity	of	the	reaction	by	using	a	cycling	program	
with	varying	annealing	 temperatures	 (Don	 et	al.,	 1991).	 This	 leads	 to	a	more	 specific	duplex	
formation	between	the	primer	and	the	DNA,	and	ultimately	a	more	specific	PCR	product.	The	
annealing	 temperature	 in	 the	 initial	 reaction	must	be	5-10°C	above	the	melting	 temperature	
(Tm)	 of	 the	 primers.	 In	 the	 following	 step,	 the	 annealing	 temperature	 is	 decreased	 in	
increments	of	0.5-2°C	per	cycle	until	 it	 is	a	few	degrees	below	that	of	the	primer	Tm	(Don	et	
al.,	1991).	The	touchdown	PCR	cycling	parameters	used	in	this	study	are	listed	in	Table	2.4.		
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Primer	Code	 Exon	 Direction	 Sequence	 Product	Size	(bp)	
AL39	
1	
Forward	 AAGCATTCAGCAAGCCACTC	
562	
AL40	 Reverse	 AAAAGAACCATAAACCAATCTCATC	
AL41	
2	
Forward	 GGGTTTATTCATGACTTTGACT	
248	
AL42	 Reverse	 TCATCCCCATCTTGCCCACT	
AL43	
3	
Forward	 TTCTAATACAACTTTCCCTAGC	
262	
AL44	 Reverse	 GTTCAATCACTACATATCTGCC	
AL45	
4	
Forward	 CCTGCAAAGGATCAGGGAG	
311	
AL46	 Reverse	 TTGATTTTGCCTACACAATTACTG	
AL47	
5	
Forward	 GTTGTGATAATAACGTAGTTAATG	
227	
AL48	 Reverse	 CTGATGACATTTTCAGAAAAGGC	
AL49	
6	
Forward	 GAGGTTGTCTACATTCATATAGAG	
270	
AL50	 Reverse	 GGGATACACTGCAGATCACAC	
AL51	
7	
Forward	 CCCAGTCTTCTGACAGGCC	
303	
AL52	 Reverse	 CTGGACAGCAAAGGCAACAG		
AL53	
8	
Forward	 GCTACGTTGTGAACTTTCTGTG		
379	
AL54	 Reverse	 GCAAAGTAACCATGATTTTCAGC			
AL55	
9	
Forward	 ACCGAAAGTTGAGGCCTTTT	
533	
AL56	 Reverse	 AAGGCCTTAGTAAAGGTCATTGC	
AL57	
10a	
Forward	 CAAACAATTCTTAGAATCAAACAC	
364	
AL58	 Reverse	 TCCCTTGTCCAGAAAAATGCC	
AL59	
10b	
Forward	 CATCGACAGAATCTTTATCGTGG	
497	
AL60	 Reverse	 GCTCCTATAAGCCATAATTTAC	
	
Table	 2.1:	 Summary	 of	SLC3A1	 PCR	 amplification	 primers	 used	 in	 this	 study.	Primers	were	
designed	by	Dr.	John	Sayer,	Newcastle	University.	Predicted	product	size	is	measured	in	base	
pairs	(bp).	
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Primer	Code	 Exon	 Direction	 Sequence	 Product	Size	(bp)	
AL61	
1	
Forward	 CTGGACTTCCTTTGCTCCTG	
213	
AL62	 Reverse	 AACCATGCACTCCTGTACCC	
AL63	
2	
Forward	 ATGACTGACTTTGACTCTGGG	
400	
AL64	 Reverse	 TCTTCTGCCGTGTCACTAGGG	
AL65	
3	
Forward	 CGCCCTCTTCCTTCCTCC	
238	
AL66	 Reverse	 TAGCAGCTGCCTGGCGTG	
AL67	
4	
Forward	 AGCCTCCGGTGGGAGGAAG	
388	
AL68	 Reverse	 GAGTCCCCAGACACCCTCTG	
AL69	
5_6	
Forward	 AAAGGAGACTCTCTCCAGGG	
599	
AL70	 Reverse	 TGGAGTTAAAGTCACCTGGAG	
AL73	
7	
Forward	 AGTCAAGGTGTGTGACGCTTG	
141	
AL74	 Reverse	 AGGAGAAGAGAAATCAGGCTG	
AL75	
8	
Forward	 CTGAACGTGGGTCTCCGTG	
235	
AL76	 Reverse	 ACCTCCAGTGCTGACACCTG	
AL77	
9	
Forward	 GACCCTCAGGACTCATCTCG	
216	
AL78	 Reverse	 TAGCTGTGTGTCTTCCTCGGG	
AL79	
10	
Forward	 GGAGCACAAGTCCTCAGTGG	
210	
AL80	 Reverse	 GCCTTGAAGATAGGCTGGTAG	
AL81	
11	
Forward	 TTCGGTCTTCTGTGACATGAG	
252	
AL82	 Reverse	 AGCCACTCGTGACTCTGGG	
AL83	
12	
Forward	 ATGATTGAAATTGGAGGAGGG	
370	
AL84	 Reverse	 TGGAGTCAGGACAGGTGAGG	
AL85	
13	
Forward	 CCTCACCCACAACAACTCC	
178	
AL86	 Reverse	 AAATTCAGCTGACTTGGCTAC	
	
Table	 2.2:	 Summary	 of	SLC7A9	PCR	 amplification	 primers	 used	 in	 this	 study.	Primers	were	
designed	by	Dr.	John	Sayer,	Newcastle	University.	Predicted	product	size	is	measured	in	base	
pairs	(bp).		
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Reagent	 Volume	(μl)	
gDNA	 1	
Qiagen	mastermix	 12.5	
Forward	primer	(10μM)	 1	
Reverse	Primer	(10μM)	 1	
m.H2O	 9.5	
	
Table	2.3:	 Touchdown	PCR	 reaction	 composition	 for	amplification	of	patient	 genomic	DNA	
(gDNA).	
	
	
	
Step	 Temperature	(°C)	 Time	 Cycles	
Activation	 95	 10min	 1	
Initial	denaturation	 94	 30s	 	
13	
	
Initial	annealing	 65,		-0.7.cycle.-1	 30s	
Initial	extension	 65	 1min	
Second	denaturation	 94	 30s	
	
30	
Second	annealing	 56	 30s	
Second	extension	 65	 1min	
Final	extension	 72	 10min	 1	
	
Table	2.4:	Touchdown	PCR	parameters	used	to	amplify	patient	genomic	DNA	(gDNA).	
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2.2.3	Resolution	of	PCR	products	by	gel	electrophoresis	
To	confirm	the	success	of	the	reaction	and	the	size	of	the	amplified	product,	samples	
were	resolved	by	gel	electrophoresis	on	a	1%	agarose	Tris-acetate-EDTA	(TAE)	gel	(Figure	2.2).	
Gels	were	made	by	adding	1%	w/v	agarose	 to	1x	TAE-buffer	 (40mM	Tris,	20mM	acetic	acid,	
1mM	EDTA,	pH	7.6)	in	a	conical	flask.	The	mixture	was	heated	in	a	microwave	for	1min,	or	until	
all	agarose	had	dissolved.	When	the	mixture	had	cooled,	1μl.ml-1	of	Safeview	nucleic	acid	stain	
(NBS	 Biologicals,	 Cambridgeshire,	 UK)	was	 added.	 Safeview	 binds	 to	DNA	 or	 RNA	 and	 emits	
green	fluorescence	when	excited	between	290-320nm,	therefore	allowing	visualisation	of	DNA	
under	UV	light.	The	solution	was	then	poured	into	a	cast	including	a	comb	of	the	appropriate	
size	and	left	to	set	at	4°C	until	use.	A	5μl	sample	of	the	25µl	PCR	reaction	was	mixed	with	1μl	
6x	 loading	dye	 (NEB,	UK)	 in	a	0.2ml	microfuge	tube.	The	total	volume	(6μl)	was	 then	 loaded	
onto	 the	1%	agarose-TAE	gel.	Samples	were	resolved	 for	1h	at	100V	 (Figure	2.2)	alongside	a	
100bp	 DNA	 ladder	 (NEB,	 UK)	 to	 ensure	 the	 size	 of	 the	 product	 was	 as	 predicted	 from	 the	
primer	design	(Table	2.1	and	2.2).	
	
Exon%1% Exon%2% Exon%3% Exon%7% Exon%8%
1%%%2%%3%%%4%%5%%1%%2%%%3%%4%%%5%%1%%2%%%3%%4%%%5%%1%%2%%%3%%4%%%5%%1%%%2%%3%%%4%%5%
500%
300%
Bases%
L%
Figure	2.2:	Resolution	of	SLC7A9	patient	amplicons	by	gel	electrophoresis.		
Samples	were	resolved	on	a	1%	agarose-TAE	gel	for	1h	at	100V.	Lanes	1-5	represent	individual	patient	samples	23-27,	respectively;	L,	
100bp	DNA	ladder	with	the	500	and	300bp	markers	highlighted.	Exon	numbers	are	listed	at	the	top	of	the	figure.	Predicted	product	
sizes	(bp):	exon	1,	213;	exon	2,	400;	exon	3,	238;	exon	7,	141;	exon	8,	235.	
	 62 
2.2.4	Isolation	and	purification	of	plant	endonuclease	from	celery	
To	detect	mutations	in	SLC3A1	and	SLC7A9,	a	technique	was	employed	that	utilised	an	
endonuclease	 enzyme.	 This	 has	 been	 reported	 in	 the	 literature	 for	 detection	of	 single	 point	
mutations	and	small	insertions	or	deletions	(indels)	in	the	BRCA1	gene	and	will	be	explained	in	
detail	in	section	2.2.6	(Oleykowski	et	al.,	1998).		
The	 CEL-I	 endonuclease	 enzyme	 can	 be	 easily	 and	 cheaply	 extracted	 from	
homogenised	raw	celery.	This	protocol	was	taken	from	Oleykowski	et	al.	(1998).	The	following	
steps	were	carried	out	at	4°C.	Fresh	celery	(1kg)	was	rinsed	in	clean	water	and	dried	before	the	
leaves	were	 removed	 and	 the	 stalks	 trimmed.	 The	 celery	was	 homogenised	with	 an	 electric	
hand	blender	(Breville,	UK)	until	no	visible	 lumps	remained.	The	subsequent	mixture	(900ml)	
was	 adjusted	 to	 pH	 7.7	 using	 Buffer	 A	 (stock	 concentration	 0.1M	
tris(hydroxymethyl)aminomethane-hydrochloric	 acid	 (Tris-HCl)	 and	 100μM	
phenylmethanesulphonylfluoride	(PMSF)).	PMSF	is	a	protease	inhibitor,	and	was	used	here	to	
prevent	degradation	of	the	celery	enzyme.	The	adjusted	mixture	was	centrifuged	at	2,600g	for	
20min,	4°C	in	250ml	centrifuge	tubes	(Sorvall	Evolution	RC	Superspeed	centrifuge).		
The	 pellet	 was	 discarded	 and	 the	 supernatant	 containing	 soluble	 proteins	 was	
adjusted	 to	 25%	 (w/v)	 (NH4)2SO4	by	 direct	 addition	 of	 the	 salt	 in	 solid	 form,	 and	mixed	 for	
30min.	 (NH4)2SO4	was	used	 to	 induce	a	“salting	out”	effect.	This	 is	a	phenomenon	where,	at	
high	 salt	 concentrations,	 proteins	 will	 precipitate	 from	 the	 solution.	 (NH4)2SO4	 is	 commonly	
used	to	achieve	this	salting	out	effect	as	it	is	highly-soluble,	yet	does	not	interfere	with	enzyme	
activity.	 Thus,	 it	 can	 be	 used	 to	 quickly	 remove	 high	 levels	 of	 contaminant	 proteins.	 The	
concentration	of	(NH4)2SO4	required	to	cause	precipitation	of	the	contaminant	proteins,	whilst	
retaining	 the	 more	 hydrophilic	 enzyme	 in	 solution,	 had	 been	 established	 previously	
(Oleykowski		et	al.,	1998).	Following	this	adjustment,	the	solution	was	centrifuged	at	16,000g	
for	 40min,	 4°C.	 The	 pellet,	 containing	 the	 undesirable,	 precipitated	 proteins,	was	 discarded.	
The	 supernatant	 volume	 was	 recorded	 (450ml),	 and	 adjusted	 to	 80%	 (w/v)	 (NH4)2SO4,	 and	
mixed	 overnight	 (16h).	 This	 higher	 salt	 concentration	 was	 used	 to	 salt	 out	 the	 remaining	
proteins	in	the	solution,	including	the	CEL-I	endonuclease.	The	following	day	the	mixture	was	
pelleted	 by	 centrifugation	 at	 16,000g,	4°C	 for	 90min.	 The	 pellet	 containing	 the	 enzyme	was	
suspended	 in	 45ml	 buffer	 A	 (10%	 previous	 supernatant	 volume),	 poured	 into	 Snake	 Skin	
dialysis	tubing	(42mm	diameter;	Thermo	Scientific,	Basingstoke,	UK)	and	dialysed	in	4l	buffer	
A,	which	was	changed	8	times	at	2h	intervals	(a	total	of	32l	buffer	A	was	required	for	dialysis).	
Dialysis	was	used	to	reduce	the	salt	concentration	in	the	solution.	The	solution	was	removed	
from	the	dialysis	tubing	and	transferred	to	10ml	Falcon	tubes.	To	each	10ml	aliquot,	100μl	of	
buffer	B	was	added	(Triton	X-100	(10%	v/v),	1M	KCl,	1M	MgCl2,	100x	BSA	stock).	Buffer	B	was	
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designed	to	 increase	protein	solubility	and	retain	maximum	stability.	The	CEL-I	endonuclease	
solution	was	stored	at	-20°C	until	use.		
2.2.5	Validation	of	CEL-I	endonuclease	extract	
The	final	concentration	of	the	enzyme	was	not	measured,	but	to	validate	the	activity	
of	 the	 enzyme	 it	 was	 tested	 against	 a	 commercially	 available	 kit.	 The	 SURVEYOR	 mutation	
detection	kit	 (Transgenomic,	Nebraska,	USA)	 contains	 two	 samples	of	double-stranded	DNA,	
both	600bp	in	length	(Control	C	and	Control	G).	One	of	the	two	samples	has	a	single	C>G	base	
change	(Control	G).		
Two	 separate	 reactions	 were	 prepared,	 one	 for	 treatment	 with	 the	 SURVEYOR	 kit	
enzyme,	 the	 second	 for	 treatment	 with	 the	 celery	 extract.	 To	 prepare	 the	 reaction,	 5μl	 of	
Control	 C	was	mixed	with	5μl	 Control	G	 from	 the	 SURVEYOR	kit	 in	 two	 separate	PCR	 tubes.	
Using	 a	 thermal	 cycler	 (BIORAD	DNA	Engine	Dyad	Peltier	 Thermal	 cycler)	 the	mixtures	were	
heated	 to	 95°C	 for	 2min	 after	 which	 the	 temperature	 was	 reduced	 to	 85°C	 over	 5s.	 The	
temperature	was	then	further	reduced	to	25°C	at	a	rate	of	-0.1°C.s-1	over	10min.	This	heating	
and	cooling	process	caused	the	separation	of	the	double	stranded	Control	C	and	G	cDNA,	and	
subsequent	 formation	of	heteroduplexes,	 in	which	one	 strand	of	 control	C	DNA	 re-annealed	
with	 the	 opposite	 strand	of	 Control	G	DNA.	Where	 heteroduplexes	 had	been	 formed,	 there	
would	be	a	single	base	pair	mismatch	at	the	site	of	the	C>G	base	change.	
One	of	the	tubes	was	treated	with	the	SURVEYOR	nuclease	(0.5μl	SURVEYOR	enhancer	
S	 and	 0.5μl	 SURVEYOR	 endonuclease).	 The	 second	 tube	was	 treated	with	 6μl	 CEL-I	 solution	
extracted	from	raw	celery	(section	2.2.4).	Samples	were	mixed	by	pipetting	and	incubated	at	
42°C	for	20min.	The	kit	endonuclease	enzyme	and	the	CEL-I	enzyme	in	the	celery	extract	can	
recognise	nicks	in	DNA	caused	by	single	base	pair	mismatches	and	cleave	both	strands	of	the	
DNA	3’	of	the	nick	(Oleykowski	et	al.,	1998).	The	aim	of	the	 incubation	with	the	two	enzyme	
solutions	was	to	cleave	the	DNA	at	the	point	of	the	single	base	pair	mismatch.	The	kit	control	
DNA	samples	are	designed	so	that	when	a	heteroduplex	is	treated	with	a	nuclease	enzyme,	the	
600bp	DNA	is	cleaved	to	form	fragments	200bp	and	400bp	in	size.		
Following	 incubation	 with	 the	 enzyme,	 2μl	 6x	 loading	 dye	 (New	 England	 Biolabs,	
Hitchin,	UK)	plus	1μl	of	the	SURVEYOR	stop	solution	was	added	to	the	kit	digest.	To	the	celery-
extracted	digest	tube,	3μl	of	our	own	stop	solution	(30%	glycerol	containing	250mM	EDTA	and	
6x	loading	dye)	was	added.	Samples	were	resolved	by	electrophoresis	on	a	2%	agarose-TAE	gel	
(Figure	2.3).	From	the	results	of	the	electrophoresis	it	was	clear	that	both	the	kit	enzyme	and	
the	 celery	 extract	 produced	 bands	 of	 200	 and	 400bp	 in	 length,	 with	 the	 600bp	 band	
representing	homoduplexes	that	were	not	cleaved	due	to	the	absence	of	any	mismatch.	This	
validated	the	celery	extract	for	use	in	mutation	detection	of	the	current	cohort.	 	
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Figure	 2.3:	 Resolution	 of	 DNA	 samples	 enzymatically	 digested	 by	 two	 different	 enzyme	
solutions.	 Heteroduplex	 DNA	 formed	 from	 the	 SURVEYOR	 kit	 Control	 C	 and	 Control	 cDNA	
samples	 resolved	 on	 a	 2%	 (w/v)	 agarose-TAE	 gel	 following	 incubation	 with	 the	 SURVEYOR	
enzyme	 or	 the	 celery	 extract.	 	 Both	 enzymes	 digested	 the	 600bp	 control	 DNA,	 designed	 to	
form	fragments	400	and	200bp	in	length.	a,	1kb	DNA	ladder,	the	sizes	of	markers	are	listed	on	
the	 left-hand	 side;	 b,	 the	 SURVEYOR	 endonuclease-digested	 DNA;	 c,	 celery	 extract	 digested	
DNA;	*,	extra	bands	were	visualised	at	400	and	200bp.	
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2.2.6	CEL-I	treatment	of	patient	samples	 	
Following	 amplification	 of	 the	 exons	 of	 SLC3A1	 and	 SLC7A9	 as	 described	 in	 section	
2.2.2,	we	were	able	to	carry	out	the	mutation	detection	protocol	described	by	Oleykowski	et	
al.	(1998).	This	protocol	is	designed	to	detect	point	mutations,	or	small	indels	in	DNA	samples.	
Due	to	the	nature	of	the	non-quantitative	PCR	method	used	to	amplify	the	DNA	(section	2.2.2)	
it	was	not	possible	to	detect	heterozygous	whole	exon	deletions	or	duplications.	In	this	case,	
the	single	wild-type	allele	would	be	amplified.	This	protocol	was	employed	as	a	way	of	rapidly	
screening	patient	samples,	treated	as	pairs.	It	also	provided	scope	for	scaling	up	the	protocol	
to	high	throughput	analysis,	in	which	multiple	patient	samples	could	be	screened	together	for	
mutations	in	each	amplicon.	A	schematic	overview	of	this	mutation	detection	protocol	is	given	
in	Figure	2.4.	
To	amplify	the	exons	by	PCR,	we	performed	a	25μl	reaction,	described	in	section	2.2.2,	
and	 used	 5μl	 of	 this	mixture	 to	 confirm	 PCR	 success	 (Figure	 2.2).	We	 then	 used	 5μl	 of	 the	
remaining	 20μl	 PCR	 amplification	 product	 for	 heteroduplex	 formation.	 The	 5μl	 of	 amplicon	
sample	from	one	patient	was	mixed	with	5µl	of	the	equivalent	product	of	another	(patient	1	
and	2,	3	and	4,	etc…)	 (Figure	2.4	a).	Double	stranded	patient	DNA	was	separated	by	heating	
the	mixtures	to	95°C	for	2min,	followed	by	a	reduction	to	85°C	over	5s.	The	temperature	was	
then	further	reduced	to	25°C	at	a	rate	of	-0.1°C.s-1	over	10min	to	form	a	mixture	of	homo-	and	
heteroduplexes	 through	 cooling	 and	 re-annealing	 of	 the	 single	 stranded	 DNA	 (BIORAD	 DNA	
Engine	Dyad	Peltier	Thermal	cycler)	(Figure	2.4	b	and	c).	
The	 10μl	 mixtures	 were	 kept	 on	 ice	 as	 6µl	 celery	 extract	 was	 added,	 and	 then	
incubated	at	 42°C	 for	 20min	 (Figure	2.4	d).	 This	 incubation	allowed	 the	CEL-I	 enzyme	 in	 the	
celery	 extract	 to	 cleave	 the	heteroduplexes	 at	 the	point	 of	 any	 single	 base	pair	mismatches	
caused	by	mutations	in	the	DNA	of	either	patient.	To	terminate	the	reaction,	3μl	stop	solution	
(30%	glycerol,	250mM	EDTA,	6x	loading	dye)	was	added	to	each	sample.		
The	 samples	 were	 loaded	 onto	 a	 2%	 agarose-TAE	 gel	 and	 were	 resolved	 by	
electrophoresis	 (100mV,	 1.5h).	 The	 separated	 digestion	 products	 were	 visualised	 under	 UV	
light	 to	 determine	 the	 presence	 of	 fragment	 bands	 of	 a	 smaller	 molecular	 weight,	 formed	
through	cleavage	of	double-stranded	heteroduplexes.	An	example	of	fragment	band	detection	
is	shown	in	Figure	2.4	e.		 	
	 66 
	
	
	
a
b
c
d
e
PCR	
amplification	of	
genomic	DNA
Amplicons	
heated	to	high	
temperature	to	
separate	double	
stranded	DNA
Patient	1
Wild-type	DNA
Patient	2
Mutant	DNA
Mixing	of	single	
stranded	DNA	
and	subsequent	
cooling	lead	to	
homo- and	
heteroduplex	
formation
Incubation	with	CEL-
1	endonuclease,	
which	recognises	
single	base	pair	
mismatches	in	
heteroduplexes	and	
cleaves	both	DNA	
strands
DNA	Fragments
200bp
400bp
600bp
Samples	resolved	by	
gel	electrophoresis	and	
single	base	mutations	
are	identified	by	the	
presence	of	DNA	
fragments	bands,	
shorter	in	length	than	
the	original	PCR	
product
i ii								iii			iv		v
*
*
500
300
100
	 67 
	
Figure	2.4:	A	schematic	diagram	of	 the	key	steps	used	 to	 identify	mutations	 in	 the	SLC3A1	
and	SLC7A9	genes	using	CEL-I	endonuclease.	The	CEL-I	endonuclease	method	for	detection	of	
point	 mutations.	 a,	 The	 exons	 of	 patient	 DNA	 samples	 were	 amplified	 by	 PCR	 to	 provide	
amplicons.	The	cartoon	of	hypothetical	“Patient	1”	DNA	is	shown	with	the	wild-type	sequence	
(left),	and	“Patient	2”	is	shown	with	a	single	base	change	mutation,	highlighted	in	red	(right);	
b,	the	amplicons	were	heated	to	a	high	temperature	to	cause	separation	of	double	stranded	
DNA;	 c,	 as	 the	 samples	 were	 cooled,	 the	 single	 strands	 re-annealed,	 forming	 a	 mixture	 of	
homoduplexes	(both	DNA	strands	from	the	same	patient)	and	heteroduplexes	(one	strand	of	
DNA	from	patient	1	and	the	second	strand	from	patient	2).	When	heteroduplexes	were	formed	
in	 the	presence	of	small	mutations,	 there	was	a	mis-match	 in	base	pairing,	 forming	a	nick	 in	
the	DNA	strands;	d,	the	re-annealed	DNA	was	incubated	with	the	celery	extract	containing	the	
CEL-I	 endonuclease,	 which	 detects	 single	 base-pair	 mismatches	 and	 can	 cleave	 both	 DNA	
strands	3’	 of	 the	nick.	 This	 created	 small	 fragments	of	DNA.	 In	 this	 cartoon	example,	 600bp	
DNA	has	 been	 cleaved	 to	 form	 fragments	 400bp	 and	 200bp	 in	 length;	 e,	 The	 samples	were	
resolved	by	gel	electrophoresis	against	a	1kb	DNA	ladder	and	the	image	was	over-exposed	to	
reveal	fragment	bands.	i,	1kb	DNA	ladder;	ii,	600bp	kit	DNA	was	cleaved	to	form	smaller	bands	
200	and	400bp	in	length.	Lanes	iii-iv	represent	patient	pairs	23/24,	25/26,	27/28,	respectively.	
Small	fragment-related	bands	were	detected	in	patient	pairs	in	lanes	iv	and	v,	highlighted	by	*.	
An	 aliquot	 of	 the	 original	 PCR	 amplicon	 product	 for	 these	 4	 patients	 was	 sent	 to	 GATC	 for	
sequencing	to	identify	the	mutation	that	had	caused	the	presence	of	the	fragment	band.	
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2.2.7	Sequencing	and	analysis	of	patient	samples	
When	smaller	fragment	bands	were	visualised	following	electrophoretic	resolution	of	
CEL-I	digest	products,	Sanger	sequencing	was	employed	to	determine	the	causative	mutations.	
Each	 lane	 in	 which	 a	 fragment	 band	 was	 identified	 contained	 the	 DNA	 amplicons	 of	 two	
patients	 used	 to	 create	 the	 heteroduplex.	 The	 remaining	 15μl	 of	 the	 original	 PCR	 reaction	
mixture	 belonging	 to	 these	 two	 patients	 was	 purified	 using	 QIAquick	 PCR	 Purification	 Kit	
(Qiagen,	Manchester,	 UK)	 according	 to	 the	manufacturer’s	 protocol.	 	 To	 each	 15µl	 sample,	
75µl	Buffer	PB	was	added	(5	volumes).	This	allowed	efficient	binding	of	DNA	fragments	to	the	
spin	 column	 silica	 membrane	 and	 contained	 a	 pH	 indicator.	 This	 is	 to	 ensure	 that	 pH	 is	
optimum	for	DNA	binding	(<7.5).	The	sample	was	applied	to	the	spin	column	and	centrifuged	
at	 13,000rpm	 for	 60s.	 The	 sample	was	washed	with	 750µl	 Buffer	 PE	 and	 the	 centrifugation	
step	was	repeated.	Flow-through	from	the	column	was	discarded	and	the	DNA	bound	to	the	
silica	membrane	was	eluted	 into	a	clean	1.5ml	centrifuge	tube	by	addition	of	30µl	molecular	
grade	water	(m.H2O)	and	repetition	of	the	centrifugation	step.	The	purified	samples	were	then	
sent	to	GATC	(Cologne,	Germany)	for	Sanger	sequencing	with	the	appropriate	forward	primer	
(Table	2.1	and	2.2).		
Sequencing	 files	 were	 returned	 from	 GATC	 in	 ab1	 format	 containing	 the	 DNA	 base	
sequence.	 These	 files	 were	 loaded	 in	 Mutation	 Surveyor	 software	 (Softgenetics,	 USA).	 This	
software	 reads	 ab1	 files	 and	 matches	 them	 to	 reference	 sequences	 from	 GenBank	
(http://www.ncbi.nlm.nih.gov/genbank/),	 identifying	variants	from	the	wild-type	sequence.	 It	
is	 able	 to	 identify	 bases	 changes	 including	 known	and	novel	mutations,	 along	with	 common	
single	nucleotide	polymorphisms	(SNPs)	and	provide	the	reference	sequence	(rs)	code.		
Patients	 in	whom	no	causative	mutations	were	 found	 in	SLC3A1	or	SLC7A9	using	the	
CEL-I	detection	protocol	had	all	PCR	amplicons	of	both	genes	sent	for	full	Sanger	sequencing	
(GATC,	 Cologne,	 Germany).	 End-point	 touchdown	 PCR	 used	 for	 exon	 amplification	 is	 a	 non-
quantitative	 technique.	 Whilst	 treatment	 of	 DNA	 samples	 amplified	 in	 this	 manner	 can	 be	
screened	 for	mutations	using	CEL-I	 digest	or	by	 complete	 Sanger	 sequencing,	 end-point	PCR	
will	not	enable	detection	of	heterozygous	whole	exon	deletions	or	duplications.	This	is	because	
the	wild-type	allele	will	be	amplified,	and	sequencing	results	will	appear	normal.	 In	order	for	
mutations	of	this	nature	to	be	detected,	quantitative	techniques	that	inform	of	the	allelic	copy	
number	were	required.	This	is	discussed	in	detail	in	Chapter	3.		
2.2.8	Multiplex	ligation-dependent	probe	amplification	
Genomic	DNA	samples	from	Patients	2-5,	11,	14,	15,	18,	19,	21	and	22	were	samples	
were	 sent	 to	 Southmead	 Hospital,	 Bristol	 for	 Multiplex	 Ligation-dependent	 Probe	
Amplification	(MLPA).	These	samples	were	included	in	a	collaborative	study	with	the	research	
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group	of	Dr.	Richard	Coward,	Bristol	University	 (Rhodes	 et	al.,	 2015).	 First	 reported	 in	2002,	
MLPA	 provides	 a	 simple,	 multiplex	 PCR	 technique	 to	 quantify	 deletions	 or	 duplications	 of	
whole	 genes	 or	 exons,	 such	 as	 those	 commonly	 seen	 in	 Down’s	 syndrome	 and	 Duchenne	
muscular	dystrophy	(Schouten	et	al.,	2002).	MLPA	has	replaced	older	quantitative	techniques,	
including	 fluorescence	 in-situ	 hybridisation	 (FISH)	 and	 Southern	 blotting,	 which	 are	 time-
consuming	and	unable	to	detect	copy	number	changes	of	single	exons	(Schouten	et	al.,	2002).		
	 MLPA	relies	on	a	pair	of	half-probes	that	contains	three	distinct	regions	(Figure	2.5	a).	
Firstly,	they	contain	a	hybridisation	sequence,	complementary	to	the	region	of	interest	in	the	
DNA.	 Secondly,	 they	 contain	universal	PCR	primer	 sequences	 for	amplification	of	 the	 ligated	
probe.	 Finally,	 there	 is	 a	 “stuffer	 sequence”,	 unique	 in	 length	 to	 each	 pair	 of	 half-probes	
(Figure	2.5	b).		
When	the	adjacent	hybridisation	sequences	of	the	two	half-probes	anneal	to	the	DNA	
they	 are	 ligated	 to	 form	 a	 single	 probe	 (Figure	 2.5	 c).	 Following	 ligation,	 the	 probes	 are	
amplified	by	PCR	using	the	universal	primers.	The	unique	stuffer	sequence	allows	each	probe	
to	 create	 a	 PCR	 product	 of	 a	 distinct	 length	 (Figure	 2.5	 d).	 The	 products	 are	 separated	 by	
capillary	electrophoresis	and	the	peak	intensities	can	be	analysed	and	normalised	to	a	control	
probe.	 This	 can	 interpreted	 to	 provide	 the	 relative	 copy	 number	 of	 each	 exon	 in	 the	 gene	
(Schouten	et	al.,	2002).		
	 Samples	were	prepared	and	sent	to	the	NHS	UK	Genetic	Testing	Network	(UKGTN)	at	
Southmead	Hospital	 in	Bristol	by	Dr.	 John	Sayer,	Newcastle	University	 (Rhodes	 et	al.,	 2015).	
Probe	sequences	for	SLC3A1	and	SLC7A9	were	taken	from	Bisceglia	et	al.	(2010)	and	are	listed	
in	Table	2.5	and	2.6.	The	universal	PCR	primer	sequences	used	for	probe	amplification	were	as	
follows:	 5’-GGGTTCCCTAAGGGTTGGA-3’	 and	 5’-TCTAGATTGGATCTTGCTGGCAC-3’	 on	 the	 5’	
and	3’	ends,	respectively	(Schouten	et	al.,	2002).	
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Figure	2.5:	A	schematic	diagram	of	the	basic	principles	of	multiplex	ligation-dependent	probe	
amplification.	a,	Each	pair	of	half-probes	contains	3	distinct	features:	a	hybridisation	sequence	
to	anneal	to	target	DNA;	a	PCR	primer	sequence	for	amplification	of	the	ligated	probe;	and	a	
stuffer	sequence	unique	in	length	to	each	probe.	b,	half-probes	anneal	to	the	complementary	
DNA	 sequence;	 c,	 ligation	 of	 the	 two	 half-probes;	 d,	 ligated	 probes	 are	 amplified	 using	
universal	PCR	primers.	The	products	are	separated	by	size	and	quantified	to	determine	exon	
copy	number.	
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Probe	code	 Exon	 Direction	 Target-specific	hybridisation	sequence	 Product	Size	
ex1_SLC3A1		 1	
Forward	 TACCGCATACCTCGGGAGATCC		
86	
Reverse	 TCTTCTGGCTCACAGTGGCTTCTG		
ex2_SLC3A1		 2	
Forward	 GTCCCTTAAAGATTTCAGATATGGTGTTGAAGATT		
112	
Reverse	 TCCGGGAAGTTGATCCCATTTTTGGAACGATGGAA		
ex3_SLC3A1		 3	
Forward	 CGGACACGGACAGGAAAATATACTGATTATTATATCTGGCATG		
128	
Reverse	 ACTGTACCCATGAAAATGGCAAAACCATTCCACCCAACAACTG		
ex4_SLC3A1		 4	
Forward	 GACGAAGTGCGAAACCAATGTTATTTTCATCAGTTTA		
116	
Reverse	 TGAAAGAGCAACCTGATTTAAATTTCCGCAATCCTGA		
ex5_SLC3A1		 5	
Forward	 GCTCACAAAGGGTGTTGATGGTTTTAGTTTGGA		
108	
Reverse	 TGCTGTTAAATTCCTCCTAGAAGCAAAGCACCT		
ex6_SLC3A1		 6	
Forward	 TGGGAATGCACGACATTGTCCGCAGCTT		
100	
Reverse	 CCGGCAGACCATGGACCAATACAGCACGGA		
ex7_SLC3A1		 7	
Forward	 CCTATGCAGAGAGTATTGACAGGACCGTGATGTACTATGGA		
124	
Reverse	 TTGCCATTTATCCAAGAAGCTGATTTTCCCTTCAACAATTA		
ex8_SLC3A1		 8	
Forward	 TTGGTGGACCAGACAGTTCACGGCTGA		
96	
Reverse	 CTTCGCGTTTGGGGAATCAGTATGTCA		
ex9_SLC3A1		 9	
Forward	 TCACCAATGCAGTGGGACAATAGTTCAAATG		
104	
Reverse	 CTGGTTTTTCTGAAGCTAGTAACACCTGGTT		
ex10_SLC3A1		 10	
Forward	 CTATGTTGTGTACACAAGAGAGCTGGATGGCATCGACAGAATCTT		
132	
Forward	 TATCGTGGTTCTGAATTTTGGAGAATCAACACTGTTAAATCTACA		
Table	2.5:	A	summary	of	the	probe	hybridisation	sequences	used	for	MLPA	in	the	SLC3A1	gene.	
	
Primer	Code	 Exon	 Direction	 Sequence	 Product	Size	
ex1_SLC7A9	 1	
Forward	 GACTCTTATTTCAGAGCCGATTACCATGCACCTTCAGAT		
120	
Reverse	 GCTAATGGAAGTGGTCCCACCGGAGGAAGACCCTGAGTA		
ex2_SLC7A9	 2	
Forward	 GATACTGGCCTGAGAAAGCGGAGAGAGGATGAGAAGTCG		
100	
Reverse	 ATCCAGAGCCAAGAGCCTAAGACCACCAGTCTCCAAAAG		
ex3_SLC7A9	 3	
Forward	 TTCCTCCACACCCAGCTGGGCCTCATCAG		
88	
Reverse	 TGGCATCTCCATCATCGTGGGCACCATCA		
ex4_SLC7A9	 4	
Forward	 TGATCGTCATTAAGCCCACGTCCT		
112	
Reverse	 TCGCCATCATCTGCCTCAGCTT		
ex5_SLC7A9	 5	
Forward	 GAAGCTACGTCCAGAACATCTTCACCGCGGCCAAG		
104	
Reverse	 CTGGTGATCGTGGCCATCATCATCATCAGCGGGCT		
ex6_SLC7A9	 6	
Forward	 TGTCTGGCTTCATTACAGGAAACACAAAGAA		
116	
Reverse	 TTTTGATAATTCTTTCGAGGGCGCCCAGCTG		
ex7_SLC7A9	 7	
Forward	 GAATCAACTCAATTACATCACAGAAGAACTTAGAAACCC		
132	
Reverse	 TTACAGGTAACAGCTGAATCAGTGCAGAGGACAGT		
ex8_SLC7A9	 8	
Forward	 CTGCCTTTGGCCATTATCATCGGGATCCCCCTGGTGACGGCGTGC		
128	
Reverse	 TACATCCTCATGAACGTGTCCTACTTCACCGTGATGACTGCCACC		
ex9_SLC7A9	 9	
Forward	 CATTTGGTGACCGTGTTCTCTATCCTGCTTCTTGGATCGTTCC		
124	
Reverse	 ACTTTTTGTGGCATTTTCAACCATCGGTGCTGCTAACGGGACC		
ex10_SLC7A9	 10	
Forward	 CAGACTCATTTACGTGGCGGGCCGGGAGGGTCACATGCTCA		
108	
Forward	 AAGTGCTTTCTTACATCAGCGTCAGGCGCCTCACTCCAGCC		
ex11_SLC7A9	 11	
Forward	 GCATGGCTGTTTTATGGCCTGACGATTCTAGGA		
136	
Reverse	 CTCATCGTGATGAGATTTACAAGGAAAGAGCTG		
ex12_SLC7A9	 12	
Forward	 CCGTAGTCATTCCCGTCTTGATGACACTCATCTCTGTGTTTTTGGTT		
96	
Reverse	 CTGGCTCCAATCATCAGCAAGCCCACCTGGGAGTACCTCTACTGTGT		
ex13_SLC7A9	 13	
Forward	 TTCAGAGCCGATTACCATGCACCTTCAGA		
132	
Forward	 TGCTAATGGAAGTGGTCCCACCGGA		
Table	2.6:	A	summary	of	the	probe	hybridisation	sequences	used	for	MLPA	in	the	SLC7A9	gene.	
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This	combination	approach	of	non-quantitative	end-point	PCR	and	quantitative	MLPA	
techniques	 to	 screen	 for	 mutations	 in	 the	 cohort	 allowed	 the	 identification	 of	 causative	
cystinuria	mutations	in	the	majority	of	the	patients	(see	Chapter	3).	The	employment	of	these	
techniques	 in	 this	 study	 is	 critically	 considered	 in	 section	3.4.	Despite	 the	 inability	 to	detect	
causative	mutations	 in	 the	DNA	sequence	of	all	patients	 in	 the	 two	genes	 considered,	many	
mutations	of	interest	were	identified.	Following	the	identification	of	mutations	in	SLC3A1	and	
SLC7A9,	 the	use	of	 the	Xenopus	 laevis	oocyte	expression	 system	was	utilised	 to	characterise	
the	proteins	encoded	by	these	two	genes:	rBAT,	and	b0,+AT,	respectively.	From	this	we	could	
determine	 the	 function	 and	 expression	 of	 the	 mutant	 proteins	 underlying	 the	 disease	
phenotype	of	our	patients.	
2.3	Production	of	template	cDNA	
	 The	second	aim	of	this	project	was	to	characterise	functionally	the	proteins	of	System	
b0,+	 and	 the	 effect	 of	 the	 mutations	 identified	 in	 our	 cohort.	 To	 achieve	 this,	 membrane	
transport	proteins	were	expressed	 in	Xenopus	 laevis	oocytes	 and	Caco-2	 intestinal	 epithelial	
cells.	Xenopus	laevis	oocytes	are	a	useful	tool	for	studying	the	function	of	rBAT,	the	protein	in	
which	 all	 novel	mutations	were	 identified	 in	 this	 study.	 This	 is	 because	 the	oocytes	have	an	
endogenous	light	chain,	homologous	to	human	b0,+AT	(Bertran	et	al.,	1992).		
Bacterial	 plasmid	 vectors	 containing	 the	 open	 reading	 frame	 (ORF)	 of	 the	 gene	 of	
interest	are	able	to	self-replicate	under	the	correct	culture	conditions	and	were	used	to	yield	
high	 quantities	 of	 the	 cDNA	 required	 for	 both	 cRNA	 production	 and	 transfection	 into	 the	
human	cell	line.	The	bacterial	plasmids	and	inserts	used	in	this	study	are	listed	in	Table	2.7.		
2.3.1	Bacterial	culture	and	isolation	of	plasmid	DNA	
	 E.	coli	cells	containing	bacterial	plasmid	cDNA	were	grown	on	Luria-Bertani	 (LB)	agar	
plates	(Table	2.8)	containing	the	appropriate	antibiotic	(Table	2.7)	(37°C,	16h).	Single	colonies	
were	picked	under	sterile	conditions	and	used	to	inoculate	5ml	LB	broth	(Table	2.9)	containing	
the	 appropriate	 antibiotic	 for	 selective	 growth	 (Table	 2.7).	 The	 inoculated	 broths	 were	
cultured	overnight	(37°C,	200rpm).		
	 Plasmid	cDNA	was	isolated	from	bacterial	cultures	using	QIAprep	Miniprep	kit	(Qiagen)	
according	 to	 the	manufacturer’s	 protocol.	 Bacterial	 cultures	were	 pelleted	 by	 centrifugation	
(10,000rpm,	 3min,	 at	 room	 temperature).	 The	 pellets	were	 re-suspended	 and	bacterial	 cells	
lysed	 to	 isolate	 plasmid	 DNA.	 	 Sodium	 acetate	 was	 added	 to	 precipitate	 proteins	 and	
chromosomal	 DNA.	 The	 solution	 was	 then	 centrifuged	 (13,000rpm,	 10min,	 at	 room	
temperature)	 to	pellet	 the	precipitate.	The	supernatant	containing	plasmid	DNA	was	 filtered	
and	through	a	column	containing	a	silica-gel	membrane.	The	membrane	binds	DNA	under	high	
salt	 conditions.	 The	 salt	was	 removed	by	 a	wash	 step.	 The	plasmid	DNA	was	 then	 eluted	 in	
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30μl	 room	 temperature	 molecular	 grade	 water	 (m.H2O)	 under	 low	 salt	 conditions	 (VWR,	
Lutterworth).	The	eluted	cDNA	was	quantified	using	NanoDrop	2000	(Thermo	Scientific).	cDNA	
purity	 was	 estimated	 by	 calculating	 the	 A260/A280	 ratio.	 Samples	 contaminated	 by	 protein,	
phenol	RNA	or	agarose,	which	absorb	light	at	260nm,	will	have	an	A260	reading	lower	than	1,	
affecting	the	ratio.	Samples	were	considered	pure	when	a	260/280	absorbance	ratio	of	1.7-1.9	
was	recorded.	The	cDNA	was	stored	at	-20°C	until	use.	
	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	2.7:	A	summary	of	the	bacterial	plasmid	vectors	used	in	this	study.	The	colours	correspond	to	those	used	in	Figure	2.6	
Protein	 cDNA	 Clone	 Plasmid	
Forward	
promoter	
Antibiotic	
resistance	
Restriction	
enzyme	
Source	
Expression	
system	
rBAT	 SLC3A1	 Human	 pSPORT1	 T7	 Ampicillin	 Hind-III	 A.	Werner	(gift)	
Xenopus	
oocyte	
NaPi-IIa	 SLC34A1	 Flounder	 pSPORT1	 T7	 Ampicillin	 Hind-III	 A.	Werner	(gift)	
Xenopus	
oocyte	
b0,+AT	 SLC7A9	 Human	 pDNR-LIB	 T7	 Ampicillin	 NotI	
IMAGE	(Source	
Bioscience,	UK)	
Xenopus	
oocyte	
b0,+AT	 SLC7A9	 Mouse	 pDNR-LIB	 T7	 Ampicillin	 NotI	
IMAGE	(Source	
Bioscience,	UK)	
Xenopus	
oocyte	
IKEPP	 SLC9A3R1	 Human	 pCMV-SPORT6	 CMV	 Ampicillin	 Hind-III	
IMAGE	(Source	
Bioscience,	UK)	
n/a	
rBAT	 SLC3A1	 Human	 pCMV-SPORT6	 CMV	 Ampicillin	 n/a	
Created	by	S.	Rice	
from	IKEPP	and	
rBAT	clones	
Caco-2	
Empty	 n/a	 n/a	 pEGFP-C3	 CMV	 Kanamycin	 n/a	 S.	Madgwick	(gift)	 Caco-2	
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Figure	2.6:	A	schematic	 representation	of	 the	bacterial	plasmid	vectors	and	 inserts	used	 in	
this	study.	Plasmid	vectors	and	inserts	are	depicted	with	promoter	regions	and	restriction	sites	
used	for	vector	linearisation	highlighted.		
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Luria-Bertani	(LB)	agar	plates	
	 Concentration	 Mass	in	1l	
NaCl	
Yeast	Extract	
Tryptone	
Agar	
d.H2O	(to	a	final	volume)	
1%	
0.5%	
1%	
2%	
-	
10g	
5g	
10g	
20g	
1l	
• Adjust	to	pH	7.5	with	NaOH	
• Autoclave	and	cool	
• Add	antibiotic	to	the	solution	(ampicillin	100μg.ml-1;	kanamycin	50μg.ml-1)	
• Pour	25ml	into	100mm	diameter	petri	dishes	
	
Table	2.8:	Composition	of	Luria-Bertani	(LB)	agar	plates	for	growth	of	bacterial	colonies.		
	
	
	
	
	
Luria-Bertani	(LB)	broth	
	 Concentration	 Mass	in	1l	
NaCl	
Yeast	Extract	
Tryptone	
d.H2O	(to	a	final	volume)	
1%	
0.5%	
1%	
-	
10g	
5g	
10g	
1l	
• Adjust	to	pH	7.5	with	NaOH	
• Autoclave	and	cool	
• Add	the	required	antibiotic	(Table	2.X)	to	a	small	volume	prior	to	use																					
(ampicillin	100μg.ml-1;	kanamycin	50μg.ml-1)	
	
	
Table	2.9:	Composition	of	Luria-Bertani	(LB)	medium	for	growth	of	bacterial	cultures.	
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2.4	Site-directed	mutagenesis	of	SLC3A1	cDNA	
Site	 directed	mutagenesis	 was	 carried	 out	 on	 human	 rBAT	 cDNA	 for	 two	 purposes.	
Firstly,	it	was	used	for	the	addition	of	FLAG	(DYKDDDDK)	motifs	to	the	rBAT	cDNA	sequence	to	
aid	immunodetection	of	rBAT	protein.	Secondly,	mutagenesis	was	used	to	introduce	the	same	
point	mutants	 into	 the	 rBAT	 cDNA	 sequence	 that	 had	been	 identified	 in	 the	patient	 cohort.	
This	 provided	 us	 with	 the	 tools	 to	 characterise	 the	 mutant	 protein	 following	 expression	 in	
oocytes.		
2.4.1	Addition	of	FLAG	epitopes	to	rBAT	
	 To	enable	immunodetection	of	rBAT	protein	following	expression	in	Xenopus	oocytes	
and	Caco-2	 cells,	 a	 series	of	 site-directed	mutagenesis	 reactions	were	performed	 to	add	 the	
FLAG	 (DYKDDDDK)	 epitope	 to	 the	 N-	 and	 C-	 termini	 of	 the	 protein.	 The	 different	 FLAG	
constructs	manufactured	and	used	as	part	of	this	study	are	shown	in	Figure	2.7.	
Mutagenesis	primers	were	designed	using	 the	online	QuikChange	primer	design	 tool	
(https://genomics.aglinet.com/)	 and	 purchased	 from	 Integrated	 DNA	 Technologies	 (IDT,	
Leuven,	Belgium).	The	mutagenesis	primers	used	in	this	study	are	listed	in	Tables	2.10	and	2.11	
and	 were	 based	 on	 the	 recommendations	 of	 Qi	 and	 Scholthof	 (2008).	 	 Mutagenesis	 was	
undertaken	 via	 inverse	 overlapping	 PCR	 with	 the	 QuikChange	 Lightning	 site-directed	
mutagenesis	kit	(Agilent	Technologies,	Stockport,	UK).	The	reaction	mixture	was	composed	as	
listed	in	Table	2.12.	PCR	was	carried	out	using	a	Thermal	Cycler	(Thermo	Electro,	Basingstoke,	
UK)	and	the	parameters	are	listed	in	Table	2.13.	 	Both	constructs	with	a	single	FLAG	epitope,	
the	N-terminally-tagged	“FLAG-rBAT”	and	C-terminally-tagged	“rBAT-FLAG”	(Figure	2.8),	were	
designed	 and	made	 by	 Dr.	 Noel	 Edwards.	 However,	 the	 primers	 synthesised	 to	 add	 a	 FLAG	
epitope	to	the	N-terminal	of	rBAT	were	incorrectly	designed	and	resulted	in	the	tag	sequence	
DYKDDDK,	 with	 a	 missing	 aspartate	 residue.	 To	 correct	 this,	 a	 further	 set	 of	 mutagenesis	
correctors	were	designed	to	add	in	the	missing	residue	(Table	2.10).		
The	 insertion	of	sequences	of	more	than	6	nucleotides	 in	 length	 is	classed	as	a	 large	
insertion	and	 in	 this	case	 the	 inverse	PCR	primers	are	designed	to	anneal	back	 to	back,	with	
each	primer	containing	half	of	the	desired	insertion	sequence	at	the	5’	end	(Figure	2.8	A	and	
B).	 	 The	 limitations	 on	 the	 length	 of	 oligonucleotide	 synthesis	 restricted	 the	 size	 of	 the	
insertion.	The	Quikchange	protocol	does	not	recommend	the	use	of	oligonucleotides	greater	
than	45	bases	in	length	due	to	an	increase	in	secondary	structure	formation,	and	decrease	in	
mutagenesis	efficiency.	Despite	this,	successful	mutagenesis	was	achieved	using	primers	of	up	
to	66	nucleotides	in	length	(Table	2.10).	To	create	rBAT-2xFLAG	and	rBAT-3xFLAG,	the	second	
(DYKDHDG)	 and	 third	 (DYKDHDI)	 FLAG	 epitopes	 were	 added	 in	 a	 step-wise	 manner	 via	
separate	reactions	to	the	C-terminally	tagged	rBAT-FLAG	(DYKDDDDK)	(Figure	2.8).		
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2.4.2	Primer	design	for	single	codon	mutagenesis	
	 Forward	 and	 reverse	 mutagenic	 primer	 pairs	 (Table	 2.11)	 were	 designed	 using	 the	
online	 Quikchange	 primer	 design	 tool	 (https://www.genomics.agilent.com).	 This	 technique	
uses	 a	 single	 pair	 of	 complementary	 primers	 that	 contain	 the	 required	 base	 changes	 in	 the	
middle	of	 the	sequence	 (Figure	2.8	d).	The	 recommendations	 for	primer	design	 to	 introduce	
base	substitutions	is	that	the	oligonucleotides	should	be	25-45	bases	in	length	and	have	a	GC	
content	 of	 40%.	 The	 design	 incorporates	 the	 desired	 base	 changes	 in	 the	 middle	 of	 the	
sequence	 with	 15-20	 bases	 of	 complementary	 sequence	 on	 either	 side.	 Primers	 were	
synthesised	by	IDT	(Leuven,	Belgium).		
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Primer	Name	 Sequence	(5'	to	3')	 Tm	(°C)	 Purification	
FLAG-rBAT	FWD*	 TAC	AAG	GAT	GAC	GAT	AAG	GCT	GAA	GAT	AAA	AGC	AAG	AGA	GAC	TCC	ATC	 65.0	 Desalting	
FLAG-rBAT	REV*	 ATC	GTC	GTC	ATC	CTT	GTA	ATC	CAT	GTC	TCA	CCG	ACT	TAT	GTC	TTC	GGA	GTG	 67.6	 Desalting	
FLAG-rBAT	corrector	FWD	 GTG	AGA	CAT	GGA	TTA	CAA	GGA	CGA	TGA	CGA	TGA	CGA	TAA	GGC	TGA	AG	 64.6	 Desalting	
FLAG-rBAT	corrector	REV	 GTG	AGA	CAT	GGA	TTA	CAA	GGA	CGA	TGA	CGA	TAA	GGC	TGA	AG	 64.6	 Desalting	
rBAT-FLAG	FWD*	 TAC	AAG	GAT	GAC	GAC	GAT	AAG	TAG	GCA	CCT	TTA	TGA	AGA	GAT	GAA	GAC	 64.8	 Desalting	
rBAT-FLAG	REV*	 ATC	GTC	GTC	ATC	CTT	GTA	ATC	ACA	CGA	GGT	ATA	CAG	TAT	GTT	CAG	TAC	AC	 65.3	 Desalting	
rBAT-2xFLAG	FWD	 ACT	GTA	TAC	CTC	GTG	TGA	TTA	TAA	AGA	TCA	TGA	CAT	CGA	TTA	CAA	GGA	TGA	CG	 64.4	 PAGE	
rBAT-2xFLAG	REV	 CGT	CAT	CCT	TGT	AAT	CGA	TGT	CAT	GAT	CTT	TAT	AAT	CAC	ACG	AGG	TAT	ACA	GT	 64.4	 PAGE	
rBAT-3xFLAG	FWD	 CTG	AAC	ATA	CGT	TAT	ACC	TCG	TGT	GAC	TAC	AAA	GAC	CAT	GGT	GAT	TAT	AAA	GAT	CAT	GAC	ATC	GAT	 67.1	 PAGE	
rBAT-3xFLAG	REV	 ATC	GAT	GTC	ATG	TTT	ATA	ATC	ACC	GTC	ATG	GTC	TTT	GTA	GTC	ACA	CGA	GGT	ATA	CAG	TAT	GTT	CAG	 67.1	 PAGE	
	
Table	2.10:	A	summary	of	the	FLAG	mutagenic	primers	used	in	this	study.	
	
Mutant	 Direction	 Sequence	
N254T	
Forward	 CCATACACACTTAACCAGGTGTTGGGTGGAATGGTTT	
Reverse	 AAACCATTCCACCCAACACCTGGTTAAGTGTGTATGG	
L416P	
Forward	 CAATTACCTCAGCATGCCAGACACTGTTTCTGGGA	
Reverse	 TCCCAGAAACAGTGTCTGGCATGCTGAGGTAATTG	
M465K	
Forward	 GTGTGAAAAGAAGCATGTTCTTCACGTTGACATACTGATTC	
Reverse	 GAATCAGTATGTCAACGTGAAGAACATGCTTCTTTTCACAC	
M467T	
Forward	 AGTGTGAAAAGAAGCGTGTTCATCACGTTGACATACTGATTC	
Reverse	 GAATCAGTATGTCAACGTGATGAACACGCTTCTTTTCACACT	
Y579D	
Forward	 CTCTTGTGTACACAACATCGTGGCTGTCATTCCTCAA	
Reverse	 TTGAGGAATGACAGCCACGATGTTGTGTACACAAGAG	
M618I	
Forward	 GTACTTAACCTTATTCTTATTTTAGCGGGAAGGCCCGAAAT	
Reverse	 ATTTCGGGCCTTCCCGCTAAAATAAGAATAAGGTTAAGTAC	
N261D	
Forward	 CACCAATGCAGTGGGACGATAGTTCAAATGCTGGT	
Reverse	 ACCAGCATTTGAACTATCGTCCCACTGCATTGGTG	
N332D	
Forward	 CCGGGATTTGGGTCTTATCTACTTGGATCTCATCTCT	
Reverse	 AGAGATGAGATCCAAGTAGATAAGACCCAAATCCCGG	
N513D	
Forward	 ACAACTGGTTAAGTGTGTATGGAGACTCCAGTTGGCA	
Reverse	 TGCCAACTGGAGTCTCCATACACACTTAACCAGTTGT	
	
Table	2.11:	Summary	of	site-directed	mutagenesis	primers	used	in	this	study	
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Table	2.12:	PCR	cycling	parameters	for	site-directed	mutagenesis	of	rBAT	in	pSPORT1.	m.H2O,	
molecular-grade	water.	
	
	
	
	
	
Table	2.13:	Composition	of	reaction	mixture	to	perform	site-directed	mutagenesis	using	the	
Quikchange	Lightning	kit.	
	
	
	
Step	 Temperature	(°C)	 Time	 Cycles	
Activation	 95	 2min	 1	
Denaturation	 95	 20s	
18	Annealing	 60	 10s	
Extension	 68	 3min	30s	
Final	Extension	 68	 5min	 1	
Reagent	 Volume	(μl)	
10x	reaction	buffer	 5	
cDNA	template	(5ng/μl)	 4	
Forward	primer	(100ng/μl)	 1.25	
Reverse	primer	(100ng/μl)	 1.25	
dNTP	mixture	 1	
Quiksolution	 1.5	
m.H2O	 35	
QuikChange	Lightning	enzyme	 1	
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Figure	 2.8:	 A	 schematic	 diagram	 showing	 the	 outline	 of	 the	 site-directed	 mutagenesis	
concept.	A,	The	mutagenic	primers	each	carrying	half	of	the	FLAG	sequence	(red)	to	be	added	
anneal	 to	 the	 template	 DNA	 (black,	 dashed)	 adjacent	 on	 opposite	 strands;	 B,	 During	 the	
temperature	cycling	the	template	DNA	is	replicated	(grey)	by	Pfu	polymerase.	Incorporation	of	
the	 FLAG	 sequence	 produces	 nicked	 DNA;	 C,	 The	 methylated	 template	 DNA	 is	 selectively	
digested	 using	 DpnI	 enzyme.	 The	 remaining	 DNA	 is	 transformed	 into	 E.	 coli	 cells	 and	
recombined;	d,	mutagenic	primers	that	inversely	overlap	and	contain	the	desired	base	changes	
in	 the	 centre	 of	 the	 sequence	 (star)	 anneal	 to	 the	 DNA	 (black,	 dashed);	 E,	 During	 the	
temperature	cycling	the	template	DNA	is	replicated	(grey)	by	Pfu	polymerase.	Incorporation	of	
the	 base	 changes	 produces	 nicked	 DNA;	 F,	 The	 methylated	 template	 DNA	 is	 selectively	
digested	 using	 DpnI	 enzyme.	 The	 remaining	 DNA	 is	 transformed	 into	 E.	 coli	 cells	 and	
recombined.	
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2.4.3	Site-directed	mutagenesis	PCR	
	 Molecular	modification	 of	 human	 rBAT	 at	 the	 cDNA	 level	was	 performed	by	 inverse	
overlapping	PCR	using	 the	Quikchange	Lightning	kit	 (Agilent	Technologies).	The	PCR	 reaction	
mix	is	listed	in	Table	2.12	and	the	PCR	cycling	parameters	used	are	displayed	in	Table	2.13.	The	
PCR	 extension	 time	 is	 calculated	 as	 30s	 per	 kb	 of	 plasmid	 length.	 The	 bacterial	 vector,	
pSPORT1	is	4109	bases	in	length,	and	the	rBAT	insert	is	2717	bases	(6826	bases	in	total).	Thus,	
an	extension	time	of	3.5min	was	used.	Following	PCR,	the	reaction	mixture	was	incubated	with	
2μl	of	the	supplied	DpnI	enzyme	to	selectively	digest	the	methylated,	supercoiled	parent	DNA.		
2.4.4	Transformation	into	XL-10	Gold	ultracompetent	cells	
	 Following	mutagenesis	PCR,	2μl	of	DpnI-treated	reaction	mixture	was	transformed	into	
22.5μl	XL10-gold	ultracompetent	cells	(Agilent	Technologies)	according	to	the	manufacturer’s	
protocol.	The	mixture	of	cells	and	DNA	was	incubated	on	ice	(30min)	before	heat	shock	(42°C	
for	30s).	The	cells	were	immediately	returned	to	the	ice	for	2min,	and	250μl	NZY+	broth	(Table	
2.14)	 was	 added	 and	 the	 culture	 was	 incubated	 at	 37°C,	 200rpm	 for	 1h.	 After	 1h,	 50μl	 of	
culture	 medium	 was	 removed	 and	 spread	 aseptically	 onto	 an	 LB-ampicillin	 agar	 plate	 and	
incubated	at	37°C	overnight.	 cDNA	was	 isolated	 from	single	colonies,	as	described	 in	section	
2.5.1,	and	sequenced	to	confirm	mutagenesis	success	(GATC,	Cologne,	Germany).		
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Table	2.14:	Composition	of	NZY+	broth.	 	
Component	 Quantity	
NZ	amine	(casein	hydrolysate)	 10g	
NaCl	 5g	
Yeast	extract	 5g	
dH2O	(to	a	final	volume)	 1l	
• pH	to	7.5	with	NaOH	and	autoclave	
• Supplement	with	filter	sterilised	1M	MgCl2	(12.5ml),	1M	MgSO4	(12.5ml),	
and	2M	D-glucose	(10ml).		
• Final	concentrations:	12.5μM,	12.5μM,	and	10μM,	respectively.	
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2.5	cRNA	synthesis	by	in	vitro	transcription		
	 To	enable	characterisation	of	 the	wild-type	and	mutant	proteins	of	System	b0,+,	 rBAT	
was	heterologously	expressed	in	in	Xenopus	laevis	oocytes.	Protein	expression	in	the	oocytes	
was	achieved	following	micro-injection	of	cRNA.	In	vitro	transcription	of	cRNA	was	performed	
using	 linearised	 bacterial	 plasmid	 cDNA.	 To	 linearise	 the	 bacterial	 vector	 plasmid	 cDNA,	 a	
restriction	enzyme	was	used	that	created	a	single	cut	in	the	plasmid	3’	of	the	coding	sequence.	
This	provided	the	template	from	which	T7	polymerase	could	synthesise	cRNA.	
2.5.1	Linearisation	of	plasmid	cDNA	
	 To	 select	 a	 restriction	 enzyme	 that	 would	 produce	 a	 single	 cut	 in	 the	 plasmid,	 the	
cDNA	 sequence	 of	 the	 plasmid	 was	 entered	 into	 the	 online	 NEBcutter	 tool	
(http://tools.neb.com/NEBcutter2/index.php).	Restriction	enzymes	were	identified	that	would	
provide	a	single	cut	downstream	of	the	ORF.		
	 High-fidelity	restriction	enzymes	were	used	with	CutSmart	buffer	(NEB),	which	allows	
1μg	cDNA	to	be	cut	by	2U	of	enzyme	in	5-15min	at	37°C.	Reactions	were	incubated	for	15min	
to	ensure	complete	digestion.	Routinely,	10μg	cDNA	was	linearised	with	20U	of	enzyme	in	10μl	
CutSmart	buffer,	and	m.H2O	to	a	final	volume	of	100μl.	
	 Following	 linearisation,	 cDNA	 was	 recovered	 by	 ethanol	 precipitation.	 To	 the	 100μl	
reaction,	 10μl	 of	 3M	 sodium	acetate	 and	 250μl	 100%	ethanol	were	 added	 and	 the	 reaction	
mixture	 was	 incubated	 at	 -20°C	 overnight	 or	 -80°C	 for	 2h.	 The	 DNA	 was	 then	 pelleted	 by	
centrifugation	 at	 18,000rpm	 (30min,	 4°C).	 The	 supernatant	 was	 removed	 and	 the	 pellet	
washed	with	1ml	100%	ethanol.	The	sample	was	centrifuged	at	18,000rpm	for	15min	at	4°C.	
The	supernatant	was	removed	and	the	pellet	air-dried	for	10min	before	being	re-suspended	in	
25μl	 Buffer	 EB	 (QIAGEN,	Manchester,	UK).	 The	 cDNA	was	 quantified	 as	 described	 in	 section	
2.5.1.	Successful	linearisation	of	DNA	was	confirmed	by	gel	electrophoresis	(Figure	2.9).	
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Figure	2.9:	Linearisation	of	plasmid	cDNA	confirmed	by	gel	electrophoresis.	Linearised	cDNA	
was	resolved	by	electrophoresis	on	a	1%	agarose-TAE	gel	 (1h,	100mV)	against	non-linearised	
plasmid	cDNA.		a,	1kb	DNA	ladder	(NEB)	with	reference	markers	numbered	(kb);	b,	linearised	
cDNA	of	rBAT	in	pSPORT-1,	6826	bases	in	size;	c,	supercoiled,	circular	plasmid	cDNA	of	rBAT	in	
pSPORT-1.	
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In	vitro	transcription	reaction	
cDNA	(3.5μg)	 Xμl	
5x	reaction	buffer	 20μl	
DTT	(10mM)	 10μl	
rNTP	mix	(1mM	ATP,	UTP,	CTP,	0.2mM	GTP)		 20μl	
BSA	(10μg)	 1μl	
CAP	analogue	(1mM)	 2.5μl	
Ribolock	(160U)	 4μl	
T7	polymerase	(50U)	 2.5μl	
mH2O	(to	100μl	final	volume)	 Xμl	
Table	2.15:	Components	of	in	vitro	transcription	reaction	mixture.	
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2.5.2	In	vitro	transcription	
	 cRNA	was	routinely	synthesised	by	T7	polymerase-mediated	in	vitro	transcription.	The	
components	 of	 this	 reaction	 mixture	 are	 listed	 in	 Table	 2.15.	 5’-7-methylguanosine	 cap	
analogue	 was	 included	 in	 the	 reaction	 to	 improve	 the	 stability	 of	 the	 cRNA	 injected	 into	
Xenopus	oocytes	(Drummond	et	al.,	1985).	Following	incubation	of	the	reaction	at	37°C	for	2h,	
28U	of	DNaseI	was	added	and	further	incubation	was	carried	out	for	15min	at	37°C	to	remove	
the	linear	DNA	template.	
	 The	 recovery	 of	 cRNA	 from	 the	 reaction	mix	was	 achieved	 by	 addition	 of	 100μl	 5:1	
phenol:chloroform.	The	mixture	was	vortexed	and	centrifuged	 (16,000rpm,	10min,	4°C).	 The	
upper	 aqueous	 phase	 containing	 the	 cRNA	 was	 removed	 and	 transferred	 to	 a	 fresh	 1.5ml	
centrifuge	 tube	containing	10μl	 sodium	acetate	 (3M)	and	250μl	ethanol	 (100%).	 The	 sample	
was	 vortexed	 and	 stored	 at	 -80°C	 overnight.	 	 The	 following	 day,	 the	 cRNA	was	 pelleted	 by	
centrifugation	(18,000rpm,	30min,	4°C).	The	supernatant	was	removed	and	the	pellet	air-dried	
for	 10min	 before	 being	 re-suspended	 in	 15μl	 Buffer	 EB	 (Qiagen).	 cRNA	 was	 quantified	 as	
described	in	section	2.5.1	and	stored	at	-80°C	until	use.		
2.6	Functional	expression	in	Xenopus	laevis	oocytes	
	 In	 this	 investigation,	human	 rBAT	 cRNA	was	 injected	 into	Xenopus	 laevis	 oocytes	 for	
heterologous	protein	expression	 (Gurdon	 et	al.,	 1971).	 Successful	expression	of	human	 rBAT	
protein	in	association	with	an	endogenous	Xenopus	light	chain	(Figure	2.10)	allowed	functional	
uptake	assays	to	be	carried	out	along	with	immunolocalisation	of	the	protein	through	Western	
blotting	and	immunocytochemistry.		
2.8.1	Preparation	and	microinjection	of	Xenopus	laevis	oocytes	
	 Female	Xenopus	laevis	frogs	were	purchased	from	Xenopus1	(Michigan,	USA).	The	frogs	
were	 sacrificed	 by	 destruction	 of	 the	 cranium	 in	 accordance	 with	 Home	 Office	 Schedule	 1	
methods.	Ovaries	were	surgically	removed,	dissected	manually	and	incubated	in	ORII	solution	
(82.5mM	 NaCl,	 2mM	 KCl,	 1mM	MgCl2,	 10mM	 HEPES,	 pH	 7.5)	 containing	 collagenase	 A	 	 at	
2.5mg.ml-1,	 for	 60-90min	 (lyophilised	 from	 Clostridium	 histolyticum,	 Roche,	 Germany).	
Collagenase-treated	 oocytes	 were	 washed	 6	 times	 with	 50ml	 ORII	 solution	 followed	 by	 6	
washes	with	 50ml	modified	 Barth’s	 solution	 (MBS)	 (88mM	NaCl,	 1mM	KCl,	 0.82mM	MgSO4,	
0.41mM	CaCl2,	 0.33mM	Ca(NO3)2,	 10mM	HEPES,	 2.4mM	Na2(HCO3),	 adjusted	 to	pH	7.5	with	
Tris)	supplemented	with	gentamycin	(0.02mg.ml-1)	(Gurdon,	1977).	Healthy-looking	stage	V-VI	
oocytes	were	 selected	 using	 a	 light	microscope	 and	 any	 remaining	 follicular	 layers	 removed	
manually.	The	oocytes	were	then	stored	at	18oC	in	MBS	overnight.		
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Oocytes	were	injected	with	50nl	cRNA	(0.5-50ng)	or	50nl	H2O	as	a	control	using	a	semi-
automatic	 microinjection	 system	 (Nanoject,	 Drummond,	 USA).	 Injected	 oocytes	 were	
incubated	in	MBS	at	18°C	for	1-6	days	to	allow	for	protein	expression.	MBS	was	changed	daily	
and	unhealthy	oocytes	were	discarded.	
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2.6.2	Radiolabelled	uptake	measurements	in	Xenopus	laevis	oocytes	
Oocytes	 (n=10)	were	washed	 for	2min	at	 room	temperature	 in	Na+-free	wash	buffer	
(100mM	choline	chloride,	2mM	KCl,	1mM	CaCl2,	1mM	MgCl2,	10mM	HEPES,	adjusted	to	pH	7.4	
with	 Tris)	 and	 then	 placed	 in	 a	 10ml	 test	 tube.	 Excess	 buffer	 was	 removed	 and	 200µl	
radiolabelled	 uptake	 solution	 (wash	 buffer	 containing	 2.5-5µCi.ml-1	 [3H]amino	 acid	 (10µM))	
was	added	immediately.	A	list	of	all	radiolabelled	compounds	used	in	this	study	can	be	found	
in	Table	2.16.	
Following	 incubation	 for	 up	 to	 3h	 at	 21-24°C,	 the	 radiolabelled	 uptake	 solution	was	
removed	and	the	oocytes	washed	three	times	in	5ml	ice-cold	wash	buffer	to	stop	the	reaction.	
Single	 oocytes	 were	 placed	 in	 individual	 scintillation	 vials	 (7ml,	 Meridian	 Biotech,	 UK)	 and	
200µl	of	10%	SDS	was	added	to	each	vial.	Cells	were	left	overnight	to	lyse,	following	which	1ml	
scintillation	fluid	(Gold	Star	Quanta,	Meridian	Biotech,	UK)	was	added	to	each	vial.	[3H]Amino	
acid	 uptake	 was	 detected	 by	 liquid	 scintillation	 counting	 using	 an	 LS	 6500	 multi-purpose	
scintillation	 counter	 (Beckman-Coulter,	 High	Wycombe,	 UK).	 Disintegrations	 per	 min	 (DPM)	
were	measured	and	used	to	determine	amino	acid	uptake	(Equation	2.1).		
	
Equation	2.1:		 Oocyte uptake = Oocyte DPM(Standard DPM x 20)  x M	
	
Oocyte	DPM	(disintegrations	per	minute)	 is	the	measured	radioactivity	per	oocyte.	 	Standard	
DPM	is	mean	of	four	10µl	standard	samples	taken	from	the	uptake	solution	and	multiplied	by	
20	to	determine	the	total	amount	of	radiolabel	in	the	200µl	uptake	solution.	M	is	the	amount	
of	 amino	 acid	 in	 the	 solution,	 in	 moles,	 available	 for	 uptake.	 Results	 are	 expressed	 as	 the	
amount	of	amino	acid	taken	into	the	oocyte	over	time	(pmol.oocyte-1.(60min)-1).	
	 For	example,	in	an	rBAT-expressing	oocyte	incubated	in	200μl	uptake	solution	(pH	7.4,	
Na+-free)	containing	10μM	[3H]arginine	at	2.5μCi.ml-1	for	60min,	uptake	was	calculated	as:	Oocyte uptake = 25106(36590 x 20)  x 2000pmol	
=68.6	pmol.oocyte-1.(60min)-1
Compound	 Isotope	 Stock	concentration		(mCi.ml-1)	
Specific	activity		
(Ci.mmol-1)	 Supplier	
Alanine	 3H	 1	 0.132	 Perkin	Elmer	
Arginine	 3H	 1	 54.6	 Perkin	Elmer	
Cystine	 14C	 0.02	 0.11	 Perkin	Elmer	
Glutamic	acid	 3H	 1	 51.9	 American	Radiolabelled	Chemicals	
Leucine	 3H	 1	 115.4	 Perkin	Elmer	
Lysine	 3H	 1	 92	 Perkin	Elmer	
Proline	 3H	 5	 71.3	 Hartmann	Analytic	
	
Table	2.16:	A	summary	of	radiolabelled	amino	acids	used	in	this	study.	
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2.7	Immunodetection	of	rBAT	protein	in	Xenopus	oocytes	
A	 range	 of	 immunodetection	 techniques	was	 employed	 in	 this	 study	 to	 support	 the	
data	from	the	functional	uptake	experiments.	These	detection	techniques	were	carried	out	to	
confirm	 the	 expression	 and	 cellular	 localisation	 of	 the	 wild-type	 and	 mutant	 proteins.	 This	
provided	information	on	the	mechanism	underlying	the	any	observed	reduction	in	function	of	
mutant	rBAT.	
2.7.1	Isolation	of	total	membrane	protein	from	Xenopus	oocytes	
	 Total	membranes	were	isolated	from	Xenopus	oocytes	injected	with	water	(control)	or	
rBAT-3xFLAG	 cRNA,	 as	 previously	 described	 (Geering	 et	 al.,	 1989).	 Oocytes	 (n=25-50)	 were	
homogenised	 on	 ice	 in	 500μl	 lysis	 buffer	 (83mM	 NaCl,	 10mM	 HEPES,	 pH	 7.8,	 plus	 one	
Complete	Mini	protease	inhibitor	cocktail	tablet	(Roche)	per	10ml	buffer)	by	repeated	passage	
through	a	P200	pipette	tip.	Samples	were	vortexed	to	remove	remaining	visible	granules	and	
pelleted	 by	 centrifugation	 (2000rpm,	 5min,	 4°C).	 The	 supernatant	 was	 removed	 and	
transferred	 to	 a	 1ml	 polycarbonate	 ultracentrifuge	 tube	 (343778,	 Beckman	 Coulter,	 High	
Wycombe,	UK)	on	ice.	The	pellet	was	re-suspended	in	500μl	lysis	buffer	and	the	centrifugation	
step	repeated.	The	supernatant	was	added	to	the	ultracentrifuge	tube.	The	total	supernatant	
was	pelleted	through	centrifugation	(45,000rpm,	1h,	4°C).	Yolk	proteins	floating	on	the	top	of	
the	 resultant	 supernatant	were	absorbed	onto	 filter	paper	and	discarded	and	 the	 remaining	
solution	was	removed	by	pipetting.		
The	pelleted	membranes	were	 re-suspended	 in	50μl	 lysis	 buffer	 and	 stored	at	 -80°C	
until	use.	Protein	concentration	was	established	by	Bradford’s	method	(Bradford,	1976)	using		
Quick	Start	protein	assay	(Bio-Rad,	UK)	according	to	the	manufacturer’s	protocol.	Absorbance	
at	 592nm	 was	 measured	 in	 triplicate	 using	 a	 FLUOstar	 Omega	 microplate	 reader	 (BMG	
LabTech,	Germany).	A	standard	curve	was	measured	using	concentrations	of	BSA	ranging	from	
0.0625mg.ml-1-2mg.ml-1	and	absorbance	values	were	fitted	to	a	standard	curve	using	a	second	
order	 polynomial	 equation,	 from	 which	 unknown	 protein	 concentrations	 could	 be	
interpolated.	An	example	of	a	standard	curve	is	shown	in	Figure	2.11.		
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Figure	2.11:	Bradford	assay	standard	calibration	curve.	A	Bradford	assay	standard	calibration	
curve	 was	 produced	 using	 solutions	 of	 BSA	 of	 known	 concentration.	 This	 was	 used	 for	
calculation	of	 protein	 concentrations	 of	 samples	 using	 linear	 regression	 analysis.	 Samples	 of	
unknown	concentration	were	diluted	to	<5µg.10µl-1.		
	 	
0 1 2 3 4 5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Protein1(μg/10μl)
Ab
so
rb
an
ce
1(5
95
nm
)
	 97 
2.7.2	Immunodetection	of	FLAG-tagged	rBAT	by	Western	blot	
	 Western	blotting	of	rBAT	in	total	oocyte	membrane	proteins	allows	the	determination	
of	 the	 rate	of	protein	 translation	versus	 the	 rate	of	degradation.	Additionally,	 this	 technique	
will	allow	the	detection	of	the	different	glycosylated	forms	of	the	protein,	providing	an	insight	
into	the	cellular	processing	of	the	wild-type	and	mutant	heavy	chains.	Total	membrane	protein	
fractions	 (25μg)	 from	 Xenopus	 oocytes	 were	 resolved	 by	 sodium	 dodecyl	 sulphate-
polyacrylamide	gel	 electrophoresis	 (SDS-PAGE)	using	 the	Criterion	Cell	 system	 (Bio-Rad,	UK).	
Protein	 (25μg)	was	 denatured	 in	 3μl	 sample	 buffer	 	 (250mM	Tris-HCl,	 40%	 glycerol,	 20%	 β-
mercaptoethanol,	8%	SDS,	0.008%	bromophenol	blue),	made	up	to	a	final	volume	of	12μl	with	
mH2O,	and	heated	to	95°C	for	5min.	Samples	were	separated	on	a	4-20%	Tris-glycine	gel	using	
a	pH	8.3	running	buffer	(200mM	glycine,	25mM	Tris,	1%	SDS).	Samples	were	resolved	at	100V	
for	2h	against	Precision	Plus	dual	colour	standards	(Bio-Rad,	UK).		 	
	 The	 separated	 protein	 was	 transferred	 to	 an	 Immobilon-P	 polyvinylidene	 fluoride	
(PVDF)	membrane	 for	 1h	 at	 50V	 (Criterion	 Blotter,	 Bio-Rad,	 UK).	 The	 PVDF	membrane	 was	
then	 blocked	 in	 TBS-TWEEN-20	 (0.1%)	 containing	 5%	 non-fat	 milk	 powder	 (1h,	 RT).	 The	
membrane	was	incubated	with	an	anti-FLAG	antibody	at	the	appropriate	dilution	(Table	2.17)	
for	16h	at	4°C,	with	gentle	agitation.	 	The	membrane	was	washed	three	times	in	TBS-TWEEN	
and	incubated	in	the	appropriate	horseradish	peroxidase-linked	secondary	antibody	for	1h	at	
RT	(Table	2.17).	Following	removal	of	the	secondary	antibody	by	three	washes	in	TBS-TWEEN,	
the	 membrane	 was	 incubated	 in	 5ml	 of	 enhanced	 chemiluminescent	 (ECL)	 substrate	
(Supersignal	West	 Pico,	 Thermo	 Scientific)	 for	 10min.	 The	membrane	was	 exposed	 to	 light-
sensitive	X-ray	film	(CL-Xposure	film,	Thermo	Fisher)	for	varying	lengths	of	time	(2s-5min)	and	
developed	using	an	automatic	film	processor	(Konica	Minolta,	Sunderland,	UK).	
	 	
	
Western	blotting	
Primary	
antibody	 Supplier	 Raised	in	 Dilution	 Secondary	antibody	 Supplier	 Raised	in	 Dilution	
Anti-FLAG	 Sigma	(F3165)	 Mouse,	monoclonal	 1:1000-1:2000	 Anti-mouse	HRP	
GE	Healthcare	
(NA931VS)	
Sheep,	
polyclonal	 1:5000	
Anti-FLAG	 Proteintech	(60,002-1)	 Mouse,	monoclonal	 1:500	 Anti-mouse	HRP	
GE	Healthcare	
(NA931VS)	
Sheep,	
polyclonal	 1:5000	
Anti-SLC7A9	 Bioss		(bs-10085R)	 Rabbit,	polyclonal	 1:100	 Anti-rabbit	HRP	
GE	Healthcare	
(RPN4301)	 Goat,	polyclonal	 1:1000	
Immunocytochemistry	
Primary	
antibody	 Supplier	 Raised	in	 Dilution	 Secondary	antibody	 Supplier	 Raised	in	 Dilution	
Anti-FLAG	 Sigma	(F3165)	 Mouse,	monoclonal	 1:50	 Anti-mouse	FITC	
Life	Technologies	(A-
11029)	 Goat,	polyclonal	 1:50	
Anti-FLAG	 Proteintech	(60,002-1)	 Mouse,	monoclonal	 1:50	 Anti-mouse	FITC	
Life	Technologies	(A-
11029)	 Goat,	polyclonal	 1:50	
Anti-SLC7A9	 Bioss	(bs-10085R)	 Rabbit,	polyclonal	 1:100	 Anti-rabbit	TRITC	 Life	Technologies	(A-11037)	 Goat,	polyclonal	 1:50	
Anti-CD98	 BD	Pharmingen	(556074)	 Mouse,	monoclonal	 1:50	 Anti-mouse	FITC	
Life	Technologies	(A-
11029)	 Goat,	polyclonal	 1:50	
Anti-Ezrin	 Santa	Cruz		(sc-20773)	 Rabbit,	polyclonal	 1:50	 Anti-rabbit	TRITC	
Life	Technologies	(A-
11037)	 Goat,	polyclonal	 1:50	
	
Table	2.17:	A	summary	of	primary	and	secondary	antibodies	used	in	this	study	for	immunodetection	of	protein	in	Western	blotting	and	immunocytochemistry.
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2.7.3	Isolation	of	plasma	membranes	from	Xenopus	laevis	oocytes	
Plasma	membranes	were	 isolated,	 as	described	previously	 (Kamsteeg	&	Deen,	2001;	
Leduc-Nadeau	 et	 al.,	 2007)	 to	 detect	 the	 amount	 of	 rBAT	 protein	 present	 in	 the	 plasma	
membrane	 of	 the	 oocyte.	 This	 technique	 would	 allow	 comparison	 of	 the	 quatity	 of	 rBAT	
subunits	 successfully	 trafficked	 to	 the	 outer	 oocyte	membrane	 in	 the	wild-type	 and	mutant	
proteins.	 Oocytes	 were	 washed	 in	 MES-buffered	 saline	 solution	 (MBSS)	 (NaCl	 80mM,	 MES	
20mM,	pH	6)	prior	to	incubation	over	5-10min	with	0.005%	Subtilisin	A	(P4560,	Sigma,	UK)	to	
partially	 digest	 vitelline	 membranes.	 Following	 removal	 of	 the	 enzyme	 by	 three	 washes	 in	
MBSS,	 oocytes	 were	 incubated	 with	 1%	 Ludox	 Cl	 colloidal	 silica	 (Sigma,	 UK)	 for	 1h	 at	 4°C.	
Oocytes	were	washed	three	times	in	MBSS	(5min,	4oC)	to	remove	the	silica	and	then	incubated	
for	1h	in	0.1%	poly(acrylic)	acid	(Sigma,	UK)	(1h,	4oC)	with	gentle	agitation.		
The	wash	 step	was	 repeated	 and	 oocytes	were	 homogenised	 by	 passage	 through	 a	
P200	 tip	 until	 no	 visible	 granules	 remained.	 Samples	were	 diluted	 in	 1.5ml	 Homogenisation	
Buffer	A	(HbA)	(5mM	MgCl2,	5mM	NaH2PO4,	1mM	EDTA,	80mM	Sucrose,	20mM	Tris,	pH	7.4)	
and	centrifuged	at		4oC	as	follows:	16g,	1min;	25g,	1min;	35g,	1min;	16,000g,	20min.	After	the	
first	centrifugation	step,	1.4ml	of	supernatant	was	removed	and	discarded	and	pellets	were	re-
suspended	in	1ml	HbA.	Between	each	subsequent	centrifugation	step	only	1ml	of	supernatant	
was	 removed,	 and	 the	 pellet	 was	 re-suspended	 in	 the	 same	 volume.	 Following	 the	 final	
centrifugation	 step,	 pellets	 were	 re-suspended	 in	 homogenisation	 buffer	 containing	 0.1%	
Triton	 X	 to	 dissociate	 protein	 leaflets	 and	 allow	 quantification	 through	 Bradford	 Assay	
(Bradford,	1976).	
2.7.4	Immunocytochemical	detection	of	membrane	protein	in	whole	oocytes	
	 Whole	 oocytes	 were	 used	 for	 the	 immunocytochemical	 detection	 of	 FLAG-tagged	
rBAT.	 The	 use	 of	 whole	 oocytes	 allowed	 the	 detection	 of	 wild-type	 rBAT	 protein,	 a	mutant	
rBAT	 proteins	 in	 the	 plasma	 membrane	 of	 the	 oocytes.	 Only	 protein	 that	 was	 successfully	
targeted	 to	 the	 plasma	 membrane	 could	 be	 detected	 using	 this	 technique.	 Following	
expression	 of	 protein,	 oocytes	were	 fixed	 in	 100%	methanol	 (-20°C,	 16h)	 and	 stored	 in	 PBS	
containing	30%	(w/v)	sucrose	for	up	to	1	week.	Oocytes	were	washed	three	times	in	PBS	and	
blocked	for	30min	at	room	temperature	in	5%	(v/v)	horse	serum-PBS	with	gentle	agitation	in	a	
1ml	test	tube.	The	block	was	removed	and	replaced	with	primary	antibody	diluted	in	50μl	5%	
(v/v)	 horse	 serum-PBS	 at	 the	 appropriate	 concentration	 (Table	 2.17)	 for	 16h	 at	 4°C	on	 a	 tilt	
table.	The	primary	antibody	was	 removed	by	 three	washes	 in	PBS	at	 room	temperature	and	
the	 oocytes	 were	 blocked	 in	 5%	 (v/v)	 goat	 serum-PBS	 for	 30min.	 Following	 removal	 of	 the	
secondary	 block,	 the	 fluorophore-conjugated	 secondary	 antibody	 was	 applied	 at	 the	
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appropriate	 dilution	 in	 50μl	 5%	 (v/v)	 goat	 serum-PBS	 (Table	 2.17)	 in	 the	 dark	 (1h,	 RT).	 The	
secondary	antibody	was	removed	and	the	oocytes	were	washed	three	times	in	PBS.		
Oocytes	were	transferred	immediately	to	individual	wells	of	a	96-well	Nunc	micro-well	
plate.	 The	 dish	 was	 carefully	 filled	 with	 PBS	 and	 oocytes	 were	 imaged	 using	 a	 20x	 water-
dipping	 lens	 on	 a	 Leica	 TCS	 SP2	 AOBS	 MP	 point	 scanning	 confocal	 microscope	 (Leica	
Microsystems,	 Germany)	 with	 the	 help	 of	 Dr.	 Trevor	 Booth	 (Bioimaging	 Facility,	 Newcastle	
University).	 The	 secondary	 antibody-conjugated	 fluorophores	 used	 in	 this	 study	 were	 FITC	
(peak	excitation/emission	495/519nm)	and	TRITC	(peak	excitation/emission	547/572nm).		
	 Each	 water-injected	 control	 oocyte	 (n=6-10)	 was	 imaged	 to	 establish	 the	 level	 of	
background	 fluorescence.	 For	 each	 control	 oocyte	 the	 gain	was	 reduced	 to	 display	minimal	
fluorescence.	The	mean	value	for	all	control	oocytes	was	calculated	and	all	control	and	RNA-
injected	oocytes	 from	the	same	experiment	were	 imaged	at	 the	same	settings.	 Images	were	
taken	at	the	equator	of	the	oocyte,	identified	by	the	widest	point	of	the	membrane	arc.		
2.7.5	Immunocytochemical	detection	of	membrane	protein	in	oocyte	sections	
	 Oocyte	 sections	 were	 used	 for	 the	 immunocytochemical	 detection	 of	 FLAG-tagged	
rBAT.	 The	 use	 of	 oocyte	 sections	 allowed	 the	 detection	 of	 rBAT	 protein	 in	 the	 plasma	
membrane	 of	 the	 oocytes	 and	 at	 intracellular	 locations.	 This	 allowed	 detection	 of	 the	
translation	of	mutant	protein,	even	in	the	absence	of	successful	trafficking.	Oocytes	(n=6)	were	
fixed	in	methanol	and	stored	as	described	in	section	2.9.4.	Fixed	oocytes	were	embedded	in	a	
small	drop	of	Optimal	Cutting	Temperature	(OCT)	medium	(Thermo	Scientific)	and	frozen	at	-
60°C	 in	 a	 Shandon	 cryotome	 E	 (Thermo	 Scientific).	 Thin	 slices	 (15μM)	were	 taken	 from	 the	
frozen	medium	and	mounted	onto	HistoBond	glass	slides	(Marienfeld	GmbH,	Germany).	Slides	
were	kept	on	 ice	and	 flooded	with	PBS	 to	 remove	 the	OCT	and	prevent	 the	oocyte	 sections	
from	dehydrating	whilst	further	sections	were	being	taken.	
	 Immunocytochemical	 detection	 was	 carried	 out	 on	 the	 glass	 slides	 as	 described	 in	
section	2.9.4,	but	without	agitation.	Slides	were	 incubated	overnight	 in	the	primary	antibody	
at	4°C	in	a	moist,	airtight	container	to	prevent	evaporation	of	the	antibody	solution	from	the	
slide	 surface.	 Following	 completion	 of	 the	 immunocytochemistry,	 slides	 were	mounted	 in	 a	
small	drop	of	Vectashield	(Vector	Laboratories,	Peterborough,	UK)	under	a	13mm	round	glass	
coverslip.		
	 Slides	 were	 imaged	 using	 a	 Zeiss	 AxioImager	 II	 (Zeiss,	 UK)	 at	 20-40x	 magnification.	
Excitation	and	emission	spectra	were	as	described	in	section	2.9.4.	
2.8	Caco-2	human	intestinal	epithelial	cells	
The	Caco-2	cell	line	endogenously	expresses	both	subunits	of	System	b0,+	(see	Chapter	
1).	 Uptake	 of	 [3H]arginine	 via	 the	 transport	 system	was	measured	 in	 these	 cell	monolayers.	
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The	effects	of	different	incubation	conditions	on	the	expression	and	function	of	the	transport	
system	was	investigated.	The	cells	were	also	transfected	with	rBAT-3xFLAG	to	allow	the	study	
of	cell	localisation	of	the	protein	by	immunocytochemical	detection.		
2.8.1	Caco-2	cell	culture	
	 The	 immortalised	 human	 intestinal	 epithelial	 cell	 line,	 Caco-2	 was	 cultured,	 as	
described	 previously	 (passage	 106-115)	 (Thwaites	 et	 al.,	 1996)	 in	 high	 glucose	 (4.5g.l-1)	
Dulbecco’s	modified	Eagle’s	medium	(DMEM)	with	supplements	(Table	2.18).	
	 Cells	were	seeded	at	a	density	of	67,000.cm-2	in	a	150cm2	flask	 (Corning	Life	Science,	
The	 Netherlands)	 containing	 75ml	 of	 Caco-2	 growth	 medium	 (Table	 2.18),	 changed	 twice	
weekly.	Cells	were	routinely	incubated	at	37°C	at	an	atmosphere	of	5%	CO2	in	air	and	passaged	
every	10-14	days.	For	passaging,	growth	medium	was	removed	and	cells	were	washed	three	
times	 in	phosphate	buffered	saline	 (PBS).	Cells	were	 incubated	(20	min,	37°C)	 in	10ml	0.05%	
trypsin,	0.02%	EDTA	with	agitation	every	5min	 to	aid	detachment	 from	the	 flask	wall.	When	
around	half	of	the	cells	had	visibly	detached,	trypsinisation	was	inhibited	by	addition	of	30ml	
growth	 medium.	 Cells	 were	 isolated	 and	 re-suspended	 by	 passage	 through	 a	 large	 bore	
needle.	 Cell	 numbers	 were	 established	 using	 a	 Cellometer	 Auto	 T4	 (Nexcelom	 Bioscience,	
Lawrence,	 MA)	 and	 cells	 were	 seeded	 in	 new	 flasks	 or	 onto	 0.4μm	 pore	 polycarbonate	
membrane	 Transwell	 permeable	 supports	 in	 (5x105	cells.cm-2)	 for	 functional	 uptake	 studies.	
Cells	 grown	 on	 Transwell	membranes	were	 supplied	with	 1ml	 growth	medium	 in	 the	 apical	
compartment	 and	2ml	 in	 the	basolateral	 compartment.	Growth	medium	was	 changed	 twice	
weekly.	
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Table	 2.18:	 Composition	 of	 supplements	 added	 to	 500ml	 Dulbecco’s	 modified	 Eagle’s	
medium	(DMEM)	to	create	Caco-2	growth	medium.	
	
	
	
	
Table	2.19:	Composition	of	Na+-free	modified	Krebs’	solution.	
Supplement	 Concentration	 Volume	(ml)	in	500ml	DMEM	
Foetal	calf	serum	 10%	 50	
Glutamine	 2mM	 5	
Non-essential	amino	acids	 1%	 5	
Gentamycin	 60μg.ml-1	 0.3	
Compound	 Modified	Krebs’	solution	(mM)	
ChoCl	 137	
KCl	 5.4	
MgSO4	 1	
KH2PO4	 0.34	
CaCl2	 2.8	
D-Glucose	 10	
MES	(pH	5.5-6.7)	 10	
HEPES	(pH	6.8-8.2)	 10	
• pH	to	desired	value	with	Tris	base	
• d.H2O	to	final	volume	
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2.8.2	Amino	acid	uptake	in	Caco-2	cell	monolayers	
	 Caco-2	cell	monolayers	grown	on	Transwell	filters	were	used	11-14	days	post-seeding	
and	 had	 the	 growth	 medium	 changed	 one	 day	 prior	 to	 experimental	 use.	 Monolayer	
confluence	 was	 established	 by	 measurement	 of	 trans-epithelial	 resistance	 (RT)	 using	 EVOM	
voltohmmeter	 (WPI,	 Stevenage,	UK).	 Resistance	 values	measured	 in	 growth	medium	 from	a	
typical	 experiment,	 11	 days	 post-seeding,	 were	 362±8Ω.cm2	 (n=60).	 Monolayers	 were	
arranged	to	create	an	equal	average	RT	value	between	treatment	groups	(n=4-5).	
	 Cell	growth	medium	was	removed	by	four	washes	 in	500ml	Na+-free	modified	Krebs’	
solution	 (Table	 2.19).	 Monolayers	 were	 placed	 in	 a	 clean	 12-well	 plate	 and	 incubated	 in	
modified	 Krebs’	 solution	 (0.5ml	 apical,	 1ml	 basolateral)	 for	 30min	 at	 37°C.	 Where	 no	 pre-
incubation	 had	 occurred	 prior	 to	 the	 experiment,	 trans-epithelial	 resistance	 was	 measured	
once	more	to	ensure	approximately	equal	distribution	of	resistance	was	achieved	between	the	
different	treatment	groups.	
	 The	 apical	 Krebs’	 solution	was	 removed	and	 immediately	 replaced	with	0.5ml	10μM	
[3H]arginine		(0.5μCi.ml-1).	For	competition	experiments	where	arginine	uptake	was	measured	
in	 the	 presence	 of	 5mM	 of	 amino	 acid	 competitors,	 the	 control	 also	 contained	 5mM	 D-
mannitol	to	exclude	effects	due	to	osmotic	changes.	Uptake	of	arginine	was	carried	out	over	
5min	 after	which	 the	 radiolabel	was	 removed	 by	 aspiration	 and	 the	 reaction	 terminated	 by	
three	washes	in	500ml	ice-cold	Krebs’	solution.		
The	 polycarbonate	 membrane-attached	 cell	 monolayers	 were	 removed	 from	 the	
plastic	supports	using	a	scalpel	and	placed	in	individual	7ml	scintillation	vials.	To	each	vial,	1ml	
scintillation	fluid	was	added	(Gold	Star	Quanta,	Meridian,	UK).	Disintegrations	per	min	(DPM)	
were	 measured	 as	 described	 in	 Section	 2.4.2	 and	 used	 to	 determine	 amino	 acid	 uptake	
(Equation	2.2).		
	
Equation	2.2:		 Apical uptake = Monolayer DPM(Standard DPM x 50)  x M  ÷ 1.13 	
	
Monolayer	DPM	 (disintegrations	 per	minute)	 is	 the	measured	 radioactivity	 accumulated	 per	
monolayer	over	5min.		The	standard	DPM	value	is	the	mean	of	four	10µl	standards	taken	from	
the	uptake	solution,	which	is	then	multiplied	by	50	to	determine	the	total	amount	of	radiolabel	
in	the	0.5ml	uptake	solution	applied	to	the	monolayers.	M	is	the	amount	of	amino	acid	in	the	
solution,	 in	moles,	 available	 for	 uptake.	 Results	 are	 expressed	 as	 the	 amount	 of	 amino	 acid	
taken	into	the	monolayer	over	time	per	cm2,	and	so	the	value	is	divided	by	the	surface	area	of	
the	membrane,	
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	(1.13cm2).	The	units	of	uptake	are	pmol.cm-2.(5min)-1.	
	 For	example,	apical	uptake	by	a	Caco-2	monolayer	incubated	in	0.5ml	uptake	solution	
(pH	7.4,	Na+-free)	containing	10μM	[3H]arginine	at	0.5μCi.ml-1	for	5min,	uptake	was	calculated	
as:	 Apical uptake = 6103(8900 x 50)  x 5000pmol	
=68.6	pmol.cm-2.(5min)-1	
	
2.8.3	Lysis	of	cells	and	protein	preparation	
	 To	isolate	Caco-2	protein	for	Western	blotting,	growth	medium	was	removed	from	the	
T150	flask.	Cell	lysis	buffer	contains	1mM	EDTA,	1mM	EGTA,	0.64mM	sucrose,	25mM	Tris,	and	
1%	Triton-X,	adjusted	to	pH	7.6	with	HCl.	One	Complete	Mini	protease	inhibitor	cocktail	tablet	
(Roche,	UK)	was	dissolved	in	10ml	lysis	buffer.	Cells	were	washed	three	times	in	PBS	and	2ml	
lysis	 buffer	 was	 added	 to	 the	 flask.	 Cells	 were	 removed	 from	 the	 wall	 of	 the	 flask	 using	 a	
rubber	 scraper	 and	 transferred	 to	 two	 1.5ml	 centrifuge	 tubes.	 The	 cell	 suspension	 was	
repeatedly	passed	through	a	P200	pipette	tip	to	complete	lysis.	The	cell	debris	was	pelleted	by	
centrifugation	(10,000g,	10min,	4°C).	The	supernatant,	containing	the	soluble	cellular	protein,	
was	removed	and	stored	at	-80°C	until	use.		
	
2.9	Transient	expression	of	FLAG-tagged	rBAT	in	Caco-2	cells	
2.9.1	Sub-cloning	of	human	rBAT	into	a	vector	with	a	CMV	promoter	
	 In	order	to	express	a	FLAG-tagged	rBAT	construct	 in	Caco-2	cells,	 it	was	necessary	to	
sub-clone	the	open	reading	frame	of	rBAT-3xFLAG	into	a	vector	containing	a	cytomegalovirus	
(CMV)	 promoter.	 The	 early	 CMV	 promoter	 region	 has	 been	 shown	 to	 drive	 high	 levels	 of	
constitutive	 protein	 expression	 in	mammalian	 cells,	 unlike	 the	 T7	 promoter	 region	which	 is	
present	in	the	pSPORT1	vector.	Expression	vectors	pSPORT1	and	pCMV-SPORT6		have	different	
promoter	 regions	 (T7	 and	 CMV,	 respectively).	 Despite	 this,	 both	 have	 very	 similar	 multiple	
cloning	sites	within	their	sequences.	The	rBAT-3xFLAG	construct	used	for	in	vitro	transcription	
of	cRNA	is	contained	in	the	pSPORT1	vector	(Table	2.7),	with	a	T7	promoter	upstream	of	the	
start	 codon	 (Figure	 2.12	 a).	 pCMV-SPORT6	 already	 contained	 an	 insert	 within	 its	 multiple	
cloning	site,	the	open	reading	frame	of	the	IKEPP	gene	(Figure	2.12	b).	Both	bacterial	plasmids	
had	the	EcoRI	restriction	site	upstream	of	the	start	codon	(ATG)	and	HindIII	downstream	of	the	
stop	 codon	 (TAG)	 (Figure	 2.12	 a	 and	 b).	 Neither	 of	 the	 open	 reading	 frames	were	 cut	with	
HindIII	or	EcoRI.	
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	 Both	bacterial	plasmids	were	grown	from	glycerol	 stocks	and	cDNA	was	 isolated	and	
purified	as	described	in	section	2.5.1.	
	 A	 double	 digest	 was	 carried	 out	 on	 the	 plasmid	 cDNA	 to	 cut	 both	 restriction	 sites	
simultaneously,	isolating	both	required	cDNA	sequences:	rBAT	and	pCMV-SPORT6	(Figure	2.12	
c,d).	 The	 enzymes	 used	 were	 HindIII-HF	 and	 EcoRI-HF	 (NEB),	 which	 have	 100%	 activity	 in	
CutSmart	 buffer.	 The	 reaction	 mixture	 was	 comprised	 as	 follows:	 2μg	 cDNA,	 5μl	 CutSmart	
buffer,	 40U	HindIII-HF,	40U	EcoRI-HF,	mH2O	 to	50μl.	 The	 reaction	was	 incubated	at	37°C	 for	
15min	and	enzymes	were	heat	inactivated	(65°C,	20min).		 	
	 To	ensure	the	success	of	both	digest	reactions,	cDNA	was	resolved	by	electrophoresis	
on	a	0.8%	agarose	–TAE	gel	(Figure	2.12	e).	It	is	recommended	to	use	a	gel	with	lower	agarose	
content	when	it	will	be	used	to	extract	cDNA.	Bands	of	the	correct	size	for	rBAT-3xFLAG	(2.1kb)	
and	pCMV-SPORT6	(4.3kb)	were	identified	and	gel	extracted	using	QIAquick	gel	extraction	kit	
(Qiagen)	according	to	the	manufacturer’s	protocol.	cDNA	was	quantified	using	Nandrop	2000	
(Thermo	Scientific).		
	 Plasmid	 and	 insert	 cDNA	 were	 ligated	 for	 1h	 at	 room	 temperature	 at	 a	 3:1	
(insert:vector)	molar	 ratio	using	T4	 ligase	 (Promega).	The	reaction	mixture	was	comprised	of	
68ng	rBAT	cDNA,	114ng	pCMV-SPORT6	cDNA,	2μl	T4	buffer,	1μl	T4	polymerase,	and	mH2O	to	
20μl.	Ligated	cDNA	was	transformed	into	JM109	competent	cells	 (Promega)	according	to	the	
manufacturer’s	protocol.	
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Figure	2.12:	A	schematic	diagram	depicting	the	subcloning	process	to	insert	rBAT	into	pCMV-
SPORT6.	 a,	 The	 rBAT	 coding	 sequence	 in	 pSPORT1	 with	 a	 T7	 promoter	 used	 for	 in	 vitro	
transcription	of	cRNA.	EcoRI	and	HindIII	restriction	sites	sit	upstream	of	the	start	codon	(ATG)	
and	downstream	of	 the	 stop	 codon	 (TAG),	 respectively;	 b,	 IKEPP	 coding	 sequence	 in	 pCMV-
SPORT-6.	 Both	 restriction	 sites	 are	 present	 in	 the	MCS	 and	 are	 in	 the	 correct	 orientation	 to	
insert	 rBAT	 downstream	 of	 the	 CMV	 promoter	 for	 expression	 in	mammalian	 cells;	 c	 and	 d,		
Double	enzyme	digest	using	EcoRI-HF	and	HindIII-HF	is	carried	out	to	produce	linear	insert	and	
plasmid	 DNA;	 e,	 digest	 products	 are	 resolved	 on	 a	 0.8%	 agarose-TAE	 gel	 and	 the	 bands	 of	
linear	rBAT	DNA	(lanes	a	and	b,	red	box,	2.1kb)	and	linear	pCMV-SPORT6	(lanes	c	and	d,	grey	
box,	4.6kb)	are	gel	extracted	 to	 isolate	purified	DNA	with	complementary	sticky	ends;	 f,	The	
purified	DNA	is	ligated	at	a	3:1	molar	ratio	and	transformed	into	E.	coli	cells.	
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2.9.2	Transfection	of	Caco-2	cells	with	p.EGFP-C2	
	 Caco-2	cells	were	seeded	on	sterile	13mm	glass	coverslips	in	a	24	well	plate	(300,000	
cells.well-1)	 for	 24h	 (37°C,	 5%	 CO2)	 in	 normal	 growth	medium	 (Table	 2.18).	 Cells	 were	 then	
washed	 three	 times	 in	 PBS	 and	 the	 medium	 was	 replaced	 with	 0.5ml	 Opti-MEM	 (Life	
Technologies,	Paisley,	UK)	supplemented	with	5%	FBS	and	1%	non-essential	amino	acids.		
	 Cell	 transfection	 was	 carried	 out	 using	 Lipofectamine	 2000	 (Life	 Technologies,	 UK)	
according	 to	 the	manufacturer’s	protocol.	Reagents	were	brought	 to	 room	 temperature	and	
gently	 vortexed	prior	 to	use.	 cDNA:lipid	 complexes	were	 formed	 in	non-supplemented	Opti-
MEM	through	 incubation	at	room	temperature	for	20min	at	a	ratio	of	1:3	 (0.5μg	cDNA:1.5μl	
lipofectamine).	 cDNA:lipid	 complex	 mixture	 (100μl)	 was	 added	 to	 the	 500μl	 Opti-MEM	
contained	 in	each	well.	The	plate	was	 rocked	gently	 for	30s	before	 incubation	at	37°C.	After	
24h,	 the	 medium	 was	 replaced	 with	 normal	 Caco-2	 growth	 medium,	 as	 long	 exposure	 to	
Lipofectamine	can	be	toxic	to	cells.		
Cells	were	fixed	in	PBS	containing	4%	paraformaldehyde	(PFA)	and	4%	sucrose	(15min,	
room	temperature)	at	24,	48,	and	72h	post-transfection.	Cells	were	stored	in	PBS	at	4°C	until	
use.		
2.9.3	 Immunocytochemical	 detection	 of	 proteins	 expressed	 in	 Caco-2	 cells	 by	 transient	
transfection		
	 Fixed	cells	were	permeabilised	in	0.1%	Triton-X	(5min,	RT)	and	washed	three	times	in	
PBS.	The	glass	coverslips	containing	the	transfected	monolayers	were	carefully	removed	from	
the	 wells	 and	 placed	 on	 a	 parafilm-covered	 surface.	 Immunocytochemical	 detection	 was	
carried	out	on	the	glass	coverslips	as	described	 in	section	2.9.4,	but	without	agitation.	Slides	
were	 incubated	 overnight	 in	 the	 primary	 antibody	 at	 4°C	 in	 a	 moist,	 airtight	 container	 to	
prevent	 evaporation	 of	 the	 solution	 from	 the	 slide	 surface.	 Following	 completion	 of	
immunocytochemistry,	slides	were	mounted	face	down	in	a	small	drop	of	Vectashield	(Vector	
Laboratories,	Peterborough,	UK)	on	glass	slides.		
	 The	transfected	cells	were	 imaged	using	a	Leica	TCS	NT	krypton-argon	 laser-scanning	
confocal	 microscope	 (Leica	 Microscope	 and	 Systems,	 Germany)	 connected	 to	 a	 computer	
running	 the	 Leica	 TCS	 NT	 software.	 Excitation	 and	 emission	 spectra	 were	 as	 described	 in	
section	2.9.4.	Images	were	taken	at	a	range	of	magnifications	(20-63x).	
2.10	Prediction	of	3D	protein	structure	by	homology	modelling	
	 Due	 to	 the	difficulties	 in	 crystallising	hydrophobic	membrane	 transport	proteins,	 the	
tertiary	 structure	 of	 many	 of	 these	 molecules	 is	 unknown.	 For	 this	 reason,	 it	 has	 become	
common	 practice	 to	 use	 computational	 methods	 to	 predict	 the	 topology	 of	 proteins	 with	
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unsolved	 structures	 to	 aid	 identification	 of	 vital	 residues.	 To	 date,	 the	 crystal	 structures	 of	
rBAT	and	b0,+AT	remain	unsolved,	thus	 in	silico	homology	modelling	was	employed	as	part	of	
this	study	to	predict	the	location	of	residues	mutated	in	cystinuric	patients.		
2.10.1	Homology	model	creation	
	 Amino	acid	sequences	for	both	rBAT	(NM_000341)	and	b0,+AT	(NM_001243036)	were	
downloaded	 in	 FASTA	 format	 from	 the	 NCBI	 nucleotide	 database	
(http://www.ncbi.nlm.nih.gov).	The	amino	acid	sequence	for	each	protein	was	individually	put	
into	 HHPRED	 (http://toolkit.tuebingen.mpg.de/),	 an	 online	 server	 that	 predicts	 the	 most	
probable	tertiary	structure	for	a	sequence	following	its	alignment	with	related	structures	(Sali	
&	Blundell,	1993).	HHPRED	selects	a	template	protein	from	an	alignment	of	homologues	that	
satisfies	3D	restraints	(Sali	&	Blundell,	1993).	It	carries	this	out	using	the	Hidden	Markov	Model	
(HMM)	to	 identify	tertiary	structure	similarities	 in	homologous	proteins	(Söding	et	al.,	2005).	
Once	 the	most	probable	 related	structures	have	been	 identified	 from	the	Protein	Data	Bank	
(PDB)	 database	 (https://www.rcsb.org/pdb/home),	 the	 most	 appropriate	 template	 can	 be	
selected	manually.		
	 Once	 selected,	 the	 alignment	with	 the	 template	 sequence	 is	 automatically	 uploaded	
into	 MODELLER	 (http//www.toolkit.tuebingen.mpg.de/modeller)	 and	 a	 PDB	 file	 is	 created	
containing	 the	 predicted	 3D	 model.	 MODELLER	 uses	 both	 Ramachandran	 analysis	 and	
MolProbity	to	assess	the	quality	of	the	model	and	validate	the	structure.	A	Ramachandran	plot	
considers	the	dihedral	backbone	angles	of	amino	acids	in	a	protein	structure	against	their	side	
chains	 and	 the	 side	 chains	of	other	 amino	acids	 in	 the	protein	 (Ramachandran	 et	 al.,	 1963).	
MolProbity	(http://molporbity.biochem.duke.edu)	 is	an	online	web	service	used	for	structure	
validation	 (Davis	 et	 al.,	 2007).	 MolProbity	 considers	 factors	 such	 as	 the	 steric	 interaction	
between	atoms	in	a	molecule	to	remove	ambiguity.	One	such	problem	can	be	with	backwards-
fit	side	chains.	This	occurs	particularly	frequently	with	Asn,	Gln	and	His	residues	as	they	have	
symmetrical	electron	density.	However,	an	NH2	group	is	much	larger	than	O	and	so	MolProbity	
automatically	 tries	 the	 residues	 in	 both	 conformations	 to	 provide	 the	 best	 steric	 fit	 and	
optimise	the	position	of	H	residues	for	hydrogen	bonding	Davis	et	al.	(2007).	
	 The	final	homology	models	were	viewed	in	PyMol	(http//www.pymol.org)	from	which	
the	 predicted	 location	 of	 functionally-important	 residues	 in	 both	 rBAT	 and	 b0,+AT	 could	 be	
identified	and	the	effects	of	the	mutations	predicted	using	the	in-built	mutagenesis	tool.		
2.11	Statistical	analysis	
Data	 are	 expressed	 as	 mean	 ±	 standard	 error	 of	 the	 mean	 (SEM),	 where	 n	 is	 the	
number	of	oocytes	or	Caco-2	monolayers	used	per	condition.	GraphPad	Prism	version	6	was	
used	 to	 determine	 kinetic	 parameters	 using	 Michaelis-Menten	 kinetics	 and	 to	 carry	 out	
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statistical	analysis	of	each	experiment.	Significance	levels	were	calculated	by	one-	or	two-way	
analysis	of	variance	(ANOVA).	A	Bonferroni	post-test	of	multiple	comparisons	was	also	carried	
out.	P	values	<0.05	were	considered	statistically	significant.		
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Chapter	3 :	Results	I	
3.1	Introduction	
The	renal	stone	disease	cystinuria	 is	caused	by	defects	 in	the	renal	transport	system,	
b0,+,	which	 is	a	heterodimeric	 transport	system	consisting	of	a	heavy	chain	 (rBAT)	and	a	 light	
chain	(b0,+AT).	The	two	protein	subunits	are	encoded	by	the	solute	carrier	genes	SLC3A1	and	
SLC7A9,	respectively	(Chairoungdua	et	al.,	1999;	Feliubadalo	et	al.,	1999).	Mutations	in	either	
of	these	two	genes	have	been	shown	to	lead	to	the	cystinuria	phenotype,	through	an	induced	
lack	 of	 reabsorption	 of	 dibasic	 amino	 acids	 and	 the	 cysteine	 dimer,	 cystine,	 from	 the	 renal	
proximal	 tubule	 (Font	 et	 al.,	 2001).	 	 Cystinuria	 is	 traditionally	 believed	 to	 be	 an	 autosomal	
recessive	 disease,	 with	 the	 majority	 of	 patients	 presenting	 with	 a	 compound	 heterozygous	
genotype	(Dello	Strologo	et	al.,	2002).	The	current	classification	system	for	cystinuric	patients	
was	 discussed	 in	 Chapter	 1.	 Patients	 carrying	mutations	 in	SLC3A1,	 are	 “Type	A”,	 and	 those	
with	mutations	in	SLC7A9	are	“Type	B”.	Thus,	a	patient	who	had	one	mutation	in	SLC3A1	and	
one	in	SLC7A9	would	be	“Type	AB”	(Dello	Strologo	et	al.,	2002).		
To	 date,	 there	 have	 been	 many	 investigations	 reported	 in	 the	 literature	 on	 the	
identification	 of	 pathogenic	mutations	 in	 cohorts	 of	 cystinuric	 patients.	 These	 cohorts	 have	
ranged	in	size	from	fewer	than	10	patients	(Calonge	et	al.,	1994;	Miyamoto	et	al.,	1995;	Yuen	
et	 al.,	 2006)	 to	 over	 150	 Spanish	 and	 Italian	 patients	 recruited	 through	 the	 International	
Cystinuria	Consortium	(ICC)	(Font-Llitjos	et	al.,	2005;	Bisceglia	et	al.,	2010).	Amongst	24	reports	
of	 mutation	 detection	 in	 these	 cohorts,	 published	 between	 1994	 and	 2015,	 the	 mutation	
detection	 success	 rates	 reported	 ranged	 from	 50-100%,	with	 a	mean	 detection	 rate	 of	 70%	
(Calonge	et	al.,	1994;	Gasparini	et	al.,	1995;	Miyamoto	et	al.,	1995;	Pras	et	al.,	1995;	Bisceglia	
et	al.,	1996;	Endsley	et	al.,	1997;	Gitomer	et	al.,	1998;	Saadi	et	al.,	1998;	Albers	et	al.,	1999;	
Egoshi	et	al.,	2000;	Bisceglia	et	al.,	2001;	Harnevik	et	al.,	2001;	Guillen	et	al.,	2004;	Schmidt	et	
al.,	2004a;	Font-Llitjos	et	al.,	2005;	Skopkova	et	al.,	2005;	Yuen	et	al.,	2006;	Chatzikyriakidou	et	
al.,	 2008;	 Popovska-Jankovic	 et	 al.,	 2009;	 Bisceglia	 et	 al.,	 2010;	 Eggermann	 et	 al.,	 2011;	
Barbosa	et	al.,	2012;	Rhodes	et	al.,	2015;	Wong	et	al.,	2015).		
The	presence	of	a	dibasic	aminoaciduria	in	heterozygote	carriers	of	SLC7A9	mutations,	
along	 with	 the	 failure	 to	 detect	 two	 causal	 variants	 in	 the	 genes	 known	 to	 be	 involved	 in	
cystinuria,	 has	 raised	 questions	 of	 the	 penetrance	 of	 phenotype.	 Genotype-phenotype	
correlation	 studies	 have	 shown	 that	 the	 penetrance	 of	 the	 cystinuria	 phenotype	 can	 vary	
between	 mutations	 and	 individuals.	 Mutations	 in	 SLC7A9	 are	 inherited	 in	 an	 autosomal	
dominant	 manner	 with	 variable	 penetrance	 of	 phenotype	 (Font-Llitjos	 et	 al.,	 2005).	 This	
variable	penetrance	of	SLC7A9	mutations	suggests	the	presence	of	other	modifying	factors	on	
the	 clinical	 course	 of	 the	 disease.	 One	 investigation	 reported	 a	 high	 urinary	 amino	 acid	
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excretion	phenotype	in	50%	of	patients	heterozygous	for	T123M	(Font-Llitjos	et	al.,	2005).	 In	
other	studies,	a	wide	variation	in	amino	acid	excretion	is	seen	amongst	distinct	patients	with	
this	mutation	(Eggermann	et	al.,	2012).	This	contrasts	with	“severe”	SLC7A9	mutation	R333W	
in	which	all	known	heterozygotes	display	a	cystinuric	phenotype	(Font	et	al.,	2001;	Font-Llitjos	
et	 al.,	 2005).	 Conversely,	 whilst	 the	 vast	 majority	 of	 SLC3A1	 mutations	 are	 considered	
autosomal	 recessive	 mutations,	 one	 SLC3A1	 variant	 has	 been	 shown	 to	 have	 a	 largely	
dominant	inheritance	pattern	(Font-Llitjos	et	al.,	2005).	A	complete	duplication	of	exons	5	to	9	
(dup5-9)	 was	 reported	 in	 6	 Spanish	 patients	 (Font-Llitjos	 et	 al.,	 2005).	 Of	 the	 6	 patients,	 4	
showed	excessive	excretion	of	cystine,	lysine,	arginine,	and	ornithine	in	their	urine	(Font-Llitjos	
et	al.,	2005).		
The	use	of	CEL-I	endonuclease	to	detect	causal	point	mutations	was	first	reported	by	
Oleykowski	 et	 al.	 (1998).	 This	 enzymatic	 approach	 to	 mutation	 detection	 was	 employed	 to	
identify	 single	 base	 changes	 in	 the	 BRCA1	 gene	 (Oleykowski	 et	 al.,	 1998).	 The	 use	 of	 an	
endonuclease	 to	 detect	 the	 causal	 variants	 in	 cohorts	 of	 patients	 with	 genetic	 disease	 has	
subsequently	been	widely-reported	 (Qiu	 et	al.,	 2004;	 Scaffino	 et	al.,	 2004;	Otto	 et	al.,	 2008;	
Voskarides	&	Deltas,	2009).	Although	the	commercial	Surveyor™	kit	is	available,	the	extraction	
of	 the	 enzyme	 from	 celery	 has	 proved	 a	 valuable	 source	 of	 a	 functional	 endonuclease	
(Oleykowski	et	al.,	1998;	Scaffino	et	al.,	2004;	Otto	et	al.,	2008).	The	CEL-I	enzyme	is	present	in	
a	wide	variety	of	vegetable	extracts,	but	celery	is	the	preferred	crude	source	of	plant	material	
due	 to	 its	 lack	 of	 chlorophyll	 pigment,	 which	 can	 interfere	 with	 activity	 (Oleykowski	 et	 al.,	
1998).	 The	 CEL-I	 endonuclease	 remains	 stable	 through	 extraction,	 storage	 and	 use,	 and	 is	
functional	at	pH	5-9.5.	The	use	of	the	heteroduplex-endonuclease	assay,	described	in	detail	in	
Chapter	 2,	 allows	 an	 increased	 throughput	 in	 the	 screening	 of	DNA	 samples.	 Additionally,	 it	
shows	 a	 high	 specificity	 for	 unique	 double-strand	 mismatches,	 and	 a	 greater	 sensitivity	 of	
detection	 than	 other	 common	 mutation	 detection	 protocols	 such	 as	 single	 strand	
conformation	 polymorphism	 (SSCP)	 analysis,	 used	 widely	 in	 other	 analyses	 of	 cystinuric	
cohorts	 (Michaud	 et	 al.,	 1992;	 Scaffino	 et	 al.,	 2004;	 Otto	 et	 al.,	 2008;	 Voskarides	 &	 Deltas,	
2009).	
In	 the	 current	 Chapter,	 we	 report	 the	 use	 a	 combination	 of	 non-quantitative	
techniques	 to	 detect	 causal	 variants	 in	 a	 cohort	 of	 cystinuria	 patients.	 Multiplex	 Ligation-
dependent	 Probe	 Amplification	 (MLPA)	 was	 also	 employed	 to	 quantify	 whole	 exon	 copy	
numbers,	 and	 identify	 gross	 deletions	 or	 duplications.	 To	 date,	 17	 distinct	 whole-exon	
mutations	have	been	identified	in	SLC3A1	(Stenson	et	al.,	2014).	Following	the	identification	of	
causal	 variants,	 segregation	 analysis	was	 carried	out	 using	 gDNA	 samples	 from	 the	patients’	
relatives	to	determine	the	mode	of	inheritance	of	both	known	and	novel	pathogenic	variants	
in	SLC3A1	and	SLC7A9.		
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3.2	Methods	
Patients	1-26	of	the	cystinuria	cohort	were	 investigated	for	mutations	 in	SLC3A1	and	
SLC7A9	 using	 the	 CEL-I	 endonuclease	 detection	 protocol	 described	 in	 Chapter	 2.	 Sanger	
sequencing	of	all	exons	of	the	two	genes	was	employed	to	determine	the	genotype	of	Patients	
28-31.	Patients	32-44	were	recruited	to	the	study	by	Dr.	John	Sayer	at	the	Freeman	Hospital,	
Newcastle	 upon	 Tyne,	 however	 their	 genotype	 was	 determined	 using	 Next	 Generation	
Sequencing	methods	by	Dr.	F	Hildebrandt	(Boston	Children’s	Hospital,	Boston,	MA)	as	part	of	a	
larger	study	to	investigate	the	genetic	cause	of	nephrolithiasis	and	nephrocalcinosis	(Halbritter	
et	al.,	2014).	Multiplex	Ligation-dependent	Probe	Amplification	(MLPA)	was	carried	out	 in	11	
patients	from	our	cohort	in	the	laboratory	of	Professor	Richard	Coward	(Bristol	University)	as	
part	of	a	collaboration	to	form	a	large	cohort	of	cystinuric	patients	(Rhodes	et	al.,	2015).	
3.3	Results	
3.3.1	A	cohort	of	cystinuric	patients	
The	 initial	 cohort	 recruited	 to	 this	 study	 consisted	 of	 27	 patients.	 Throughout	 the	
course	of	the	study	a	further	17	patients	were	recruited	and	the	complete	cohort	consisted	of	
44	patients.	In	this	report,	we	include	the	genotyping	data	of	42	of	these	patients.	Patients	16	
and	27	were	initially	included	in	the	investigation,	however	they	were	discovered	to	not	have	a	
clinical	 diagnosis	 of	 cystinuria.	 Therefore,	 retrospectively,	 they	 did	 not	 meet	 the	 inclusion	
criteria.	 Thus,	 for	 the	 purposes	 of	 this	 report	 they	 have	 been	 excluded.	 All	 of	 the	 patients	
included	 in	 this	 report	 had	 a	 clinical	 diagnosis	 of	 cystinuria	 confirmed	 through	 chemical	
analysis	of	 cystine	 stones.	The	 three	exceptions	 to	 this	 inclusion	criterion	were	Patients	7,	9	
and	13,	who	presented	with	renal	colic	and	were	found	to	have	a	dibasic	aminoaciduria.		
Clinical	data	were	available	for	Patients	1-21	(Table	3.1).	From	these	data	we	can	see	
that	there	 is	 large	range	in	the	age	of	presentation	and	diagnosis	of	cystinuria	(2-48y,	and	2-
49y,	 respectively).	 These	 data	 are	 also	 displayed	 in	 Figure	 3.1A	 and	 B.	 The	 calculated	mean	
ages	of	presentation	and	clinical	diagnosis	in	cystinuria	are	24.3y	and	22.8y,	respectively.	This	
is	 in	 agreement	with	 the	 findings	 of	Wong	 et	 al.	 (2015)	who	 showed	 that	 the	mean	 age	 of	
clinical	 presentation	 in	 a	 cohort	 of	 74	 patients	 in	 the	 UK	 was	 23y.	 Rhodes	 et	 al.	 (2015)	
identified	the	median	age	at	first	stone	event	in	a	cohort	of	72	patients	to	be	23y.	The	mean	
number	of	stones	requiring	surgical	intervention	in	the	cohort	was	5.6	(Figure	3.1D),	although	
from	 the	data	 presented	 in	 Table	 3.1	 it	 is	 clear	 that	many	patients	 pass	 stones	 through	 the	
urethra,	 without	 requiring	 intervention.	 The	 figures	 for	 patients	 passing	 stones	 without	
intervention	may	not	be	accurate	as	it	has	been	suggested	that	patients	do	not	reliably	report	
stone	episodes	(Thomas	et	al.,	2014).	
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The	mean	solubility	of	cystine	in	the	urine	at	pH7,	37°C	is	1.4mM	(300mg.l-1)	(Goldfarb	
et	al.,	2006;	Thomas	et	al.,	2014).	In	water,	at	25°C,	this	is	reduced	to	<460μM	(O'Neil,	2006).	
From	the	data	in	Table	3.1,	we	can	see	that	only	Patient	19	has	a	urinary	cystine	concentration	
higher	than	this	value	(1.8mM).	The	mean	urinary	cystine	concentration	for	the	patients	in	this	
cohort	was	0.92mM	(Figure	3.1C).	However,	 these	were	spot	urine	 tests	 taken	 following	 the	
commencement	of	various	cystinuria	therapies.	They	may	not	be	reflective	of	the	patients’	24h	
urinary	 cystine	 levels,	 or	 those	 that	 would	 be	 measured	 in	 the	 absence	 of	 therapeutic	
intervention.	Additionally,	it	can	be	noted	from	the	data	that	despite	the	apparently	low	levels	
of	cystine	in	the	urine,	patients	continue	to	form	cystine	stones	(Table	3.1).	Additionally,	it	has	
been	 reported	 that	 urinary	 cystine	 is	 a	 poor	 marker	 of	 disease	 activity	 due	 to	 the	 rapid	
precipitation	 of	 cystine	 at	 pathophysiological	 concentrations	 (Wong	 et	 al.,	 2015).	 For	 this	
reason,	 it	 may	 be	 more	 reliable	 to	 assess	 urinary	 arginine	 or	 lysine	 concentrations	 as	 a	
measure	of	phenotype	severity	(Pardy	et	al.,	2011;	Thomas	et	al.,	2014;	Wong	et	al.,	2015)	
Of	the	20	patients	presented	in	Table	3.1,	17	were	receiving	treatment	for	cystinuria.	
Patients	 7,	 9,	 and	13,	who	have	no	 reported	 incidence	of	 kidney	 stone	 formation,	were	not	
undergoing	therapeutic	intervention	(Table	3.1).	The	most	common	treatment	reported	in	our	
cohort	(15/20)	was	the	administration	of	30-40ml	potassium	citrate	daily	(Table	3.1).	The	use	
of	sodium	bicarbonate	for	urinary	alkalinisation	was	less	popular	(6/20),	most	likely	due	to	the	
hypertensive	risk	accompanying	the	administration	of	the	sodium	salt	(Thomas	et	al.,	2014).		
	 Of	 the	 20	 patients	 for	 which	 clinical	 data	 was	 collected,	 12	 had	 been	 prescribed	 at	
least	one	 cystine	binding	 thiol	drug	 (CBTD)	 following	 their	diagnosis.	Of	 these	12	patients,	 6	
had	discontinued	treatment	with	at	least	one	CTBD	due	to	intolerable	side	effects	(Table	3.1).	
This	 is	 in	 accordance	 with	 the	 statistics	 reported	 in	 the	 literature	 on	 the	 high	 incidence	 of	
adverse	reactions,	which	include	renal	or	hepatic	failure,	rashes	and	SLE	(Thomas	et	al.,	2014).	
The	 poor	 tolerance	 of	 CBTD	 highlights	 the	 importance	 of	 the	 discovery	 of	 novel	 therapies,	
which	 are	 targeted	 to	 correcting	 the	 function	 of	 the	 transport	 system,	 and	 have	 a	 lower	
adverse	 reaction	 profile.	 For	 this	 reason,	 the	 focus	 of	 cystinuria	 research	 has	 turned	 to	 the	
genetic	basis	of	the	disease	to	further	understand	the	underlying	pathophysiology.		
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Table	3.1:	Clinical	data	 from	20	patients	of	 the	cystinuria	cohort.	Where	data	for	 individual	
patients	were	unavailable,	this	is	indicated	by	--.	Dark	grey	boxes	indicate	the	patient	has	not	
taken	the	indicated	therapy;	green	boxes	indicate	the	patient	is	currently	receiving	therapy	at	
the	stated	dose;	orange	boxes	indicate	that	the	drug	was	discontinued	at	the	stated	dose	due	
to	inefficacy;	red	boxes	indicate	that	therapy	was	terminated	due	to	the	side	effects	stated	in	
the	 box.	 OD,	 once	 daily;	 BD,	 twice	 daily;	 TDS,	 three	 times	 daily;	 QDS,	 four	 times	 daily;	 SLE,	
systemic	 lupus	 erythematosus.	 The	 three	 patients	 who	 have	 never	 presented	 with	 kidney	
stones	but	were	diagnosed	with	cystinuria	based	upon	a	dibasic	aminoaciduria	and	renal	colic	
are	 highlighted	 in	 blue.	 y,	 year;	 w,	 week.	 These	 data	 were	 supplied	 by	 Dr.	 John	 Sayer,	
Newcastle	University.	
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Figure	3.1:	Analysis	of	 the	clinical	data	 for	cystinuria	Patients	1-21.	Calculation	of	the	mean	
values	for	age	of	first	renal	colic	(A),	age	at	diagnosis	(B),	urinary	cystine	concentration	(C),	and	
the	 number	 of	 stones	 requiring	 surgical	 intervention	 (D)	 from	 the	 available	 patient	 data	
presented	in	Table	3.1.	The	mean	values	are	stated	next	to	the	mean	bar	on	each	graph.	These	
data	were	supplied	by	Dr.	John	Sayer,	Newcastle	University.	
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3.3.2	Detection	of	cystinuria	mutations	using	CEL-I	endonuclease	
As	described	in	section	3.3.1,	the	initial	cohort	recruited	to	this	study	consisted	of	27	
patients,	2	of	which	(16	and	27)	were	excluded	from	analysis	in	this	report.	The	25	remaining	
patients	 of	 the	 cohort	 (1-15,	 17-26)	 were	 investigated	 through	 the	 employment	 of	 a	 CEL-I	
endonuclease	detection	protocol	 (Oleykowski	 et	al.,	 1998).	 This	mutation	detection	protocol	
was	 outlined	 in	 detail	 in	 Chapter	 2.	 The	 reason	 for	 the	 use	 of	 this	method	 in	 our	 cystinuria	
cohort	was	to	rapidly	screen	through	the	exons	of	SLC3A1	and	SLC7A9	in	a	pair-wise	fashion	to	
detect	 pathogenic	mutations.	 Additionally,	 this	was	 proposed	 to	 be	 a	 technique	 that	would	
allow	 expansion	 to	 high-throughput	 screening	 in	 a	 larger	 cohort,	 where	 larger	 numbers	 of	
patient	 samples	would	be	combined	 to	 form	heteroduplexes.	As	described	 in	Chapter	2,	 the	
detection	 of	 a	 DNA	 fragment	 band	 following	 endonuclease	 treatment	 of	 patient-pair	
heteroduplexes	 led	 to	 both	 samples	 being	 sent	 for	 Sanger	 sequencing.	 This	 allowed	 the	
identification	 of	 the	 sequence	 variant	 that	 led	 to	 a	 heteroduplex	 mismatch,	 and	 ultimately	
cleavage	of	the	double-stranded	DNA.	Patients	1-15	and	17-21	were	investigated	by	Dr.	Noel	
Edwards	 in	 the	 preliminary	 investigations	 of	 this	 study.	 The	 remaining	 patients	 (22-26),	 I	
investigated	personally.		
Using	 this	 method	 we	 “solved”	 the	 genotype	 of	 14/25	 patients	 (56%)	 (Table	 3.2).	
Patients	 were	 classed	 as	 “solved”	 following	 the	 identification	 of	 two	 pathogenic	 SLC3A1	
mutations	 (Type	AA),	 at	 least	 one	 variant	 in	SLC7A9	 (Type	B	 or	 BB),	 or	 one	mutant	 allele	 in	
each	gene	 (Type	AB).	No	patients	 in	 this	 cohort	were	discovered	 to	have	Type	AB	cystinuria	
(Table	3.2).	Five	of	the	patients	had	two	causative	mutations	in	SLC3A1	(Type	AA),	and	six	had	
a	single	mutated	allele	in	SLC7A9	(Table	3.2).	Additionally,	three	patients	had	two	mutations	in	
SLC7A9	 (BB).	 Two	 of	 these	 patients	 (15	 and	 19)	 were	 compound	 heterozygotes	 for	 known	
SLC7A9	missense	mutations,	and	a	single	patient	had	a	homozygous	intronic	deletion	(Patient	
21,	Table	3.2).	
Genetic	variants	 in	the	two	genes	were	classed	as	pathogenic	 if	they	were	previously	
reported	 cystinuria	mutations.	 Repeated	 Sanger	 sequencing	 of	 the	 single	 exon	 in	which	 the	
mutation	 fell	 confirmed	 the	 identification	 of	 novel,	 potentially	 causal,	 variants.	 These	
potentially	 pathogenic	 variants	 were	 confirmed	 as	 being	 absent	 in	 the	 general	 population	
through	 consultation	 with	 the	 Exome	 Aggregation	 Consortium	 (ExAC)	 database.	 This	 online	
resource	holds	the	genetic	data	of	121,142	sequenced	alleles	taken	from	disease-specific	and	
population	 genetic	 studies	 	(Exome	 Aggregation	 Consortium	 (ExAC),	 Cambridge,	 MA	 (URL:	
http://exac.broadinstitute.org),	August,	2015).	To	date,	this	is	the	largest	available	resource	of	
population	genetic	data.			
In	 SLC3A1,	 the	 gene	 encoding	 rBAT,	 most	 mutations	 are	 inherited	 in	 an	 autosomal	
recessive	 pattern	 (Dello	 Strologo	 et	 al.,	 2002).	 In	 this	 gene,	 6	 rare	 sequence	 variants	 were	
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discovered	 (Table	 3.2).	 Two	 of	 these	 mutations,	 M467T	 and	 R452W,	 had	 previously	 been	
reported	in	the	literature	as	causal	cystinuria	mutations	(de	Sanctis	et	al.,	1996;	Endsley	et	al.,	
1997;	Gitomer	 et	al.,	 1998;	Guillen	 et	al.,	 2000;	Bisceglia	 et	al.,	 2001;	Kleparnik	 et	al.,	 2004;	
Schmidt	et	al.,	2004a;	Skopkova	et	al.,	2005).	Four	novel,	and	potentially	pathogenic,	variants	
were	identified:	N254T	(exon	3),	L416P	(exon	7),	M465K	(exon	8),	and	Y579D	(exon	10)	(Table	
3.2).		
Novel	mutation	N254T	was	identified	in	Patient	2	of	the	cohort	(Table	3.2).	A	fragment	
band	 of	 lower	 molecular	 weight	 than	 the	 262bp	 exon	 band	 was	 identified	 following	
electrophoretic	 resolution	 of	 CEL-I	 treated	 heteroduplexes	 formed	 between	 SLC3A1	 exon	 3	
amplicons	of	Patients	1	and	2	(Figure	3.2A).	Following	Sanger	sequencing,	the	chromatograph	
revealed	a	heterozygous	Asn>Thr	missense	mutation	caused	by	a>c	base	change	in	exon	3	of	
SLC3A1	 (Figure	3.2A).	This	base	change	was	absent	 in	Patient	1,	who	had	 the	wild-type	DNA	
sequence	in	this	region	of	exon	3	(Figure	3.2A).	The	N254T	variant	was	not	identified	in	any	of	
the	alleles	recorded	 in	the	ExAC	database	and	was,	therefore,	proposed	to	be	a	novel	casual	
variant	 of	 cystinuria.	 A	 missense	 mutation,	 N253S,	 was	 recorded	 as	 a	 rare	 variant	 in	 the	
flanking	 residue	 in	 1/121168	 alleles	 of	 the	 ExAC	 database	 (http://exac.broadinstitute.org,	
August,	2015).		
A	 second	 novel	 variant	 was	 identified	 in	 exon	 7	 of	 SLC3A1	 (Table	 3.2).	 The	
heterozygous	leucine	to	proline	amino	acid	substitution	at	position	416	in	the	protein	(L416P)	
was	 identified	 in	 Patient	 26	 of	 the	 cohort	 in	 combination	 with	 known	 cystinuria	 mutation	
M467T	(Table	3.2).	The	amplicon	of	exon	7	was	303	bases	in	size,	yet	following	CEL-I	treatment	
of	 the	 Patient	 25/26	 heteroduplex,	 a	 fragment	 band	 of	 around	 150bp	 in	 size	was	 identified	
(Figure	3.2B).	This	led	to	the	Sanger	sequencing	of	both	of	these	patients	in	exon	7	of	SLC3A1.	
The	 sequencing	 results	 revealed	 a	 heterozygous	 t>c	 base	 change	 in	 Patient	 26,	 causing	 the	
mutation	L416P	at	the	protein	level	(Figure	3.2B).	Patient	25	carried	the	wild-type	allele	in	the	
region	of	this	mutation	(Figure	3.2B).	This	mutation	has	not	been	reported	in	the	literature	as	a	
cystinuria	 variant	 (Stenson	 et	 al.,	 2014).	 However,	 in	 the	 ExAC	 database	 L416P	 has	 been	
detected	heterozygously	in	two	individuals	of	South	Asian	and	European	origin.	Unfortunately,	
from	the	ExAC	database,	we	cannot	retrieve	any	clinical	 information	about	the	phenotype	of	
the	patients.			
A	novel	missense	variant,	M465K,	was	detected	homozygously	in	exon	8	of	SLC3A1	of	
Patient	25	(Table	3.2).	This	mutation	was	identified	following	the	detection	of	a	fragment	band	
produced	with	CEL-I	endonuclease	treatment	of	the	Patient	25/26	exon	8	heteroduplex	(Figure	
3.3A).	 Following	Sanger	 sequencing,	 a	homozygous	 t>a	base	 change	was	detected	 in	Patient	
25,	which	was	absent	in	Patient	26	(Figure	3.3A).	The	missense	mutation	M465K	has	not	been	
recorded	 in	 the	 ExAC	 database.	 However,	 rare	 variants	 are	 present	 at	 flanking	 residues	
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(Q460E,	Y461H,	V464M,	M467T	and	M467K).	This	could	 indicate	an	importance	in	the	region	
of	the	translated	protein	on	transporter	function.		
The	 final	 novel	 missense	 variant	 detected	 in	 SLC3A1	 of	 our	 cohort	 by	 the	 CEL-I	
endonuclease	detection	method	was	Y579D.	This	mutation	was	 identified	 in	exon	10	of	 two	
unrelated	 patients,	 6	 and	 20	 (Table	 3.2).	 Fragment	 bands	 were	 detected	 following	
endonuclease	treatment	of	Patient	5/6	and	19/20	exon	10	heteroduplexes	(Figure	3.3B,	lanes	c	
and	d,	respectively).	Sanger	sequencing	revealed	a	heterozygous	t>g	base	change	in	exon	10	of	
both	 of	 these	 patients,	which	 led	 to	 a	 Tyr	 to	 Asp	 amino	 acid	 change	 at	 position	 579	 in	 the	
protein	 (Figure	 3.3B).	 This	mutation	 has	 not	 been	 reported	 previously	 as	 a	 causal	 variant	 in	
cystinuria,	 nor	 is	 it	 recorded	 in	 the	 ExAC	 database	 (http://exac.broadinstitute.org,	 August,	
2015).	 The	 mutation	 was	 present	 in	 the	 genotype	 of	 Patients	 6	 and	 20,	 along	 with	 known	
pathogenic	SLC3A1	variants	R452W	and	M467T	(Table	3.2).		
A	 rare	 variant	was	also	detected	 in	SLC7A9	 (Table	3.2).	 The	 intronic	deletion	of	 four	
bases	 (AGTA),	 3	 bases	 downstream	 of	 exon	 12	 (c.1586+3)	 was	 detected	 heterozygously	 in	
Patient	9	and	homozygously	in	Patient	21	(Table	3.2).	This	mutation	was	identified	by	Sanger	
sequencing	following	detection	of	a	fragment	band	of	smaller	size	than	the	exon	12	amplicon	
(370bp)	in	heteroduplexes	of	Patients	9/10	and	21/22	(Figure	3.4B,	lanes	c	and	d,	respectively).	
In	 the	 chromatograph	 of	 Patient	 9	 (Figure	 3.4A),	 the	 frame	 shift	 caused	 by	 the	 four-base	
deletion	can	be	seen	clearly	in	this	heterozygous	patient.	In	Patient	22,	both	alleles	have	this	
deletion	(Figure	3.4A).	As	the	deletion	lies	so	close	to	the	3’	coding	region	of	exon	12,	it	is	likely	
that	the	variant	could	affect	mRNA	splicing	in	vivo.	This	variant	was	unreported	at	the	time	of	
identification,	however,	has	subsequently	been	identified	in	a	distinct	cohort	of	UK	cystinuric	
patients,	supporting	the	hypothesis	that	this	intronic	mutation	affects	splicing	and	subsequent	
protein	function	(Wong	et	al.,	2015).	Additionally,	other	rare	mutations	have	been	reported	in	
this	 intronic	 region	 on	 the	 ExAC	 database.	 These	 include	 c.1586+2insA,	 c.1586+9delA,	 and	
c.1586+9delAGTA.	All	3	variants	were	identified	in	<0.0001	of	the	participants	in	the	database		
(http://exac.broadinstitute.org,	August,	2015).	
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Gene	 SLC3A1	 SLC7A9	 Mutated	
alleles	 Type	 Solved	Patient	 Allele	1	 Allele	2	 Allele	1	 Allele	2	
1	 	 	 A224A/V	 	 1	 B	 Y	
2	 N254N/T	 	 	 	 1	 A	 N	
3	 	 	 	 	 0	 --	 N	
4	 	 	 	 	 0	 --	 N	
5	 M467M/T	 	 	 	 1	 A	 N	
6	 R452R/W	 Y579Y/D	 	 	 2	 AA	 Y	
7	 	 	 G105G/R	 	 1	 B	 Y	
8	 	 	 	 	 0	 --	 N	
9	 	 	
	Heterozygous	
c.1586+3_delAGTA	  1	 B	 Y	
10	 	 	 A224A/V	 	 1	 B	 Y	
11	 	 	 	 	 0	 --	 N	
12	 	 	 A224A/V	 	 1	 B	 Y	
13	 	 	 	 	 0	 --	 N	
14	 M467M/T	 	 	 	 1	 A	 N	
15	 	 	 A182A/T	 A354A/T	 2	 BB	 Y	
17	 R452R/W	 M467M/T	 	 	 2	 AA	 Y	
18	 M467M/T	 	 	 	 1	 A	 N	
19	 	 	 T132T/M	 A224A/V	 2	 BB	 Y	
20	 M467M/T	 Y579Y/D	 	 	 2	 AA	 Y	
21	 	 	
Homozygous	
c.1586+3_delAGTA	 	 2	 BB	 Y	
22	 	 	 	 	 0	 --	 N	
23	 	 	 	 	 0	 --	 N	
24	 	 	 A224A/V	 	 1	 B	 Y	
25	 M465K	 	 	 	 2	 AA	 Y	
26	 M467M/T	 L416L/P	 	 	 2	 AA	 Y	
	
	
Table	3.2:	Summary	of	pathogenic	mutations	identified	by	the	CEL-I	endonuclease	detection	
method	in	patients	1-15	and	17-26	of	the	cohort.	Heterozygous	missense	mutations	are	listed	
with	both	the	wild-type	and	mutant	allele	i.e.	M467M/T.	c.,	mutations	at	the	cDNA	level;	del,	
deletion.	Novel	variants	are	highlighted	 in	red.	Patients	1-15	and	17-21	were	 investigated	by	
Dr.	Noel	Edwards	prior	to	the	start	of	this	investigation.		
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Figure	3.2:	Chromatographs	of	patients	 in	which	novel	SLC3A1	mutations	N254T	and	L416P	
were	 identified.	A,	Sanger	sequencing	results	of	SLC3A1	exon	3	in	Patients	1	and	2.	Patient	2	
had	 a	 heterozygous	 A>C	 base	 change	 leading	 to	 the	 missense	 mutation	 N254T	 (*).	 This	
mutation	was	 detected	 following	 identification	 of	 a	 DNA	 fragment	 band	 of	 lower	molecular	
weight	 than	the	262bp	amplicon	of	exon	3.	A,	100bp	DNA	 ladder;	b,	Surveyor™	control	DNA	
heteroduplex	 (600bp)	with	 a	 single	 base	mismatch	 leading	 to	 cleavage	 products	 400bp	 and	
200bp	 in	 size	 following	CEL-I	 treatment;	 c,	P1/2	SLC3A1	exon	3	amplicon	heteroduplex	band	
(262bp)	 and	 a	 fragment	 band	 of	 lower	 molecular	 weight.	 B,	 Sanger	 sequencing	 results	 of	
SLC3A1	exon	7	in	Patients	25	and	26.	Patient	26	had	a	heterozygous	T>C	base	change	leading	
to	the	missense	mutation	L416P	(*).	This	mutation	was	detected	following	 identification	of	a	
DNA	fragment	band	of	lower	molecular	weight	than	the	303bp	amplicon	of	exon	7.	A,	100bp	
DNA	 ladder;	 b,	 Surveyor™	 control	 DNA	 heteroduplex	 (600bp)	 with	 a	 single	 base	 mismatch	
leading	 to	 cleavage	 products	 400bp	 and	 200bp	 in	 size	 following	 CEL-I	 treatment;	 c,	 P25/26	
SLC3A1	exon	7	amplicon	heteroduplex	band	(303bp)	and	a	fragment	band	of	lower	molecular	
weight.	
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Figure	3.3:	Chromatographs	of	patients	in	which	novel	SLC3A1	mutations	M465K	and	Y579D	
were	identified.	A,	Sanger	sequencing	results	of	SLC3A1	exon	8	in	Patients	25	and	26.	Patient	
25	 had	 a	 homozygous	 T>A	 base	 change	 leading	 to	 the	 missense	 mutation	M465K	 (*).	 This	
mutation	was	 detected	 following	 identification	 of	 a	 DNA	 fragment	 band	 of	 lower	molecular	
weight	 than	the	379bp	amplicon	of	exon	8.	A,	100bp	DNA	 ladder;	b,	Surveyor™	control	DNA	
heteroduplex	 (600bp)	with	 a	 single	 base	mismatch	 leading	 to	 cleavage	 products	 400bp	 and	
200bp	in	size	following	CEL-I	treatment;	c,	P25/26	SLC3A1	exon	8	amplicon	heteroduplex	band	
(379bp)	 and	 2	 fragment	 bands	 of	 lower	 molecular	 weight.	 B,	 Sanger	 sequencing	 results	 of	
SLC3A1	 exon	 10a	 in	 Patients	 5,	 6	 and	 20.	 Patients	 6	 and	 20	 had	 a	 heterozygous	 T>G	 base	
change	 leading	 to	 the	 missense	 mutation	 Y579D	 (*).	 This	 mutation	 was	 detected	 following	
identification	of	a	DNA	fragment	band	of	lower	molecular	weight	than	the	364bp	amplicon	of	
exon	10a.	A,	100bp	DNA	ladder;	b,	Surveyor™	control	DNA	heteroduplex	(600bp)	with	a	single	
base	 mismatch	 leading	 to	 cleavage	 products	 400bp	 and	 200bp	 in	 size	 following	 CEL-I	
treatment;	 c,	 P5/6	 SLC3A1	 exon	 10a	 amplicon	 heteroduplex	 band	 (364bp)	 and	 a	 fragment	
band	 of	 lower	 molecular	 weight;	 d,	 P19/20	 SLC3A1	 exon	 10a	 amplicon	 heteroduplex	 band	
(364bp)	and	a	fragment	band	of	lower	molecular	weight.	
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Figure	3.4:	Chromatographs	of	patients	in	which	a	four	base	intronic	deletion	in	SLC7A9	was	
identified.	A,	Sanger	sequencing	results	of	SLC7A9	exon	12	in	Patients	9	and	22,	plus	the	wild-
type	 reference	 sequence.	 Patient	 9	 had	 a	 heterozygous	 deletion	 of	 AGTA,	 3	 bases	 down	
stream	 of	 the	 end	 of	 exon	 12,	 in	 the	 splicing	 region.	 This	mutation	was	 detected	 following	
identification	of	a	DNA	fragment	band	of	lower	molecular	weight	than	the	370bp	amplicon	of	
exon	12.	The	same	mutation	was	identified	homozygously	in	Patient	22.	B,	Image	of	the	gel	on	
which	 the	 fragment	 band	 was	 identified	 following	 CEL-I	 endonuclease	 treatment	 of	
heteroduplexes;	a,	100bp	DNA	ladder;	b,	Surveyor™	control	DNA	heteroduplex	(600bp)	with	a	
single	 base	mismatch	 leading	 to	 cleavage	 products	 400bp	 and	 200bp	 in	 size	 following	 CEL-I	
treatment;	 c,	 P9/10	 SLC7A9	 exon	 12	 amplicon	 heteroduplex	 band	 (370bp)	 and	 a	 fragment	
band	 of	 lower	 molecular	 weight;	 d,	 P21/22	 SLC3A1	 exon	 12	 amplicon	 heteroduplex	 band	
(370bp)	and	a	fragment	band	of	lower	molecular	weight.	
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3.3.3	Mutation	detection	by	Sanger	Sequencing	
Not	 all	 patients	 had	 their	 phenotype	 explained	 by	 causal	 mutations	 following	
investigation	 with	 the	 CEL-I	 endonuclease	 protocol.	 Therefore,	 patients	 who	 remained	
unsolved	had	all	exons	of	SLC3A1	and	SLC7A9	sequenced	by	Sanger	sequencing	following	PCR	
amplification.	 Four	 additional	 patients	 had	 also	 been	 recruited	 to	 this	 study,	 and	 were	
investigated	by	Sanger	sequencing	of	all	SLC3A1	and	SLC7A9	amplicons.		
In	 Patients	 1-15,	 and	 17-26	 no	 additional	mutations	were	 discovered.	 This	 validated	
the	use	of	the	CEL-I	endonuclease	treatment	as	a	sensitive	mutation	detection	protocol	in	the	
identification	of	small	point	mutations	in	the	amplified	regions	of	DNA.	We	must	assume	that	
the	patients	who	remain	unsolved	have	mutations	in	intronic	regions,	or	heterozygous	whole	
exon	 deletions	 or	 duplications,	 which	 cannot	 be	 identified	 through	 non-quantitative	 Sanger	
sequencing.	To	date,	no	other	genes	have	been	confirmed	to	have	a	role	in	cystinuria	(Leclerc	
et	al.,	2001;	Brauers	et	al.,	2005).		
The	four	additional	patients	recruited	to	the	study	had	their	genotype	solved	through	
Sanger	 sequencing	of	all	exonic	 regions	of	SLC3A1	 and	 SLC7A9.	Patients	28	and	29	were	not	
recruited	through	the	Freeman	Hospital,	but	were	siblings	recruited	to	the	study	at	 the	Rare	
Kidney	 Stone	 Consortium	 (RKSC)	 patient	 information	 day.	 They	 are	 the	 only	 two	 patients	
recruited	remotely,	and	the	only	two	related	patients	in	the	cohort.	They	were	discovered	to	
have	 homozygous	 R452W	 mutations	 in	 SLC3A1,	 solving	 their	 genotype	 (Table	 3.3).	 The	
segregation	analysis	of	this	mutation	was	investigated	and	is	reported	in	section	3.3.7.	Patients	
30	 and	 31	were	 unrelated,	 but	 both	 had	 known	 causal	 variant	G105R	 in	SLC7A9	 (Table	 3.3)	
(Feliubadalo	et	al.,	1999;	Font	et	al.,	2001;	Schmidt	et	al.,	2004a;	Chatzikyriakidou	et	al.,	2008).	
However,	Patient	31	also	had	a	novel	variant,	the	duplication	of	an	adenosine	base	in	exon	6,	
causing	the	missense	mutation	N260E,	and	a	frame	shift	 in	the	coding	sequence.	This	variant	
leads	to	an	early	termination	codon	(TGA)	3	amino	acids	downstream	from	the	site	of	the	base	
duplication,	 at	 position	 262	 (Figure	 3.5).	 This	 is	 previously	 unreported,	 and	 due	 to	 the	
introduction	of	an	early	termination	codon,	we	would	expect	it	to	be	pathogenic.		
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Gene	 SLC3A1	 SLC7A9	
Mutated	alleles	 Type	 Solved	
Patient	 Allele	1	 Allele	2	 Allele	1	 Allele	2	
28	 R452W	 		 	 	 2	 AA	 Y	
29	 R452W	 		 	 	 2	 AA	 Y	
30	 	 	 G105G/R	
c.614dup	
p.N206Efs*3	 2	 BB	 Y	
31	 	
	
	 G105G/R	 	 1	 B	 Y	
	
Table	 3.3:	 Pathogenic	 variants	 identified	 in	 Patients	 28-31	 of	 the	 cohort	 by	 Sanger	
Sequencing.	Heterozygous	missense	mutations	are	listed	with	both	the	wild-type	and	mutant	
allele	 i.e.	 G105G/R;	 c.,	 mutations	 at	 the	 cDNA	 level;	 dup,	 duplication.;	 fs,	 frame	 shift;	 *3,	
introduction	of	a	termination	codon	(TGA)	3	amino	acids	downstream	of	the	duplication.	Novel	
variants	are	highlighted	in	red.	
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Figure	 3.5:	 A	 novel	 SLC7A9	 base	 duplication	 identified	 in	 Patient	 31	 of	 the	 cohort.	 Sanger	
sequencing	results	of	SLC7A9	exon	5	in	Patient	31,	plus	the	wild-type	reference	sequence	from	
Patient	2,	shown	as	an	example.	Patient	31	had	a	heterozygous	insertion	of	an	adenosine	base,	
leading	 to	 the	missense	mutation	N260E,	 and	 a	 frame	 shift.	 The	 frame	 shift	 also	 led	 to	 the	
introduction	of	a	termination	codon	(TGA)	at	position	262	in	the	protein.		
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3.3.4	Mutation	detection	by	Next	Generation	Sequencing		
Patients	32-44	of	the	cohort	were	recruited	to	the	study	through	the	Freeman	Hospital	
in	Newcastle-upon-Tyne.	However,	their	DNA	samples	were	sequenced	using	Next	Generation	
Sequencing	(NGS)	methods	in	the	laboratory	of	Dr.	F	Hildebrandt,	Boston	Children’s	Hospital,	
Boston,	MA.	This	was	because	they	were	 included	 in	the	report	by	Halbritter	et	al.	 (2014)	as	
part	of	a	cohort	of	272	genetically	unresolved	individuals	with	nephrolithiasis.	Once	identified,	
the	 detection	 of	mutations	 by	 the	 high-throughput	 NGS	 platform	was	 confirmed	 by	 Sanger	
sequencing.	 In	 the	published	study,	 the	 individuals	were	screened	 for	mutations	 in	30	genes	
known	 to	 be	 involved	 in	 nephrolithiasis.	 This	 included	 SLC3A1	 and	 SLC7A9	 (Table	 3.4)	
(Halbritter	 et	 al.,	 2014).	 For	 the	 amplification	 of	 SLC3A1	 and	 SLC7A9,	 the	 same	 primer	
sequences	were	used.	Therefore,	the	same	regions	of	gDNA	were	investigated.	The	use	of	the	
high-throughput	sequencing	platform	enabled	the	simultaneous	screening	of	an	additional	28	
genes	in	these	patients	(Table	3.4).		
Next	Generation	Sequencing	(NGS)	technologies	have	been	developed	in	recent	years	
to	replace	Sanger	technology.	The	principles	behind	NGS	were	discussed	 in	Chapter	1.	 In	the	
current	study,	Patients	32-44	were	sequenced	by	NGS	following	amplification	of	428	amplicons	
across	 30	 genes	 known	 to	 be	 involved	 in	 monogenic	 causes	 of	 nephrolithiasis	 (Table	 3.5).	
Through	NGS	of	Patients	32-44,	85%	had	 their	genotype	solved	 through	 the	 identification	of	
mutations	 in	 SLC3A1	 and	 SLC7A9	 (Table	 3.5).	 In	 the	 two	 unsolved	 patients,	 one	 was	
heterozygous	 for	 M467T	 in	 SLC3A1	 (Patient	 38)	 and	 in	 the	 second,	 no	 mutations	 were	
discovered	(Patient	35).	It	is	possible	that	these	patients	had	large	deletions	or	duplications	of	
whole	or	multiple	exons,	which	would	only	be	identified	through	a	quantitative	technique	such	
as	 MLPA.	 No	 pathogenic	 mutations	 were	 identified	 in	 the	 28	 other	 genes	 included	 in	 the	
investigation,	 supporting	 the	 hypothesis	 that	 only	 SLC3A1	 and	 SLC7A9	 are	 involved	 in	
cystinuria.	 However,	 SLC7A9	 mutations	 were	 identified	 in	 calcium	 phosphate	 and	 calcium	
oxalate-stone	forming	patients,	who	were	not	previously	thought	to	be	cystinuric	(Halbritter	et	
al.,	2014).	This	supports	the	hypothesis	that	a	cystine	nidus	in	the	filtrate	of	a	cystinuric	patient	
can	 lead	to	calcium	aggregation	and	the	 formation	of	calcium	stones,	 leading	 to	a	missed	or	
delayed	diagnosis	of	cystinuria	 (Rice	et	al.,	2014).	A	summary	of	all	point	mutations	or	small	
insertions/deletions	(indels)	identified	in	the	cohort	using	the	methods	described	thus	far	are	
displayed	in	Table	3.6.	
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Gene	Symbol	 Accession	Number	 Disease	 Mode	
ADCY10/SAC	 NM_018417.4	 Idiopathic	hypercalciuria	 AD	
AGXT	 NM_000030.2	 Primary	hyperoxaluria	 AR	
APRT	 NM_000485.2	 APRT	deficiency	 AR	
ATP6V0A4	 NM_020632.2	 dRTA	 AR	
ATP6V1B1	 NM_001692.3	 dRTA	with	deafness	 AR	
CA2	 NM_000067.2	 Osteopetrosis	+dRTA	 AR	
CASR	 NM_001178065.1	 Hypocalcaemia	with	Bartter	Syndrome	 AD	
CLCN5	 NM_001127898.3	 Dent	disease	 XR	
CLCNKM	 NM_000085.4	 Bartter	Syndrome	 AR	
CLDN16	 NM_006580.3	 FHHNC	 AR	
CLDN19	 NM_001123395.1	 FHHNC	and	ocular	abnormalities	 AR	
CYP24A1	 NM_000782.4	 Infantile	hypercalcaemia	 AR	
FAM20A	 NM_017565.3	 Enamel-Renal	syndrome	 AR	
GRHPR	 NM_012203.1	 Primary	hyperoxaluria	 AR	
HNF4A	 NM_000457.4	 MODY	and	Fanconi	Syndrome	 AD	
HOGA1	 NM_138413.3	 Primary	hyperoxaluria	 AR	
HPRT1	 NM_000194.2	 Kelley-Seegmiller	syndrome	 XR	
KCNJ1	 NM_000220.4	 Bartter	syndrome	 AR	
OCRL	 NM_000276.3	 Lowe	syndrome	 XR	
SLC12A1	 NM_000338.2	 Bartter	syndrome	 AR	
SLC22A12	 NM_144585.3	 Renal	hypouricemia	(RHUC1)	 AD/AR	
SLC2A9	 NM_001001290.1	 Reanl	hypouricemia	(RHUC2)	 AD/AR	
SLC34A1	 NM_003052.4	 NPHLOP1	 AD/AR	
SLC34A3	 NM_001177316.1	 Hypophosphatemic	rickets	 AR	
SLC3A1	 NM_000341.3	 Cystinuria,	Type	A	 AR	
SLC4A1	 NM_000342.3	 dRTA	 AD/AR	
SLC7A9	 NM_014270.4	 Cystinuria,	Type	B	 AD/AR	
SLC9A3R1	 NM_004252.4	 NPHLOP2	 AD	
VDR	 NM_000376.2	 Idiopathic	hypercalciuria	 AD	
XDH	 NM_000379.3	 Xanthinuria	 AR	
Table	 3.4:	 The	 30	 genes	 involved	 in	 nephrolithiasis	 investigated	 by	 Next-Generation	
Sequencing	 in	 Patients	 32-44	 of	 the	 cohort.	 APRT,	 adenine	 phosphoribosyltransfease	
deficiency;	 dRTA,	 distal	 renal	 tubular	 acidosis;	 FHHNC,	 familial	 hypomagnesemia	 with	
hypercalciuria	 and	 nephrocalcinosis;	MODY,	maturity	 onset	 diabetes	 of	 the	 young;	NPHLOP,	
hypophosphatemic	 nephrolithiasis/osteoporosis;	 mode,	 mode	 of	 genetic	 inheritance;	 AR,	
autosomal	recessive;	AD,	autosomal	dominant;	XR,	X-linked	recessive.		
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Table	 3.6	 Summary	 of	 mutations	 identified	 in	 the	 current	 cohort	 through	 endonuclease	
analysis,	 Sanger	 sequencing	 and	 NGS.	 Exons	 of	 both	 SLC3A1	 and	 SLC7A9	 genes	 in	 which	
variants	 were	 identified	 are	 displayed	 in	 this	 table.	 Other	 exons	 have	 been	 omitted.	
Heterozygous	missense	mutations	 are	 indicted	 by	 the	 denotation	 of	 both	 alleles,	 or,	 in	 the	
case	 of	 synonymous	 coding	 SNPs,	 (het).	 Yellow,	 common	 SNPs;	 green,	 missense	 mutations	
previously	 reported	 in	 cystinuric	 cohorts;	 blue,	 insertions	 or	 deletions;	 red,	 novel	mutations	
identified	in	the	current	cohort;	--,	no	variants	identified.			
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3.3.5	Detection	of	whole	exon	deletions	or	duplications	by	MLPA	
To	 identify	 whether	 large	 deletions	 or	 duplications	 of	 whole	 exons	 in	 SLC3A1	 or	
SLC7A9	were	responsible	for	the	cystinuria	phenotype	in	the	unsolved	patients	of	the	current	
study,	 samples	 were	 sent	 to	 Southmead	 Hospital,	 Bristol	 for	 Multiplex	 Ligation-dependent	
Probe	Amplification	(MLPA).	This	protocol	was	described	 in	Chapter	2,	along	with	 the	primer	
sequences	used	 for	exon	amplification.	Genomic	DNA	samples	 from	Patients	2-5,	11,	14,	15,	
18,	19,	21	and	22	were	sequenced	by	MLPA	as	they	were	included	in	a	collaborative	study	with	
the	research	group	of	Professor	Richard	Coward,	Bristol	University	(Rhodes	et	al.,	2015).		
Of	 the	10	patient	samples	sent	 for	MLPA	sequencing,	6	patients	were	 found	to	have	
heterozygous	 whole	 exon	 duplications	 in	 SLC3A1	 (Table	 3.7).	 These	 two	 mutations	 were	 a	
duplication	of	exons	5-9	and	a	duplication	of	exon	8	(Table	3.7).	These	duplications	have	both	
been	reported	previously	by	Bisceglia	et	al.	(2010)	upon	detection	of	cystinuria	mutations	in	a	
cohort	of	patients	using	MLPA.	Additionally,	2	patients	(21	and	22)	were	discovered	that	have	
a	deletion	of	exon	12	in	SLC7A9.	The	presence	of	a	single	allele	for	the	duplication	of	exons	5-9	
in	SLC3A1	was	considered	sufficient	to	explain	a	cystinuria	phenotype	in	a	patient	(Font-Llitjos	
et	al.,	2005;	Bisceglia	et	al.,	2010).	Of	the	10	patients	who	had	their	DNA	sequenced	by	MLPA,	
20%	were	genetically	“solved”	prior	 to	 this	protocol	 (Table	3.6).	Following	MLPA,	a	 further	6	
patients	were	solved	(80%).	Of	the	remaining	unsolved	patients,	1	had	one	identified	mutation	
in	 SLC3A1,	 and	 one	 patient	 (Patient	 3)	 had	 no	 sequence	 variants	 identified	 in	 either	 gene	
(Table	3.7).		
Using	a	series	of	mutation	detection	techniques	in	the	patients	of	our	cohort	we	have	
managed	to	solve	the	genotype	of	83.3%	of	the	cohort,	and	find	one	SLC3A1	mutant	allele	in	
7%	(Table	3.7).		No	mutations	were	identified	in	4/42	patients	(9.7%)	of	the	cohort	(Table	3.7).	
It	is	likely	that	MLPA	analysis	of	the	remaining	patients	in	the	cohort	would	allow	the	genetic	
resolution	of	these	individuals.	These	data	closely	fit	with	the	report	of	Bisceglia	et	al.	(2010)	
who	 analysed	 a	 cohort	 of	 172	 cystinuria	 patients	 from	 168	 Italian	 families.	 They	 solved	 the	
genotype	of	88%	of	the	families,	found	one	causal	mutation	in	8%,	and	detected	no	mutations	
in	4%	(Bisceglia	et	al.,	2010)	
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Table	3.7:	Summary	of	all	mutations	detected	in	42	cystinuric	patients	through	endonuclease	
analysis,	Sanger	sequencing,	NGS,	and	MLPA.	Heterozygous	missense	mutations	are	indicated	
by	the	depiction	of	both	alleles	i.e.	M467M/Y.	For	all	other	mutations:	het,	heterozygous;	hom,	
homozygous;	c.,	cDNA	base	changes;	p.,	amino	acid	changes	at	the	protein	level;	del,	deletion;	
dup,	duplication;	fs,	frame	shift;	*x,	introduction	of	a	termination	codon	(TAG	or	TGA),	x	bases	
downstream	of	the	mutation.	Novel	variants	are	highlighted	in	red.		
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3.3.6	Segregation	analysis	of	SLC3A1	mutations	
Due	to	the	uncertainty	as	to	the	mode	of	inheritance	of	some	cystinuria	mutations,	it	
was	 desirable	 to	 perform	 segregation	 analysis	 on	 the	 mutations	 detected	 in	 our	 cohort.	
Samples	were	 requested	 from	obligate	 heterozygote	 relatives	 of	 the	 patients	 of	 the	 cohort.	
Salival	swabs	were	obtained	from	relatives	of	patients	5,	6,	14,	25,	26,	and	the	sibling	pair	28	
and	29	(Table	3.8).	Where	provided,	gDNA	samples	were	sequenced	by	Sanger	sequencing	in	
the	exon	in	which	mutations	had	been	identified	in	the	patient.	A	summary	of	the	mutations	
detected	in	the	relatives	of	the	cohort	is	provided	in	Table	3.7.	
Samples	of	gDNA	were	obtained	from	the	mother,	father	and	sister	of	Patient	5	(Table	
3.7).	 The	 patient	 was	 found	 to	 have	 M467M/T	 in	 exon	 8	 of	 SLC3A1	 and	 a	 heterozygous	
duplication	 of	 exons	 5-9	 in	 SLC3A1	 (Table	 3.6).	 Analysis	 of	 SLC3A1	 exon	 8	 in	 the	 samples	
obtained	from	the	relatives	of	this	patient	revealed	that	the	father	(Figure	3.6,	I.2)	and	sister	
(Figure	3.6,	 II.1)	 of	 Patient	 5	 (Figure	3.6,	 II.2)	were	both	heterozygous	 carriers	 of	M467M/T.	
The	mother	 carried	 the	 wild-type	 allele	 of	 exon	 8	 (Figure	 3.6,	 I.1).	 Unfortunately,	 we	 were	
unable	 to	 perform	MLPA	 analysis	 of	 SLC3A1	 in	 the	mother	 of	 Patient	 5.	 However,	we	must	
assume	that	the	patient	has	inherited	this	mutation	from	his	mother.	The	relatives	of	Patient	5	
did	 not	 report	 a	 cystinuria	 phenotype.	 Therefore,	 we	 can	 conclude	 from	 these	 data	 that	
mutations	M467T	and	the	duplication	of	exons	5-9	in	SLC3A1	are	autosomal	recessive	variants	
in	this	family.	
Segregation	analysis	was	performed	using	gDNA	samples	 from	the	mother	and	sister	
of	Patient	6	(Figure	3.7).	The	father	of	Patient	6	is	deceased	and	so	we	were	unable	to	obtain	a	
gDNA	sample	for	this	family	member	(Figure	3.7,	I.2).	Patient	6	had	a	compound	heterozygous	
genotype	 for	mutations	 R452W	 and	 the	 novel	 variant	 Y579D	 in	 exons	 8	 and	 10	 of	 SLC3A1,	
respectively	 (Figure	 3.7,	 II.2).	 It	 was	 discovered	 that	 the	 mother	 of	 Patient	 6	 was	 a	
heterozygous	 carrier	 of	 known	 cystinuria	mutation	R452W	 (Figure	 3.7,	 I.1).	 Additionally,	 the	
sister	of	the	proband	was	a	heterozygous	carrier	of	the	novel	mutation	Y579D	(Figure	3.7,	II.1).	
We	can	assume	that	both	Patient	6	and	his	female	sibling	 inherited	the	novel	mutation	from	
their	father.	These	data	support	the	evidence	that	known	cystinuria	mutation	R452W,	and	the	
novel	variant	Y579D	are	autosomal	recessive	pathogenic	variants.			
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Patient	
Number	 Mutation	1	 Mutation	2	 Fig.	 ID	 Relationship	 SLC3A1	 SLC7A9	
5	 M467M/T	 Het	dup	5-9	 3.5	
I.1	 Mother	 --	 --	
I.2	 Father	 M467M/T	 --	
II.1	 Sister	 M465M/T	 --	
6	 R452R/W	 Y579Y/D	 3.6	
I.1	 Mother	 R452R/W	 --	
II.1	 Sister	 Y579Y/D	 --	
14	 M467M/T	 Het	dup	5-9		 3.7	
I.1	 Mother	 --	 --	
III.1	 Son	 --	 --	
25	 M465K	 		 3.8	
I.1	 Mother	 M465M/K	 --	
I.2	 Father	 M465M/K	 --	
II.3	 Sister	 M465K	 --	
III.1	 Daughter	 M465M/K	 --	
26	 M467M/T	 L416L/P	 3.9	 I.1	 Mother		 M467M/T	 --	
28,29	 R452W	 		 3.9	
I.1	 Mother	 R452R/W	 --	
I.2	 Father	 --	 --	
II.3	 Cousin	 M467M/T	 --	
	
Table	 3.8:	 A	 summary	 of	 the	 mutations	 identified	 in	 patients	 involved	 in	 segregation	
analysis.	All	mutations	listed	in	this	table	were	identified	in	SLC3A1.		
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Figure	 3.6:	 Segregation	 analysis	 of	 a	 mutation	 identified	 in	 Patient	 5.	 A,	 Pedigree	 of	 the	
obligate	heterozygote	 relatives	of	Patient	5	who	had	a	compound	heterozygous	genotype	of	
M467M/T	 and	 dup5-9	 in	 SLC3A1.	 The	 father	 (I.2)	 and	 sister	 (II.1)	 of	 Patient	 5	 were	
heterozygote	carriers	of	M467M/T;	B,	chromatographs	of	Sanger	sequencing	of	SLC3A1	exon	
8.	The	encoded	amino	acid	residues	are	indicated	above	their	respective	codons,	with	residue	
numbers	 below.	 *,	 the	 location	 of	 DNA	 sequence	 variation	 from	 the	 wild-type;	 green;	
adenosine;	red,	thiamine;		blue,	cytosine;	black,	guanine.		
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Figure	3.7:	Segregation	analysis	of	SLC3A1	mutations	in	the	family	of	Patient	6.	A,	Pedigree	of	
the	obligate	heterozygote	relatives	of	Patient	6	who	had	a	compound	heterozygous	genotype	
of	R452R/W	and	Y579Y/D	in	SLC3A1.	The	mother	(I.1)	was	a	heterozygote	carrier	of	R452R/W	
and	the	sister	(II.1)	of	Patient	6	was	a	heterozygote	carrier	of	Y579Y/D;	B,	chromatographs	of	
Sanger	 sequencing	of	SLC3A1	 exons	8	 and	10a	 in	 the	 region	of	 the	mutations.	 The	encoded	
amino	acid	residues	are	indicated	above	their	respective	codons,	with	residue	numbers	below.	
*,	the	location	of	DNA	sequence	variation	from	the	wild-type;	green;	adenosine;	red,	thiamine;		
blue,	cytosine;	black,	guanine.	
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Patient	14	of	the	cohort	had	a	compound	heterozygous	genotype	of	M467M/T	and	a	
duplication	of	exons	5-9	(Table	3.7).	We	were	able	to	obtain	gDNA	samples	from	the	mother	
(I.1)	and	son	(III.1)	of	Patient	14	(Figure	3.8).	Sanger	sequencing	was	employed	to	investigate	
SLC3A1	exon	8	of	both	relatives	and	they	were	found	to	carry	the	wild-type	allele	for	this	gene	
(Figure	 3.8).	 However,	 as	 the	 exon	 5-9	 duplication	 would	 be	 undetectable	 by	 Sanger	
sequencing,	 we	 must	 assume	 that	 both	 of	 the	 relatives	 carry	 this	 mutation,	 as	 obligate	
heterozygotes.	Further	investigation	by	MLPA	would	be	required	to	confirm	this.		
In	Patient	25	of	the	cohort	we	identified	a	homozygous	novel	SLC3A1	variant,	M465K	
(Figure	 3.9,	 II.2).	 We	 identified	 the	 same	 homozygous	 change	 in	 the	 sister	 of	 the	 proband	
(Figure	3.9,	II.3),	who	was	also	discovered	to	have	a	cystinuric	phenotype.	Upon	investigation,	
it	was	discovered	that	the	parents	of	the	siblings	were	third	cousins,	and	both	carried	M465K	
in	exon	8	of	SLC3A1	 	 (Figure	3.9).	The	daughter	of	Patient	25	 (Figure	3.9,	 III.1)	 inherited	one	
M465K	 allele	 from	 her	 homozygous	 father,	 and	 one	wild-type	 allele	 from	 her	mother,	 who	
carried	both	wild-type	alleles	in	exon	8	(Figure	3.9B,	II.1).	The	heterozygous	carriers	of	M465K	
reported	no	symptoms	of	renal	colic.	These	data	suggest	that	novel	SLC3A1	variant	M465K	is	
an	autosomal	recessive,	pathogenic	mutation.		
The	novel	SLC3A1	mutation,	L416P,	was	identified	heterozygously	in	exon	7	of	Patient	
26,	 along	 with	 the	 heterozygous	 causal	 variant	 M467T	 (Figure	 3.10,	 II.1).	 We	 were	 able	 to	
obtain	 a	 gDNA	 sample	 from	 the	 mother	 of	 the	 patient	 who	 was	 a	 heterozygous	 carrier	 of	
M467T	(Figure	3.10,	I.1).	Neither	parent	has	a	history	of	cystinuria.	We	must	assume	that	the	
father	would	have	been	a	heterozygous	carrier	of	L416L/P.	These	data	support	the	hypothesis	
that	 L416P	 is	 a	 pathogenic	 mutation	 in	 SLC3A1,	 with	 an	 autosomal	 recessive	 inheritance	
pattern.		
Patients	 28	 and	29	 are	 a	 pair	 of	 siblings,	 recruited	 to	 this	 study	 at	 the	RKSC	patient	
information	day	at	 the	Royal	Free	Hospital,	 London	 in	December	2012.	Upon	 investigation	 it	
was	discovered	that	both	patients	were	homozygous	for	the	known	cystinuria	variant	R452W,	
in	exon	8	of	SLC3A1	 (Figure	311,	 II.1	and	 II.2).	 It	was	anticipated	that	both	parents	would	be	
carriers	 of	 the	 mutation.	 However	 it	 was	 discovered	 that	 only	 the	 mother	 (I.1)	 was	
heterozygous	 for	 R452W	 whilst	 the	 father	 was	 wild-type	 in	 this	 region	 (I.2).	 This	 raised	
questions	as	to	the	paternity	of	the	siblings	and	was	not	investigated	further.	However,	neither	
parent	had	a	history	of	renal	stone-forming	disease.	It	was	reported	that	a	paternal	cousin	of	
the	siblings	also	had	an	unconfirmed	diagnosis	of	cystinuria.	Upon	analysis	she	was	found	to	be	
a	heterozygous	carrier	of	SLC3A1	mutation	M467T	(Figure	3.11,	II.3).	However,	no	other	family	
members	tested	were	found	to	carry	this	mutation,	including	her	paternal	uncle	(Figure	3.11,	
I.2).	 Although	 the	 results	 of	 this	 segregation	 analysis	 are	 unclear,	 these	 data	 support	 the	
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hypothesis	 that	 SLC3A1	 mutation	 R452W	 has	 an	 autosomal	 recessive	 penetrance	 of	
phenotype.	The	paternal	cousin	of	Patients	28	and	29	remains	genetically	unsolved.		
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Figure	3.8:	Segregation	analysis	of	SLC3A1	mutations	in	Patient	14.	A,	Pedigree	of	the	obligate	
heterozygote	 relatives	 of	 Patient	 14	 who	 had	 a	 compound	 heterozygous	 genotype	 of	
M467M/T	 and	 dup5-9	 in	 SLC3A1.	 The	mother	 (I.1)	 and	 sister	 (II.1)	 of	 Patient	 14	 carried	 the	
wild-type	allele	 in	exon	8;	B,	 chromatographs	of	Sanger	 sequencing	of	SLC3A1	 exon	8	 in	 the	
region	of	the	M467T	missense	mutation.	The	encoded	amino	acid	residues	are	indicated	above	
their	 respective	 codons,	 with	 residue	 numbers	 below.	 *,	 the	 location	 of	 DNA	 sequence	
variation	from	the	wild-type;	green;	adenosine;	red,	thiamine;		blue,	cytosine;	black,	guanine.	
The	double	line	indicates	a	consanguineous	relationship.	
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Figure	3.9:	Segregation	analysis	of	SLC3A1	mutations	in	Patient	25.	A,	Pedigree	of	the	obligate	
heterozygote	 relatives	 of	 Patient	 25	 who	 had	 the	 novel	 homozygous	 mutation	 M465K	 in	
SLC3A1.	 The	mother	 (I.1)	 and	 father	 (II.2)	 of	 Patient	 25	were	 both	 heterozygous	 carriers	 of	
M465M/K,	 as	 was	 the	 daughter	 of	 the	 proband	 (III.1).	 The	 sister	 of	 Patient	 25	 had	 also	
inherited	both	mutant	alleles	and	had	a	homozygous	genotype	of	M465K;	B,	chromatographs	
of	 Sanger	 sequencing	of	 SLC3A1	exon	8	 in	 the	 region	of	 the	M465K	missense	mutation.	The	
encoded	 amino	 acid	 residues	 are	 indicated	 above	 their	 respective	 codons,	 with	 residue	
numbers	 below.	 *,	 the	 location	 of	 DNA	 sequence	 variation	 from	 the	 wild-type;	 green;	
adenosine;	red,	thiamine;		blue,	cytosine;	black,	guanine.	
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Figure	 3.10:	 Segregation	 analysis	 of	 SLC3A1	 mutations	 in	 Patient	 26.	 A,	 Pedigree	 of	 the	
obligate	heterozygote	relatives	of	Patient	26	who	has	a	compound	heterozygous	genotype	for	
M467M/T	and	L416L/P	in	SLC3A1.	The	mother	(I.1)	of	Patient	26	was	a	heterozygous	carrier	of	
M467M/T;	B,	chromatographs	of	Sanger	sequencing	of	SLC3A1	exons	7	and	8	in	the	region	of	
the	 L416P	 and	M467T	missense	mutations.	 The	 encoded	 amino	 acid	 residues	 are	 indicated	
above	their	respective	codons,	with	residue	numbers	below.	*,	the	location	of	DNA	sequence	
variation	from	the	wild-type;	green;	adenosine;	red,	thiamine;		blue,	cytosine;	black,	guanine.	
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Figure	3.11	Segregation	analysis	of	SLC3A1	mutations	 in	Patients	28	and	29.	A,	Pedigree	of	
the	 obligate	 heterozygote	 relatives	 of	 Patients	 28	 and	 29	 had	 the	 homozygous	 R452W	
mutation	in	SLC3A1.	The	mother	(I.1)	of	the	siblings	was	a	heterozygous	carrier	of	R452W.	The	
paternal	 cousin	 of	 the	 siblings	 was	 a	 carrier	 of	 the	 heterozygous	 mutation	 M467M/T;	 B,	
chromatographs	 of	 Sanger	 sequencing	 of	 SLC3A1	 exon	 8	 in	 the	 region	 of	 the	 R452W	 and	
M467T	 missense	 mutations.	 The	 encoded	 amino	 acid	 residues	 are	 indicated	 above	 their	
respective	 codons,	 with	 residue	 numbers	 below.	 *,	 the	 location	 of	 DNA	 sequence	 variation	
from	the	wild-type;	green;	adenosine;	red,	thiamine;		blue,	cytosine;	black,	guanine.	
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3.3.7	Analysis	of	SNP	prevalence	in	the	current	cohort	
	 In	 the	 current	 study,	 single	 nucleotide	 polymorphisms	 (SNPs)	 were	 detected	 in	 our	
patients	 along	 with	 pathogenic	 variants.	 Unfortunately,	 these	 data	 were	 not	 provided	 for	
patients	who	were	sequenced	by	Dr	F	Hildebrandt	using	NGS	(Table	3.5).	The	initial	aim	of	this	
study	did	not	 include	the	detection	of	SNP	frequencies	 in	the	patients.	Therefore,	we	cannot	
be	certain	that	all	SNPs	were	 identified	 in	Patients	1-15	and	17-26,	who	were	analysed	using	
the	CEL-I	detection	system.	If	two	patients	treated	as	a	pair	to	form	a	heteroduplex	were	both	
homozygous	 for	 the	 same	 SNP,	 this	 would	 not	 lead	 to	 the	 cleavage	 of	 DNA	 following	 the	
endonuclease	treatment.	Due	to	this,	it	is	possible	that	not	all	SNPs	in	Patients	1-16	and	17-26	
were	 recorded	 (Table	 3.2).	 However,	 as	 not	 all	 patients	 in	 the	 cohort	 were	 genotypically	
“solved”,	 the	 incidence	 of	 seemingly	 benign	 SNPs	 was	 considered.	 The	 missing	 heredity	 in	
cystinuric	patients	is	discussed	in	section	3.4.	Due	to	the	fact	that	not	all	patients	of	cystinuria	
cohorts	are	solved	following	the	use	of	a	combination	of	techniques	such	as	Sanger	sequencing	
and	MLPA	(Bisceglia	et	al.,	2010)	and	no	other	genes	have	been	linked	to	the	pathogenesis	of	
cystinuria	(Leclerc	et	al.,	2001;	Brauers	et	al.,	2005),	it	has	been	suggested	that	SNPs	could	act	
as	modifying	 factors	 on	 the	 penetrance	 of	 disease	 (Albers	 et	 al.,	 1999).	 The	 involvement	 of	
non-environmental	 modifying	 factors	 is	 highlighted	 by	 the	 finding	 that	 sibling	 pairs	 with	
identical	genotypes	have	diverse	clinical	courses	of	the	disease	(Rhodes	et	al.,	2015).	
Until	recently,	synonymous	common	DNA	mutations	(sSNP),	such	as	G38G	(rs3738985)	
in	SLC3A1,	were	known	as	“silent”	variants.	Due	to	their	lack	of	effect	on	the	translated	protein	
sequence,	 they	 were	 considered	 non-pathogenic	 and	 unable	 to	 confer	 a	 phenotype	 to	 the	
folding	 or	 function	 of	 the	 gene	 product	 (Sauna	 &	 Kimchi-Sarfaty,	 2011).	 However,	 recent	
advances	in	our	understanding	of	protein	translation	have	discovered	several	mechanisms	by	
which	 sSNPs	 can	 confer	 a	 disease	 phenotype	 (Sauna	 &	 Kimchi-Sarfaty,	 2011).	 The	
phenomenon	of	codon	usage	bias	 is	widely	accepted.	However,	 the	reasons	 for	evolutionary	
pressure	upon	synonymous	codons	have	remained	poorly	understood	(Plotkin	&	Kudla,	2011).	
The	 advent	 of	 Genome-Wide	 Association	 Studies	 (GWAS),	 which	 identify	 causal	 variants	 in	
common	 diseases	 without	 a	 prior	 hypothesis	 of	 gene	 involvement,	 have	 highlighted	 the	
prevalence	of	sSNPs	in	disease	phenotypes	(Manolio	et	al.,	2008).		
	 From	the	data	collected	in	Table	3.9,	it	is	clear	that	the	prevalence	of	some	sSNP	in	our	
cohort	differ	from	those	reported	in	the	ExAC	database.	Of	particular	note,	the	sSNP	S77S	was	
identified	 in	 9%	 of	 alleles,	 whereas	 it	 is	 only	 found	 in	 0.3%	 of	 alleles	 in	 the	 ExAC	 database	
(Table	3.9).	The	influence	of	these	sSNP	on	the	expression	of	the	SLC3A1	gene	product	requires	
further	investigation	to	determine	whether	they	have	any	influence	on	the	regulation	of	gene	
expression,	or	function	of	the	protein.	This	is	discussed	in	detail	in	section	3.4.	
	 	
	 157	
SNP	 Change	 Gene	
ExAC	
Frequency	
Estimated	frequency	in	the	
current	cohort	
rs3738985	 G38G	 SLC3A1	 35.17%	 41%	
rs146630359	 S77S	 SLC3A1	 0.27%	 9%	
rs556841667	 c.1137+1T>C	 SLC3A1	 11.18%	 6%	
rs61179824	 c.1137+2_delT	 SLC3A1	 --	 6%	
rs3738984	 c.1331+7C>T	 SLC3A1	 27.10%	 35%	
rs140821819	 N466N	 SLC3A1	 0.23%	 1%	
rs698761	 M618I	 SLC3A1	 59.60%	 46%	
rs8886	 c.*132T>C	 SLC3A1	 57.55%	 22%	
rs12150904	 c.236+21T>G	 SLC7A9	 30.48%	 7%	
rs35170371	 S133S	 SLC7A9	 19.40%	 6%	
rs12150889	 V142A	 SLC7A9	 30.98%	 15%	
rs12150890	 C137C	 SLC7A9	 10.60%	 7%	
rs6510300	 c.478+9T>C	 SLC7A9	 11.30%	 7%	
rs1007160	 L233M	 SLC7A9	 29.71%	 17%	
rs1007161	 L229L	 SLC7A9	 29.73%	 15%	
rs11084673	 S169S	 SLC7A9	 30.05%	 24%	
rs11084671	 c.603+25T>C	 SLC7A9	 30.04%	 17%	
rs11084672	 c.603+11G>A	 SLC7A9	 10.60%	 13%	
rs2287880	 c.977+50A>G	 SLC7A9	 12.70%	 9%	
rs34347941	 V455V	 SLC7A9	 2.30%	 6%	
rs61730903	 A324A	 SLC7A9	 1.20%	 2%	
rs2287881	 A381A	 SLC7A9	 12.41%	 2%	
	
Table	3.9:	The	incidence	of	SNPs	in	Patients	1-15	and	17-26	of	our	cohort.	 	
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3.3.8	Putative	location	of	mutations	in	the	protein	structure	
	 The	 predicted	 structure	 of	 the	 proteins	 rBAT	 and	 b0,+AT,	 encoded	 by	 SLC3A1	 and	
SLC7A9,	respectively,	was	outlined	in	Chapter	1.	To	aid	the	investigation	on	how	variants	in	the	
two	genes	could	affect	the	function	of	these	proteins,	the	putative	 locations	of	the	missense	
mutations	identified	in	the	current	cohort	were	mapped	to	the	homology	models	(Figure	3.12-
13).	
	 In	our	cystinuria	cohort,	7	missense	variants	were	identified	in	SLC3A1:	N254T,	L416P,	
R452W,	M465K,	M467T,	 Y579D,	 and	M618I.	 The	missense	 variant	M618I	 is	 a	 common	 SNP,	
found	in	around	half	of	the	alleles	in	the	general	population	(Kent	et	al.,	2002).	Due	to	this	high	
frequency	 it	 is	not	thought	to	be	pathogenic.	Novel	mutations	M465K	and	L416P,	along	with	
known	cystinuria	mutations	R452W	and	M467T,	are	putatively	located	in	the	A2	domain	of	the	
TIM	barrel	structure	of	rBAT	(Figure	3.12).	Novel	mutation	N254T	is	predicted	to	sit	in	loop-rich	
domain	B,	whilst	novel	mutation	Y579D	and	the	common	SNP	M618I	are	located	in	the	β-sheet	
of	domain	C	 (Figure	3.12).	 The	putative	effect	of	 these	amino	acid	 substitutions	based	upon	
their	location	in	the	protein	structure	is	discussed	in	section	5.4.		
In	 the	current	cohort,	5	pathogenic	missense	variants	were	 identified	 in	SLC7A9,	 the	
gene	encoding	the	light	chain	of	System	b0,+,	b0,+AT.	These	are:	G105R,	T123M,	A182T,	A224V,	
and	Y451X	(Figure	3.13).	Whilst	mutations	in	rBAT	are	predicted	to	cause	“trafficking”	defects	
in	System	b0,+,	it	is	predicted	that	a	misfolding	of	the	light	chain	would	lead	to	a	change	in	the	
capacity	 of	 the	 transport	 system	 to	bind	 amino	acid	 substrates	 and	 translocate	 them	across	
the	apical	membrane	of	the	epithelium	(Font	et	al.,	2001).	From	the	homology	model,	it	can	be	
seen	 than	 3/5	 of	 the	 mutations	 are	 predicted	 to	 be	 located	 in	 the	 “core”	 transmembrane	
domains:	 1,	 3,	 6,	 and	 8	 (Figure	 3.13).	 The	 functional	 characterisation	 of	 these	mutations	 on	
System	b0,+	is	outside	of	 the	scope	of	 this	 investigation	due	 to	 the	difficulties	 in	expressing	a	
functional	 light	 chain	 in	 Xenopus	 oocytes,	 discussed	 in	 Chapter	 4	 (Pfeiffer	 et	 al.,	 1999a).	
However,	we	can	predict	the	effects	of	these	mutations	based	upon	our	knowledge	of	critical	
residues	 in	 structurally	 homologous	 proteins	 such	 as	 LeuT	 and	 SteT	 (Yamashita	 et	 al.,	 2005;	
Bartoccioni	et	al.,	2010).	This	concept	is	discussed	in	Chapter	7.			
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Figure	3.12:	Homology	model	of	the	rBAT	extracellular	domain	and	the	putative	locations	of	
cystinuria	 mutations.	 Top	 view	 of	 the	 rBAT	 extracellular	 domain	model	 based	 on	 oligo-1,6-
glucoside	 from	B.	 cereus	 (PDB	 code	 1UOK)	 to	 show	 the	 putative	 location	 of	 the	mutations,	
denoted	by	black	arrows.	The	mutations	highlighted	are	those	investigated	in	this	study.	This	
includes	the	common	SNP,	M618I;	pathogenic	mutation,	M467T;	and	the	four	novel	mutations	
identified	 in	 the	 current	 cohort:	M465K,	N254T,	 L416P,	 and	 Y579D.	Red,	 domain	A1;	 yellow,	
domain	B;	green,	domain	A2;	blue,	domain	C.		
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Figure	3.13:	The	putative	b0,+AT	protein	location	of	SLC7A9	missense	mutations	identified	in	
the	current	cohort.	Homology	model	of	b0,+AT	based	upon	the	known	crystal	structure	of	the	
E.	 coli	 arginine:agmatine	 antiporter	 (AdiC,	 PDB	 code	 3L1L;	 Gao	 et	 al.,	 2010).	 A,	 Homology	
model	of	all	12	transmembrane	domains	(TMD)	of	b0,+AT;	B,	homology	model	of	the	core	TMD	
1	 (green),	 3	 (blue),	 6	 (orange),	 and	 8	 (purple).	 The	 putative	 location	 of	 cystinuria	missense	
mutations	G105R,	A182T,	T213M,	A224V,	and	Y451X	are	indicated	with	arrows.	N,	N-terminal;	
C,	C-terminal.		
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3.4	Discussion	
3.4.1	Detection	of	causal	variants	in	cystinuric	cohorts	
One	 common	 theme	amongst	 reports	 of	mutation	detection	 in	 cystinuria	patients	 is	
the	failure	to	identify	all	causal	variants	following	screening	of	SLC3A1	and	SLC7A9.	Eggermann	
et	al.	 (2012)	reported	an	average	mutation	detection	rate	of	85%	amongst	cystinuria	cohorts	
worldwide.	There	are	several	proposed	reasons	for	the	failure	to	identify	all	causal	variants	in	
cohorts	 of	 cystinuria	 patients.	 The	 first	 reason	 accounting	 for	 the	 low	 detection	 rate	 in	 the	
early	literature	is	that	whilst	SLC3A1	was	identified	as	a	gene	involved	in	the	pathogenesis	of	
cystinuria	in	1994,	it	was	1999	before	the	involvement	of	SLC7A9	was	confirmed	(Feliubadalo	
et	 al.,	 1999).	 Of	 the	 24	 reports	 of	 cystinuria	 cohort	 data	 listed	 in	 the	 introduction	 to	 this	
chapter,	the	mean	detection	rate	of	mutations	in	those	published	prior	to	1999	was	54%,	rising	
to	79.5%	in	those	published	post-identification	of	SLC7A9.	Additionally,	the	methods	employed	
in	 the	 detection	 of	 mutations	 have	 likely	 played	 a	 major	 role	 in	 the	 inability	 to	 solve	 the	
genotype	of	all	patients.		
Of	 24	 reports	 of	 cohort	 data	 in	 cystinuria	 patients,	 18	 employed	 single	 strand	
conformation	polymorphism	(SSCP)	analysis	to	detect	mutations	in	SLC3A1	and	SLC7A9.	SSCP	
was	first	reported	by	Orita	et	al.	(1989)	as	a	way	of	rapidly	screening	for	novel	point	mutations	
in	 a	DNA	 sequence.	 The	 SSCP	 technique	 relies	 on	 differences	 in	 the	 conformation	of	 single-
stranded	DNA	or	RNA,	which	occur	upon	the	introduction	of	a	sequence	variant.	Following	PCR	
amplification	 of	 wild-type	 DNA,	 the	 strands	 are	 separated	 and	 denatured,	 forming	 a	
characteristic	 single-stranded	 conformation.	 When	 mutated	 samples	 are	 resolved	 by	
electrophoresis	against	wild-type	control	strands,	a	shift	 in	band	size	can	be	detected	due	to	
the	 different	 migration	 distances	 of	 mutated	 strands	 (Orita	 et	 al.,	 1989;	 Grompe,	 1993).	
Following	the	identification	of	a	shift	in	band	size,	samples	can	be	sent	for	Sanger	sequencing	
to	identify	the	causal	mutation.	This	technique	became	the	most	widely-employed	method	of	
mutation	detection	 in	 cystinuric	 cohorts	 for	 over	 a	 decade,	 due,	 in	 part,	 to	 the	 high	 cost	 of	
Sanger	sequencing	 (Grompe,	1993).	 	Through	the	 identification	of	mutated	DNA	by	SSCP	the	
need	for	full	Sanger	sequencing	of	the	entire	gene	in	each	patient	was	eliminated.	The	method	
was	 also	 deemed	 to	 be	 simple	 and	 sensitive,	 whilst	 allowing	 the	 simultaneous	 analysis	 of	
multiple	 samples.	 Michaud	 et	 al.	 (1992)	 measured	 a	 70%	 detection	 rate	 of	 known	 point	
mutations	in	200bp	fragments	of	the	ornithine	amino-transferase	gene	by	SSCP.	The	efficacy	of	
SSCP	on	detecting	 known	SLC3A1	 variants	was	 investigated	by	Giannattasio	 et	 al.	 (1995).	Of	
the	 mutations	 investigated	 (M467T,	 M467K,	 T652R,	 P615T	 and	 L678P),	 4	 out	 of	 5	 were	
identified	 through	 SSCP.	 However,	 it	 was	 not	 possible	 to	 detect	 missense	 mutation	 L678P	
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using	 this	 technique	 (Giannattasio	 et	 al.,	 1995).	 The	 failure	 to	 detect	 all	 SLC3A1	 mutations	
using	the	SSCP	technique	could	account	for	some	of	the	missing	heredity	in	cystinuria	cohorts.		
Around	the	same	time	of	the	development	of	this	technique,	the	use	of	heteroduplex	
analysis	 to	 detect	 DNA	 mutations	 also	 emerged.	 This	 technique	 initially	 relied	 upon	 the	
formation	 of	 heteroduplexes	 between	 radiolabelled	 wild-type	 RNA	 “riboprobe”	 and	 the	
sample	 mutant	 DNA	 being	 investigated	 (Grompe,	 1993).	 Following	 DNA-RNA	 heteroduplex	
formation,	 samples	 are	 treated	with	RNase	A,	which	 cleaves	 the	 single-stranded	RNA	at	 the	
point	 of	 heteroduplex	 base	 mismatching	 (Gibbs	 &	 Caskey,	 1987).	 A	 mutation	 detection	
sensitivity	 of	 80-90%	was	 reported	 through	 the	 use	 of	 the	 heteroduplex	mismatch	 protocol	
(White	 et	 al.,	 1992).	 In	 the	 current	 study,	 we	 used	 a	 CEL-I	 endonuclease	 isolated	 from	 raw	
celery	 to	detect	 single	base	pair	mismatches	 in	heteroduplex	DNA.	This	was	based	upon	 the	
protocol	reported	by	Oleykowski	et	al.	(1998).	The	efficacy	of	the	endonuclease	protocol	in	the	
detection	of	sequence	variants	has	been	reported	to	be	90-93%	(Scaffino	et	al.,	2004;	Otto	et	
al.,	2008;	Voskarides	&	Deltas,	2009).	The	CEL-I	mutation	detection	protocol	has	been	reported	
to	be	more	informative	than	traditional	detection	protocols	such	as	SSCP	due	to	the	fact	that	
the	size	of	the	cleavage	fragments	can	provide	information	about	the	location	of	the	mutation,	
and	the	presence	of	more	than	one	cleavage	product	indicates	the	presence	of	more	than	one	
mutation.	 Additionally,	 throughput	 is	 increased	 due	 to	 the	 ability	 to	 pool	 PCR	 products	
(Voskarides	&	Deltas,	2009).	For	these	reasons,	the	CEL-I	detection	protocol	was	employed	in	
the	investigation	of	Patients	1-15	and	17-26	of	the	current	study	(section	3.3.2).	However,	the	
use	of	this	protocol	only	led	to	the	identification	of	causal	variant	alleles	in	56%	of	the	cohort	
(Table	3.2).	Sanger	sequencing	of	all	SLC3A1	and	SLC7A9	exons	for	patients	in	whom	a	genetic	
diagnosis	 remained	 unconfirmed	 did	 not	 lead	 to	 the	 identification	 of	 any	 further	 causative	
mutations	(Section	3.3.3).	This	validated	the	use	of	the	CEL-I	detection	protocol	in	the	current	
cohort	as	a	robust	tool	for	the	identification	of	exonic	single	point	mutations.	The	reason	for	
the	low	efficiency	of	this	protocol	in	the	current	cohort	could	be	due	to	a	higher	incidence	of	
large	 genomic	 rearrangements	 such	 as	whole	 exon	 duplications,	which	 are	 undetectable	 by	
this	technique.		
Chillarón	et	al.	 (2010)	employed	a	cohort	of	175	cystinuric	patients	and	 their	known	
heterozygous	 relatives	 in	 order	 to	 attempt	 to	 establish	 the	 inheritance	 pattern	 of	 SLC7A9	
mutations.	 Direct	 sequencing	 of	 the	 entire	 cohort	 for	 all	 23	 exons	 spanning	 the	 two	 known	
cystinuria	genes	revealed	mutations	in	only	56%	of	alleles,	in	78%	of	patients	(Chillarón	et	al.,	
2010).	They	hypothesised	that	this	could	be	due	to	the	presence	of	mutations	outside	of	the	
open	reading	frame	(ORF)	or	a	still-unknown	second	light	chain	for	rBAT-association.		
	 Due	to	this	missing	heredity	 in	cystinuria,	 the	search	for	other	gene	 involvement	has	
been	 attempted.	 Linkage	 analysis	 in	 cystinuric	 patients	 only	 maps	 the	 locations	 of	 gene	
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involvement	 to	 2p21	 and	 19q13.11,	 the	 locations	 of	 SLC3A1	 and	 SLC7A9,	 respectively.	 This	
ignited	 the	 search	 for	 other	 solute	 carrier	 genes	 at	 these	 locations.	 Two	 were	 identified:	
SLC7A10,	 encoding	 Asc-1,	 a	 high-affinity	 serine	 transporter;	 and	 SLC1A5,	 encoding	 ASCT2,	
which	 is	 related	 to	 the	 classical	 amino	 acid	 transporter	 system	 ASC	 (Brauers	 et	 al.,	 2005).	
Mutations	in	SLC7A10	were	not	found	in	a	cohort	of	20	Greek	patients,	who	collectively	had	15	
mutations	in	the	two	established	genes,	nor	in	three	further	studies	in	which	the	involvement	
of	this	gene	in	cystinuria	was	considered	(Leclerc	et	al.,	2001;	Pineda	et	al.,	2004a;	Schmidt	et	
al.,	 2004b;	 Chatzikyriakidou	 et	 al.,	 2005).	 Additionally,	 two	 families	 of	 cystinuric	 patients	
without	any	detected	mutations	in	SLC3A1	or	SLC7A9	had	their	DNA	sequenced	in	all	exons	of	
the	SLC1A5	gene.	However,	no	mutations	were	identified	(Brauers	et	al.,	2005).	Subsequently,	
these	two	genes	have	been	eliminated	from	potential	involvement	in	cystinuria.	In	the	current	
study,	Patients	32-44	were	screened	by	NGS	in	the	laboratory	of	Dr.	F.	Hildebrandt	to	identify	
mutations	 in	 SLC3A1	 and	 SLC7A9	 (Table	 3.5).	 Of	 these	 13	 patients,	 11	 had	 their	 genotype	
“solved”	 using	 this	 protocol	 (Table	 3.5).	 Additionally,	 using	 the	 high	 throughput	 assay,	 they	
were	 investigated	 in	 28	 other	 genes	 known	 to	 be	 involved	 in	 nephrolithiasis	 or	
nephrocalcinosis	(Halbritter	et	al.,	2014).	No	causal	variants	were	identified	in	any	of	the	other	
genes	screened	 in	 the	cystinuria	patients.	This	eliminates	the	putative	 involvement	of	any	of	
these	genes	in	the	unsolved	patients	(35	and	38,	Table	3.5).		
To	enable	the	detection	of	large	genomic	rearrangements	in	the	cohort,	we	employed	
the	use	of	MLPA.	MLPA	was	first	reported	as	a	tool	for	mutation	detection	in	cystinuria	in	2010	
to	identify	mutations	in	the	patients	of	a	large	cohort	who	had	an	incomplete	genetic	diagnosis	
following	investigation	with	Sanger	sequencing	of	all	SCL3A1	and	SLC7A9	exons	(Bisceglia	et	al.,	
2010).	 Bisceglia	 et	 al.	 (2010)	 identified	 large	 deletions	 or	 duplications	 accounted	 for	 11%	of	
causal	 alleles	 in	 their	 cohort.	 Using	 a	 combination	 of	 Sanger	 sequencing	 and	 MLPA,	 the	
cystinuria	 phenotype	 of	 88%	 of	 patients	 was	 genetically	 solved.	 However,	 7/172	 (4%)	 of	
patients	still	had	no	mutant	alleles	identified	(Bisceglia	et	al.,	2010).	Subsequent	studies	have	
emerged	 that	 have	 used	 MLPA	 to	 detect	 these	 large	 genomic	 rearrangements	 in	 patient	
cohorts	(Rhodes	et	al.,	2015;	Wong	et	al.,	2015).	In	the	current	study,	patients	were	classified	
as	 “solved”	 following	 the	 identification	 of	 two	 SLC3A1	 mutations	 (Type	 AA),	 or	 one	 SLC7A9	
mutation	(Type	B).	It	has	been	identified	previously	that	the	duplication	of	exons	5-9	in	SLC3A1	
can	 have	 a	 variable	 penetrance	 (Font-Llitjos	 et	 al.,	 2005).	 If	 we	 assume	 that	 heterozygote	
carriers	 of	 this	 mutation	 are,	 therefore,	 genetically	 solved,	 83%	 of	 causal	 mutations	 were	
identified	 following	 the	 combination	 of	 CEL-I	 and	 MLPA	 protocols.	 	 Of	 the	 3	 patients	 who	
remained	unsolved,	only	one	had	no	identified	mutations	(Patient	3).		
	 165	
3.4.2	The	incidence	of	causal	variants	in	cystinuria	
	 To	 date,	 280	 causal	 cystinuria	 variants	 have	 been	 reported	 in	 SLC3A1	 and	 SLC7A9	
(Stenson	 et	 al.,	 2014).	 This	 includes	 missense/nonsense	 mutations,	 splicing	 variants,	 small	
deletions,	 insertions	 and	 duplications,	 and	 gross	 deletions	 and	 duplications	 of	 whole	 exons	
(Stenson	et	al.,	2014).	The	prevalence	of	the	mutations	varies	between	different	populations	
(Schmidt	et	al.,	2002).	For	example,	in	Jewish	communities	of	Libyan	origin,	the	prevalence	of	
cystinuria	is	relatively	high	(1:2500)	due	to	a	founder	effect	of	the	V170M	missense	mutation	
in	SLC7A9,	which	dates	back	to	around	1500	AD	(Colombo,	2000).	The	prevalence	of	cystinuria	
worldwide	is	1:7000	(Colombo,	2000).	In	Spanish	and	Italian	populations,	the	SLC3A1	missense	
mutation	M467T	accounts	 for	more	than	25%	of	cystinuria	alleles,	and	T216M	is	common	 in	
Greek	populations	(Bisceglia	et	al.,	1996;	Albers	et	al.,	1999;	Eggermann	et	al.,	2011).		
This	 year,	 two	 reports	 of	UK	 cystinuria	 cohort	 analysis	 have	 emerged,	 providing	 the	
first	insight	into	the	prevalence	of	mutations	in	the	UK	(Rhodes	et	al.,	2015;	Wong	et	al.,	2015).	
The	report	by	Rhodes	et	al.	(2015)	investigated	a	cohort	of	76	cystinuric	patients,	11	of	which	
were	from	the	 initial	25-patient	cohort	reported	 in	this	thesis	(Table	3.6).	Wong	et	al.	(2015)	
found	 the	 most	 common	 SLC3A1	 mutations	 in	 their	 UK	 cohort	 to	 be	 M467T	 (25%)	 and	 a	
duplication	of	exons	5-9	 (27%).	The	 same	 result	was	 identified	by	Rhodes	et	al.	 (2015),	with	
mutant	allele	frequencies	of	23%	and	24%,	respectively.	The	duplication	of	exons	5-9	in	SLC3A1	
has	 a	 lower	 frequency	 worldwide	 (5%),	 with	 German	 patients	 carrying	 the	 duplication	 at	 a	
similar	 rate	 to	 that	 detected	 in	 the	UK	 cohorts	 (28%)	 (Chillarón	 et	 al.,	 2010).	 In	 the	 current	
study,	the	most	common	causal	SLC3A1	variant	was	M467T	(33%),	followed	by	the	duplication	
of	 exons	 5-9	 (19%).	 However,	 not	 all	 patients	 were	 investigated	 using	 MLPA	 (Table	 3.6).	
Amongst	 the	11	patients	 that	were	 analysed	by	 the	quantitative	method,	 the	duplication	of	
exons	5-9	was	 the	most	common	causal	variant	 (31%,	Table	3.6).	 If	all	of	 the	patients	 in	 the	
cohort	were	investigated	using	a	quantitative	detection	method	such	as	MLPA,	it	is	likely	that	a	
higher	incidence	of	the	exon	duplication	would	be	detected.		
The	most	common	SLC7A9	mutation	identified	in	the	cohort	of	Wong	et	al.	(2015)	was	
c.614dupA	 (20%),	 which	 leads	 to	 a	 frame	 shift,	 causing	 the	 N260E	missense	mutation,	 and	
then	 a	 termination	 codon	 3	 amino	 acids	 downstream	 (p.N260Efs*3).	 The	 same	 variant	 was	
identified	as	the	most	common	SLC7A9	allele	(24%)	in	the	report	by	Rhodes	et	al.	(2015).	The	
prevalence	of	this	mutation	is	much	lower	worldwide	(7%)	(Chillarón	et	al.,	2010).	
To	date,	many	causal	cystinuria	mutations	have	been	identified,	with	the	prevalence	of	
different	mutations	varying	worldwide,	amongst	distinct	populations.	 In	an	entirely	 Japanese	
cohort,	the	common	European	SLC3A1	mutation	M467T	was	not	detected	(Egoshi	et	al.,	2000;	
Eggermann	et	al.,	2012).	In	the	same	cohort,	5	novel	SLC3A1	variants	were	identified	that	have	
not	been	detected	in	Caucasian	populations.	These	were:	L346P,	I445T,	C673R,	c.1820delT	and	
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c.1898insTA	 (Egoshi	 et	 al.,	 2000;	 Schmidt	 et	 al.,	 2002).	 This	 highlights	 the	 need	 for	 the	
identification	of	mutations	in	different	populations	and	the	determination	of	their	effect	at	the	
protein	level	to	develop	targeted	therapies	for	cystinuria	treatment.		
	
3.4.3	The	incidence	of	SNPs	in	cystinuria	patients	
Several	mechanisms	have	been	proposed	for	the	way	in	which	synonymous	SNP	(sSNP)	
can	 affect	 the	 function	 of	 the	 gene	 product	 (Sauna	 &	 Kimchi-Sarfaty,	 2011).	 One	 of	 the	
mechanisms	by	which	a	synonymous	change	in	codon	sequence	can	affect	protein	expression	
is	through	an	alteration	in	mRNA	structure.	The	most	common	Cystic	Fibrosis	mutation	in	the	
Cystic	Fibrosis	Transmembrane	conductance	Regulator	(CFTR)	is	a	deletion	of	a	phenylalanine	
residue	at	position	508.	This	is	caused	by	a	deletion	of	3	bases	(CTT)	in	the	DNA	sequence.	This	
deletion	removes	F508	from	the	sequence,	but	also	causes	the	 isoleucine	residue	at	position	
507	 to	 be	 encoded	 by	 ATT,	 rather	 than	 the	 wild-type	 ATC	 (Bartoszewski	 et	 al.,	 2010).	
Bartoszewski	 et	 al.	 (2010)	 used	 a	 biochemical	mRNA	 folding	 assay	 to	 demonstrate	 that	 the	
mRNA	 for	 wild-type	 CFTR	 folded	 in	 a	 hairpin	 loop	 conformation.	 However,	 the	 mRNA	 for	
ΔF508-CFTR	folded	into	two	enlarged	single-stranded	loops	(Bartoszewski	et	al.,	2010).	When	
the	mRNA	for	ΔF508-Ile507ATC-CFTR	was	created,	in	which	I507	is	encoded	by	the	same	codon	
as	in	the	wild-type	sequence,	the	mRNA	displayed	the	same	hairpin	loop	conformation	as	the	
wild-type	cRNA,	despite	the	missing	codon	(Bartoszewski	et	al.,	2010).	Through	expression	of	
these	 mRNAs	 in	 HeLa	 cells,	 it	 was	 determined	 that	 the	 alteration	 in	 folding	 significantly	
reduced	 (p<0.05)	 the	 rate	 of	 translation	 of	 ΔF508-CFTR,	measured	 through	 incorporation	 of	
[35S]methionine	 into	 the	 translated	 protein,	 compared	 to	 the	wild-type	 channel.	 The	 rate	 of	
translation	 of	 ΔF508-Ile507ATC-CFTR	 was	 not	 significantly	 different	 from	 the	 wild-type	
(p>0.05)	 (Bartoszewski	 et	 al.,	 2010).	 Previous	 studies	 had	 shown	 that	 levels	 of	 ΔF508-CFTR	
expression	increases	significantly	when	expressed	in	HeLa	cells	incubated	at	low	temperatures	
(27°C)	 due	 to	 a	 proposed	 inhibition	 of	 the	 ERAD	 pathway	 (Jurkuvenaite	 et	 al.,	 2010).	
Interestingly,	 when	 the	 temperature-dependent	 release	 of	 ΔF508-Ile507ATC-CFTR	 was	
investigated	 in	239-F	cells,	 it	was	discovered	that	pre-incubation	of	 the	cells	at	27°C,	did	not	
increase	the	amount	of	translated	protein.	These	results	indicate	that	the	phenotype	of	ΔF508	
is	conferred	by	the	I507I	sSNP,	as	opposed	to	the	deletion	of	F508.	The	authors	proposed	that	
the	mechanism	of	this	change	in	expression	was	due	to	an	increased	pause	in	the	translation	
of	ΔF508-CFTR	mRNA,	with	the	altered	secondary	structure,	during	which	the	ERAD	pathways	
are	activated	(Bartoszewski	et	al.,	2010;	Bali	et	al.,	2015).		
Another	 transport	 protein	 in	which	 a	 sSNP	has	been	 shown	 to	 affect	 function	 is	 the	
ATP-Binding	Cassette	(ABC)	transporter,	ABCB1.	A	sSNP	in	the	MDR1	gene	has	been	shown	to	
affect	 substrate	 specificity	 of	 the	 P-glycoprotein	 (ABCB1)	 transporter	 (Kimchi-Sarfaty	 et	 al.,	
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2007).	It	was	hypothesised	that	the	C>T	base	change	led	to	the	presence	of	a	rare	codon,	and	
increased	the	time	taken	for	 translation,	affecting	the	co-translational	 folding	of	 the	protein,	
and	the	extent	of	stabilisation	between	non-sequential	areas	of	the	polypeptide	chain	(Kimchi-
Sarfaty	et	al.,	2007;	Tsai	et	al.,	2008).		
Although	 the	 detection	 of	 common	 SNPs	 was	 not	 a	 primary	 aim	 of	 this	 study,	 the	
frequency	of	those	 identified	was	analysed	following	the	 inability	to	detect	causal	variants	 in	
100%	of	the	cohort.	It	is	likely	that	not	all	SNPs	were	identified	in	the	current	cohort,	as	due	to	
their	high	frequency,	the	presence	of	a	homozygous	SNP	in	the	genotype	of	two	patients	used	
to	form	a	heteroduplex	for	CEL-I	analysis,	would	not	lead	to	the	formation	of	a	fragment	band.	
Additionally,	only	the	pathogenic	variants	identified	by	NGS	in	Patients	32-44	were	reported	by	
Dr.	 F.	 Hildebrandt	 (Table	 3.5).	 Three	 sSNP	 in	 SLC3A1	 were	 identified	 in	 Patients	 1-31	 at	 a	
frequency	>20%	of	that	reported	in	the	ExAC	database	(Table	3.9).	The	most	notable	was	S77S,	
which	is	only	reported	in	0.27%	of	the	alleles	in	the	ExAC	database,	yet	was	identified	in	6/62	
alleles	(9%)	in	the	current	cohort	(Table	3.9).	To	date,	only	one	published	large-scale	report	of	
cystinuric	 cohort	 data	 considers	 the	 frequency	 of	 SNP	 detection.	 Schmidt	 et	 al.	 (2002)	
identified	 a	 statistical	 association	 of	 SLC7A9	 SNPs	 L233M	 and	 L229L	 with	 cystine	 stone	
formation.	These	SNPs	were	both	identified	in	patients	of	the	current	cohort,	at	frequencies	of	
17%,	and	15%,	respectively	(Table	3.9).	This	was	lower	than	the	rates	of	these	SNP	reported	in	
the	 ExAC	 database	 (29.7%).	 However,	 they	 showed	 that	 these	 two	 SNP	 are	 in	 linkage	
disequilibrium	with	each	other,	and	may	also	be	in	disequilibrium	with	causal	variants,	which	
would	 explain	 the	 statistical	 association	 (Schmidt	 et	 al.,	 2002).	 Despite	 this,	 the	 failure	 to	
identify	 all	 causal	 variants	 in	 patients	 following	 the	 employment	 of	 a	 range	 of	 detection	
techniques,	and	the	inability	to	identify	a	third	gene	involved	in	the	pathogenesis,	it	is	possible	
that	SNPs	could	play	a	role	in	the	penetrance	of	phenotype	in	cystinuria.		
3.4.3	Genotype-phenotype	correlation	in	cystinuria	
	 Several	reports	have	considered	the	relationship	between	genotype	and	phenotype	in	
cystinuria	 cohorts	 (Font	 et	 al.,	 2001;	 Dello	 Strologo	 et	 al.,	 2002;	 Font-Llitjos	 et	 al.,	 2005;	
Rhodes	 et	 al.,	 2015;	Wong	 et	 al.,	 2015).	 The	 traditional	 classifications	 of	 “Type-I”	 and	 “non	
Type-I”	 cystinuria	 was	 based	 upon	 the	 finding	 that	 some	 heterozygote	 carriers	 of	 SLC7A9	
mutations	presented	with	a	dibasic	aminoaciduria	(Rosenberg	et	al.,	1966).	Harris	et	al.	(1955)	
screened	the	relatives	of	cystinuric	patients	and	detected	that	some	heterozygotes,	although	
not	 stone-forming,	 had	 elevated	 levels	 of	 cystine	 in	 their	 urine.	 In	 type-I	 patients	 urinary	
cystine	 levels	were	normal	and	the	disease	displayed	as	a	completely	recessive	trait.	 In	“non	
type-I”	heterozygotes	elevated	urinary	cystine	 levels	were	seen,	but	stones	were	not	formed	
(Harris	et	al.,	1955;	Rosenberg	et	al.,	1966).		
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		 The	identification	of	both	genes	involved	in	cystinuria,	and	the	difficulties	in	classifying	
cystinuric	patients	with	the	traditional	system,	led	to	the	introduction	of	a	new	nomenclature,	
based	 upon	 the	 genotype	 of	 the	 patient	 (Dello	 Strologo	 et	 al.,	 2002).	 In	 the	 modern	
classification	 system,	 type	 “A”	 patients	 carry	 mutations	 in	 SLC3A1,	 and	 type	 “B”	 have	
mutations	 in	 SLC7A9.	 An	 individual	 can,	 therefore,	 be	 type	 AA,	 AB,	 BB,	 or	 B	 (Gucev	 et	 al.,	
2011).	 It	 was	 initially	 thought	 that	 Type	 A	 mutations	 led	 to	 a	 “type-I”	 phenotype,	 being	
inherited	 in	 an	 autosomal	 recessive	 manner,	 with	 Type	 B	 mutations	 being	 dominant	 with	
variable	penetrance	(Dello	Strologo	et	al.,	2002).	 In	a	cohort	of	162	cystinuric	patients,	Font-
Llitjos	 et	 al.	 (2005)	 discovered	 that	 the	 majority	 of	 “type	 A”	 alleles	 segregated	 with	 the	
traditional	 “type-I”	 phenotype	 (recessive)	 and	 “type	 B”	 with	mainly	 “non	 type-I”	 (dominant	
inheritance).	However,	Dello	Strologo	et	al.	(2002)	found	that	14%	of	patients	with	a	mutation	
in	SLC7A9,	had	an	amino	acid	excretion	profile	identical	to	that	of	the	“type-I”	individuals,	with	
SLC3A1	 mutations	 (Dello	 Strologo	 et	 al.,	 2002).	 Moreover,	 the	 duplication	 of	 exons	 5-9	 in	
SLC3A1	shows	dominant	expression	in	the	majority	of	heterozygotes,	but	not	all	(Font-Llitjos	et	
al.,	2005).	The	penetrance	of	SLC7A9	mutations	appears	variable	amongst	 individual	carriers.	
In	one	study,	a	 recessive	penetrance	of	mutations	was	observed	 in	SLC7A9	mutations	A182T	
(6/11),	T213M	(2/4),	V170M	(4/16),	and	G105R	(1/32)	(Font-Llitjos	et	al.,	2005).	Conversely,	all	
R333W	heterozygotes	displayed	a	cystinuria	phenotype	(Font-Llitjos	et	al.,	2005).	The	analysis	
of	 a	 UK	 cohort	 by	 Rhodes	 et	 al.	 (2015)	 identified	 that	 subgroups	 of	 patients	 who	 have	 the	
same	 genotype,	 including	 pairs	 of	 siblings,	 show	 great	 diversity	 in	 clinical	 presentation,	 and	
progression	of	the	disease.	
	 Attempts	to	relate	genotype	to	phenotype	in	cystinuria	have	been	inconclusive.	Dello	
Strogolo	 et	 al.	 (2002)	 and	 Rhodes	 et	 al.	 (2015)	 failed	 to	 identify	 any	 significant	 difference	
(p>0.05)	between	the	phenotype	of	Type	A	and	B	patients	when	the	age	at	first	stone,	number	
of	stone	episodes	per	year,	or	renal	function	were	considered.	Dello	Strologo	et	al.	(2002)	did	
not	identify	any	correlation	between	urinary	amino	acid	excretion	and	Type	A	or	B	cystinuria.	A	
study	 by	Wong	et	 al.	 (2015),	 supported	 the	 findings	 that	 there	was	 no	 difference	 in	 clinical	
presentation	 between	 Type	 A	 or	 Type	 B	 patients.	 However,	 it	 was	 indicated	 that	 Type	 AB	
patients	presented	with	 later	onset	of	disease	 (mean	47y)	compared	to	Type	AA	 (21y)	or	BB	
(23.5y).	 However,	 Type	 AB	 cystinuria	 is	 rarely	 reported	 in	 the	 literature.	 This	 genotype	 has	
been	reported	with	an	average	rate	of	2.7%	in	cohort	studies	(Font-Llitjos	et	al.,	2005;	Rhodes	
et	al.,	2015;	Wong	et	al.,	2015).	Despite	this,	 the	frequency	of	Type	A	and	Type	B	patients	 is	
equally	 distributed	 (Dello	 Strologo	 et	 al.,	 2002).	 In	 the	 current	 study,	 no	 patients	 were	
identified	 as	 being	 Type	 AB	 (Table	 3.6).	 Wong	 et	 al.	 (2015)	 divided	 Type	 A	 patients	 into	
subgroups:	 those	with	missense	mutation	 and	 those	with	 any	 other	 type	 of	mutation.	 They	
found	that	patients	who	carried	missense	mutations	did	not	have	urinary	dibasic	amino	acid	
	 169	
levels	significantly	greater	(p>0.05)	than	healthy	control	patients	(Wong	et	al.,	2015).	However,	
in	the	Type	A	subgroup	carrying	other	types	of	mutations,	the	levels	of	urinary	arginine,	lysine,	
and	ornithine	were	significantly	greater	 than	 the	control	group,	and	 those	carrying	missense	
mutations	 (p<0.0001)	 (Wong	 et	 al.,	 2015).	Due	 to	 the	diversity	 in	 the	 clinical	 progression	of	
cystinuria,	even	within	 relatives	 carrying	 the	 same	genotype,	 the	consideration	of	genotype-
phenotype	correlation	was	outside	of	the	scope	of	this	report.		
In	 this	Chapter	we	have	 investigated	a	 cohort	of	 cystinuria	patients	 for	mutations	 in	
SLC3A1	 and	 SLC7A9	 using	 a	 variety	 of	 mutation	 detection	 techniques.	 Through	 this	 we	
identified	eight	different	pathogenic	alleles	of	SLC3A1	and	ten	different	pathogenic	variants	of	
SLC7A9	(Table	3.6).	In	total,	we	identified	the	underlying	genetic	cause	of	cystinuria	in	83.3%	of	
our	patients.	This	detection	rate	is	comparable	to	those	reported	in	the	literature,	from	large-
scale	 investigations	 using	 a	 combination	 of	 Sanger	 sequencing	 and	 MLPA	 (Bisceglia	 et	 al.,	
2010).	We	have	shown	through	analysis	of	obligate	heterozygote	 relatives	of	 the	patients	of	
our	 cohort,	 that	 the	SLC3A1	mutations	 show	autosomal	 recessive	penetrance	of	 phenotype.	
Moreover,	 we	 have	 identified	 4	 novel	 missense	 mutations	 in	 SLC3A1.	 The	 aims	 of	 this	
investigation	will	focus	upon	the	expression	of	rBAT	and	our	novel	mutant	proteins	in	Xenopus	
laevis	 oocytes	 to	 try	 and	 identify	 the	 effect	 that	 these	 mutations	 have	 on	 the	 proteins	 of	
System	b0,+.	We	have	shown	from	the	clinical	data	in	our	cohort,	that	despite	treatment	with	a	
range	of	CBTD,	with	a	spectrum	of	severe	adverse	effects,	many	cystinuric	patients	have	poor	
control	 over	 their	 disease.	 The	 identification	 of	 novel	 therapeutic	 targets	 through	 further	
understanding	 of	 the	 biogenesis	 of	 rBAT	 and	 the	mutant	 proteins	 could	 potentially	 improve	
the	quality	of	life	of	cystinuria	sufferers	in	the	future.		
In	summary:	
• We	have	solved	the	genotype	of	83%	of	our	cohort	of	patients.	
• Mutations	 identified	 in	 SLC3A1	 appear	 to	 have	 a	 recessive	 mode	 of	
inheritance.	
• Four	 novel	 missense	 variants	 were	 identified	 in	 SLC3A1,	 the	 gene	 encoding	
rBAT.	These	are	M465K,	N254T,	L416P	and	Y579D.	
• A	homology	model	of	the	rBAT	extracellular	domain	allowed	mapping	of	these	
mutations	and	other	variants	to	the	predicted	protein	structure.	
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Chapter	4:	Results	II 	
4.1	Introduction	
For	 successful	 reabsorption	of	hydrophilic	molecules	 from	the	 renal	proximal	 tubule,	
the	 presence	 of	 a	wide	 range	 of	 transport	 proteins	 in	 the	 apical	 phospholipid	membrane	 is	
required	(see	Chapter	1).	These	transport	systems	have	distinct	substrate	specificities	and	ion-
coupling	 mechanisms	 that	 permit	 selective	 reabsorption	 of	 molecules	 into	 the	 renal	
epithelium,	and,	ultimately,	the	blood.		
One	 proximal	 tubular	 transport	 system,	 System	 b0,+,	 is	 an	 obligatory	 exchanger	 of	
dibasic	 and	 neutral	 amino	 acids,	 first	 identified	 by	 Van	 Winkle	 et	 al.	 (1988).	 Van	 Winkle	
observed	Na+-independent	transport	of	cationic	and	zwitterionic	amino	acids	that	was	strongly	
inhibited	in	the	presence	of	leucine	or	lysine.	This	high	affinity	transport	system,	unaffected	by	
changes	in	pH	between	6.3	and	8.0,	was	unable	to	transport	amino	acids	branched	at	the	α-	or	
β-carbon,	 thus	 displaying	 greater	 substrate	 selectivity	 than	 the	Na+-dependent	 transport	 via	
System	B0,+.		
	 The	 identification	 of	 System	 b0,+	 and	 its	 proposed	 involvement	 in	 the	 renal	 stone	
disease,	 cystinuria	 (see	 Chapter	 1),	 led	 to	 a	 breakthrough	 in	 the	 early	 1990s,	 when	 three	
groups	 independently	 identified	 cDNA	 clones	 that	 induced	 System	 b0,+-like	 transport	 by	
functional	 expression	 cloning	 in	 Xenopus	 oocytes	 (Gurdon	 et	 al.,	 1971).	 The	 cloned	 cDNAs	
were	 isolated	 from	 tissues	 of	 rabbit	 (Bertran	 et	 al.,	 1992b),	 rat	 (Tate	 et	 al.,	 1992;	Wells	 &	
Hediger,	1992),	and	human	(Bertran	et	al.,	1993;	Lee	et	al.,	1993)	kidney	and	small	 intestine.	
All	 three	 research	 groups	 identified	 that	 expression	 of	 these	 proteins	 in	 oocytes	 induced	
transport	 function	 with	 the	 same	 selectivity	 profile	 as	 that	 reported	 by	 Van	 Winkle	 (Van	
Winkle	 et	 al.,	 1988).	 The	 hypothesis	 that	 the	 isolated	 cDNAs	 encoded	 a	 Type-II	 membrane	
glycoprotein	with	only	one	membrane-spanning	domain	(see	Chapter	1)	led	to	the	belief	that	
this	protein	served	as	a	“modulator”	of	transport,	rather	than	a	transport	pore	(Bertran	et	al.,	
1992b;	 Wells	 &	 Hediger,	 1992;	 Lee	 et	 al.,	 1993).	 The	 protein,	 named	 D2,	 NBAT,	 or	 rBAT	
(related	 to	 b0,+AT	 amino	 acid	 transporter)	 was	 predicted	 to	 induce	 transport	 through	
association	 with	 an	 endogenous	 protein.	 Hence,	 the	 measured	 transport	 activity,	 and	
conferred	substrate	specificity,	was	that	of	the	Xenopus	protein	(Wells	&	Hediger,	1992;	Wang	
&	Tate,	1995).		
All	 three	 research	 groups	 reported	 high-affinity	 transport	 of	 cystine,	 dibasic,	 and	
neutral	 amino	 acids	with	measured	 Km	 values	 in	 the	 1-100μM	 range	 (Bertran	 et	 al.,	 1992b;	
Tate	 et	 al.,	 1992;	Wells	 &	 Hediger,	 1992).	 The	 uptake	 of	 5μM	 cystine,	 leucine,	 alanine	 and	
arginine	was	 inhibited	by	 the	presence	of	 5mM	unlabelled	 competitors	 in	 the	order:	 dibasic	
amino	acids	>	leucine	>	phenylalanine	>	histidine	>	unbulky	amino	acids	or	those	branched	at	
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the	 β-carbon	 >	 α-AIB	 >	 proline	 >	 MeAIB	 (Bertran	 et	 al.,	 1992b).	 No	 measurable	 transport	
activity	was	observed	for	small	or	acidic	amino	acids,	proline	or	α-AIB	(Bertran	et	al.,	1992b).	
These	 data	 confirmed	 the	 induced	 transport	 system	 was	 in	 fact	 System	 b0,+,	 with	 identical	
transport	properties	to	those	reported	by	Van	Winkle	in	mouse	blastocysts	(Van	Winkle	et	al.,	
1988).	
In	addition	to	Mus	musculus	and	Xenopus	laevis	light	chains,	measurements	of	System	
b0,+	 substrate	 specificity	 have	 also	 been	 made	 in	 human	 Caco-2	 cells,	 which	 endogenously	
express	both	subunits,	and	COS-7	cells	stably	transfected	with	human	rBAT	and	rat	b0,+AT	(Van	
Winkle	 et	 al.,	 1988;	 Ferruzza	 et	 al.,	 1995;	 Chairoungdua	 et	 al.,	 1999).	 No	 discernable	
differences	have	been	reported	in	the	transport	kinetics	of	System	b0,+	in	different	species.		
In	this	chapter,	we	report	the	use	of	an	epitope	tag	to	aid	rBAT	detection	in	oocytes.	
Epitope	tagging	utilises	recombinant	DNA	methods	to	add	a	polypeptide	chain	to	a	protein	of	
interest.	 The	polypeptide	 serves	 as	 an	 antigen	 to	 an	 antibody	 raised	 against	 the	 amino	 acid	
sequence.	 This	 can	 allow	 the	 determination	 of	 protein	 size	 and	 abundance,	 trafficking	 and	
cellular	 localisation,	 and	 the	 post-translational	modification	 state	 of	 proteins	 expressed	 in	 a	
wide	 range	 of	 biological	 systems	 (Maue,	 2007).	 The	 FLAG	 epitope	 (DYKDDDDK)	 was	 first	
designed	by	Hopp	et	al.	(1988).	The	polypeptide	sequence	was	designed	so	as	not	to	interfere	
with	 folding	 of	 the	 native	 protein,	 and	 to	 have	 a	 high	 degree	 of	 hydrophilicity	 for	maximal	
exposure	 of	 the	 surface	 and	 ligand	 interaction	 (Hopp	 et	 al.,	 1988;	 Einhauer	 &	 Jungbauer,	
2001).	 In	 1960	 it	 was	 reported	 that	 the	 major	 factor	 in	 antibody-antigen	 interaction	 is	 the	
presence	 of	 aromatic	 amino	 acids	 (Sela	 &	 Arnon,	 1960),	 and	 so	 a	 tyrosine	 (Y)	 residue	 was	
placed	in	the	sequence,	flanked	by	charged	amino	acids	aspartic	acid	(D)	and	lysine	(K)	Hopp	et	
al.	 (1988).	The	remainder	of	the	peptide	sequence	(KDDDDK)	 is	highly	hydrophilic	and	serves	
as	the	recognition	site	for	enterokinase	to	facilitate	cleavage	of	the	tag	polypeptide	from	the	
protein	of	interest	(Hopp	et	al.,	1988).	The	FLAG	tag	has	been	widely	reported	in	the	literature	
for	successful	detection	and	purification	of	proteins.	
The	 objectives	 of	 the	 work	 described	 in	 this	 chapter	 were	 to	 induce	 System	 b0,+	
transport	activity	 in	Xenopus	oocytes	by	heterologous	expression	of	 the	human	rBAT	protein	
and	 its	 association	 with	 the	 endogenous	 Xenopus	 light	 chain;	 and	 to	 optimise	 a	 range	 of	
immunodetection	 techniques	 that	would	 allow	 identification	 of	 rBAT	 expression	 in	 Xenopus	
oocytes.	 	The	optimisation	of	these	techniques	to	accurately	measure	rBAT	expression	 in	the	
oocytes	was	essential	for	characterisation	of	the	SLC3A1	mutations	identified	in	Chapter	3.		
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4.2	Methods	
Radiolabelled	 amino	 acid	 uptake	 was	 performed	 in	 Xenopus	 laevis	 oocytes	 as	
described	 in	 Chapter	 2.	 Substrate	 specificity	 and	 affinity	 were	 determined	 by	 uptake	 and	
competition	experiments.	
A	multiple	 sequence	alignment	of	 the	human	and	Xenopus	 b0,+AT	protein	 sequences	
was	 created	 using	 ClustalW	 (http://www.ebi.ac.uk/Tools/msa/clustalw2/).	 Nucleotide	
sequences	 were	 taken	 from	 the	 National	 Centre	 for	 Biotechnology	 Information	 website	
(http://www.ncbi.nlm.nih.gov/).	
4.3	Results	
The	 aim	 of	 the	 investigations	 reported	 in	 this	 chapter	 was	 to	 establish	 a	 range	 of	
techniques	 to	 accurately	 measure	 the	 expression	 of	 rBAT	 protein.	 This	 would	 enable	
subsequent	 characterisation	 of	 mutant	 rBAT	 expression,	 informed	 by	 the	 data	 reported	 in	
Chapter	 3.	 Throughout	 this	 study,	 the	 functional	 expression	 of	 rBAT	 is	 measured	 indirectly	
though	uptake	of	System	b0,+	substrates	 into	oocytes	 injected	with	rBAT	cRNA.	This	 is	 reliant	
upon	the	expressed	human	rBAT	protein	associating	with	an	endogenous	Xenopus	light	chain,	
homologous	to	mammalian	b0,+AT.	All	amino	acids	used	in	the	study	were	in	the	L-isoform.	
4.3.1	Function	of	rBAT	with	a	C-terminal	FLAG-tag	
During	the	preliminary	investigations	of	this	study,	a	single	FLAG	(DYKDDDDK)	epitope	
was	added	to	the	C-terminal	of	rBAT	(rBATF)	by	Dr.	Noel	Edwards	to	aid	immunodetection	of	
the	protein	 (see	Chapter	2).	 It	was	 important	 to	establish	 that	 the	epitope	did	not	 interfere	
with	protein	folding	and	subsequent	function	or	expression.	In	a	single	experiment,	uptake	of	a	
prototypical	 System	 b0,+	 substrate,	 [3H]arginine	 (10μM,	 pH	 7.4,	 Na+-free),	 was	 increased	 by	
approximately	20-fold	in	oocytes	expressing	human	rBAT	compared	to	water-injected	control	
oocytes	 (Figure	 4.1).	 No	 significant	 difference	 in	 uptake	 levels	 (p>0.05)	 was	 observed	 in	
oocytes	expressing	rBATF	compared	to	untagged	rBAT.	Uptake	of	 [3H]arginine	via	System	b0,+	
was	 53.1±10	 and	 59.1±6	 pmol.oocyte-1.(60min)-1	 into	 oocytes	 injected	 with	 rBAT	 and	 rBATF	
cRNA,	respectively	(Figure	4.1).	Due	to	the	lack	of	significant	difference	in	the	function	of	rBAT	
and	rBATF,	the	C-terminally	tagged	construct	was	routinely	used	in	subsequent	experiments.		
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Figure	 4.1:	Uptake	 of	 [3H]arginine	 into	Xenopus	oocytes	 expressing	 untagged	 rBAT	 and	 C-
terminally	FLAG-tagged	rBAT	(rBATF).	[3H]Arginine	(10μM)	uptake	into	water-injected	(control,	
open	 bar),	 rBAT-,	 or	 rBATF-expressing	 (10ng,	 black	 bars)	 Xenopus	 oocytes	 measured	 over	
60min	(pH	7.4,	Na+-free).	Data	are	mean±SEM	(n=10).	***,	p<0.001	vs.	water-injected	oocytes;	
ns,	p<0.05	vs.	uptake	in	untagged	rBAT.	
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4.3.2	Measurement	of	[3H]arginine	uptake	following	injection	of	rBAT	cRNA		
Xenopus	oocytes	were	injected	with	rBAT	cRNA	over	the	range	of	1-50ng.		[3H]Arginine	
uptake	 was	 measured	 via	 the	 induced	 b0,+	 transport	 over	 40min	 (Figure	 4.2).	 In	 this	 single	
experiment	(n=8-10),	the	fold	uptake	into	cRNA-injected	oocytes	above	water-injected	control	
oocytes	was	 low	 (1.6-3.7).	 The	measured	 levels	of	background	 [3H]arginine	uptake	 (14.1±0.5	
pmol.oocyte-1.(40min)-1)	 were	 more	 than	 double	 the	 mean	 control	 values	 observed	 in	 10	
different	batches	of	oocytes	over	 a	 10-month	period	 (6.1±0.4	pmol.oocyte-1.(40min)-1,	 n=97)	
(Figure	4.3).	This	is	indicative	of	poor	oocyte	quality	in	this	single	experiment	and	reflects	the	
variability	 in	 results	 sometimes	 observed	 during	 the	 course	 of	 this	 study.	 Despite	 this,	 an	
increase	in	uptake	of	[3H]arginine	was	observed	with	an	increase	in	the	quantity	of	rBAT	cRNA	
injected.	There	was	no	 further	 increase	 in	uptake	when	amounts	of	cRNA	greater	 than	10ng	
(0.2μg.μl-1)	 were	 injected	 (Figure	 4.2).	 As	 a	 result	 of	 this	 experiment,	 10ng	 rBAT	 cRNA	 was	
routinely	injected	into	oocytes	to	provide	maximal	uptake	of	[3H]arginine	via	System	b0,+.	
To	 determine	 the	 extent	 of	 the	 inter-experiment	 variability	 in	 protein	 expression,	
uptake	of	 [3H]arginine	 in	oocytes	 injected	with	 rBATF	 cRNA	 (10ng)	was	measured	over	 a	10-
month	 period,	 2-3	 days	 post-injection	 (May	 2012	 -	 February	 2013).	 The	 mean	 uptake	 of	
[3H]arginine	 (33.6±3.1	 pmol.oocyte-1(40min)-1)	 was	 5-fold	 greater	 than	 in	 water-injected	
control	oocytes	(Figure	4.3).	Over	this	period,	uptake	in	water-injected	control	oocytes	ranged	
from	2.5±0.5	–	14.1±0.5	pmol.oocyte-1.(40min)-1	 and	 	 from	20.3±3.3	–	41.8±4.4	pmol.oocyte-
1.(40min)-1	 in	 oocytes	 injected	 with	 10ng	 rBATF	 cRNA.	 These	 data	 indicate	 that	 through	
injection	of	10ng	rBATF	cRNA,	it	is	possible	to	consistently	induce	significant	(p<0.05)	uptake	of	
arginine	 compared	 to	 water-injected	 control	 oocytes.	 However,	 due	 to	 variability	 in	 oocyte	
quality	between	batches,	and	seasonal	fluctuations	in	oocyte	maturation,	the	absolute	uptake	
values	measured	throughout	the	year	might	not	be	directly	comparable.		
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Figure	 4.2:	 An	 increase	 in	 [3H]arginine	 uptake	 into	Xenopus	oocytes	 is	 observed	 upon	
injection	 of	 increasing	 amounts	 of	 rBAT	 cRNA.	 [3H]Arginine	 (10μM)	 uptake	 into	 water-
injected	 (control,	 open	 bar),	 or	 rBAT-expressing	 (1-50ng,	 black	 bars)	 Xenopus	 oocytes	
measured	 over	 40min	 (pH	 7.4,	 Na+-free).	 Data	 are	 mean±SEM	 (n=8-10).	 ***,	 p<0.001;	 **,	
p<0.01;	ns,	p<0.05	vs.	water-injected	oocytes.	
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Figure	 4.3:	 [3H]Arginine	 uptake	 into	 rBATF-expressing	 Xenopus	 oocytes	 via	 System	 b0,+	
transport.	[3H]Arginine	(10μM)	uptake	into	water-injected	(control,	n=97,	open	bar),	or	rBATF-
expressing	(10ng,	n=95,	black	bar)	Xenopus	oocytes	measured	over	40min	(pH	7.4,	Na+-free).	
Data	are	mean±SEM.	***,	p<0.001;	vs.	water-injected	oocytes.	
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4.3.3	Measurement	of	[3H]arginine	uptake	1-6	days	post-injection	of	oocytes	
Uptake	experiments	were	carried	out	1-6	days	following	injection	of	rBATF	cRNA.	This	
was	 to	 determine	 whether	 increased	 levels	 of	 rBATF	 expression	 were	 observed	 at	 different	
days	post-injection	 (Figure	4.4).	Any	 significant	difference	 (p<0.05)	 in	uptake	 levels	 between	
experiments	conducted	on	different	days	post-injection	of	cRNA	would	mean	that	this	 factor	
would	have	to	be	controlled	for	to	minimise	the	variability	observed	between	experiments.		
Oocytes	 were	 injected	 with	 0.5,	 5,	 or	 20ng	 of	 rBATF	 cRNA	 and	 uptake	 experiments	
performed	over	60min.	[3H]Arginine	uptake	levels	increased	over	1-6	days	post-injection,	with	
maximal	uptake	observed	by	day	3	 (Figure	4.4A).	 In	oocytes	 injected	with	20ng	 rBATF	 cRNA,	
the	 fold-increase	 over	water-injected	 oocytes	 ranged	 from	 27-43	 fold	 over	 days	 1-6	 (Figure	
4.4B).	This	high	 fold	 increase	 in	 [3H]arginine	uptake	was	due	to	 low	uptake	 in	water-injected	
control	 oocytes	 over	 days	 1-3	 in	 this	 single	 experiment	 (0.5±0.1	 -	 1.9±1.1	 	 pmol.oocyte-
1(60min)-1).	 Again,	 this	 reflects	 the	 variability	 in	 oocyte	 quality	 between	 batches,	 as	 this	
background	uptake	value	was	12-fold	lower	than	the	mean	value	between	10	oocyte	batches	
reported	 in	Figure	4.3.	A	decline	 in	oocyte	quality	by	day	6	 led	to	an	 increase	 in	 [3H]arginine	
uptake	 in	 	water-injected	 control	 oocytes	 (10.7±1.6	pmol.oocyte-1.(60min-1),	 and	 subsequent	
decrease	 in	 the	 calculated	 fold	uptake	 (Figure	4.4B).	 In	oocytes	 injected	with	all	 amounts	of	
rBATF	 cRNA,	 no	 significant	 increase	 (p>0.05)	 in	 [3H]arginine	 uptake	 is	 observed	 after	 2	 days	
post-injection,	with	maximal	uptake	values	observed	by	day	3	(Figure	4.4).		
These	 data	 indicate	 that	 the	 level	 of	 uptake	 observed	 in	 oocytes	 via	 System	 b0,+	 is	
dependent	on	the	amount	of	cRNA	injected	(Figure	4.4).	This	likely	affects	the	extent	of	rBATF	
protein	 translation	 and	membrane	 trafficking	 of	 the	 heterodimer.	 These	 data	 represent	 the	
results	of	a	single	experiment,	in	which	oocyte	quality	was	high.	Due	to	the	variability	in	oocyte	
quality,	it	cannot	be	assumed	that	maximal	protein	expression	will	always	be	observed	by	day	
3.	For	this	reason,	[3H]arginine	uptake	measurements	carried	out	to	investigate	the	expression	
of	mutant	rBAT	protein	(as	described	in	Chapter	5)	were	performed	using	cRNA	amounts	over	
the	range	1-50ng,	over	1-6	days	post-injection.		
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Figure	4.4:	An	 increase	 in	 [3H]arginine	uptake	 is	observed	over	a	number	of	days	 following	
injection	 of	 rBATF	 cRNA.	 [3H]Arginine	 (10μM)	uptake	 into	 rBATF-expressing	Xenopus	oocytes	
measured	over	40min	(pH	7.4,	Na+-free).	A,	[3H]Arginine	uptake	following	subtraction	of	water-
injected	control	values;	!,	0.5ng;	",	5ng;	#,	20ng	rBAT	cRNA;	B,	Data	are	as	in	panel	A	prior	to	
subtraction	 of	water-injected	 control	 values;	 ns;	 p>0.05;	 **,	 p<0.01;	 ***,	 p<0.001	 vs.	 day	 6	
uptake	value.	Data	are	mean±SEM	(n=9-10).	
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4.3.4	Time	and	temperature	dependence	of	System	b0,+-mediated	transport	
All	uptake	measurements	reported	thus	far	were	carried	out	at	room	temperature	in	
the	 laboratory.	 To	establish	whether	 fluctuations	 in	 room	 temperature	 could	 lead	 to	uptake	
variability,	[3H]arginine	uptake	was	carried	out	at	18,	24,	and	32°C.	To	determine	the	linearity	
of	the	transport	reaction	uptake	measurements	were	carried	out	on	rBATF-expressing	oocytes	
between	10s	and	180min.	[3H]Arginine	uptake	was	measured	at	the	following	time	points:	10s,	
1min,	 2min,	 5min,	 10min,	 20min,	 40min,	 120min,	 150min,	 and	 180min	 at	 the	 three	
temperatures	 (Figure	 4.5).	 Due	 to	 a	 rapid	 deterioration	 in	 oocyte	 quality	 at	 higher	
temperatures,	 the	 uptake	 at	 32°C	 was	 terminated	 after	 10min.	 From	 the	 time-dependent	
uptake	 results,	 it	 appears	 as	 though	 the	 linear	 phase	 of	 transport	 is	 up	 to	 2h.	 Subsequent	
uptake	experiments	were	carried	out	at	a	maximum	length	of	60min	(Figure	4.5).		
These	data	support	the	experimental	conditions	reported	 in	the	 literature.	Uptake	of	
amino	 acids	 via	 System	b0,+	 in	Xenopus	oocytes	 has	 been	 carried	 out	 between	 5min	 and	 1h	
(Bertran	et	al.,	1992b;	Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	
et	 al.,	 1993;	 Lee	 et	 al.,	 1993;	Markovich	 et	 al.,	 1993;	 Calonge	 et	 al.,	 1994;	 Chillarón	 et	 al.,	
1997).	Tate	et	al.,	and	Chillarón	et	al.,	reported	that	their	uptake	measurements	were	carried	
out	at	20°C	and	25°C,	 respectively	 (Tate	et	al.,	1992;	Chillarón	et	al.,	1997).	Most	 reports	do	
not	 state	 the	 temperature	 at	 which	 the	 uptake	 was	 carried	 out,	 suggesting	 that	 small	
fluctuations	in	room	temperature	are	not	a	contributing	factor	to	uptake	variability	(Moeller	&	
Fenton,	2010).	Subsequently,	the	uptakes	in	this	study	were	carried	out	at	room	temperature	
in	the	laboratory,	measured	at	21-24°C.	
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Figure	 4.5:	 Time-dependent	 uptake	 of	 [3H]arginine	 via	 System	 b0,+	 at	 18,	 24,	 and	 32°C.	
[3H]Arginine	(10μM)	uptake	into	rBATF	expressing	Xenopus	oocytes	(pH	7.4,	Na+-	free,	10s-3h).	
",	water-injected	control	oocytes;	",	10ng	rBATF-injected	oocytes.	Data	are	mean±SEM	(n=9-
10).		
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4.3.5	System	b0,+	substrate	specificity	
It	was	 important	 to	 ensure	 that	 uptake	 studies	were	 a	 reliable	measurement	 of	 the	
functional	 expression	 of	 rBATF.	 Therefore,	 a	 series	 of	 experiments	 was	 carried	 out	 to	
determine	 the	 substrate	 selectivity	 of	 the	 rBATF-induced	 transport	 (Figures	 4.6-4.7).	
[3H]Arginine,	[3H]lysine,	and	[3H]leucine	all	demonstrated	significantly	higher	uptake	in	rBATF-
expressing	 oocytes	 versus	 water-injected	 controls	 (Figures	 4.6-4.7).	 Although	 [3H]Alanine	
uptake	 was	 not	 significant	 (p>0.05),	 it	 was	 3.2-fold	 above	 background	 uptake	 in	 the	 rBATF-
injected	oocytes	(Figures	4.6-4.7).	This	is	supported	by	published	reports	that	alanine	is	a	weak	
substrate	for	System	b0,+	(Lee	et	al.,	1993).	[3H]Proline	and	[3H]glutamate	were	not	transported	
into	rBATF-expressing	oocytes	(Figure	4.7).	This	selectivity	(arginine	>	lysine	>	leucine	>	alanine	
>>	proline	=	glutamate)	is	similar	to	that	observed	in	other	studies	(Bertran	et	al.,	1992b;	Tate	
et	 al.,	 1992;	 Wells	 &	 Hediger,	 1992;	 Bertran	 et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	 Competition	
experiments	confirmed	and	extended	these	observations	(Figure	4.8).	Unlabelled	amino	acids	
(all	 5mM)	 inhibited	 [3H]arginine	 uptake	 in	 the	 order	 arginine	 >	 lysine	 >	 leucine	 >	 alanine	 >	
histidine,	with	no	inhibition	observed	with	glycine	or	proline	(Figure	4.8).		
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Figure	 4.6:	 Expression	 of	 rBATF	 in	 Xenopus	 oocytes	 induces	 transport	 with	 b0,+-like	
substrate	 selectivity.	 Uptake	 of	 [3H]amino	 acids	 (10μM,	 2.5-5μCi.ml-1)	 into	 water-injected	
control	 (open	bars)	and	 rBATF-expressing	Xenopus	oocytes	 (closed	bars)	over	40min	 (pH	7.4,	
Na+-free).	Data	are	mean±SEM	(n=20).	***,	p<0.001;	ns,	p<0.05	vs.	water-injected	oocytes.	
	
	
	
	 	
Arg Lys Leu Pro Glu
0
10
20
30
Water
rBAT
***
***
***
ns
ns[³ H
]A
m
in
o>
ac
id
>u
pt
ak
e>
(p
m
ol
.o
oc
yt
eE
¹ .(
40
m
in
)E¹
)
[3 H
]A
m
in
o	
ac
id
	u
pt
ak
e	
(p
m
ol
.o
oc
yt
e-
1 .(
40
m
in
)-1
)	
	 183	
		
	 	
Arginine Lysine
0
10
20
30
40
***
***
Arginine Alanine
0
10
20
30
40
50 ***
ns
Arginine Glutamic8Acid
0
10
20
30 ***
ns
Arginine Leucine
0
10
20
30
40
***
***
Arginine Proline
0
10
20
30
40
***
ns
A																																													B	
	
	
	
	
	
C																																													D	
	
	
	
	
	
E	
	
	
[3 H
]A
rg
in
in
e	
up
ta
ke
		
(p
m
ol
.o
oc
yt
e-
1 .(
40
m
in
)-1
)	
[3 H
]A
rg
in
in
e	
up
ta
ke
		
(p
m
ol
.o
oc
yt
e-
1 .(
40
m
in
)-1
)	
[3 H
]A
rg
in
in
e	
up
ta
ke
		
(p
m
ol
.o
oc
yt
e-
1 .(
40
m
in
)-1
)	
[3 H
]A
rg
in
in
e	
up
ta
ke
		
(p
m
ol
.o
oc
yt
e-
1 .(
40
m
in
)-1
)	
[3 H
]A
rg
in
in
e	
up
ta
ke
		
(p
m
ol
.o
oc
yt
e-
1 .(
40
m
in
)-1
)	
	 184	
	
	
	
	
	
	
	
	
Figure	 4.7:	 Substrate	 selectivity	 of	 System	 b0,+.	 Uptake	 of	 [3H]amino	 acids	 (10μM)	 into	
water-injected	 controls	 (open	 bars)	 and	 rBATF-expressing	Xenopus	oocytes	 (black	 bars)	 over	
40min	(pH	7.4,	Na+-free).	A,	Arginine	(2.5μCi.ml-1,	n=39-40)	vs.	 lysine	(5μCi.	ml-1,	n=35-38);	B,	
arginine	(2.5μCi.ml-1,	n=38-39)	vs.	leucine	(5μCi.ml-1,	n=37-40);	C,	arginine	(2.5μCi.ml-1,	n=9-10)	
vs.	alanine	 (5μCi.ml-1,	 n=6-10);	D,	 arginine	 (2.5μCi.ml-1,	 n=29-30)	vs.	proline	 (5μCi.ml-1,	 n=29-
30);	E,	arginine	(2.5μCi.ml-1,	n=29)	vs.	glutamic	acid	(5μCi.ml-1,	n=30).	Data	are	mean±SEM.	ns,	
p>0.05;	***,	p<0.001	vs.	water-injected	control	oocytes.	
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Figure	 4.8:	 System	 b0,+
	
substrate	 specificity	 determined	 by	 competitive	 inhibition	 of	
[3H]arginine	uptake.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	in	the	absence	(control)	or	
presence	of	5mM	competitor	compounds	measured	over	40min.	Arginine	(+Arg);	lysine	(+Lys);	
leucine	 (+Leu);	 alanine	 (+Ala);	 histidine	 (+His);	 glycine	 (+Gly),	 proline	 (+Pro).	 A,	 Uptake	 of	
[3H]arginine	 in	 water-injected	 control	 (open	 bars,	 n=18-20)	 and	 rBATF-expressing	 oocytes	
(black	bars,	n=19-20);	B,	data	 (as	shown	 in	panel	A)	are	expressed	as	 the	percentage	uptake	
relative	to	uptake	in	the	absence	of	competitor	compound	following	the	subtraction	of	water-
injected	control	 values	 (control=100%).	 	Amino	acid	 structures	are	 shown	below	 figure;	***,	
p<0.001;	ns,	p>0.05	vs.	uptake	in	the	absence	of	competitor	in	rBATF-expressing	oocytes.	
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4.3.6	Addition	of	FLAG	epitopes	does	not	affect	rBAT	function	
A	 series	 of	 different	 FLAG	 epitopes	 was	 added	 to	 rBAT	 to	 aid	 sensitive	
immunodetection	of	the	protein	by	western	blotting.	This	process	is	reported	in	detail	later	in	
this	chapter	(section	4.3.7,	Figure	4.18A)	and	a	summary	of	the	different	constructs	created	is	
shown	in	Figure	4.9A.	It	was	essential	to	determine	that	the	addition	of	FLAG	epitopes	at	the	
N-	and	C-termini	of	the	protein	did	not	affect	function	of	the	protein	nor	 its	association	with	
the	endogenous	light	chain.	[3H]Arginine	uptake	was	measured	in	oocytes	injected	with	water	
(control)	or	50ng	cRNA	encoding	rBAT	(untagged),	rBATF,	FrBATF,	rBAT2F	or	rBAT3F	(Figure	4.9B).	
Uptake	in	rBAT-injected	oocytes	(37.4±8.1	pmol.oocyte-1.(60min)-1)	was	9-fold	greater	than	in	
water-injected	 control	 oocytes	 (4.2±0.7	 pmol.oocyte-1.(60min)-1).	 None	 of	 the	 FLAG-tagged	
rBAT	constructs	tested	in	the	uptake	experiments	showed	significantly	different	(p>0.05)	levels	
of	uptake	to	the	untagged	construct	(Figure	4.9B).		
Concentration-dependent	 [3H]arginine	uptake	 (pH	7.4,	Na+-free)	was	measured	using	
rBAT3F	 to	 calculate	 the	 kinetic	 parameters	 of	 System	 b0,+.	 In	 a	 single	 experiment,	 uptake	 of	
[3H]arginine	was	performed	at	0.01-20mM	(Figure	4.10A).	When	the	data	were	plotted	up	to	
1mM,	the	measured	affinity	(Km)	of	the	transport	system	was	70±17μM	with	a	capacity	(Vmax)	
of	 280±19	 pmol.oocyte-1.(60min)-1	 (Figure	 4.10B).	 This	 experiment	 was	 repeated	 four	 times	
with	measured	Km	values	ranging	from	24-114μM,	all	within	the	high-affinity	range	reported	in	
the	literature	(Bertran	et	al.,	1992b;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Lee	et	al.,	1993)	
(see	Chapter	1).	The	capacity	measurements	varied	10-fold,	reflecting	the	variability	in	protein	
expression	between	oocyte	batches.	This	highlighted	 the	 importance	of	 the	use	of	wild-type	
rBAT	controls	in	mutant	characterisation	experiments.	When	transformed	to	the	linear	Eadie-
Hofstee	equation,	the	r2	value	of	the	data	was	0.94	(Figure	4.10C).	This	high	level	of	correlation	
of	the	data	to	the	linear	equation	indicates	one-site	binding	kinetics	of	[3H]arginine	transport.		
These	data	indicate	that	the	addition	of	FLAG	epitopes	does	not	affect	rBAT	function	in	
association	 with	 the	 endogenous	 light	 chain.	 Therefore,	 it	 is	 suitable	 to	 use	 these	 tagged	
constructs	in	the	functional	expression	studies	of	rBAT	in	oocytes.		
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Figure	4.9:	Addition	of	FLAG	tags	to	human	rBAT.	A,	schematic	representation	of	the	FLAG-
tagged	rBAT	constructs	used	 in	this	study;	B,	 [3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	 in	
Xenopus	oocytes	injected	with	water	(control,	open	bar),	rBAT,	rBATF,	FrBATF,	rBAT2F,	or	rBAT3F	
cRNA	(50ng).	Data	are	mean±SEM	(n=18-20);	
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Figure	 4.10:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT3F-induced	 transport	 in	
oocytes.	 	[3H]Arginine	uptake	(0.01-20mM,	pH	7.4,	Na+-free)	in	Xenopus	oocytes	injected	with	
rBAT3F	cRNA	 (50ng).	Uptake	was	carried	out	3	days	post-injection	of	oocytes.	Water-injected	
control	 values	 have	 been	 subtracted.	Data	 are	mean±SEM	of	 a	 single	 experiment	 (n=10).	 A,	
Data	 for	 rBAT3F-mediated	uptake	 from	0.01-20mM	were	 fitted	 to	Michaelis-Menten	one-site	
binding	kinetics	 (r2=0.46);	B,	Data	 for	 rBAT3F-mediated	uptake	 from	0.01-1mM	were	 fitted	to	
Michaelis-Menten	one-site	binding	kinetics	(r2=0.64);	C,	Data	for	rBAT3F-mediated	uptake	from	
0.01-1mM	 were	 transformed	 to	 the	 linear	 Eadie-Hofstee	 equation,	 displayed	 on	 the	 graph	
(r2=0.94).	
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Further	uptake	and	 competition	 studies	were	 carried	out	with	 rBAT3F	 to	 confirm	 the	
substrate	 selectivity	 of	 System	 b0,+.	 In	 addition	 to	 the	 dibasic	 amino	 acids,	 a	 prototypical	
substrate	of	System	b0,+	is	cystine,	the	cysteine	dimer.	Uptake	of	[3H]arginine	and	[14C]cystine	
(10μM,	pH	7.4,	Na+-free)	was	measured	in	oocytes	injected	with	water	(control)	or	50ng	rBAT3F	
cRNA.	Significant	(p<0.01)	uptakes	of	arginine	(6.5-fold),	and	cystine	(6-fold)	were	measured	in	
rBAT3F	 expressing	 oocytes	 above	 water-injected	 control	 oocytes	 (Figure	 4.11A).	 The	
[14C]cystine	 uptake	 was	 carried	 out	 in	 the	 presence	 of	 0.1mM	 diamide	 to	 prevent	 the	
reduction	 of	 cystine	 to	 the	 thiol	 amino	 acid	 cysteine	 (Bertran	 et	 al.,	 1992b;	 Thwaites	 et	 al.,	
1996).	
Competition	experiments	showed	inhibition	of	[3H]arginine	uptake	in	the	presence	of	
5mM	 arginine	 (99%	 inhibition),	 ornithine	 (95%	 inhibition),	 and	 cysteine	 (80%	 inhibition).	
Cysteine	 competition	was	measured	 in	 the	 presence	 of	 0.1mM	DTT	 to	 prevent	 oxidation	 of	
cysteine	to	the	dimer	cystine	(Bertran	et	al.,	1992b;	Thwaites	et	al.,	1996).	In	Figure	4.11C	the	
same	data	are	shown	as	in	panel	B,	expressed	as	percentage	control	of	arginine	uptake	in	the	
absence	of	 any	 competitor.	Water-injected	 control	 values	have	been	 subtracted.	 These	data	
further	 confirm	 that	 the	 substrate	 selectivity	 measured	 in	 this	 investigation	 correlate	 with	
those	reported	in	the	literature,	along	with	the	results	reported	in	section	4.3.5.	No	change	in	
function	is	measurable	in	rBAT	with	a	3xFLAG	epitope	on	the	C	terminal	of	the	protein	(rBAT3F).		
The	 data	 reported	 thus	 far	 in	 this	 chapter	 indicate	 successful	 optimisation	 of	
conditions	 for	 System	 b0,+	 transport	 in	 oocytes	 following	 injection	 of	 untagged	 and	 FLAG-
tagged	rBAT	cRNA.	This	function	was	mediated	through	an	associated	of	human	rBAT	with	an	
endogenous	 light	 chain	 in	 the	 oocyte.	 The	 secondary	 aim	 of	 these	 studies	 was	 to	
heterologously	 express	 both	 subunits	 of	 the	 mammalian	 transport	 system	 in	 order	 that	
cystinuria	mutations	in	either	subunit	could	be	characterised.		
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Figure	4.11:	Substrate	selectivity	of	System	b0,+.	A,	[3H]Arginine	uptake	(10μM,	2.5μCi.ml-1)	vs.	
[14C]cystine	 (10μM,	1μCi.ml-1)	 in	water-injected	 (open	bars)	 or	 rBAT3F-expressing	 (black	bars)	
Xenopus	oocytes	over	60min	(pH	7.4,	Na+-free).	Data	are	mean±SEM	(n=13-20).	**,	p<0.01	vs.	
water-injected	control	oocytes;	B,	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	in	the	absence	
(control)	or	presence	of	5mM	competitor	 compounds	measured	over	60min.	Arginine,	+Arg;	
ornithine,	 +Orn;	 cysteine,	 +Cys.	 Data	 are	 mean±SEM	 (n=18-20).	 ns,	 p>0.05;	 ***,	 p<0.01	 vs.	
water-injected	control	oocytes;	C,	Data	(as	shown	in	Figure	4.11B)	expressed	as	the	percentage	
uptake	 relative	 to	 uptake	 in	 the	 absence	 of	 competitor	 compound	 following	 subtraction	 of	
water-injected	 control	 values	 (control=100%).	 	 ***,	 p<0.001;	 vs.	 uptake	 in	 the	 absence	 of	
amino	acid	competitor	in	rBAT3F-expressing	oocytes.	
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4.3.7	Co-expression	of	mammalian	System	b0,+	subunits	in	oocytes		
To	characterise	the	functional	effects	of	cystinuria	mutations	located	in	the	light	chain	
of	System	b0,+	it	would	be	necessary	to	co-express	the	human	b0,+AT	protein	with	human	rBAT	
in	 Xenopus	 oocytes.	 This	 would	 allow	 site-directed	 mutagenesis	 to	 be	 performed	 on	 the	
exogenous	 cDNA	 sequence.	 Thus,	 it	 was	 important	 to	 determine	 whether	 rBAT	 would	
selectively	associate	with	a	heterologously-expressed	human	or	mouse	b0,+AT,	rather	than	the	
Xenopus	light	chain,	when	the	cRNAs	for	both	subunits	were	co-injected	into	oocytes.	
Firstly,	 it	 was	 established	 whether	 injection	 of	 the	 two	 subunits	 in	 isolation	 would	
induce	uptake	of	arginine	above	that	observed	in	water-injected	control	oocytes	(Figure	4.12).	
The	 expression	 of	 rBATF	 in	 the	 oocytes	 following	 injection	 of	 10ng	 cRNA	 led	 to	 a	 significant	
increase	 in	uptake	 (p<0.01)	 above	water-injected	oocytes	 (Figure	4.12A).	 In	oocytes	 injected	
with	25ng	of	human	or	mouse	b0,+AT	cRNA,	no	uptake	of	arginine	was	measured	above	that	in	
water-injected	 control	 oocytes	 (Figure	 4.12B).	 In	 fact,	 the	 uptake	 values	 for	 the	 oocytes	
injected	 with	 the	 light	 chain	 cRNAs	 were	 lower	 than	 the	 water-injected	 control	 values,	
although	 these	differences	were	not	 significant	 (p>0.05).	 In	 the	absence	of	 rBATF,	 the	b0,+AT	
protein	 is	 not	 trafficked	 to	 the	 plasma	membrane	 (Chairoungdua	 et	 al.,	 1999).	 However,	 as	
shown	 previously	 in	 this	 study,	 the	 introduction	 of	 rBATF	 protein	 allows	 association	with	 an	
endogenous	light	chain	in	the	oocyte.		
Human	 rBATF	 cRNA	 (1-10ng)	 was	 injected	 into	 Xenopus	 oocytes	 in	 the	 absence	 or	
presence	of	human	b0,+AT	cRNA	(1-50ng)	 (Figure	4.13A-C).	At	all	 three	rBATF	cRNA	quantities	
tested,	 [3H]arginine	 uptake	 was	 significantly	 greater	 (<0.001)	 than	 water-injected	 controls	
(Figure	4.13A-C).	No	 further	 stimulation	of	uptake	was	measured	upon	co-injection	of	b0,+AT	
cRNA	 (1-50ng).	 In	 fact,	 in	 some	 instances	 an	 apparent	 reduction	 in	 uptake	 was	 observed	
(Figure	 4.13B).	 The	 same	 measurements	 were	 carried	 out	 in	 oocytes	 injected	 with	 mouse	
b0,+AT	cRNA,	and	broadly	similar	observations	were	made	(Figure	4.14).		
These	 data	 are	 consistent	 with	 results	 reported	 in	 the	 literature,	 where	 oocyte	
injection	 of	 human	 rBAT	 and	mouse	 b0,+AT	 cRNA	 did	 not	 stimulate	 [3H]arginine	 above	 that	
observed	when	rBAT	cRNA	was	 injected	alone	(Pfeiffer	et	al.,	1999a;	Fernandez	et	al.,	2006).	
Additionally,	 it	 should	 be	 noted	 that,	 in	 these	 studies,	 it	 is	 not	 clear	 whether	 the	 observed	
amino	acid	transport	was	via	the	mouse	or	Xenopus	light	chain.	
	 To	address	the	problem	of	in	vitro	subunit	assembly	in	Xenopus	oocytes,	Pfeiffer	et	al.	
reported	use	of	a	concatenated	cDNA,	which	encoded	both	subunits	of	System	b0,+,	linked	by	a	
10	amino	acid	 linker	sequence	(Pfeiffer	et	al.,	1999a).	When	the	cRNA	for	this	 fusion	protein	
was	 injected	 into	oocytes,	significant	(p<0.05)	uptake	of	arginine	was	observed	above	water-
injected	control	oocytes.			
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Prior	to	the	start	of	this	study,	a	concatenated	human	rBATF	and	human	b0,+AT	cDNA	
was	created	in	our	laboratory	by	Dr.	Noel	Edwards,	based	on	the	report	by	Pfeiffer	et	al.	(1999)	
(see	 section	 4.4).	 Uptake	 of	 arginine,	 lysine,	 leucine,	 alanine	 and	 proline	 was	 carried	 out	
(10μM,	pH	7.4,	Na+-free)	in	oocytes	injected	with	water	(control),	rBATF	cRNA	(10ng),	or	rBATF-
b0,+AT	 concatenated	 cRNA	 (10ng)	 (Figure	 4.15).	 Significant	 uptake	 (p<0.001)	 of	 System	 b0,+	
substrates	 arginine	 (16-fold),	 lysine	 (8.5-fold),	 and	 leucine	 (4-fold)	was	measured	 in	 oocytes	
expressing	rBATF	 in	association	with	Xenopus	b0,+AT	compared	to	water-injected	controls.	No	
significant	uptake	was	measured	in	oocytes	expressing	the	fusion	protein	compared	to	water-
injected	controls,	with	 the	exception	of	arginine.	However,	 this	 is	 likely	within	 the	margin	of	
error	 and	 to	 produce	 reliable	 uptake	 via	 the	 fusion	 protein,	 significant	 uptake	 of	 all	 b0,+	
substrates	 would	 need	 to	 be	 identified.	 These	 data	 are	 the	 mean	 of	 two	 individual	
experiments	(n=20)	and	are	consistent	with	the	results	achieved	by	Dr.	Noel	Edwards.		
The	 failure	 to	measure	uptake	of	b0,+	 substrates	via	 the	human	or	mouse	 light	 chain	
was	disappointing.	However,	all	novel	mutants	reported	in	this	study	were	located	in	the	gene	
encoding	the	rBAT	protein	(SLC3A1)	(Chapter	3).	Therefore,	for	characterisation	of	the	SLC3A1	
mutations	 identified	 in	 the	 current	 cohort	 of	 patients,	 the	 association	 of	 rBAT	 with	 the	
endogenous	light	chain	in	Xenopus	oocytes	is	a	valuable	tool.	This	will	allow	the	measurement	
of	 rBAT	 protein	 expression	 and	 trafficking	 to	 the	 plasma	 membrane.	 Following	 the	
optimisation	 of	 the	 functional	measurements	 to	 determine	 rBAT	 expression	 in	 the	 oocytes,	
several	immunodetection	techniques	were	established	to	support	these	data.	
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Figure	4.12:	 System	b0,+-like	 activity	 is	 not	observed	 following	 injection	of	b0,+AT	 cRNA	
alone.	 [3H]Arginine	uptake	 (10μM,	pH	7.4,	Na+-free,	 60min)	via	oocytes	 injected	with	water	
(controls),	 rBATF	 cRNA	 (10ng),	 human	 b0,+AT	 cRNA	 (25ng),	 or	mouse	 b0,+AT	 cRNA	 (25ng).	 A,	
[3H]Arginine	 uptake	 in	 water-injected	 control	 (open	 bar,	 n=8)	 and	 rBATF-injected	 oocytes	
(black	bars,	1-10ng	cRNA,	n=8-10);	B,	[3H]Arginine	uptake	in	water-injected	controls	(open	bar,	
n=8),	human	b0,+AT-expressing	 (black	bar,	n=10),	and	mouse	b0,+AT-expressing	oocytes	 (black	
bar,	 n=7).	 Data	 are	 expressed	 as	 mean±SEM.	 	 ***,	 p<0.001;	 ns,	 p>0.05	 vs.	 water-injected	
control	oocytes.	
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Figure	 4.13:	 Co-injection	 of	 Xenopus	 oocytes	 with	 rBATF	 and	 human	 b0,+AT	 cRNA.	
[3H]Arginine	uptake	(pH	7.4,	Na+-free)	via	oocytes	 injected	with	water	 (controls),	 rBATF	cRNA	
(1-10ng),	 and/or	 human	b0,+AT	 cRNA	 (1-50ng).	 [3H]Arginine	 uptake	 (10μM)	 in	water-injected	
control	oocytes,	with	or	without	co-injection	of	1-50ng	b0,+AT	cRNA	(open	bars,	n=9-10),	and	
rBATF	cRNA-injected	oocytes	(A,	1ng;	B,	5ng;	C,	10ng),	with	or	without	co-injection	of	1-50ng	
b0,+AT	cRNA	(black	bars,	n=7-10).		
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Figure	 4.14:	 Co-injection	 of	 Xenopus	 oocytes	 with	 rBATF	 and	 mouse	 b0,+AT	 cRNA.	
[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	injected	with	water	(controls),	
rBATF	 cRNA	 (1-10ng),	 and/or	 mouse	 b0,+AT	 cRNA	 (1-50ng).	 [3H]Arginine	 uptake	 (10μM)	 in	
water-injected	control	oocytes,	with	or	without	co-injection	of	1-50ng	b0,+AT	cRNA	(open	bars,	
n=9-10),	 and	 rBATF	 cRNA-injected	 oocytes	 (A,	 1ng;	 B,	 5ng;	 C,	 10ng),	 with	 or	 without	 co-
injection	of	1-50ng	b0,+AT	cRNA	(black	bars,	n=9-10).		
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Figure	4.15:	Uptake	of	System	b0,+	substrates	in	Xenopus	oocytes	expressing	human	rBATF	or	
an	 rBATF-b0,+AT	 fusion	 protein.	 [3H]Amino	 acid	 uptake	 (10μM,	 2.5-5μCi.ml-1)	 into	 water-
injected	 control	 oocytes	 (open	 bars),	 rBATF-expressing	 oocytes	 (black	 bars),	 and	 oocytes	
expressing	the	rBATF-	b0,+AT	fusion	protein	over	40min	(pH	7.4,	Na+-free).	Data	are	mean±SEM	
(n=20).	***,	p<0.001;	*,	p<0.01;	ns,	p<0.05	vs.	water-injected	oocytes.	
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4.3.8	Immunodetection	of	rBAT	protein	by	western	blot	
	 It	was	essential	to	establish	a	method	of	detecting	rBAT	protein	in	oocyte	membranes	
to	support	the	functional	expression	data	obtained	through	uptake	measurements.	Mutations	
located	in	rBAT	have	been	hypothesised	to	cause	a	cystinuria	phenotype	due	to	a	reduction	in	
trafficking	of	System	b0,+	to	the	cell	membrane,	as	opposed	to	any	changes	in	the	affinity	of	the	
transporter	(see	Chapter	1)	(Chillarón	et	al.,	1997;	Bartoccioni	et	al.,	2008).	Western	blotting	
was	 optimised	 to	 help	 identify	whether	 the	 reduction	 in	 [3H]arginine	 uptake	was	 due	 to	 an	
alteration	in	protein	expression	or	localisation.			
Oocyte	membranes	were	isolated	using	two	different	techniques	(see	Chapter	2).	The	
first	technique	enabled	detection	of	the	total	amount	of	rBAT	protein	produced	in	the	oocyte	
by	 isolating	 total	 membrane	 proteins	 from	 homogenised	 oocytes	 (see	 section	 2.9.1).	 The	
second	 technique	 isolated	 oocyte	 plasma	 membrane	 proteins	 to	 detect	 rBAT	 at	 the	 outer	
membrane	of	the	cells.	This	was	achieved	through	incubation	of	whole	oocytes	with	positively-
charged	 silica	 and	 coating	 them	 in	 high	 molecular	 weight	 poly(acrylic)acid,	 before	
centrifugation,	as	described	in	section	2.9.3.		
	 Water,	 or	 rBATF	cRNA	 (50ng)	 (Figure	 4.16A)	was	 injected	 into	Xenopus	 oocytes	 and,	
following	 incubation	 (3	 days),	 membranes	 were	 separately	 prepared	 by	 ultracentrifugation	
(total	 membranes)	 and	 silica	 isolation	 (plasma	 membranes).	 The	 protein	 samples	 were	
separated	by	SDS-PAGE	and	transferred	onto	PVDF	membranes	prior	to	 immunodetection	as	
described	 in	 Chapter	 2.	 The	 mouse	 M2	 anti-FLAG	 primary	 antibody	 (Sigma,	 UK)	 was	 used,	
along	 with	 a	 HRP-conjugated	 anti-mouse	 secondary	 antibody	 (see	 Chapter	 2).	 As	 a	 positive	
control	 for	antibody	application,	protein	samples	using	both	 techniques	were	prepared	 from	
oocytes	 injected	with	 50ng	 cRNA	of	 flounder	 sodium-phosphate	 transporter,	NaPi-IIa,	which	
had	FLAG-tags	on	both	the	N-	and	C-termini	(Figure	4.16B).		
When	 detected	 through	 western	 blotting,	 rBAT	 protein	 appears	 as	 a	 double	 band	
between	 85	 and	 90	 kDa	 in	 size.	 These	 “doublets”	 correspond	 to	 the	 core	 glycosylated,	
immature	 protein	 (lower	 band,	 85kDa)	 and	 the	 mature	 glycosylated	 protein	 (upper	 band,	
90kDa)	processed	by	the	Golgi	apparatus	(Chillarón	et	al.,	1997).	No	rBAT-specific	bands	were	
detected	 (Figure	 4.16C,	 lanes	 b	 and	 d).	 In	 lanes	 e	 and	 f,	 bands	 of	 90kDa	 were	 detected,	
corresponding	to	NaPi-IIa	total	membrane	protein	and	plasma	membrane	protein,	respectively	
(Figure	4.16C).	This	western	blot	was	repeated	several	times	using	the	M2	primary	antibody	at	
concentrations	ranging	from	1:200	to	1:50	(16h,	4°C),	and	secondary	antibody	concentrations	
as	high	as	1:1000.	Despite	these	alterations	to	the	protocol,	it	was	not	possible	to	detect	rBATF	
by	western	blot	following	injection	of	50ng	cRNA	in	Xenopus	oocytes.	However,	it	was	possible	
to	detect	FNaPi-IIaF,	and	so	to	increase	the	sensitivity	of	rBAT	detection	a	second	FLAG	tag	was	
added	to	the	N-terminal	of	the	protein	to	produce	FrBATF.	
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Figure	 4.16:	 Immunodetection	 of	 FLAG-tagged	 proteins	 in	 oocyte	 membranes	 by	 western	
blot.	A,	Schematic	representation	of	the	rBAT	cDNA	sequence	with	a	single	FLAG-tag,	3’	of	the	
protein	coding	sequence	(rBATF);	B,	Schematic	representation	of	the	NaPi-IIa	cDNA	sequence	
with	single	FLAG-tags	5’	and	3’	of	the	protein	coding	sequence	(FNaPi-IIaF)	from	which	cRNA	is	
in	vitro	 transcribed.	Start,	 start	codon	 (atg);	 rBAT,	 rBAT	open	reading	 frame	(ORF)	sequence;	
FLAG,	 position	 of	 DYKDDDDK	 epitope;	 Stop,	 stop	 codon	 (tag);	 C,	Western	 blot	 detection	 of	
rBATF	and	NaPi-IIa	in	oocyte	total	membrane	and	plasma	membrane	fractions	using	the	Sigma	
M2	anti-FLAG	primary	 antibody	 (1:200).	 The	 lanes	 represent	 oocytes	 injected	with:	 a,	water	
(control,	total	membranes);	b,	50ng	rBATF	cRNA	(total	membranes);	c,	water	(control,	plasma	
membranes);	 d.	 50ng	 rBATF	 cRNA	 (plasma	 membranes);	 e,	 50ng	 FNaPi-IIaF	 cRNA	 	 (total	
membranes);	f,	50ng	FNaPi-IIaF	cRNA	(plasma	membranes).	Lanes	a-d,	100μg	protein;	lanes	e-f	
5μg	protein.	
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Western	blot	detection	of	the	double-tagged	construct,	FrBATF,	was	unsuccessful	using	
the	M2	 primary	 antibody	 (not	 shown).	 However,	 the	 use	 of	 a	 Proteintech	mouse	 anti-FLAG	
primary	 antibody	 led	 to	 the	 detection	 of	 FrBATF-specific	 bands	 in	 total	 membrane	 proteins	
(Figure	4.17C	 lanes	e	and	 f).	No	bands	were	detected	 in	 lanes	 representing	 total	membrane	
proteins	from	oocytes	injected	with	rBATF	cRNA	(Figure	4.17C	lanes	c	and	d),	or	water	(Figure	
4.17,C,	 lanes	 a	 and	 b).	 Increasing	 the	 amount	 of	 protein	 used	 in	 the	 blot	 from	 50-100μg	
resulted	 in	 increased	 intensity	 of	 the	 FrBATF	 bands	 (Figure	 4.17C,	 lanes	 e	 and	 f).	 These	 data	
confirm	successful	detection	of	in	FrBATF	in	oocytes	injected	with	50ng	cRNA.		
This	technique	was	optimised	further	to	allow	detection	of	FrBATF	proteins	by	western	
blotting	using	protein	samples	from	oocytes	injected	with	cRNA	over	the	range	1-50ng	(Figure	
4.18).	However	 the	experimental	 conditions	 led	 to	 the	presence	of	many	non-specific	bands	
(Figure	4.18D,	lanes	b,	c,	and	d).		
To	 increase	 the	 sensitivity	 of	 rBAT	 detection,	 and	 enable	 a	 lower	 antibody	
concentration	 to	 be	 used,	 a	 3xFLAG	 epitope	 (DYKDHDG-DYKDHDI-DYKDDDDK)	was	 added	 to	
the	C-terminal	of	the	protein	by	a	three-step	inverse	overlapping	PCR	method	to	create	rBAT3F	
(Chapter	2).	The	triple	FLAG-tag	was	first	reported	as	a	method	of	increasing	the	sensitivity	of	
epitope	detection	in	low-expression	mammalian	systems	(Hernan	et	al.,	2000).	As	a	by-product	
of	the	three-step	process	of	rBAT3F	production,	rBAT2F	was	created	(DYKDHDI-DYKDDDDK)	(see	
Chapter	 2).	 Using	 the	 Proteintech	 anti-FLAG	 primary	 antibody,	 rBAT2F	 (Figure	 4.18C,	 lane	 e)	
and	 rBAT3F	 (Figure	 4.18C,	 lanes	 f-h)	 were	 detected	 with	 less	 sensitivity	 than	 FrBATF	 (Figure	
4.18C,	 lanes	 b-d).	 In	 the	 literature	 differences	 in	 critical	 binding	 residues	 for	 different	 anti-
FLAG	antibodies	are	 reported	 (Hernan	et	al.,	2000).	The	Sigma	M2	anti-FLAG	antibody	had	a	
markedly	 increased	 sensitivity	 of	 detection	 of	 the	 3xFLAG	 epitope	 compared	 to	 other	
antibodies	 (Hernan	 et	 al.,	 2000).	 Consequently,	 the	 western	 blot	 detection	 of	 rBAT3F	 was	
repeated	 with	 the	 M2	 anti-FLAG	 primary	 antibody	 (Figure	 4.19F).	 This	 was	 carried	 out	 to	
determine	 whether	 the	 M2	 anti-FLAG	 antibody	 measured	 detection	 of	 rBAT-3xFLAG	 with	
greater	sensitivity	than	the	Proteintech	anti-FLAG	antibody.	Total	membrane	protein	samples	
from	 oocytes	 injected	with	 1,	 2,	 5,	 10,	 20	 and	 50ng	 rBAT3F	 cRNA	were	 used	 (Figure	 4.19F).	
Doublet	 bands	 80-90kDa	 in	 size	were	 detected	with	 increasing	 intensity	 in	 lanes	 containing	
total	membrane	protein	from	oocytes	injected	with	1-50ng	rBAT3F	cRNA	(Figure	4.19F,	lanes	b-
g,	 respectively).	No	bands	were	detected	 in	the	water-injected	control	oocyte	 lysates	 (Figure	
4.19F,	lane	a).			
To	 illustrate	 the	 sensitivity	 in	detection	of	 the	different	 tagged	constructs	by	 the	
M2	antibody,	Figure	4.19F	lanes	h-m	represent	25μg	total	membrane	protein	from	oocytes	
injected	with	water	 (h),	or	50ng	of	 rBAT	 (i),	 rBATF	 (j),	 FrBATF	 (k),	 rBAT2F	 (l),	or	 rBAT3F	 (m)	
cRNA.	 rBAT-specific	 bands	were	 only	 detected	 in	 lanes	 representing	 FrBATF,	 rBAT2F,	 and	
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rBAT3F	cRNA-injected	oocytes	(50ng).	The	rBAT2F	and	rBAT3F	protein	samples	led	to	bands	
of	greater	intensity	than	those	from	FrBATF	samples	(lane	k).	This	indicates	that	the	3xFLAG	
tag	has	 increased	the	sensitivity	of	detection	by	the	M2	antibody	over	that	measured	by	
two	 single	 FLAG	 tags.	 This	 was	 not	 observed	 using	 the	 Proteintech	 anti-FLAG	 antibody	
(Figure	4.18).		
The	optimised	detection	system	also	worked	successfully	with	plasma	membrane	
proteins	 isolated	using	 the	silica-based	preparation	method	 (Figure	4.19F,	 lanes	n-q).	No	
bands	were	detected	in	lanes	containing	water-injected	oocyte	protein	(n,	2μg;	p,	1μg)	but	
strong	 bands	 of	 around	 80kDa	were	 detected	 in	 rBAT3F	 protein	 preparations	 (o,	 2μg;	 q,	
1μg).	However,	the	successful	optimisation	of	the	plasma	membrane	preparation	was	only	
achieved	 as	 this	 study	 was	 nearing	 the	 end.	 The	 preparation	 of	 oocytes	 using	 this	
technique	 was	 carried	 out	 using	 oocytes	 injected	 with	 wild-type	 and	 mutant	 rBAT3F.	
However,	the	oocytes	were	of	poor	quality	and	quickly	disintegrated	when	incubated	with	
the	 protease	 to	 partially	 digest	 the	 vitelline	 membranes	 (see	 Chapter	 2).	 A	 second	
preparation	 was	 carried	 out	 successfully	 on	 a	 separate	 batch	 of	 oocytes	 although,	
unfortunately,	the	western	blot	failed.	Disappointingly,	due	to	time	constraints,	it	was	not	
possible	to	repeat	this	western	blot.	As	a	result,	the	plasma	membrane	localisation	of	the	
mutant	proteins	by	western	blot	is	not	reported	in	this	thesis.		
These	data	demonstrate	successful	optimisation	of	a	western	blotting	protocol	to	
detect	rBAT3F	protein	in	total	membrane	protein	samples	and	plasma	membrane	samples	
from	 Xenopus	 oocytes.	 The	 optimisation	 of	 these	 protocols	 enabled	 the	 expression	 of	
mutant	 rBAT	protein	 in	oocytes	 to	be	compared	 to	 that	of	 the	wild-type	 (Chapter	5).	To	
confirm	the	results	of	these	immunodetection	studies,	it	was	also	desirable	to	establish	a	
technique	 for	 the	 fluorescent	 immunocytochemical	 detection	 of	 the	 proteins	 at	 the	
plasma	membrane	 of	 oocytes.	 This	 allowed	 plasma	membrane	 localisation	 of	 wild-type	
and	mutant	rBAT3F	to	be	investigated	despite	the	failure	to	carry	out	western	blotting	on	
plasma	membrane	samples.		
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Figure	 4.17:	 Western	 blot	 detection	 of	 FrBATF	 in	 total	 oocyte	 membrane	 samples.	 A,	
Schematic	 representation	 of	 rBATF	 cDNA;	 B,	 Schematic	 representation	 of	 FrBATF	 cDNA	 from	
which	 cRNA	 is	 in	 vitro	 transcribed.	 Start,	 start	 codon	 (atg);	 rBAT,	 rBAT	 open	 reading	 frame	
(ORF)	sequence;	FLAG,	position	of	DYKDDDDK	epitope;	Stop,	stop	codon	(tag);	C,	Western	blot	
detection	of	 rBATF	and	 FrBATF	 in	oocyte	 total	membrane	proteins	using	 the	Proteintech	anti-
FLAG	 antibody	 (1:200,	 16h,	 4°C).	 The	 lanes	 represent	 protein	 from	 oocytes	 injected	 with:	
water	(loaded	protein	per	lane	was:	a,	50μg;	b,	100μg);	50ng	rBATF	cRNA	(c,	50μg;	d,	100μg);	
50ng	FrBATF	cRNA	(e,	50μg;	f,	100μg).	
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Figure	 4.18:	 Detection	 of	 FLAG-tagged	 rBAT	 constructs	 by	 western	 blot	 using	 the	
Proteintech	 anti-FLAG	 primary	 antibody.	 A,	 Schematic	 representation	 of	 FrBATF	 cDNA;	 B,	
Schematic	 representation	of	 rBAT2F	 cDNA;	C,	 Schematic	 representation	of	 rBAT3F	 cDNA	 from	
which	 cRNA	 is	 in	 vitro	 transcribed.	 Start,	 start	 codon	 (atg);	 rBAT,	 rBAT	 open	 reading	 frame	
(ORF)	sequence;	FLAG,	position	of	DYKDDDDK,	DYKDHDI,	or	DYKDHDG	epitope	(as	indicated);	
Stop,	 stop	 codon	 (tag);	 D,	 Western	 blot	 detection	 of	 FrBATF,	 rBAT2F,	 and	 rBAT3F	 with	 the	
Proteintech	anti-FLAG	primary	antibody	(1:100,	20h,	4°C)	in	50μg	total	oocyte	membranes.	The	
lanes	 represent	oocytes	 injected	with:	a,	water	 (control);	b,	50ng	 FrBATF	 cRNA;	 c,	5ng	 FrBATF	
cRNA;	d,	1ng	 FrBATF	cRNA;	e,	50ng	rBAT2F	cRNA;	 f,	50ng	rBAT3F	cRNA;	g,	5ng	rBAT3F	cRNA;	h,	
1ng	rBAT3F	cRNA.	
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Figure	 4.19:	 Detection	 of	 rBAT3F	 by	 western	 blot	 using	 the	 Sigma	 M2	 anti-FLAG	 primary	
antibody.	A,	Schematic	representation	of	untagged	rBAT	cDNA;	B,	Schematic	representation	of	
rBATF	 cDNA;	 C,	 Schematic	 representation	 of	 FrBATF	 cDNA;	 D,	 Schematic	 representation	 of	
rBAT2F	 cDNA;	 E,	 Schematic	 representation	 of	 rBAT3F	 cDNA	 from	 which	 cRNA	 is	 in	 vitro	
transcribed.	 Start,	 start	 codon	 (atg);	 rBAT,	 rBAT	 open	 reading	 frame	 (ORF)	 sequence;	 FLAG,	
position	of	DYKDDDDK,	DYKDHDI,	or	DYKDHDG	epitope	(as	indicated);	Stop,	stop	codon	(tag);	
F,	Western	blot	detection	of	rBAT3F	using	the	Sigma	M2	primary	antibody	(1:2000,	16h,	4°C).	
Oocytes	were	 injected	with	 increasing	amounts	of	rBAT3F	cRNA	(1-50ng).	Lanes	a-g	represent	
25μg	 total	membrane	protein	 samples	 from	oocytes	 injected	with:	a,	water	 (control);	b,	1ng	
rBAT3F;	 c,	 2ng	 rBAT3F;	 d,	 5ng	 rBAT3F;	 e,	 10ng	 rBAT3F;	 f,	 20ng	 rBAT3F;	 g,	 50ng	 rBAT3F	 cRNA.	
Oocytes	were	injected	with	the	different	tagged	rBAT	constructs	to	demonstrate	the	different	
sensitivity	 of	 detection	 by	 the	 antibody.	 Lanes	 h-m	 represent	 25μg	 total	membrane	 protein	
from	oocytes	injected	with:	h,	water	(control);	i,	rBAT	(untagged);	j,	rBATF;	k,	FrBATF;	i,	rBAT2F;	
m,	rBAT3F	cRNA	(50ng).	Oocytes	were	injected	with	rBAT3F	cRNA	and	plasma	membranes	were	
isolated	to	detect	protein	specifically	at	the	plasma	membrane.	Lanes	n	and	o	represent	2μg	
plasma	membrane	protein	from	oocytes	injected	with:	n,	water	(control);	o,	50ng	rBAT3F	cRNA;	
lanes	p	and	q	 represent	1μg	plasma	membrane	protein	 from	oocytes	 injected	with	p,	water	
(control);	q,	50ng	rBAT3F	cRNA.	
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4.3.9	Immunocytochemical	detection	of	rBAT	at	the	oocyte	plasma	membrane		
For	 the	 purposes	 of	 immunocytochemical	 detection	 of	 rBAT	 at	 the	 oocyte	 plasma	
membrane,	 whole	 oocytes	 were	 imaged	 by	 confocal	 microscopy	 following	 application	 of	
primary	 and	 secondary	 antibodies	 as	 described	 in	 Chapter	 2.	 Oocytes	 injected	 with	 water	
(control),	rBATF	cRNA	(50ng),	and	FNaPi-IIaF	cRNA	(50ng)	were	incubated	in	one	of	two	primary	
antibodies:	Proteintech	anti-FLAG	(Figure	4.20A),	or	Sigma	M2	anti-FLAG	(Figure	4.20B).	In	the	
earlier	studies	 FNaPi-IIaF	protein	was	detected	with	a	high	 level	of	 sensitivity	using	anti-FLAG	
antibodies	 in	western	blotting	(section	4.3.9).	Therefore,	this	cRNA	was	injected	as	a	positive	
control	for	the	optimisation	of	rBAT	immunocytochemical	detection.	The	mean	fluorescence	of	
water-injected	 control	oocytes	was	measured	and	 the	gain	was	adjusted	accordingly	 so	 that	
minimal	fluorescence	was	visible	(Chapter	2)	(Figure	4.20A-B).	Using	the	Proteintech	antibody	
(Figure	 4.20A)	 a	 faint	 signal	 was	 detected	 in	 rBATF	 expressing	 oocytes	 compared	 to	 water-
injected	controls.	However,	bright	membrane	fluorescence	was	visible	in	FNaPi-IIaF	expressing	
oocytes	 (Figure	4.20A).	Using	 the	Sigma	M2	antibody,	no	 fluorescence	was	detectable	 in	 the	
membrane	of	either	rBATF	or	FNaPi-IIaF	expressing	oocytes	(Figure	4.20B).	Due	to	the	presence	
of	 strong	 membrane	 fluorescence	 detected	 in	 the	 FNaPi-IIaF	 expressing	 oocytes	 using	 the	
Proteintech	 primary	 antibody,	 this	 was	 selected	 for	 use	 in	 rBAT	 detection	 in	 subsequent	
optimisation	experiments.	As	discussed	in	section	4.3.9,	an	rBAT	construct	with	single	N	and	C	
terminal	FLAG-tags	(FrBATF)	was	created	to	try	and	increase	the	sensitivity	of	rBAT	detection	in	
western	 blotting	 (Figure	 4.17).	 The	 immunocytochemical	 detection	 protocol	 was	 repeated	
using	this	construct.		
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Figure	 4.20:	 Immunocytochemical	 detection	 of	 rBATF	 in	 the	 plasma	 membrane	 of	 intact	
oocytes.	Confocal	microscopy	of	intact	oocytes	injected	with	water	(control,	left-hand	panel),	
50ng	rBATF	cRNA	(middle	panel),	or	50ng	FNaPi-IIaF	cRNA	(right-hand	panel).	A,	Incubation	with	
the	Proteintech	anti-FLAG	antibody	(1:100,	3h,	RT,	n=5-6);	B,	 Incubation	with	Sigma	M2	anti-
FLAG	 antibody	 (1:100,	 3h,	 RT,	 n=6).	 Scale	 bar,	 50μm.	 Arrows	 indicate	 the	 location	 of	 the	
plasma	membrane.		
	
	
	
	
	
	
A"
"
"
"
"
"
"
"
"
"
B"
Water&&&&&&&&&&&&&&rBATF&&&&&&&&&&FNaPi.IIaF&
Sigma&M2&
an6.FLAG&
Proteintech&&
an6.FLAG&
Water&&&&&&&&&&&&&&rBATF&&&&&&&&&&FNaPi.IIaF&
	 213	
Following	 the	 production	 of	 FrBATF,	 the	 choice	 and	 concentration	 of	 secondary	
antibody	 was	 also	 optimised	 for	 immunocytochemical	 detection	 (Figure	 4.21).	 Following	
incubation	with	a	Zymed	FITC-conjugated	goat	anti-mouse	secondary	antibody,	only	very	faint	
membrane	 fluorescence	was	measured	 in	 FrBATF	expressing	oocytes	 (Figure	4.21A,	 left-hand	
panel).	However,	bright	membrane	fluorescence	was	observed	 in	oocytes	 injected	with	50ng	
FNaPi-IIaF	cRNA	(Figure	4.21A,	right-hand	panel).		
The	 AlexaFluor	 488,	 goat	 anti-mouse	 secondary	 antibody	 (Life	 Technologies)	 was	
applied	separately	to	oocytes	expressing	FrBATF	and	FNaPi-IIaF	at	two	different	concentrations	
(Figure	 4.20B-C).	 At	 both	 concentrations,	 the	 oocytes	 expressing	 FNaPi-IIaF	 had	 bright	
membrane	 fluorescence	 that	 appeared	 saturated	 in	 some	 cases	 (Figure	 4.21B-C,	 right-hand	
panel).	 Membrane	 fluorescence	 representing	 FrBATF	 was	 observed	 using	 this	 secondary	
antibody	at	both	concentrations	(Figure	4.12B-C,	middle	panel).	However,	the	signal	appeared	
greater	 in	 oocytes	 incubated	 with	 the	 antibody	 at	 a	 1:50	 dilution.	 From	 these	 data	 it	 was	
evident	 that	 both	 the	 choice	 of	 secondary	 antibody,	 and	 the	 concentration	 at	which	 it	 was	
applied	 to	 the	 oocytes,	 could	 affect	 the	 sensitivity	 of	 FrBATF	 detection.	 Subsequent	
experiments	were	carried	out	using	the	AlexaFluor	secondary	antibody	at	a	dilution	of	1:50.	
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Figure	 4.21:	 Immunocytochemical	 detection	 of	 FrBATF	 in	 the	 oocyte	 membrane	 using	
different	 secondary	 antibodies.	Confocal	microscopy	of	 intact	oocytes	 injected	with	water	
(control,	left-hand	panel),	50ng	FrBATF	cRNA	(middle	panel)	or	50ng	FNaPi-IIaF	cRNA	(right-hand	
panel)	following	incubation	with	the	Proteintech	anti-FLAG	primary	antibody	(1:50).	A,	Oocytes	
incubated	 with	 Zymed	 goat	 anti-mouse	 FITC-conjugated	 secondary	 antibody	 (1:100);	 B,	
Oocytes	 incubated	 with	 AlexaFluor	 488	 goat	 anti-mouse	 secondary	 antibody	 (1:100);	 C,	
Oocytes	incubated	with	AlexaFluor	488	goat	anti-mouse	secondary	antibody	(1:50).	Scale	bar,	
50μm.	 Images	 are	 representative	 of	 n=6.	 Arrows	 indicate	 the	 location	 of	 the	 plasma	
membrane.	
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The	 rBAT3F	 construct	 was	 produced	 in	 our	 laboratory	 for	 the	 purposes	 of	 rBAT	
detection	 by	western	 blot,	 as	 reported	 in	 section	 4.3.9.	 The	 immunocytochemical	 detection	
protocol	was	 repeated	 using	 this	 triple	 FLAG-tagged	 construct.	 The	 cRNA	 (1-50ng)	 of	 rBAT3F	
was	injected	into	oocytes.	Positive	membrane	fluorescence	was	visible	in	oocytes	injected	with	
50ng	 cRNA	 (Figure	 4.22).	 However,	 in	 oocytes	 injected	 with	 1ng	 or	 5ng	 cRNA,	 much	 lower	
levels	 of	 fluorescence	were	 observed,	 and	membranes	 were	 barely	 visible	 (Figure	 4.22).	 To	
calculate	 any	 measurable	 difference	 in	 expression,	 the	 fluorescence	 of	 these	 oocytes	 was	
quantified	and	normalised	per	μm	membrane	 length	using	 ImageJ	 (Figure	4.23A).	 The	mean	
fluorescence	observed	 in	oocytes	 injected	with	either	1ng	(4.3±1	arbitrary	units	 (AU))	or	5ng	
cRNA	(4.3±1.3AU)	was	8.6-fold	greater	than	water-injected	controls	(0.5±0.2AU),	although	this	
was	not	significant	(p>0.05).	The	mean	membrane	fluorescence	of	50ng-injected	oocytes	was	
164.8±47AU,	which	was	significantly	greater	(p<0.01)	than	that	in	either	water-injected	control	
oocytes	or	those	injected	with	1-5ng	rBAT3F	cRNA	(Figure	4.23A).		
In	parallel,	[3H]arginine	uptake	was	measured	in	oocytes	injected	with	water	(control),	
or	 1ng,	 5ng,	 or	 50ng	 rBAT3F	 cRNA	 (Figure	 4.23B).	 In	 oocytes	 injected	 with	 50ng	 (25.5	
pmol.oocyte-1.(60min)-1)	and	5ng	(12.0	pmol.oocyte-1.(60min)-1)	rBAT	cRNA,	significant	uptake	
(p<0.05)	 was	 measured	 compared	 to	 water-injected	 control	 oocytes	 (3.8	 pmol.oocyte-
1.(60min)-1).	 In	 the	 uptake	 experiment,	 there	 was	 a	 significant	 difference	 (p<0.05)	 in	
[3H]arginine	uptake	between	1ng	and	5ng-injected	oocytes.	A	 significant	difference	was	also	
observed	 between	 oocytes	 injected	 with	 5ng	 and	 50ng	 cRNA	 (Figure	 4.23B).	 When	 the	
fluorescence	of	these	oocytes	was	quantified,	there	was	no	detectable	difference	in	expression	
between	 1ng	 and	 5ng-injected	 oocytes	 (Figure	 4.23A).	 This	 indicates	 that	 at	 lower	 levels	 of	
protein	expression,	this	technique	is	not	sensitive	enough	to	detect	a	change	 in	fluorescence	
intensity.		
These	 data	 have	 shown	 successful	 optimisation	 of	 an	 immunocytochemical	 protocol	
for	 detection	 of	 rBAT3F	 at	 the	 plasma	membrane	 of	whole	 oocytes	 at	 high	 levels	 of	 protein	
expression.	 However,	 this	 is	 not	 reliably	 quantifiable	 following	 injection	 of	 all	 amounts	 of	
cRNA.	Therefore,	for	the	purposes	of	immunocytochemical	detection	of	rBAT	mutants	in	whole	
oocytes,	the	protocol	was	carried	out	following	injection	of	50ng	cRNA	only	(Chapter	5).		
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Figure	 4.22:	 Immunocytochemical	 detection	 of	 rBAT3F	 in	 intact	 oocytes.	 Confocal	
microscopy	of	whole	oocytes	using	Proteintech	mouse	anti-FLAG	(1:50,	3h,	RT)	and	AlexaFluor	
488	 goat	 anti-mouse	 secondary	 antibody	 (1:50,	 1h,	 RT).	 Oocytes	 were	 injected	 with	 water	
(control)	 or	 1-50ng	 rBAT3F	 cRNA.	 Three	 images	 are	 shown,	 representative	 of	 the	 mean	
observed	fluorescence	(n=13-15).	Scale	bar,	50μm.		
!!!Water!!!!!!!!!!!!!!!!!!!1ng!!!!!!!!!!!!!!!!!!!!!!5ng!!!!!!!!!!!!!!!!!!!!!!50ng!
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Figure	 4.23:	 Quantification	 of	 membrane	 fluorescence	 measured	 by	 confocal	 imaging	
and	 the	 relationship	 to	 uptake	 activity.	 A,	 Corrected	 total	 membrane	 fluorescence	 in	
oocytes	injected	with	water	(control),	or	1ng,	5ng,	or	50ng	rBAT3F	cRNA.	ns,	p>0.05;	**	p<0.01	
versus	water-injected	control	oocytes.	Data	are	mean±SEM	(n=13-15);	B,	 [3H]Arginine	uptake	
(10μM,	pH	7.4,	Na+-free)	in	Xenopus	oocytes	injected	with	water	(control),	or	1ng,	5ng,	or	50ng	
rBAT3F	 cRNA.	ns,	p>0.05;	*	p<0.05;	***,	p<0.001	versus	water-injected	control	oocytes.	Data	
are	mean±SEM	(n=10).	
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4.3.10	Immunocytochemical	detection	of	System	b0,+	at	the	plasma	membrane	of	sectioned	
oocytes	
The	 second	 immunocytochemical	 technique	 employed	 for	 detection	 of	 rBAT	 utilised	
sectioned	oocytes.	This	allowed	 localisation	of	 the	protein	at	 the	plasma	membrane	or	 in	an	
intracellular	compartment	to	be	determined.		
Intracellular	 protein	 localisation	 is	 undetectable	 using	 confocal	 imaging	 of	 whole	
oocytes	 (Chubb	 et	 al.,	 2006).	 To	 be	 able	 to	 detect	 mutant	 rBAT	 protein	 in	 an	 intracellular	
compartment	of	 the	oocyte,	 it	was	necessary	 to	optimise	an	 immunocytochemical	detection	
technique	on	sectioned	oocytes.	Oocytes	were	injected	with	50ng	rBAT3F	cRNA	and,	following	
3	days’	 expression,	 fixed	 in	methanol	 and	 sliced	 into	15μm	 sections	 in	OCT	 (see	Chapter	 2).	
Water-injected	oocytes	were	 used	 as	 a	 negative	 control	 for	 plasma	membrane	 fluorescence	
(Figure	4.24).	 In	all	negative	control	oocytes	some	intracellular	non-specific	 fluorescence	was	
visible.	However,	no	non-specific	membrane	fluorescence	was	observed.	When	incubated	with	
the	 Proteintech	 anti-FLAG	 antibody,	 oocytes	 expressing	 rBAT3F	 showed	 a	 bright	 band	 of	
fluorescence	in	the	plasma	membrane,	which	was	absent	in	the	controls	(Figure	4.24A).		
To	detect	 the	 cellular	 localisation	of	 the	Xenopus	 light	 chain,	 an	anti-b0,+AT	antibody	
was	 used	 (Figure	 4.24B).	 The	 antibody	 was	 raised	 against	 human	 b0,+AT,	 although	 was	
predicted	to	cross-react	with	the	Xenopus	protein	based	upon	the	sequence	alignment	(Figure	
4.24C).	 Intracellular	 fluorescence	 was	 observed	 in	 water-injected	 oocytes,	 suggesting	 cross-
reactivity	 with	 the	 Xenopus	 light	 chain	 (Figure	 4.24B).	 Upon	 application	 of	 the	 anti-b0,+AT	
antibody	to	rBAT3F-expressing	oocytes	specific	membrane	fluorescence	was	visible,	 indicating	
trafficking	of	the	endogenous	light	chain	to	the	membrane	by	the	human	rBAT	(Figure	4.24B).	
Increased	 intracellular	 fluorescence	 was	 also	 visible	 in	 these	 oocytes,	 from	 which	 we	 can	
hypothesise	 that	expression	of	 rBAT3F	 stimulated	 further	production	of	 the	endogenous	 light	
chain.	These	data	 identify	that	both	rBAT3F	 (via	 the	anti-FLAG	antibody)	and	the	endogenous	
Xenopus	light	chain	can	be	detected	in	15μm	oocyte	sections.		
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Figure	 4.24:	 Cellular	 localisation	 of	 rBAT3F	 and	 Xenopus	 b0,+AT	 in	 oocyte	 sections.	
Fluorescence	 microscopy	 of	 15μm	 oocyte	 sections.	 A,	 Sections	 from	 oocytes	 injected	 with	
water	 (control,	 left-hand	panel),	 or	 50ng	 rBAT3F	 cRNA	 (right-hand	panel)	 incubated	with	 the	
Proteintech	anti-FLAG	antibody	(1:50,	16h,	4°C);	B,	Sections	from	oocytes	injected	with	water	
(control,	 left-hand	 panel),	 or	 50ng	 rBAT3F	 cRNA	 (right-hand	 panel)	 incubated	 with	 the	 anti-
b0,+AT	antibody	 (1:50,	16h,	4°C).	 Scale	bar;	50μm;	C,	Multiple	 sequence	alignment	of	human	
(AF_421181),	mouse	(NM_001199016)	and	Xenopus	laevis	(NM_001112863)	b0,+AT	amino	acid	
sequences.	 Peptide,	 the	 antigenic	 peptide	 sequence	 against	which	 the	 antibody	was	 raised.	
Residue	numbers	are	listed	on	the	right.	Fully	conserved	residues	in	the	region	of	the	antigenic	
peptide	are	highlighted	in	red. 
	 	
rBAT% b0,+AT%
!!A!!!!!Water%%%%%%%%%%%%%rBAT3F% !B%%%%%Water%%%%%%%%%%%%%%rBAT3F%
Human       MGDT--GLRKRREDEKSIQSQEPKTTSLQKELGLISGISIIVGTIIGSGIFVSPKSVLSN 58 
Mouse       MEET--SLRRRREDEKSTHSTELKTTSLQKEVGLLSGICIIVGTIIGSGIFISPKSVLAN 58 
Peptide     ----------------------------------------------------SPKSVLSN 8 
Xenopus     MAKKRKGLQNGDADQKSIQSQESNSMNLKQQVGLISGISLIVGTIIGSGIFISPKSVLSN 60 
                                                                ******:* 
 
Human       TEAVGPCLIIWAACGVLATLGALCFAELGTMITKSGGEYPYLMEAYGPIPAYLFSWASLI 118 
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Peptide     TE---------------------------------------------------------- 10 
Xenopus     TGAIGPCLIIWAVCGVIATMGALCFAELGTMITKSGGEYPYLMEAFGPIPAFLFSWASLI 120 
            *  
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The	 co-localisation	 of	 the	 two	 System	 b0,+	 proteins	 was	 investigated	 using	 the	 anti-
FLAG	 and	 anti-b0,+AT	 antibodies	 in	 sectioned	 oocytes	 (Figure	 4.25).	 Figure	 4.25A	 shows	 a	
representative	 image	 of	 a	 water-injected	 control	 oocyte	 incubated	 with	 both	 antibodies.	
Oocytes	 injected	 with	 rBAT3F	 cRNA	 (Figure	 4.25B)	 showed	 bright	 membrane	 fluorescence	
representative	 of	 rBAT3F	 protein	 from	 the	 anti-FLAG	 antibody	 (green).	 In	 these	 oocytes,	
intracellular	fluorescence	from	the	anti-b0,+AT	antibody	(red)	was	higher	than	in	water-injected	
control	oocytes	and	the	plasma	membrane	was	also	visible.	The	merged	image	of	fluorescence	
from	 both	 antibodies	 indicated	 co-localisation	 of	 both	 proteins	 in	 the	 plasma	 membrane,	
although	 the	 fluorescence	 from	 the	 anti-b0,+AT	 antibody	 (red)	was	 not	 as	 bright	 as	 the	 anti-
FLAG	(rBAT3F,	green).		
The	co-incubation	with	both	antibodies	was	also	carried	out	 in	oocytes	 injected	with	
the	cRNA	of	both	rBAT3F	and	human	b0,+AT	(Figure	4.25C).	Once	again,	rBAT3F	was	detected	at	
the	membrane	of	 the	oocyte	with	 the	 anti-FLAG	antibody	 (green).	 Intracellular	 fluorescence	
from	 the	 anti-b0,+AT	 antibody	 (red)	 appeared	 greater	 than	 in	 the	 oocytes	 expressing	 only	
endogenous	 b0,+AT,	 although	 the	plasma	membrane	 fluorescence	 remained	unchanged.	 This	
supports	the	hypothesis	that	human	b0,+AT	can	be	expressed	in	Xenopus	oocytes,	but	that	rBAT	
preferentially	associates	with	the	endogenous	light	chain	(see	section	4.4).		
To	validate	that	the	anti-b0,+AT	antibody	was	detecting	the	correct	protein,	a	western	
blot	 was	 carried	 out	 using	 total	 membrane	 proteins	 from	 oocytes	 injected	 with	 water	
(control),	 or	 rBAT3F	 cRNA,	 human	 b0,+AT	 cRNA,	 rBAT3F	 and	 human	 b0,+AT	 cRNAs,	 or	 the	
concatenated	 rBATF-b0,+AT	 cRNA	 (Figure	4.26A).	 Protein	 from	oocytes	 injected	with	water	or	
rBAT	alone	were	resolved	alongside	other	samples	and	blotted	separately	with	the	anti-FLAG	
antibody.	As	expected,	no	bands	were	visible	in	water-injected	control	oocytes	(Figure	4.26A,	
lane	 a)	 and	 a	 doublet	 band	 80-90kDa	 in	 size	was	 identified	 in	 the	 lane	 representing	 rBAT3F-
expressing	oocytes	(Figure	4.26A,	lane	b).	In	Figure	4.26A	a	single	band	of	50kDa	was	observed	
in	lanes	c-g,	representing	total	membrane	protein	samples	from	oocytes,	injected	as	described	
above.	This	band	is	equivalent	to	the	predicted	size	of	b0,+AT	(53kDa).	The	absence	of	a	higher	
molecular	weight	band	(135kDa)	in	lane	G,	representing	protein	from	oocytes	injected	with	the	
concatenated	cRNA	suggests	that	this	fusion	protein	is	not	translated.	Lane	i	contains	11μg	of	
protein	from	human	Caco-2	cells	(see	Methods),	which	endogenously	express	both	subunits	of	
System	b0,+,	 and	was	used	as	 	 a	positive	 control	 for	 the	anti-b0,+AT	antibody	 raised	against	a	
human	 immunogen.	 A	 single	 band	 was	 observed	 identical	 in	 size	 to	 that	 observed	 in	 the	
oocyte	samples.		
An	 uptake	 experiment	 was	 carried	 out	 in	 parallel	 to	 confirm	 successful	 protein	
expression	following	cRNA	injection.	Significant	[3H]arginine	uptake	(p<0.001)	was	measured	in	
oocytes	expressing	rBAT3F,	or	rBAT3F	plus	human	b0,+AT	versus	water-injected	control	oocytes.	
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No	significant	uptake	(p>0.05)	was	observed	in	oocytes	expressing	human	b0,+AT	alone,	nor	the	
concatenated	protein	(Figure	4.26B).	It	can	now	be	assumed	that	the	lack	of	uptake	observed	
through	the	fusion	protein	is	due	to	non-translation	of	the	concatenated	cRNA.		
The	 results	 of	 the	 immunocytochemical	 detection	 of	 rBAT	 and	 b0,+AT	 in	 sectioned	
oocytes	 show	 that	 it	 is	 possible	 to	 successfully	 detect	 protein	 expression	 at	 the	 plasma	
membrane,	and	intracellularly.	This	will	be	a	valuable	tool	to	support	the	functional	expression	
of	rBAT	protein.	These	data	also	support	those	reported	earlier	in	this	chapter.	We	have	shown	
through	 immunocytochemical	detection	of	 the	endogenous	 light	chain	that	co-localisation	of	
rBAT	 and	 the	 Xenopus	 protein	 can	 be	 detected.	 However,	 there	 is	 no	 increase	 in	 the	
fluorescence	 from	human	b0,+AT	at	 the	plasma	membrane	 following	expression	of	 the	cRNA.	
This	 is	 in	agreement	with	the	lack	of	stimulation	of	[3H]arginine	uptake	into	the	oocytes	over	
that	observed	with	expression	of	 rBAT	cRNA	alone.	These	data	 further	support	 the	evidence	
that	 rBAT	 preferentially	 associates	 with	 the	 endogenous	 light	 chain	 over	 the	 human	
homologue	when	the	two	cRNAs	are	co-injected.		
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Figure	 4.25:	 Cellular	 localisation	 of	 rBAT3F	 and	 human	 b0,+AT	 in	 sections	 of	 oocytes.	
Fluorescence	microscopy	of	 15μm	oocyte	 sections	 incubated	with	 the	Proteintech	anti-FLAG	
and	 anti-b0,+AT	 antibodies.	 A,	 Water-injected	 oocytes	 (control);	 B,	 rBAT3F	 cRNA-injected	
oocytes	 (50ng);	 C,	 rBAT3F	 (25ng)	 and	 b0,+AT	 (25ng)	 cRNA-injected	 oocytes.	 White	 arrows	
indicate	the	location	of	the	plasma	membrane;	scale	bar,	50μm.		
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Figure	4.26:	Validation	of	anti-b0,+AT	antibody	binding	 in	 the	detection	of	 the	Xenopus	
light	 chain.	 A,	Western	 blot	 detection	 of	 rBAT	 and	 b0,+AT	 in	 total	 membrane	 protein	 from	
oocytes	and	Caco-2	monolayers.	Total	membrane	protein	(25μg)	from	oocytes	injected	with:	a,	
water	(control);	b,	50ng	rBAT3F	cRNA	incubated	with	M2	anti-FLAG	antibody	(1:1000,	16h,	4°C).	
Lanes	c-g	represent	total	membrane	proteins	from	oocytes	injected	with:	c,	water	(control);	d,	
50ng	rBAT3F	cRNA;	e,	50ng	human	b0,+AT	cRNA;	 f,	25ng	 rBAT3F	cRNA	plus	25ng	human	b0,+AT	
cRNA;	 g,	 50ng	 rBATF-b0,+AT	 concatenated	 cRNA,	 incubated	 with	 the	 anti-SLC7A9	 antibody	
(1:200,	16h,	4°C);	h,	blank	lane;	i,	Caco-2	membrane	protein	(11μg)	incubated	with	anti-b0,+AT	
antibody	(1:200,	16h,	4°C).	B,	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	in	Xenopus	oocytes	
injected	 with	 water	 (control),	 50ng	 rBAT3F	 cRNA,	 50ng	 b0,+AT	 cRNA,	 25ng	 rBAT3F	 cRNA	 plus	
25ng	b0,+AT	cRNA,	or	50ng	of	the	concatenated	rBATF-b0,+AT	cRNA.	Data	are	mean±SEM	(n=10).	
ns,	p>0.05;	***,	p<0.001	vs.	water-injected	control	oocytes.		
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4.4	Discussion	
The	 objective	 of	 the	 studies	 presented	 in	 this	 chapter	 was	 to	 optimise	 a	 range	 of	
techniques	 that	would	 allow	 the	measurement	 of	 rBAT	 expression	 in	Xenopus	 oocytes.	 This	
has	been	demonstrated	successfully	in	three	distinct	ways.	We	have	shown	that	the	expression	
of	 rBAT	 can	 be	 indirectly	 measured	 through	 the	 function	 of	 induced	 System	 b0,+	 transport	
(Figures	4.1-4.10);	that	rBAT	expression	can	be	detected	in	oocyte	membrane	protein	fractions	
through	 western	 blotting	 (Figure	 4.19);	 and	 that	 immunocytochemical	 detection	 can	 be	
employed	 to	 detect	 expression	 of	 the	 protein	 in	 the	 plasma	 membranes	 of	 whole	 and	
sectioned	oocytes	(Figures	4.22	and	4.25,	respectively).	The	purpose	of	establishing	this	range	
of	complementary	techniques	was	to	perform	reliable	measurements	of	the	levels	of	protein	
expression.	This	will	allow	wild-type	protein	expression	and	function	to	be	compared	to	that	of	
rBAT	containing	the	four	novel	SLC3A1	mutations	identified	in	Chapter	3.		
It	was	also	necessary	to	establish	the	limits	of	detection	sensitivity	of	all	three	of	these	
techniques.	It	has	been	reported	that	when	measuring	the	expression	of	suspected	trafficking	
mutations	 in	 proteins	 expressed	 in	 Xenopus	 oocytes	 that	 there	 is	 an	 apparent	 recovery	 of	
function	over	time,	and,	rarely,	that	no	loss	of	function	can	be	detected	(Chillarón	et	al.,	1997;	
Leduc-Nadeau	 et	 al.,	 2010).	 It	 has	 been	 hypothesised	 that	 this	 effect	 is	 due	 to	 the	 high	
translational	capacity	of	the	oocytes,	which	leads	to	an	over-expression	of	the	protein,	in	turn	
overcoming	the	“trafficking”	defect	(Chillarón	et	al.,	1997;	Leduc-Nadeau	et	al.,	2010).	To	this	
end,	 the	 techniques	optimised	 in	 this	 chapter	were	used	 to	monitor	 rBAT	expression	over	 a	
range	of	different	conditions.	Expression	of	rBAT	was	varied	by	injection	of	different	amounts	
of	 cRNA	 (1-50ng)	 and	by	 allowing	 expression	 to	 continue	over	 a	 number	of	 days	 (1-6)	 post-
injection.	 Under	 the	 different	 conditions,	 the	 absolute	 levels	 of	 rBAT	 translation	 and	
movement	 to	 the	 plasma	 membrane	 will	 vary.	 The	 important	 factor	 was	 to	 optimise	 the	
techniques	to	allow	detection	of	different	levels	of	protein	expression.		
4.4.1	Expression	of	human	rBAT	protein	is	associated	with	induced	[3H]arginine	transport	
To	measure	 rBAT	 expression	 by	 function,	we	were	 reliant	 on	 the	 association	 of	 the	
exogenous	 human	 protein	 with	 an	 endogenous	 oocyte	 light	 chain,	 which	 is	 homologous	 to	
mammalian	b0,+AT.	The	ability	to	express	System	b0,+	 in	Xenopus	oocytes	through	injection	of	
rBAT	cRNA,	and	the	substrate	selectivity	of	the	induced	transport	systems	has	previously	been	
studied	in	detail	(Bertran	et	al.,	1992b;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	et	al.,	
1993;	Lee	et	al.,	1993).		
As	expected,	the	data	from	the	current	study	demonstrate	an	increase	in	[3H]arginine	
uptake	 following	 injection	 of	 increasing	 amounts	 of	 rBAT	 cRNA	 (Figures	 4.2,	 4.4).	 This	 is	
predicted	 to	be	due	 to	 an	 increased	 abundance	of	 rBAT	protein	 and	 increased	 trafficking	of	
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System	 b0,+	 to	 the	 plasma	 membrane	 of	 oocytes.	 The	 increased	 protein	 levels	 following	
increased	cRNA	injection	was	confirmed	by	western	blot	(Figure	4.19).	However,	variability	in	
absolute	expression	 levels	was	detected	between	different	batches	of	oocytes.	For	example,	
[3H]arginine	 uptake	 after	 3	 days	 incubation	 was	 only	 1.6-2.0	 fold	 higher	 than	 water	 when	
oocytes	were	 injected	with	1	or	2ng	of	rBAT	cRNA,	respectively	 (Figure	4.2).	 In	contrast,	 in	a	
separate	experiment,	 injection	of	0.5ng	cRNA	led	to	a	13-fold	 increase	 in	[3H]arginine	uptake	
after	 only	 one	 day	 (post-injection)	 (Figure	 4.4).	 Calonge	 et	 al.	 (1994)	 reported	 successful	
expression	of	System	b0,+	following	injection	of	as	little	as	0.05ng	rBAT	cRNA.	The	variability	in	
protein	 expression,	 and	 resultant	 uptake	 levels	 observed	 in	 the	 current	 study	 has	 been	
reported	by	other	 research	 groups,	 and	 appears	 common	 to	 the	use	of	 the	Xenopus	oocyte	
expression	system	(Chillarón	et	al.,	1997).	Provided	that	careful	experimental	measurements	
of	mutant	rBAT	function	are	made,	in	which	positive	(wild-type	protein)	and	negative	(water-
injected)	 control	 oocytes	 are	 used	 routinely,	 the	 variability	 in	 expression	 will	 not	 be	
problematic	in	the	subsequent	functional	studies.		
To	measure	 the	 variability	 in	 rBAT	protein	expression	over	 time,	 [3H]arginine	uptake	
was	 measured	 over	 a	 number	 of	 days	 (1-6)	 post-injection.	 Tate	 et	 al.,	 and	 Chillarón	 et	 al.,	
measured	 uptake	 of	 phenylalanine	 and	 cystine,	 respectively,	 in	 oocytes	 injected	 with	 rBAT	
cRNA,	1-8	days	post-injection.	Tate	et	al.,	observed	an	increase	in	expression	in	rBAT-injected	
oocytes	 (5ng)	 from	 days	 1-3,	 after	 which	 the	 uptake	 levels	 plateaued	 (Tate	 et	 al.,	 1992).	
Chillarón	 et	 al.	 observed	 a	 similar	 effect,	with	 uptake	 of	 cystine	 in	 rBAT-expressing	 oocytes	
(25ng)	reaching	a	plateau	after	2	days	(Chillarón	et	al.,	1997).	These	data	support	those	of	the	
current	study,	where,	in	a	single	experiment,	uptake	of	[3H]arginine	appeared	to	increase	until	
day	2,	after	which	a	plateau	was	observed	until	day	6,	in	oocytes	injected	with	0.5-20ng	rBAT	
cRNA	 (Figure	 4.4).	 However,	 due	 to	 the	 observed	 variability	 in	 oocyte	 protein	 expression	
between	batches,	only	measurements	made	on	the	same	day	post-injection	will	be	considered	
comparable.	 It	 cannot	be	assumed	 that	maximal	uptake	 levels	will	 always	be	 reached	at	 the	
same	 time-point	 post-injection.	 In	 Chapter	 5,	 comparative	 studies	 of	 wild-type	 and	 mutant	
rBAT	expression	will	be	carried	out	at	a	range	of	time-points	post	cRNA	injection	(1-6	days).	
4.4.2	Functional	characteristics	of	substrate	transport	by	System	b0,+	
Investigations	 into	the	substrate	specificity	of	System	b0,+	confirmed	previous	reports	
in	which	selective	transport	activity	was	induced	in	Xenopus	oocytes	by	injection	of	rBAT	cRNA	
(Bertran	et	al.,	1992b;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	et	al.,	1993;	Lee	et	al.,	
1993).	Prototypical	substrates	 for	System	b0,+	are	the	bulky,	dibasic	amino	acids	arginine	and	
lysine,	 and	 neutral	 amino	 acid	 leucine	 (Figure	 4.7).	 	 System	 b0,+	 does	 not	 transport	 smaller	
amino	 acids,	 including	 the	 imino	 acid	 proline,	 or	 anionic	 amino	 acids	 such	 as	 glutamic	 acid	
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(Figure	4.8	D	and	E).	 These	data	 support	 the	original	 report	of	 System	b0,+	 activity	 in	mouse	
blastocysts	(Van	Winkle	et	al.,	1988).	Early	reports	on	System	b0,+	activity	 in	Xenopus	oocytes	
include	detailed	measurements	of	the	functional	properties	of	the	mammalian	rBAT-Xenopus	
b0,+AT	transport	system	(Bertran	et	al.,	1992b;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	
et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	 The	 functional	 expression	 cloning	 of	 System	 b0,+-associated	
proteins	 and	 substrate	 specificity	 of	 the	 induced	 transport	 system	 is	 discussed	 in	 detail	 in	
Chapter	1.		
4.4.3	Co-expression	of	both	System	b0,+	subunits	in	Xenopus	oocytes	
Although	 not	 the	 main	 focus	 of	 the	 work	 described	 in	 this	 chapter,	 it	 was	 also	
investigated	 whether	 it	 would	 be	 possible	 to	 heterologously	 co-express	 the	 two	 human	
subunits	of	System	b0,+.	 If	successful,	this	would	enable	 injection	of	a	mammalian	(preferably	
human)	 light	 chain	 of	 the	 transport	 system,	 allowing	 studies	 into	 SLC7A9	 mutations	 to	 be	
carried	 out.	 The	 Mus	 musculus	 light	 chain	 of	 System	 b0,+	 was	 first	 cloned	 in	 1999,	 and	
investigated	by	 functional	 co-expression	with	 rBAT	 in	Xenopus	oocytes	 (Chairoungdua	 et	 al.,	
1999;	Pfeiffer	et	al.,	1999a).	Expression	of	mouse	b0,+	AT	in	isolation	in	oocytes	did	not	induce	
[3H]arginine	 uptake	 above	 background	 (Pfeiffer	 et	 al.,	 1999a),	 an	 observation	 made	
independently	 as	 part	 of	 this	 study	 (Figure	 4.10B).	 In	 the	 absence	 of	 rBAT,	 the	 heteromeric	
transport	system	is	not	trafficked	to	the	plasma	membrane.	Pfeiffer	et	al.	also	observed	that	
there	was	no	further	stimulation	of	uptake	of	arginine	in	oocytes	expressing	both	mammalian	
subunits,	 over	 those	 expressing	 rBAT	 alone	 (Pfeiffer	 et	 al.,	 1999a).	 This	 made	 it	 unclear	
whether	observed	uptake	was	via	rBAT	in	association	with	the	co-expressed	mouse	light	chain	
or	 the	 endogenous	 light	 chain.	Western	 blot	 evidence	 of	 light	 chain	 expression	 in	 Xenopus	
oocytes	in	the	absence	of	rBAT	suggests	that	rBAT	preferentially	associates	with	the	Xenopus	
light	 chain	upon	co-injection	 (Pfeiffer	 et	al.,	 1999a).	 This	was	 further	 supported	by	evidence	
from	 additional	 studies	 indicating	 the	 co-translational	 nature	 of	 subunit	 association	
(Bartoccioni	et	al.,	2008).	Similarly,	in	the	current	study,	no	further	stimulation	of	[3H]arginine	
uptake	was	observed	following	co-expression	of	mouse	or	human	b0,+AT	 in	Xenopus	oocytes,	
above	that	observed	in	oocytes	injected	with	rBAT	cRNA	alone	(Figures	4.11-4.12).	It	has	been	
hypothesised	 that	 the	apparent	decrease	 in	arginine	uptake	observed	 in	 co-injected	oocytes	
compared	 to	 rBAT-injected	 oocytes	 can	 be	 attributed	 to	 a	 limitation	 on	 the	 translational	
capacity	 of	 the	 oocyte	when	 both	 cRNAs	 are	 injected	 (Pfeiffer	 et	 al.,	 1999a).	 In	 the	 current	
study,	 immunocytochemical	analysis	of	 sectioned	oocytes	expressing	 rBAT	and	human	b0,+AT	
appeared	 to	 support	 the	 hypothesis	 that	 co-injection	 of	 both	 subunits	 did	 not	 lead	 to	
association	 of	 rBAT	 with	 the	 human	 light	 chain	 (Figure	 4.24).	 In	 oocytes	 expressing	 human	
rBAT,	membrane	 localisation	was	 observed,	which	was	 absent	 in	 the	water-injected	 control	
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oocytes,	 confirming	 association	 of	 the	 exogenous	 and	 endogenous	 subunits	 (Figure	 4.25B).	
Bright	 intracellular	 fluorescence	 was	 observed	 upon	 expression	 of	 human	 b0,+AT.	 However,	
plasma	membrane	co-localisation	was	not	detected	(Figure	4.25C).		
Pfeiffer	 et	 al.	 injected	 Xenopus	 oocytes	 with	 mouse	 b0,+AT	 cRNA,	 2	 days	 prior	 to	
injection	 with	 rBAT	 cRNA	 (Pfeiffer	 et	 al.,	 1999a).	 Uptake	 of	 [3H]arginine	 in	 the	 b0,+AT	 pre-
injected	 oocytes	 (150	 pmol.oocyte-1.(60min)-1)	 appeared	 to	 be	 lower	 than	 in	 oocytes	 pre-
injected	 with	 water	 (220	 pmol.oocyte-1.(60min)-1,	 which	 was	 considered	 evidence	 of	
competition	 of	 the	 two	 cRNAs	 for	 the	 translational	machinery	 of	 the	 oocyte	 (Pfeiffer	 et	 al.,	
1999a).	Mouse	b0,+AT	 containing	 the	 loss	of	 function	mutation	E244Q,	was	 also	pre-injected	
into	oocytes.	In	oocytes	pre-injected	with	E244Q	cRNA,	uptake	of	arginine	was	reduced	to	40	
pmol.oocyte-1.(60min)-1,	 which	 was	 not	 significantly	 different	 to	 background,	 despite	 the	
presence	of	the	functional	Xenopus	light	chain.	This	indicated	that	when	the	mouse	light	chain	
was	 expressed	 prior	 to	 injection	 of	 rBAT	 cRNA,	 the	 human	 rBAT	 appeared	 to	 preferentially	
associate	with	mouse	b0,+AT	(Pfeiffer	et	al.,	1999a).		
To	address	the	question	of	which	light	chain	is	bound	by	the	heterologously	expressed	
human	rBAT,	Pfeiffer	et	al.,	(1999)	injected	a	concatenated	cRNA,	which	led	to	the	translation	
of	an	rBAT-b0,+AT	 fusion	protein	 (Pfeiffer	et	al.,	1999a;	Fernandez	et	al.,	2006).	The	reported	
protein	was	structurally	distinct	from	the	physiological	heterodimer	due	to	the	association	of	
the	 two	 subunits	 through	 a	 10	 amino	 acid	 alanine	 and	 proline-rich	 “linker	 sequence”	
connecting	the	intracellular	N-	terminus	of	rBAT	with	the	C-terminus	of	b0,+AT	(Pfeiffer	et	al.,	
1999a).	It	has	been	demonstrated	by	Fernandez	et	al.	that	the	functional	unit	of	System	b0,+	is	
the	 covalently-linked	 heterodimer,	 with	 an	 observed	 molecular	 weight	 of	 135kDa	 when	
resolved	by	SDS-PAGE,	although	the	transport	system	structurally	sits	in	the	plasma	membrane	
as	 a	hetero-tetramer	with	an	apparent	molecular	weight	of	 270kDa	 (Fernandez	 et	 al.,	 2002;	
Fernandez	et	al.,	2006).	However,	the	concatenated	protein	does	not	appear	to	form	a	hetero-
tetramer	 (Fernandez	 et	 al.,	 2006).	 Despite	 this	 difference	 in	 structure,	 significant	 uptake	
(p<0.05)	 of	 System	b0,+	 substrates	 in	 oocytes	 expressing	 the	 concatamer	 has	 been	 observed	
compared	 to	 water-injected	 controls,	 demonstrating	 its	 potential	 as	 a	 method	 of	
characterising	 mutations	 in	 b0,+AT	 (Pfeiffer	 et	 al.,	 1999a).	 In	 the	 current	 study,	 preliminary	
investigations	into	rBAT	and	b0,+AT	expression	in	Xenopus	oocytes	were	carried	out	by	Dr.	Noel	
Edwards,	during	which	time	a	concatenated	human	rBAT-b0,+AT	cRNA	was	made.	However,	we	
were	unable	 to	 express	 this	 protein	 in	oocytes	 and	no	uptake	of	 System	b0,+	 substrates	was	
observed	 above	 background	 levels	 (Figures	 4.14	 and	 4.26B).	 Homogenates	 from	 oocytes	
injected	with	the	concatenated	cRNA	were	used	for	western	blotting	with	an	antibody	raised	
against	human	b0,+AT,	shown	to	cross-react	with	the	Xenopus	light	chain.	No	band	was	visible	
at	135kDa,	the	predicted	size	of	the	concatamer	(Figure	4.26A),	 indicating	that	the	cRNA	was	
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not	translated	by	the	oocyte.	Due	to	the	absence	of	any	novel	mutations	detected	in	SLC7A9	in	
the	cohort	of	the	current	study,	attempts	to	express	a	human	light	chain	for	rBAT	in	oocytes	
were	not	pursued	further.	Despite	this,	the	literature	reports	that	the	pre-injection	of	oocytes	
with	mouse	 b0,+AT	 appear	 promising	 (Pfeiffer	 et	 al.,	 1999a).	 In	 future	 studies	 this	 could	 be	
investigated	through	injection	of	a	tagged	b0,+AT	construct	or	 immunocytochemical	detection	
with	the	anti-b0,+AT	antibody.	
4.4.4	FLAG	epitope	tagging	for	protein	detection	
Following	successful	optimisation	of	the	System	b0,+	uptake	measurements,	the	focus	
of	 these	 studies	 turned	 to	 the	 optimisation	 of	 rBAT	 expression	 levels	 by	 immunodetection.	
Due	 to	 the	unavailability	of	 a	 validated	antibody	 raised	against	human	 rBAT,	we	utilised	 the	
FLAG-tag	 system.	 The	 FLAG	 system	 had	 been	 used	 previously	 to	 detect	 expression	 of	 the	
sodium-phosphate	 transporter	 NaPi-IIa	 (Kohl	 et	 al.,	 1998).	 As	 a	 result,	 several	 anti-FLAG	
antibodies	 had	 been	 successfully	 validated	 for	 use	 in	 both	 western	 blotting	 and	
immunocytochemistry.		
In	 the	 current	 study,	 it	 was	 established	 that	 there	 was	 no	 significant	 difference	
(p>0.05)	in	function	of	rBAT	with	added	FLAG-tags	(Figures	4.1	and	4.9A).	To	enhance	protein	
detection,	multiple	FLAG	epitopes	have	been	added	to	proteins	 in	tandem.	In	2004,	Dubel	et	
al.	 added	 4	 FLAG	 epitopes	 to	 the	 N-terminal	 of	 the	 Cav3.3	 calcium	 channel	 to	 detect	 the	
protein	following	transfection	into	HEK293	cells	(Dubel	et	al.,	2004).	They	reported	a	failure	to	
detect	the	protein	using	a	single	or	double	FLAG	tag	(Dubel	et	al.,	2004).	In	the	current	study,	
the	sensitivity	of	rBAT	detection	by	western	blot	and	immunocytochemistry	was	increased	by	
the	addition	of	a	FLAG	epitope	on	both	the	N	and	C	termini	(Figures	4.15	and	4.20).		
Variations	 on	 the	 FLAG	 amino	 acid	 sequence	 have	 been	 investigated	 to	 improve	
sensitivity	 of	 detection	 by	 antibodies.	 Sigma	 Aldrich	 produced	 three	 antibodies	 against	 the	
FLAG	epitope.	M1	was	found	to	only	work	in	the	presence	of	Ca2+	ions	and	when	the	epitope	
was	positioned	on	the	N-terminus	of	the	protein.	M2	was	found	to	detect	FLAG	in	the	absence	
of	Ca2+	and	irrespective	of	the	position	of	the	FLAG	sequence	in	the	native	protein.	Finally,	M5	
was	found	to	detect	intracellular	epitopes	with	greater	sensitivity	than	the	other	two	enzymes,	
also	functioning	in	the	absence	of	Ca2+	(Slootstra	et	al.,	1997).	Slootstra	et	al.	reported	that	the	
critical	 residues	 for	 binding	 of	 the	 M2	 antibody	 were	 D1,	 Y2,	 K3,	 and	 D6.	 To	 increase	 the	
sensitivity	 of	 protein	 detection,	 Hernan	 et	 al.	 reported	 a	 triple	 FLAG	 (3xFLAG)	 epitope,	
designed	to	meet	the	detection	criteria	of	the	M2	antibody	(Hernan	et	al.,	2000).	The	designed	
sequence	 DYKDHDG-DYKDHDI-DYKDDDDK	 retained	 the	 critical	 residues,	 whilst	 remaining	 as	
short	as	possible	 to	minimise	the	risk	of	 interference	with	native	protein	 folding	or	 function.	
The	first	two	FLAG	epitopes	do	not	contain	the	enteropeptidase	recognition	sequence,	as	this	
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would	 only	 be	 required	 once	 in	 the	 sequence	 for	 removal	 of	 the	 tag	 (Hernan	 et	 al.,	 2000).	
Hernan	 et	 al.	 compared	 the	multiple	 epitope	 tag	 to	 the	 single	 FLAG	 epitope	 by	 transiently	
expressing	S.	aureus	biofilm	associated	protein	(BAP)	tagged	with	a	single	FLAG	or	with	3xFLAG	
in	COS-7	 cells.	 They	demonstrated	a	10-fold	 increase	 in	 sensitivity	of	western	blot	detection	
using	the	multiple	epitope	tag	(Hernan	et	al.,	2000).	The	reported	 increase	 in	sensitivity	was	
not	observed	using	the	M5	antibody.	These	data	are	strongly	supported	by	the	findings	of	the	
current	 study.	 Through	 western	 blot	 detection	 of	 rBAT3F	 expressed	 in	 Xenopus	 oocytes,	 we	
have	 observed	 an	 increase	 in	 sensitivity	 of	 protein	 detection	 using	 the	M2	 antibody	 (Figure	
4.15).	We	have	also	observed	 that	 the	 increase	 in	 sensitivity	 is	not	 common	 to	all	 anti-FLAG	
antibodies.	 An	 anti-FLAG	 antibody	 from	 Proteintech	 detected	 two	 single	 FLAG	 polypeptides	
(FrBATF)	with	higher	 sensitivity	 than	 the	 triple	 FLAG	epitope	 (Figure	4.15).	 This	 suggests	 that	
D1,	Y2,	K3,	D6	are	not	the	critical	residues	for	the	Proteintech	antibody.		
4.4.5	Immunodetection	of	proteins	in	Xenopus	oocytes		
The	 size	 of	 the	 rBAT	 protein	was	 first	 determined	 by	 in	 vitro	 translation	 in	 a	 rabbit	
reticulocyte	lysate	system	in	the	presence	of	canine	pancreatic	membranes	(Wells	&	Hediger,	
1992).	Two	bands	were	visualised	at	87	and	90	kDa	following	resolution	of	the	product	by	SDS-
PAGE	(Wells	&	Hediger,	1992).	Chillarón	et	al.	(1997)	identified	rBAT	heterologously-expressed	
in	 oocytes	 using	 a	 preparation	 to	 isolate	 total	 membranes,	 adapted	 from	 methods	 first	
reported	by	Geering	et	al.	(1989).	Chillarón	et	al.	(1997)	identified	double	bands	at	85	and	94	
kDa	 when	 detecting	 rBAT	 by	 western	 blot	 in	 oocyte	 total	 membranes,	 representing	 the	
mature-glycosylated,	and	core-glycosylated	forms	of	the	protein,	respectively.	These	data	are	
strongly	supported	by	the	findings	of	the	current	study,	in	which	a	double	band	for	rBAT	was	
detected	between	80	and	90	kDa	(Figure	4.26A).		
The	 use	 of	 colloidal	 silica	 to	 specifically	 isolate	 the	 plasma	 membrane	 proteins	 in	
Xenopus	 oocytes	 has	 been	 established	 (Leduc-Nadeau	 et	 al.,	 2007).	 Leduc-Nadeau	 et	 al.	
reported	that	this	technique	increased	the	sensitivity	of	detection	of	the	renal	water	channel,	
aquaporin-2	 (AQP2),	 expressed	 in	 oocytes	 10-fold	 compared	 to	 the	 total	 membrane	
preparation	 (Chillarón	 et	 al.,	 1997;	 Leduc-Nadeau	 et	 al.,	 2007).	 This	 technique	 enabled	
identification	and	quantification	of	AQP2	mutants	 at	 the	oocyte	plasma	membrane	at	 lower	
levels	 than	 the	 wild-type,	 which	 was	 not	 detected	 using	 the	 total	 membrane	 isolation	
technique	 (Leduc-Nadeau	 et	al.,	 2010).	 In	 the	 current	 study,	 isolation	of	plasma	membranes	
following	 injection	 of	 50ng	wild-type	 rBAT	 cRNA	 into	Xenopus	 oocytes	 allowed	 detection	 of	
bands	of	identical	size	as	that	detected	in	total	membranes	(Figure	4.15D).	The	band	observed	
was	of	a	similar	intensity	to	that	detected	in	the	total	membrane	preparation	following	loading	
of	1-2μg	of	protein,	compared	to	25μg	of	total	membrane	protein	(Figure	4.15D).		These	data	
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strongly	 support	 the	 results	 of	 Leduc-Nadeau	et	 al.	 that	 the	 silica-based	 isolation	 of	 plasma	
membranes	 increases	 the	 sensitivity	 of	 protein	 detection,	 in	 this	 study	 by	 12.5-25-fold.	
However,	although	appearing	promising	(Figure	4.25),	the	western	blot	results	using	the	silica-
based	preparation	of	plasma	membrane	that	are	presented	in	this	chapter,	were	not	reliably	
reproducible.	Unfortunately,	due	to	the	time	limitations	on	these	studies,	we	were	unable	to	
optimise	the	technique	 fully	 to	produce	a	reliable	 technique.	Consequently,	western	blotting	
was	 performed	 with	 total	 membrane	 proteins	 to	 measure	 protein	 translation,	 and	
immunocytochemical	detection	of	rBAT	in	whole	and	sectioned	oocytes	was	used	to	measure	
plasma	membrane	expression.		
In	 2006,	 Chubb	 et	 al.	 expressed	 CD98	 and	 its	 light	 chain	 y+LAT2	 conjugated	 to	
enhanced	green	fluorescent	protein	(EGFP)	in	Xenopus	oocytes	and	measured	the	fluorescence	
in	 whole	 and	 intact	 oocytes	 (Chubb	 et	 al.,	 2006).	When	 both	 subunits	 were	 expressed	 and	
whole	 oocytes	 viewed	 by	 confocal	microscopy,	 a	 band	 of	 fluorescence	was	 observed	 at	 the	
perimeter	of	the	oocyte.	In	the	absence	of	CD98,	no	fluorescence	was	visible	at	the	membrane	
(Chubb	 et	 al.	 (2006).	 This	 suggested	 that	 the	density	 of	 the	oocyte	 is	 too	 great	 to	 allow	 for	
intracellular	 fluorescence	using	 this	 technique	and	 that	 the	observed	 fluorescence	correlates	
to	proteins	at	the	plasma	membrane.	The	ability	to	detect	proteins	in	the	plasma	membrane	of	
Xenopus	 oocytes	 using	 confocal	 imaging	 of	 intact	 oocytes	 was	 demonstrated	 in	 this	 study	
(Figures	 4.20-4.22).	 Bright,	 positive	 staining	 was	 visualised	 at	 the	 membrane	 of	 oocytes	
expressing	FLAG-tagged	rBAT	or	NaPi-IIa,	which	was	absent	at	the	membrane	of	water-injected	
control	oocytes.	
Chubb	 et	 al.	 confirmed	 that	 the	 observed	 fluorescence	 was	 specific	 to	 the	 plasma	
membrane	 by	 repeating	 the	 experiment	 in	 sectioned	 oocytes.	 They	 observed	 specific	
membrane	 fluorescence	 in	 the	presence	of	both	System	y+L	 subunits	and	bright	 intracellular	
fluorescence	when	y+LAT2	was	expressed	alone	(Chubb	et	al.,	2006).	The	results	of	the	current	
study	demonstrate	 that	 it	was	not	possible	 to	 completely	eliminate	background	 intracellular	
fluorescence	due	to	non-specific	binding	of	the	antibodies	to	the	high-density	yolk	proteins	in	
water-injected	 oocytes	 (Figure	 4.23A),	 consistent	with	 other	 images	 of	 sectioned	 oocytes	 in	
published	reports	(Bianchi	et	al.,	2000).	Despite	this,	specific	plasma	membrane	fluorescence	
was	 only	 visible	 in	 oocytes	 expressing	 FLAG-tagged	 proteins,	 predicted	 to	 be	 located	 in	 the	
membrane	(Figure	4.22-4.23).	These	data	from	the	current	study,	along	with	those	reported	in	
the	literature	(Bianchi	et	al.,	2000;	Chubb	et	al.,	2006),	confirm	the	reliability	of	whole	oocyte	
and	sectioned	oocyte	 immunocytochemistry	as	 techniques	to	 identify	 the	plasma	membrane	
localisation	of	exogenous	and	endogenous	proteins	expressed	in	Xenopus	oocytes.	
In	 conclusion,	 the	 data	 in	 this	 chapter	 present	 successful	 optimisation	 of	 rBAT	
detection	following	expression	in	oocytes	at	a	range	of	different	protein	levels.	We	can	detect	
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rBAT	expression	at	the	plasma	membrane	through	functional	uptake	of	System	b0,+	substrates	
and	 immunocytochemistry.	 Western	 blotting	 using	 total	 membrane	 proteins	 has	 allowed	
detection	 of	 rBAT	 expression	 and	 cellular	 processing	 to	 form	 two	 glycosylated	 states	 of	 the	
protein.	Through	these	investigations	we	have	identified	a	certain	level	of	variability	in	oocyte	
quality	and	capacity	to	express	rBAT	protein	between	batches.	However,	we	have	also	shown	
that	through	careful	measurements	of	protein	expression	at	a	range	of	expression	 levels,	we	
can	control	for	this	variability	and	obtain	reproducible,	comparable	results	using	the	Xenopus	
oocyte	 expression	 system.	 This	 will	 enable	 accurate	measurements	 of	mutant	 rBAT	 protein	
expression	 and	 function	 to	 identify	 the	 underlying	 cause	 of	 the	 cystinuria	 phenotype	 of	 the	
patients	in	the	cohort.		
In	summary:	
• A	 range	 of	 techniques	 has	 been	 optimised	 to	 allow	 the	 measurement	 of	
System	b0,+	function	in	oocytes.	
• The	 function	 of	 System	 b0,+	 provides	 an	 indirect	 measurement	 of	 rBAT	
expression	at	the	oocyte	membrane.	
• Using	 a	 FLAG-tagged	 rBAT	 construct	 (rBAT3F)	 we	 can	 detect	 different	
glycosylated	forms	of	rBAT	by	western	blot.	
• Immunocytochemical	 detection	 of	 rBAT	 allows	 the	 identification	 of	 plasma	
membrane	expression	in	oocytes.	
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Chapter	5:	Results	III 	
5.1	Introduction	
The	 heavy	 chain	 subunit	 of	 System	 b0,+,	 known	 as	 rBAT,	 is	 widely	 regarded	 as	 the	
“trafficking”	protein	of	the	transport	heterodimer	(Chillarón	et	al.,	1997;	Chillarón	et	al.,	2010).	
To	date,	91	pathogenic	missense	mutations	have	been	reported	in	SLC3A1,	the	gene	encoding	
this	 protein	 (Stenson	 et	 al.,	 2014).	Of	 these	91	pathogenic	mutations,	 only	 9	have	been	 the	
focus	of	functional	expression	studies:	L89P,	T216M,	S217R,	R270L,	L346P,	R365W,	M467T	and	
M467K	 (Calonge	 et	 al.,	 1994;	 Chillarón	 et	 al.,	 1997;	 Saadi	 et	 al.,	 1998;	 Ishihara	 et	 al.,	 2002;	
Pineda	et	al.,	2004b;	Bartoccioni	et	al.,	2008).	The	expression	systems	used	to	characterise	the	
function	of	rBAT	mutants	have	included	Xenopus	oocytes	(Calonge	et	al.,	1994;	Chillarón	et	al.,	
1997;	Saadi	et	al.,	1998;	 Ishihara	et	al.,	2002)	and	the	mammalian	cell	 lines	MDCK	and	HeLa	
(Pineda	 et	 al.,	 2004b;	 Bartoccioni	 et	 al.,	 2008).	 However,	 oocytes	 have	 remained	 the	
predominant	 system	 employed	 for	 the	 functional	 studies	 of	 rBAT	 due	 to	 their	 high	
translational	 capacity,	 reliability	 of	 expression,	 and	 ability	 to	 perform	 post-translational	
modifications.		
Single	nucleotide	polymorphisms	(SNPs)	are	 individual	base	changes	 in	genomic	DNA	
sequences	 that	occur	 in	>1%	of	 the	population	 (Kirk	et	al.,	2002).	Due	to	 their	abundance	 in	
healthy	 individuals,	SNPs	are	commonly	non-pathogenic.	They	can	be	classed	as	synonymous	
or	non-synonymous	depending	on	whether	or	not	the	change	 in	base	sequence	results	 in	an	
alteration	 in	the	translated	amino	acid	sequence.	 In	SLC3A1,	 the	gene	encoding	rBAT,	a	non-
synonymous	SNP,	M618I,	is	found	in	the	genome	of	around	half	of	the	population.	The	online	
resources	UCSC	Genome	Database	and	the	Exome	Aggregation	Consortium	(EXAC),	suggest	the	
prevalence	 of	M618I	 to	 be	 43%	 and	 59%	 of	 the	 population,	 respectively	 (Kent	 et	 al.,	 2002;	
Stenson	 et	 al.,	 2014).	 Literature	 reports	 of	 mutation	 detection	 in	 cystinuric	 patients	
acknowledge	 the	 identification	 of	 this	 polymorphism,	 although	 the	 prevalence	 within	 the	
cohorts	 is	 often	 unspecified	 (Horsford	 et	 al.,	 1996;	 Saadi	 et	 al.,	 1998;	 Egoshi	 et	 al.,	 2000;	
Barbosa	et	al.,	2012).	Ishihara	et	al.,	(2002)	did	report	a	lower	incidence	of	the	SNP	(23%)	in	an	
entirely	 Japanese	 cohort,	 which	 could	 be	 reflective	 of	 the	 frequency	 in	 that	 particular	
population.	 The	 investigation	 of	 M618I	 expression	 in	 oocytes	 has	 been	 reported	 in	 the	
literature	 (Saadi	 et	 al.,	 1998;	 Ishihara	 et	 al.,	 2002).	 No	 difference	 in	 [14C]cystine	 uptake	 in	
M618I-expressing	 oocytes	 was	 detected,	 compared	 to	 wild-type	 rBAT-expressing	 controls	
(Saadi	 et	 al.,	 1998;	 Ishihara	 et	 al.,	 2002).	 In	 the	 current	 study,	 we	 also	 investigated	 the	
expression	of	this	polymorphism,	to	serve	as	a	negative	control	(in	the	sense	that	the	change	
will	cause	no	alteration	in	function)	for	expression	of	rBAT	following	cDNA	mutagenesis.		
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To	date,	the	most	extensively	characterised	rBAT	mutation	has	been	M467T,	the	most	
common	cystinuria-causing	mutation	 in	Mediterranean	populations	 (Bartoccioni	 et	al.,	 2008;	
Barbosa	et	al.,	2012).	The	expression	of	this	mutant	protein	has	been	investigated	in	Xenopus	
oocytes	(Calonge	et	al.,	1994;	Chillarón	et	al.,	1997)	and	MDCK	cells	(Bartoccioni	et	al.,	2008).	
Following	 the	 expression	 of	M467T	 in	 oocytes,	 a	 significant	 reduction	 in	 [14C]cystine	 uptake	
was	measured	compared	 to	wild-type	 rBAT	controls,	one	day	post-injection	 (Chillarón	 et	al.,	
1997).	 	However,	 the	 function	of	 this	mutant	protein	appeared	 to	 “recover”	over	 time.	At	6	
days	post-injection	of	cRNA,	the	function	of	M467T	was	not	significantly	different	(p>0.05)	to	
that	of	the	wild-type	(Chillarón	et	al.,	1997).	 Interestingly,	when	the	sister	mutation,	M467K,	
was	 investigated,	 a	 complete	 recovery	 in	 function	was	not	observed.	 The	authors	 suggested	
that	 this	 was	 due	 to	M467K	 being	 a	more	 “severe”	mutation,	 with	 the	 basic	 lysine	 residue	
conferring	a	more	detrimental	effect	on	protein	 folding	than	the	uncharged,	polar	 threonine	
(Chillarón	 et	 al.,	 1997).	 It	 has	 been	 hypothesised	 that	 the	 observed	 decrease	 in	 function	
following	mutant	protein	expression	in	oocytes	is	due	to	a	mis-folding	of	the	protein,	and	rapid	
degradation	by	the	ER.	The	observed	recovery	in	function	has	been	attributed	to	a	saturation	
of	 these	 pathways,	 allowing	 escape	 of	 the	mutant	 protein	 from	 the	 endoplasmic	 reticulum	
(Chillarón	et	al.,	1997).		
In	Chapter	4,	a	series	of	techniques	was	reported	that	allow	the	measurement	of	rBAT	
expression	 in	oocytes.	 In	 this	 chapter,	we	 report	 the	use	of	 these	 techniques	 to	 identify	 the	
effects	of	the	novel	SLC3A1	mutations,	identified	in	Chapter	3.	To	validate	the	reproducibility	
of	 our	 experimental	 approach,	 we	 first	 investigated	 the	 expression	 of	 common	 SNP	M618I,	
and	 pathogenic	 M467T.	 This	 enabled	 comparison	 of	 our	 findings	 to	 those	 reported	 in	 the	
literature.	 Following	 this,	 we	 were	 able	 to	 utilise	 the	 Xenopus	 oocyte	 expression	 system	 to	
investigate	the	novel	missense	rBAT	mutations	M465K,	N254T,	L416P,	and	Y579D.	
5.2	Methods	
	 Mutant	 rBAT	 proteins	 were	 produced	 by	 site-directed	 mutagenesis	 of	 cDNA	 in	
pSPORT1	 (see	 Chapter	 2).	 [3H]Arginine	 uptake	 experiments	 were	 performed	 in	 oocytes	
injected	 with	 water	 (control),	 or	 1-50ng	 rBAT	 or	 mutant	 cRNA.	 Uptake	 experiments	 were	
performed	1-6	days	post-injection	of	cRNA	to	enable	the	measurement	of	protein	expression	
over	 time.	 Immunodetection	of	protein	 in	oocytes	by	western	blot	or	 immunocytochemistry	
was	performed	as	described	in	Chapter	4.	
Homology	modelling	of	the	rBAT	extracellular	domain	was	performed	as	described	in	
Chapter	 2.	 The	 measurement	 of	 distances	 between	 atoms	 in	 amino	 acid	 side	 chains	 was	
carried	out	using	the	Pymol	measurement	tool.	In	silico	mutagenesis	was	performed	using	the	
	 235	
PyMol	mutagenesis	wizard	 tool.	 The	 PyMol	 polar	 interaction	 tool	was	 used	 to	 estimate	 the	
changes	in	intramolecular	forces	in	the	mutated	protein.	
5.3	Results	
In	 this	 study	we	have	 reported	 the	 identification	of	 four	novel	mutations	 in	SLC3A1,	
the	 gene	 encoding	 rBAT.	 The	 location	 of	 these	mutations	 in	 the	 protein	 structure	 has	 been	
predicted	using	a	homology	model	of	the	rBAT	extracellular	domain	(Chapter	3).	We	have	also	
demonstrated	 that	 rBAT	 expression	 can	 be	 measured	 through	 a	 combination	 of	 functional	
studies	 and	 immunodetection	 techniques	 (Chapter	 4).	 In	 this	 chapter,	we	 report	 the	 use	 of	
these	protocols	to	measure	the	function	of	mutated	rBAT	protein	in	oocytes.	The	function	of	
these	mutant	 proteins	 was	measured	 against	 that	 of	 the	 wild-type	 protein	 in	 all	 instances.	
Figure	5.1	summarises	the	putative	location	of	the	novel	mutations	on	the	predicted	model	of	
the	rBAT	extracellular	domain.	An	in	silico	approach	to	predict	the	effect	of	these	mutations	on	
rBAT	is	presented	in	section	5.4.	All	of	the	rBAT	and	mutant	proteins	used	in	this	chapter	have	
a	3xFLAG	epitope	on	the	C-terminal	(rBAT3F)	and	will	be	referred	to	as	rBAT.	
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Figure	5.1:	Homology	model	of	the	rBAT	extracellular	domain	and	the	putative	locations	of	
cystinuria	 mutations.	 Top	 view	 of	 the	 rBAT	 extracellular	 domain	model	 based	 on	 oligo-1,6-
glucoside	 from	B.	 cereus	 (PDB	 code	 1UOK)	 to	 show	 the	 putative	 location	 of	 the	mutations,	
denoted	by	black	arrows.	The	mutations	highlighted	are	those	investigated	in	this	study.	This	
includes	the	common	SNP,	M618I;	pathogenic	mutation,	M467T;	and	the	four	novel	mutations	
identified	in	the	current	cohort:	M465K,	N254T,	L416P,	and	Y579D.	
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5.3.1	Function	of	common	SNP,	M618I	
The	 first	 rBAT	mutation	 investigated	 in	 this	 study	was	 the	common	single	nucleotide	
polymorphism	 (SNP),	 M618I.	 This	 SNP	 causes	 a	 conservative	 methionine	 to	 isoleucine	
substitution	at	position	618	of	the	protein.	From	the	homology	model,	we	predict	M618I	to	be	
located	in	rBAT	extracellular	domain	C	(Figure	5.1).	Found	in	around	half	of	the	population,	this	
SNP	is	not	expected	to	cause	a	disease	phenotype	(Kent	et	al.,	2002;	Stenson	et	al.,	2014).	For	
this	reason,	M618I	function	was	investigated	first.	We	wanted	to	confirm	the	hypothesis	that	
introducing	 this	 mutation	 into	 the	 protein	 sequence	 would	 not	 have	 any	 effect	 on	 rBAT	
function	in	oocytes.		
	[3H]Arginine	 uptake	 was	 performed	 in	 oocytes	 injected	 with	 water	 (control)	 or	 the	
cRNA	for	rBAT	or	M618I	(1-50ng).	Uptake	experiments	were	performed	1-3	days	post-injection	
(Figures	5.2	and	5.3).	On	day	1	post-injection,	 [3H]arginine	uptake	 into	oocytes	 injected	with	
1ng,	5ng,	or	50ng	of	wild-type	cRNA	was	not	significantly	different	(p>0.05)	to	that	measured	
in	 M618I-expressing	 oocytes	 (Figure	 5.2).	 When	 water-injected	 control	 values	 were	
subtracted,	 no	 significant	 difference	 (p>0.05)	 was	 observed	 in	 rBAT	 or	 M618I	 function	
following	the	injection	of	any	amount	of	cRNA	1-3	days	post-injection	(Figure	5.3).		
Concentration-dependent	[3H]arginine	uptake	(0.01-20mM)	was	measured	 in	oocytes	
expressing	 rBAT	 and	 M618I,	 3	 days	 post-injection	 of	 oocytes.	 Following	 the	 subtraction	 of	
background	 uptake	 values,	 these	 data	 were	 plotted	 to	 one-site	 binding	 Michaelis-Menten	
kinetics	 (Figure	5.4A	and	B).	No	significant	difference	(p>0.05)	was	observed	between	any	of	
the	calculated	kinetic	parameters.	The	uptake	levels	at	10μM	[3H]arginine	in	rBAT	and	M618I-
expressing	oocytes	were	36±5	and	31±3	pmol.oocyte-1.(60min)-1,	respectively.	These	data	are	
almost	 identical	 to	 those	 measured	 in	 the	 uptake	 experiments	 represented	 by	 Figure	 5.2C	
(31±7	 and	 32±6	 pmol.oocyte-1.(60min)-1,	 respectively),	 demonstrative	 of	 inter-experimental	
reproducibility.	 The	 concentration-dependent	 uptake	 data	 were	 also	 transformed	 to	 fit	 the	
linear	 Eadie-Hofstee	 plot	 (Figure	 5.4C).	 This	 confirmed	 that	 the	 gradients	 of	 the	 two	 slopes	
(representative	of	the	Km	values)	were	not	significantly	different	(p=0.87).	Additionally,	t-tests	
were	 performed	 using	 the	 interpolated	 Km	 and	 Vmax	 values	 from	 each	 of	 the	 3	 data	 fits	
displayed	in	Figure	5.3.	No	significant	difference	was	calculated	between	any	of	the	3	Km	values	
(p=0.5-0.9)	 or	 Vmax	 values	 (p=0.1-0.2).	 These	 data	 validate	 the	 use	 of	 the	Michaelis-Menten	
equation	 to	 establish	 reliable	 kinetic	 parameters	 up	 to	 1mM	 [3H]arginine	 (Figure	 5.3B).	
Additionally,	 the	 linear	 transformation	 to	 the	 Eadie-Hofstee	 plot	 identifies	 one-site	 binding	
transport	kinetics	(Figure	5.3C).	These	data,	consistent	between	uptake	experiments,	support	
the	 hypothesis	 that	 the	 introduction	 of	 a	 SNP	 into	 the	 sequence	 of	 rBAT	would	 not	 always	
have	a	detrimental	effect	on	protein	function	in	oocytes.	These	results	are	further	supported	
by	the	published	data	of	Saadi	et	al.	(1998)	and	Ishihara	et	al.	(2001),	in	which	no	reduction	in	
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[14C]cystine	 uptake	 was	 observed	 in	 M618I-expressing	 oocytes,	 compared	 to	 the	 wild-type	
expressing	controls.		
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Figure	 5.2:	 [3H]Arginine	 uptake	 in	 oocytes	 expressing	wild-type	 rBAT	or	 the	 common	 SNP,	
M618I.	 [3H]Arginine	uptake	 (10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	 injected	with	water	
(controls),	 rBAT,	 or	 M618I	 (1-50ng)	 cRNA.	 A,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=29),	
rBAT-	 (n=29-30),	 and	 M618I-cRNA	 injected	 oocytes	 (n=30-31),	 1	 day	 post-injection;	 B,	
[3H]Arginine	uptake	in	water-injected	(n=27),	rBAT-	(n=28-29),	or	M618I-cRNA	injected	oocytes	
(n=29-30),	2	days	post-injection;	C,	[3H]Arginine		uptake	in	water-injected	(n=27),	rBAT-	(n=29-
30),	 or	 M618I-cRNA	 injected	 oocytes	 (n=30),	 3	 days	 post-injection.	 Data	 are	 expressed	 as	
mean±SEM.	ns,	p>0.05	vs.	wild-type	oocytes	injected	with	the	same	amount	of	cRNA.	
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Figure	 5.3:	 Transporter-specific	 [3H]arginine	 uptake	 induced	 by	 wild-type	 rBAT	 or	 the	
common	SNP,	M618I.	Data	(as	in	Figure	5.2)	are	shown	with	the	water-injected	control	values	
subtracted.	 A,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	 rBAT	 (black,	 n=28-30),	 or	M618I	
(blue,	n=30-31)	cRNA	(1ng)	1-3	days	post-injection;	B,	[3H]Arginine	uptake	in	oocytes	injected	
with	 rBAT	 (black,	 n=29-30),	 or	M618I	 (blue,	 n=29-30)	 cRNA	 (5ng)	 1-3	 days	 post-injection;	 C,	
[3H]Arginine	uptake	 in	oocytes	 injected	with	 rBAT	 (black,	n=29-30)	or	M618I	 (blue,	n=29-30)	
cRNA	(50ng)	1-3	days	post-injection.	Data	are	expressed	as	mean±SEM.		
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Figure	 5.4:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 M618I-induced	
transport	 in	 oocytes.	 rBAT	 (black)	 and	 M618I	 (blue)-mediated	 [3H]arginine	 uptake	 (0.01-
20mM,	pH	7.4,	Na+-free)	in	Xenopus	oocytes	injected	with	rBAT	or	M618I	cRNA	(50ng).	Uptake	
was	 carried	 out	 3	 days	 post-injection	 of	 oocytes.	 Water-injected	 control	 values	 have	 been	
subtracted.	Data	are	mean±SEM	of	two	separate	experiments	(n=18-20).	A,	Data	for	rBAT	and	
M618I-mediated	uptakes	 from	0.01-20mM	were	 fitted	 to	Michaelis-Menten	one-site	binding	
kinetics	 (r2=0.46	and	0.42,	 respectively);	B,	Data	 for	 rBAT	and	M618I-mediated	uptakes	 from	
0.01-1mM	 were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 (r2=0.69	 and	 0.66,	
respectively);	 C,	 Data	 for	 rBAT	 and	 M618I-mediated	 uptakes	 from	 0.01-1mM	 were	
transformed	to	the	linear	Eadie-Hofstee	equation	(r2=0.95	and	0.93,	respectively).	
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Western	 blotting	 was	 performed	 to	 detect	 rBAT	 and	 M618I	 protein	 expression	 in	
oocytes.	Total	membrane	protein	samples	were	prepared	from	oocytes	injected	with	water,	or	
rBAT	or	M618I	cRNA	(1-50ng),	1-3days	post-injection	(Figure	5.5).	No	rBAT-specific	bands	were	
detected	 in	water-injected	 control	 oocytes	 (Figure	 5.5,	 lane	 a).	 Doublet	 bands	 of	 increasing	
intensity	were	observed	between	85	and	90	kDa	in	oocytes	injected	with	1-50ng	cRNA	(Figure	
5.5,	lanes	b-d,	and	e-g).	This	corresponds	to	the	size	of	rBAT	protein	reported	in	the	literature	
(Chillarón	et	al.,	1997).	Over	days	1-3,	band	intensity	became	greater	as	the	levels	of	translated	
protein	 increased.	 In	 samples	 taken	at	day	3	post-injection,	where	 large	amounts	of	protein	
were	resolved,	bands	appeared	smeary	(Figure	5.5).	Due	to	the	smearing	of	the	bands	at	day	6,	
the	western	blots	were	not	quantified.	Although	no	loading	controls	were	used	in	the	western	
blotting	experiments,	equivalent	amounts	of	total	protein	from	each	preparation	were	loaded	
following	spectrophotometric	quantification	(see	Chapter	2).	In	each	western	blot	presented	in	
this	 chapter,	wild-type	 rBAT	proteins	were	prepared	 from	 the	 same	batch	of	oocytes	 as	 the	
mutant	 samples	 to	control	 for	variability	 in	expression	 levels	between	batches.	This	ensured	
that	 the	 protein	 bands	 detected	 on	 the	 western	 blots	 are	 directly	 comparable.	 From	 the	
western	blot	(Figure	5.5)	it	is	apparent	that	there	is	no	visible	difference	in	band	intensity	from	
oocytes	 injected	with	 the	 same	quantity	 of	 rBAT	or	M618I	 cRNA,	 on	 any	day	 post-injection.	
This	 indicated	 that	 the	 introduction	 of	 M618I	 to	 the	 protein	 sequence	 did	 not	 affect	 the	
amount	of	total	protein	produced	in	oocytes.		
The	localisation	of	rBAT	and	M618I	proteins	at	the	plasma	membrane	of	oocytes	was	
determined	 by	 whole	 oocyte	 fluorescent	 confocal	 microscopy	 (Figure	 5.6).	 Oocytes	 were	
injected	 with	 water,	 rBAT,	 or	 M618I	 cRNA	 and	 fixed	 3	 days	 post-injection.	 Bright	 plasma	
membrane	fluorescence	was	observed	in	oocytes	expressing	wild-type	rBAT	(Figure	5.6B)	and	
M618I	protein	(Figure	5.6C),	which	was	absent	in	water-injected	control	oocytes	(Figure	5.6A).	
There	was	no	observed	difference	in	the	membrane	fluorescence	between	wild-type	rBAT	and	
M618I-expressing	 oocytes.	 These	 results	 are	 consistent	 with	 those	 of	 the	 functional	
experiments	 and	 the	western	blotting	of	 total	 protein	 levels,	 indicating	no	effect	upon	 rBAT	
function	 conferred	 by	M618I.	 This	 is	 consistent	with	 a	 polymorphism	 present	 in	 half	 of	 the	
population.	 Following	 measurement	 of	 M618I	 expression	 in	 oocytes,	 which	 served	 as	 a	
negative	 control	 for	 mutant	 rBAT	 expression,	 the	 focus	 of	 this	 study	 turned	 to	 the	
measurement	of	pathogenic	variant	expression.	
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Figure	5.6:	Immunocytochemical	detection	of	rBAT	in	whole	oocytes.	Representative	confocal	
microscopy	images	(n=12)	of	intact	oocytes	injected	with:	A,	water;	B,	rBAT	cRNA	(50ng);	or	C,	
M618I	cRNA	 (50ng).	 Images	were	 taken	 from	oocytes	 fixed	3	days	post-injection	of	cRNA.	 In	
water-injected	oocytes,	a	white	arrow	 indicates	 the	 location	of	 the	plasma	membrane.	Scale	
bar,	150µm.	
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5.3.2	Function	and	expression	of	cystinuria	mutation,	M467T	
The	 expression	 of	 the	 most	 common	 cystinuria-causing	 mutation	 in	 European	
populations,	M467T,	has	been	 characterised	previously	 in	Xenopus	oocytes	 (see	Section	5.1)	
(Chillarón	 et	 al.,	 1997;	 Bartoccioni	 et	 al.,	 2008).	 Based	 on	 the	 homology	model	 of	 the	 rBAT	
extracellular	domain,	the	methionine	residue	at	position	467	is	putatively	located	on	the	7th	α-
helix	of	the	TIM	barrel	structure	(Figure	5.1).	To	confirm	that	our	results	were	consistent	with	
those	reported	by	other	groups,	the	second	mutation	investigated	in	this	study	was	M467T.	
	[3H]Arginine	uptake	was	performed	in	oocytes	injected	with	water,	or	rBAT	or	M467T	
cRNA,	 1-6	 days	 post-injection	 (Figures	 5.7	 and	 5.8).	 On	 day	 1	 post-injection,	 [3H]arginine	
uptake	 in	 oocytes	 expressing	 M467T	 was	 significantly	 lower	 (p<0.05-0.001)	 than	 in	 those	
expressing	 wild-type	 rBAT,	 following	 injection	 of	 the	 same	 amount	 of	 cRNA	 (Figure	 5.7).	
However,	by	day	6	post-injection,	a	recovery	of	 function	was	observed	 in	oocytes	expressing	
the	mutant	protein.	At	day	6,	no	significant	difference	 (p>0.05)	was	observed	between	wild-
type	rBAT-	or	M467T-expressing	oocytes,	injected	with	the	same	amount	of	cRNA	(Figure	5.7).	
This	is	clearly	demonstrated	in	Figure	5.8,	which	presents	the	same	data	as	those	in	Figure	5.7,	
following	 subtraction	 of	 background	 uptake	 values.	 The	 rate	 of	 recovery	 of	M467T	 function	
was	dependent	on	 the	amount	of	 cRNA	 injected.	No	uptake	of	 [3H]arginine	was	observed	 in	
oocytes	 injected	with	1ng	cRNA	on	days	1-3.	However,	 [3H]arginine	uptake	was	measured	 in	
oocytes	 injected	with	5-50ng	cRNA	at	day	2	post-injection	(Figure	5.8).	These	data	 indicate	a	
delay,	or	“lag”,	 in	 function	of	 the	M467T-mediated	transport	system,	which	 is	dependent	on	
the	amount	of	cRNA	injected.	This	reduction	in	[3H]arginine	uptake	appeared	to	recover	by	day	
6	in	oocytes	injected	with	all	amounts	of	cRNA	and	support	the	data	reported	by	Chillarón	et	
al.	(1997).		
To	determine	whether	the	observed	lack	of	function	in	oocytes	expressing	M467T	was	
due	 to	 a	 decrease	 in	 protein	 at	 the	 oocyte	 membrane,	 or	 a	 change	 in	 the	 affinity	 of	 the	
transport	 system,	concentration-dependent	 [3H]arginine	uptake	 (0.01-1mM)	was	carried	out.	
Background	 uptake	 values	 were	 subtracted	 and	 the	 results	 were	 plotted	 to	 the	 Michaelis-
Menten	non-linear	equation	(Figure	5.9A).	As	shown	in	section	5.3.1,	the	 interpolated	values	
for	these	data	fitted	to	the	Michaelis-Menten	equation	provide	reliable	Km	and	Vmax	values	up	
to	 1mM	 [3H]arginine.	 The	 measured	 affinity	 (Km)	 of	 the	 wild-type	 rBAT-induced	 transport	
system	 was	 85±19μM.	 In	 oocytes	 injected	 with	 M467T	 cRNA,	 the	 affinity	 of	 the	 induced	
transport	 system	 was	 measured	 at	 30±14μM,	 significantly	 higher	 than	 the	 wild-type	
(measured	by	a	decrease	in	Km	p=0.02).	Although	we	did	not	expect	M467T	to	affect	the	Km	of	
the	transport	system,	the	possibility	of	this,	through	an	altered	interaction	of	M467T	rBAT	with	
b0,+AT,	 cannot	 be	 excluded.	 The	 circulating	 plasma	 concentrations	 of	 arginine	 and	 lysine	 in	
adults	have	been	estimated	at	52-126μM	and	121-268μM,	respectively,	depending	upon	the	
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time	 of	 day	 they	 were	 measured	 and	 the	 protein	 intake	 of	 the	 participants	 (Maher	 et	 al.,	
1984).	As	amino	acids	are	freely	filtered	by	the	glomerulus,	these	values	are	also	reflective	of	
the	 dibasic	 amino	 acid	 concentrations	 in	 the	 renal	 filtrate	 of	 the	 proximal	 tubule.	 The	
concentration	of	these	amino	acids	in	the	renal	filtrate	is	very	close	to	the	measured	affinity	of	
the	 transport	 system.	 Therefore,	 a	 2.8-fold	 decrease	 in	 the	 Km,	 which	 would	 increase	 the	
affinity	of	the	carrier	for	its	substrates	and	thus	increase	the	uptake	at	 lower	concentrations,	
could	have	a	great	impact	on	the	net	arginine	transport	by	System	b0,+.	A	broadly	similar	effect	
was	 measured	 by	 Chillarón	 et	 al.	 (1997).	 They	 measured	 the	 Km	of	 wild-type	 rBAT	 induced	
arginine	 transport	 to	 be	 93±13μM,	 3	 days	 post-injection	 of	 oocytes,	 and	 that	 of	 M467T-
induced	 transport	 to	 be	 51±8.	 However,	 they	 regarded	 this	 decrease	 to	 be	 non-significant.	
Some	 variability	 in	 the	 affinity	 of	 rBAT-induced	 transport	 in	 oocytes	 has	 been	 observed	
amongst	different	research	groups.	Bertran	et	al.	(1992)	calculated	the	affinity	of	System	b0,+	
for	 arginine	 to	 be	 105μM,	 and	 the	 affinity	 for	 cystine	 has	 been	 reported	 to	 range	 from	 30-
67μM	 (Bertran	 et	 al.,	 1992b;	Wells	&	Hediger,	 1992;	 Bertran	 et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	
However,	 this	variability	 is	between	batches	of	oocytes,	and	we	would	expect	 the	affinity	of	
rBAT	and	mutant	transport	measured	within	the	same	experiment	to	be	directly	comparable.	
Further	 investigation	 is	 required,	 perhaps	 using	 a	 different	 rBAT	 expression	 system,	 to	
determine	whether	the	observed	variability	 in	affinity	 is	a	true	measurement,	or	reflective	of	
the	variability	in	oocyte	quality.		
The	 calculated	 Vmax	 values,	 interpolated	 from	 the	 Michaelis-Menten	 kinetics	 were	
356±23,	 and	 28±3	 pmol.oocyte-1.(60min)-1,	 for	 wild-type	 and	mutant	 transport,	 respectively	
(Figure	 5.9A).	 This	 shows	 a	 significant	 reduction	 in	 the	 capacity	 of	 the	 transport	 system	
(p<0.001),	 indicative	 of	 a	 lack	 of	 trafficked	 protein	 at	 the	 oocyte	 membrane.	 This	 is	 in	
accordance	with	what	we	would	 have	 anticipated	 in	 rBAT	mutations.	 Chillarón	et	 al.	 (1997)	
measured	 the	Vmax	 value	of	 [3H]arginine	 transport	via	M467T-expressing	oocytes	 to	be	81±6	
pmol.oocyte-1.(5min)-1,	 compared	 to	 196±16	 in	 the	 wild-type	 expressing	 oocytes.	 The	 data	
were	 transformed	 to	 the	 linear	 Eadie-Hofstee	equation	 to	demonstrate	 the	one-site	binding	
kinetics	 of	 [3H]arginine	 transport	 (Figure	 5.9B).	 When	 fitted	 to	 the	 linear	 equation,	 the	 r2	
values	for	rBAT-	and	M467T-induced	transport	were	0.90	and	0.85,	respectively	(Figure	5.9B).	
Following	 the	 Eadie-Hofstee	 transformation	 the	 gradients	 of	 the	 slopes	 (-Km)	 were	 not	
significantly	 different	 (p=0.45).	 Again,	 this	 raises	 the	 question	 of	 whether	 the	 observed	
difference	in	Km	calculated	by	Michaelis-Menten	kinetics	was	a	true	observation.		
The	 data	 from	 the	 concentration-dependent	 uptakes	 (Figure	 5.9)	 are	 the	mean	 of	 3	
experiments.	They	correlate	with	 the	10μM	uptake	measurements	presented	 in	Figure	5.7C,	
which	are	 the	mean	of	 two	experiments	performed	with	separate	batches	of	oocytes.	These	
data	demonstrate	the	fluidity	of	rBAT	expression	in	the	oocytes,	by	providing	a	measurement	
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of	 function	 at	 different	 time	 points	 post-injection	 of	 oocytes	 (Figure	 5.7).	 At	 day	 3	 post-
injection	 of	 cRNA	 (50ng),	 10μM	 [3H]arginine	 uptake	 via	M467T-expressing	 oocytes	was	 15%	
and	 43%,	 of	 that	 measured	 in	 wild-type	 expressing	 oocytes	 in	 Figure	 5.9A	 and	 5.7C,	
respectively.	 This	 demonstrates	 some	 variability	 in	 the	 relative	 expression	 and	 subsequent	
function	of	the	mutant	protein	compared	to	wild-type	rBAT.	However,	this	is	reflective	of	the	
variability	 in	 protein	 expression	 between	 oocyte	 batches.	 At	 3	 days	 post-injection	 of	 cRNA,	
M467T	 function	was	always	significantly	 lower	 (p<0.05)	 than	 the	wild-type	 (Figures	5.7C	and	
5.9A).	We	are	consistently	measuring	a	marked	delay	 in	the	expression	of	M467T,	relative	to	
wild-type	rBAT,	which	recovers	over	time.		
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Figure	 5.7:	 [3H]Arginine	 uptake	 in	 oocytes	 expressing	 wild-type	 rBAT	 or	 the	 pathogenic	
mutant,	M467T.	 [3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	 in	oocytes	injected	with	water	
(control),	 rBAT,	 or	 M467T	 cRNA	 (1-50ng).	 A,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=20),	
rBAT-	 (n=18-20),	 or	M467T-injected	 oocytes	 (n=19-20),	 1	 day	 post-injection;	 B,	 [3H]Arginine	
uptake	in	water-injected	(n=18),	rBAT-	(n=18-20),	or	M467T-injected	oocytes	(n=18-20),	2	days	
post-injection;	 C,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=20),	 rBAT-	 (n=20),	 or	 M467T-
injected	 oocytes	 (n=14-20),	 3	 days	 post-injection;	 D,	 [3H]Arginine	 uptake	 in	 water-injected	
(n=19),	rBAT-	(n=18-19),	or	M467T-injected	oocytes	(n=10-16),	6	days	post-injection.	Data	are	
expressed	 as	 mean±SEM.	 ***,	 p<0.0001;	 **,	 p<0.001;	 *,	 p<0.05;	 ns,	 p>0.05	 versus	 oocytes	
injected	with	the	same	amount	of	wild-type	cRNA.	
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Figure	 5.8:	 Transporter-specific	 [3H]arginine	 uptake	 induced	 by	 wild-type	 rBAT	 or	 the	
pathogenic	 cystinuria	 mutant,	M467T.	 Data	 (as	 in	 Figure	 5.6)	 are	 shown	 with	 the	 water-
injected	 control	 values	 subtracted.	 [3H]Arginine	 uptake	 (10μM,	 pH	 7.4,	 Na+-free,	 60min)	 via	
oocytes	injected	with	rBAT	or	M467T	cRNA	(1-50ng).	A,	[3H]Arginine	uptake	in	oocytes	injected	
with	 rBAT	 (black,	 n=18-20),	 or	M467T	 (red,	 n=10-20)	 cRNA	 (1ng),	 1-6	 days	 post-injection;	 B,	
[3H]Arginine	uptake	 in	oocytes	 injected	with	 rBAT	 (black,	n=18-20),	or	M467T	 (red,	n=13-20)	
cRNA	 (5ng),	 1-6	 days	 post-injection;	 C,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 rBAT	
(black,	 n=18-20),	 or	 M467T	 (red,	 n=16-20)	 cRNA	 (50ng),	 1-6	 days	 post-injection.	 Data	 are	
expressed	as	mean±SEM.	
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Figure	 5.9:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 M467T-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-20mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	injected	with	rBAT	(black)	or	M467T	(red)	cRNA	(50ng).	Data	are	mean±SEM	(n=27-30,	
from	3	separate	experiments).	A,	Data	 for	rBAT	and	M467T-mediated	uptakes	were	 fitted	to	
Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	 water-injected	 control	
values	 (r2=0.47	 and	0.08,	 respectively);	 B,	Data	 for	 rBAT	 and	M467T-mediated	uptakes	 from	
panel	 A	 were	 transformed	 to	 the	 linear	 Eadie-Hofstee	 equation	 (r2=0.90	 and	 0.85,	
respectively).	
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The	expression	of	 rBAT	protein	was	measured	by	western	blotting.	 Total	membrane	
protein	samples	were	taken	 from	oocytes	 injected	with	water,	 rBAT,	or	M467T	cRNA	(Figure	
5.10A	and	B).	Figure	5.10A	and	B	show	western	blots	carried	out	with	samples	taken	from	two	
different	 batches	 of	 oocytes.	 In	 both	 blots,	 band	 intensity	 increased	 over	 days	 1-3.	 Bands	
appeared	 smeary	 at	 day	 6,	where	 large	 amounts	 of	 protein	were	 resolved	 (Figure	 5.10B).	 A	
reduction	 in	band	 intensity	was	observed	 in	oocytes	expressing	M467T	protein	compared	 to	
equivalent	 wild-type	 samples.	 Despite	 the	 absence	 of	 an	 experimental	 loading	 control,	 we	
believe	the	equivalent	amount	of	protein	has	been	loaded	into	each	lane,	measured	through	
spectrophotometric	quantification.	By	detecting	the	amount	of	total	membrane	protein	in	the	
oocytes	we	are	acknowledging	equilibrium	in	the	oocyte	between	the	rate	of	translation	and	
degradation	of	the	wild-type	and	mutant	rBAT.	Therefore,	the	lower	band	intensity	observed	
in	M467T	could	 indicate	that	the	M467T	mutation	decreases	the	rate	at	which	the	protein	 is	
translated,	or	increases	the	rate	at	which	it	is	degraded.	From	published	data	on	the	effect	of	
mutations	on	the	biogenesis	of	rBAT,	 it	 is	 likely	that	the	protein	 is	being	rapidly	degraded	by	
the	ER,	creating	a	reduction	in	the	total	amount	of	M467T	protein	in	the	oocyte,	compared	to	
the	wild-type		(see	Section	5.4).	However,	a	reduction	in	mutant	rBAT	protein	compared	to	the	
wild-type	has	not	been	reported	previously	in	the	literature	(Chillarón	et	al.,	1997;	Bartoccioni	
et	al.,	2008).	Due	to	the	high	 intensity	of	the	bands	after	day	2,	some	bands	appear	unclear,	
yet	doublet	bands	of	90	and	85kDa	were	detected	in	wild-type	rBAT	protein,	representing	both	
the	mature	and	core-glycosylated	forms	of	the	protein,	respectively.	In	the	samples	taken	from	
oocytes	expressing	M467T,	 the	90kDa	band	appears	 to	be	absent	 (Figure	5.10A	and	B).	 This	
can	 be	most	 clearly	 observed	 from	 the	 1ng	 samples	 taken	 at	 day	 1	 post-injection	 in	 Figure	
5.10A	and	1ng	samples	 taken	at	days	1-3	 in	Figure	5.10B.	This	provides	 further	evidence	 for	
degradation	of	M467T	by	the	ER.	The	mature	glycosylated	form	of	the	protein	(90kDa)	is	only	
produced	 following	 processing	 by	 the	 Golgi	 apparatus.	 These	 data	 support	 the	 results	 of	
Chillarón	et	al.	(1997)	who	observed	a	lack	of	the	mature	glycosylated	form	of	M467T,	yet	did	
not	report	a	decrease	in	the	total	amount	of	85kDa	protein.				
The	detection	of	 rBAT	at	 the	plasma	membrane	was	determined	 through	 imaging	of	
whole	 and	 sectioned	 oocytes	 (Figure	 5.11A-D).	 A	 strong	 signal	 was	 detected	 at	 the	 plasma	
membrane	of	oocytes	expressing	wild-type	rBAT	protein	(Figure	5.11B).	A	much	weaker	signal	
was	visible	in	oocytes	expressing	M467T	(Figure	5.11C).	The	detection	of	low	levels	of	M467T	
protein	 in	 the	plasma	membrane,	 3	days	post-injection,	 is	 consistent	with	 the	 results	 of	 the	
functional	 studies	 (Figures	 5.7C	 and	 5.9A).	 These	 data	 were	 supported	 by	 the	 fluorescence	
measured	 in	 sectioned	 oocytes	 (Figure	 5.11D).	 Bright	 plasma	 membrane	 fluorescence	 was	
visible	 in	 wild-type	 rBAT-expressing	 oocytes	 (middle	 panel),	 with	 some	 intracellular	
fluorescence	 visible	 in	 M467T-expressing	 oocytes.	 However,	 in	 sections	 of	 oocytes	 injected	
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with	 M467T	 cRNA,	 no	 bright	 membrane	 staining	 was	 observed	 (right-hand	 panel).	 Some	
M467T	 protein	 must	 be	 present	 in	 the	 plasma	 membrane	 as	 [3H]arginine	 uptake	 was	
measured	 in	 these	 oocytes	 3	 days	 post-injection	 (Figures	 5.6C	 and	 5.7C).	 However,	 the	
quantity	of	M467T	protein	at	the	membrane	was	not	sufficient	to	produce	a	detectable	signal,	
visibly	brighter	than	the	intracellular	staining.	The	immunocytochemical	detection	of	rBAT	and	
M467T	in	oocytes	broadly	support	the	results	of	the	functional	data	(Figures	5.7-5.9)	and	the	
western	blotting	(Figure	5.10),	providing	evidence	that	M467T	is	translated	in	the	oocyte,	but	
there	is	a	lag	in	trafficking	of	the	protein	to	the	plasma	membrane,	which	recovers	over	time.	
These	 data	 report	 the	 functional	 expression	 of	 M467T	 in	 oocytes	 and	 indicate	 a	
reduction	in	expression	of	the	protein	and	a	large	reduction	in	Vmax,	which	recovers	over	time.	
A	significant	(p<0.05)	increase	in	the	affinity	of	the	transport	system	was	also	detected	when	
the	 concentration	 dependent	 uptake	 data	 were	 fitted	 to	 the	 Michaelis-Menten	 kinetics.	
However	this	requires	further	investigation.	Furthermore,	it	appears	as	though	only	the	core-
glycosylated	 form	 of	 rBAT	 is	 produced	 following	 the	 introduction	 of	 the	 M467T	 mutation,	
indicating	 that	 the	cell	does	not	process	 this	protein	 in	 the	 same	manner	as	wild-type	 rBAT.	
These	data	are	supported	by	the	broadly	similar	findings	of	Chillarón	et	al.	(1997),	confirming	
that	 the	 techniques	 employed	 in	 this	 investigation	 are	 a	 reliable	 tool	 for	 the	 study	 of	 rBAT	
mutant	proteins	in	oocytes.		
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Figure	5.10:	Immunodetection	of	rBAT	and	M467T	in	oocyte	membranes	by	western	blot.	A,	
Western	blot	of	total	membrane	protein	samples	from	oocytes	 injected	with	water	(control),	
rBAT	or	M467T	 cRNA	 (1-50ng),	 1-3	days	post-injection.	 Lanes	 represent	 samples	 taken	 from	
oocytes	injected	with:	a,	water	(control);	b,	rBAT	cRNA	(1ng);	c,	rBAT	cRNA	(5ng);	d,	rBAT	cRNA	
(50ng);	e,	M467T	cRNA	(1ng);	f,	M467T	cRNA	(5ng);	g,	M467T	cRNA	(50ng);	B,	western	blot	of	
total	membrane	protein	samples	 from	oocytes	 injected	with	water	 (control),	 rBAT	or	M467T	
cRNA	 (1-50ng),	 1-6	 days	 post-injection.	 Data	 are	 from	 a	 different	 batch	 of	 oocytes	 to	 those	
represented	 in	 panel	 A.	 They	 are	 presented	 using	 the	 same	 letters	 as	 in	 panel	 A.	 Where	
doublet	bands	were	most	clearly	visible	they	are	indicated	by	*.	
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Figure	 5.11:	 Immunocytochemical	 detection	 of	 rBAT	 and	 M467T	 in	 whole	 and	 sectioned	
oocytes.	A-C,	representative	confocal	microscopy	images	(n=12)	of	intact	oocytes	injected	with	
water	(A),	or	50ng	cRNA	for	rBAT	(B)	or	M467T	(C).	Scale	bar,	150µm;	a	white	arrow	indicates	
the	location	of	the	oocyte	membrane	in	water-injected	oocytes;	D,	representative	microscopy	
images	 (n=5)	 of	 oocyte	 sections	 (15μm)	 injected	with	water	 (left-hand	 panel),	 rBAT	 (middle	
panel),	or	M467T	(right-hand	panel)	cRNA	(50ng).	Scale	bar,	150μm.		
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5.3.3	Function	and	expression	of	the	novel	rBAT	mutation,	M465K	
The	 experimental	 measurements	 of	 rBAT	 expression	 described	 in	 section	 5.3.1	 and	
5.3.2	served	as	controls	for	characterisation	of	novel	mutant	function.	Firstly,	we	established,	
through	 investigation	 of	 a	 common	 SNP,	 that	 not	 all	 amino	 acid	 substitutions	 in	 the	 rBAT	
protein	 would	 affect	 function.	 Secondly,	 we	 confirmed	 that	 the	 results	 of	 our	 oocyte	
expression	studies	of	the	pathogenic	mutation,	M467T	replicated	published	findings	(Chillarón	
et	al.,	1997).	Following	these	control	observations,	we	 looked	at	 the	expression	of	 the	novel	
cystinuria	mutation,	M465K.	This	mutation	was	found	in	Patient	25	of	our	cohort	(Chapter	3).	
The	methionine	residue	at	position	465	in	the	rBAT	protein	is	predicted	to	sit	on	the	7th	α-helix	
of	the	extracellular	TIM	barrel	structure	(Figure	5.1).	The	effect	of	in	silico	mutagenesis	of	this	
residue	is	discussed	in	section	5.4.	
	[3H]Arginine	 uptake	 was	 performed	 in	 oocytes	 1-6	 days	 post-injection	 of	 water,	 or	
cRNA	for	rBAT	or	M465K	(Figures	5.12-5.13).	One	day	post-injection	of	1-50ng	wild-type	rBAT	
cRNA,	 [3H]arginine	uptake	was	measured	at	3-11	–fold	above	background	 (Figure	5.12A).	No	
significant	 [3H]arginine	 uptake	 (p>0.05)	 was	 measured	 in	 oocytes	 expressing	 M465K	 cRNA.	
Despite	 this,	 some	uptake	was	measured	 in	oocytes	 injected	with	50ng	 cRNA	 for	M465K,	 at	
2.5-fold	 above	 background	 (Figure	 5.12A).	 In	 a	 similar	 manner	 to	 that	 observed	 in	
measurements	of	the	M467T	mutant	protein	(section	5.3.2),	a	recovery	of	M465K	function	was	
observed	over	time	post-injection	(Figure	5.13).	However,	with	M465K,	a	complete	recovery	of	
function	was	 not	 detected.	 By	 day	 6	 post-injection,	 the	 function	 of	 the	mutant	 protein	 had	
reached	16%,	28%,	and	44%	of	wild-type	uptake	 in	oocytes	 injected	with	1,	5	or	50ng	cRNA,	
respectively	(Figure	5.13).	These	data	suggest	that	the	observed	recovery	of	M465K	function	in	
the	oocytes	is	dependent	on	the	amount	of	cRNA	injected.		
Concentration-dependent	[3H]arginine	uptake	was	measured	in	oocytes	 injected	with	
wild-type	rBAT	or	M465K	cRNA,	3	days	post-injection.	This	was	to	determine	to	effect	of	the	
M465K	mutation	on	 the	kinetic	parameters	of	 [3H]arginine	 transport.	Water-injected	 control	
values	 were	 subtracted	 and	 the	 results	 were	 plotted	 using	 the	 Michaelis-Menten	 equation	
(Figure	 5.14A).	 The	 Km	 of	 the	wild-type	 rBAT	 induced	 transport	 system	 for	 [3H]arginine	was	
measured	at	97±28μM,	1.6-fold	higher	than	the	value	calculated	in	M465K-expressing	oocytes	
(59±25μM).	This	was	a	non-significant	change	 (p=0.3).	The	capacity	of	 the	 induced	 transport	
systems	varied	4-fold	(p<0.001)	between	wild-type	rBAT	(519±30	pmol.oocyte-1.(60min)-1)	and	
M465K-expressing	oocytes	(127±10	pmol.min-1.(60min)-1)	(Figure	5.14B).	The	uptake	of	10μM	
[3H]arginine	via	M465K	at	 3	 days	post-injection	of	 oocytes	was	 52%	of	 the	wild-type.	 In	 the	
previous	 figure,	which	was	 the	mean	of	 two	 single	experiments,	 the	 function	of	M465K	was	
32%	 of	 the	 wild-type	 (Figure	 5.13C).	 This	 demonstrates	 consistency	 in	 the	 measurements	
made	 between	 the	 individual	 experiments.	 	 At	 3	 days	 post-injection	 of	 oocytes	 with	 50ng	
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cRNA,	 the	 function	of	 the	mutant	 protein	 is	 significantly	 lower	 than	 the	wild-type.	 The	data	
were	transformed	to	the	linear	Eadie-Hofstee	equation	(Figure	5.14B).	The	r2	values	(0.90	and	
0.69	 for	 rBAT	 and	M465K,	 respectively)	 obtained	 following	 the	 transformation	 indicate	 one-
site	binding	kinetics	of	[3H]arginine	transport.	These	values	support	our	hypothesis	that	M465K	
does	 not	 significantly	 alter	 the	 affinity	 of	 System	 b0,+	 for	 arginine,	 but	 hinders	 efficient	
trafficking	of	the	transport	system	to	the	oocyte	membrane.		
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Figure	5.12:	[3H]Arginine	uptake	in	oocytes	expressing	wild-type	rBAT	or	the	novel	cystinuria	
mutant,	M465K.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	via	oocytes	injected	with	water	
(control),	 rBAT,	 or	 M465K	 cRNA	 (1-50ng).	 A,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=20),	
rBAT-	 (n=20),	 or	 M465K-injected	 oocytes	 (n=19-20),	 1	 day	 post-injection;	 B,	 [3H]Arginine	
uptake	in	water-injected	(n=16),	rBAT-	(n=19-20),	or	M465K-injected	oocytes	(n=19-20),	2	days	
post-injection;	 C,	 [3H]Arginine	 	 uptake	 in	water-injected	 (n=19),	 rBAT-	 (n=19-20),	 or	M465K-
injected	 oocytes	 (n=19-20),	 3	 days	 post-injection;	 D,	 [3H]Arginine	 	 uptake	 in	 water-injected	
(n=17),	rBAT-	(n=16-20),	or	M465K-injected	oocytes	(n=13-21),	6	days	post-injection.	Data	are	
expressed	 as	 mean±SEM.	 ***,	 p<0.0001;	 *,	 p<0.05;	 ns,	 p>0.05	 vs.	 water-injected	 control	
oocytes.	
rBAT M465K
0
20
40
60
[³ H
]A
rg
in
in
e4
up
ta
ke
4(p
m
ol
.o
oc
yt
e.
(6
0m
in
)B¹
)
Water
1ng
5ng
50ng
ns ns ns
Day41
ns
***
***
rBAT M465K
0
20
40
60
[³ H
]A
rg
in
in
e4
up
ta
ke
4(p
m
ol
.o
oc
yt
e.
(6
0m
in
)B¹
) Day43
***
*
***
ns
ns
*
rBAT M465K
0
20
40
60
[³ H
]A
rg
in
in
e4
up
ta
ke
4(p
m
ol
.o
oc
yt
e.
(6
0m
in
)B¹
)
ns
Day42
ns
***
***
ns
ns
rBAT M465K
0
20
40
60
[³ H
]A
rg
in
in
e4
up
ta
ke
4(p
m
ol
.o
oc
yt
e.
(6
0m
in
)B¹
) Day46
*
***
***
ns
ns
ns
A	 B	
C	 D	
[3
H
]A
rg
in
in
e	
up
ta
ke
	(p
m
ol
.o
oc
yt
e-
1 .(
60
m
in
)-1
)	
[3
H
]A
rg
in
in
e	
up
ta
ke
	(p
m
ol
.o
oc
yt
e-
1 .(
60
m
in
)-1
)	
[3
H
]A
rg
in
in
e	
up
ta
ke
	(p
m
ol
.o
oc
yt
e-
1 .(
60
m
in
)-1
)	
[3
H
]A
rg
in
in
e	
up
ta
ke
	(p
m
ol
.o
oc
yt
e-
1 .(
60
m
in
)-1
)	
	 262	
2 4 6
0
20
40
60
1ng
M465K
rBAT
Day
[³ H
]A
rg
in
in
e8
up
ta
ke
8
(p
m
ol
.o
oc
yt
e.
(6
0m
in
)D¹
)
0 2 4 6
0
20
40
60
5ng
Day
[³ H
]A
rg
in
in
e8
up
ta
ke
8
(p
m
ol
.o
oc
yt
e.
(6
0m
in
)D¹
)
0 2 4 6
0
20
40
60
50ng
Day
[³ H
]A
rg
in
in
e8
up
ta
ke
8
(p
m
ol
.o
oc
yt
e.
(6
0m
in
)D¹
)
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
[3
H
]A
rg
in
in
e	
up
ta
ke
	
(p
m
ol
.o
oc
yt
e-
1 .(
60
m
in
)-1
)	
	
[3
H
]A
rg
in
in
e	
up
ta
ke
	
(p
m
ol
.o
oc
yt
e-
1 .(
60
m
in
)-1
)	
	
[3
H
]A
rg
in
in
e	
up
ta
ke
	
(p
m
ol
.o
oc
yt
e-
1 .(
60
m
in
)-1
)	
A	
B	
C	
	 263	
	
	
	
	
	
	
	
	
Figure	5.13:	Transporter-specific	[3H]arginine	uptake	induced	by	wild-type	rBAT	or	the	novel	
cystinuria	mutant,	M465K.	Data	(as	in	Figure	5.10)	are	shown	with	the	water-injected	control	
values	 subtracted.	 A,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	 rBAT	 (black,	 n=19-20),	 or	
M465K	 (red,	n=16-20)	 cRNA	 (1ng),	 1-6	days	post-injection;	B,	 [3H]Arginine	uptake	 in	oocytes	
injected	 with	 rBAT	 (black,	 n=16-20),	 or	 M465K	 (red,	 n=19-21)	 cRNA	 (5ng),	 1-6	 days	 post-
injection;	C,	[3H]Arginine	uptake	in	oocytes	injected	with	rBAT	(black,	n=18-20),	or	M465K	(red,	
n=13-19)	cRNA	(50ng),	1-6	days	post-injection.	Data	are	expressed	as	mean±SEM.		
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Figure	 5.14:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 M465K-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-20mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	 injected	with	 rBAT	 (black)	 or	M467T	 (red)	 cRNA	 (50ng).	Data	 are	mean±SEM	 (n=10,	
from	a	single	experiment,	representative	of	3).	A,	Data	for	rBAT	and	M465K-mediated	uptakes	
were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	 water-
injected	control	values	(r2=0.47	and	0.25,	respectively);	B,	Data	for	rBAT	and	M467T-mediated	
uptakes	 from	 panel	 A	 were	 transformed	 to	 the	 linear	 Eadie-Hofstee	 equation	 (r2=0.90	 and	
0.69,	respectively).	
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For	western	blotting,	 total	membrane	protein	 samples	were	 taken	 from	oocytes	 1-6	
days	post-injection	with	water,	or	1-50ng	 rBAT	or	M465K	cRNA	 (Figure	5.15).	Over	days	1-6,	
the	band	intensities	grew	stronger	as	the	levels	of	protein	expression	increased.	The	intensities	
of	bands	representing	M465K-injected	oocytes	were	lower	than	those	representing	equivalent	
wild-type	rBAT-injected	oocytes.	This	phenomenon	has	not	been	reported	in	previous	studies	
where	western	blotting	was	performed	with	mutant	rBAT	proteins	M467T	or	R365W	(Chillarón	
et	al.,	1997;	Pineda	et	al.,	2004b).	Additionally,	when	Bartoccioni	et	al.	 (2008)	compared	the	
expression	 levels	 of	 rBAT	 and	 mutants	 L89P,	 T216M,	 R365W,	 M467T	 and	 M467T	 in	 total	
membrane	 protein	 fractions	 taken	 from	HeLa	 cells,	 they	 did	 not	 see	 any	 reduction	 in	 band	
intensity	of	mutant	proteins	compared	to	the	wild-type.	This	discovery	appears	to	be	unique	to	
our	investigation.	However,	it	could	be	explained	by	an	increase	in	the	rate	of	degradation	of	
the	 mutant	 proteins	 in	 the	 ER,	 compared	 to	 the	 wild-type	 protein.	 By	 measuring	 total	
membrane	protein	expression,	we	are	essentially	taking	a	“snapshot”	of	the	equilibrium	within	
the	oocyte	between	protein	synthesis	and	degradation	at	different	time	points	post-injection	
of	cRNA.	From	day	2	onwards,	a	second	band	of	higher	molecular	weight	(90kDa)	was	present	
in	wild-type	expressing	oocytes	(Figure	5.15).	This	is	indicative	of	mature	glycosylated	protein	
processed	by	the	Golgi	(Bartoccioni	et	al.,	2008).	The	higher	molecular	weight	band	was	absent	
in	 oocytes	 expressing	 the	mutant	 protein.	 This	 is	most-clearly	 visible	 at	 day	 6	 post-injection	
(Figure	5.15).	These	data	are	consistent	with	the	report	of	Chillarón	et	al.	(1997)	on	the	cellular	
processing	 of	 the	 M467T	 rBAT	 mutant,	 and	 that	 of	 Bartoccioni	 et	 al.	 (2008)	 regarding	 the	
expression	 of	 L89P,	 T216M,	 R365W,	 M467T	 and	 M467K.	 The	 absence	 of	 the	 mature	
glycosylated	 form	 of	 M465K	 indicates	 degradation	 of	 the	 mutant	 protein	 by	 the	 ERAD	
pathways,	and	a	lack	of	processing	by	the	Golgi	apparatus.	This	is	discussed	in	detail	in	section	
5.4.		
Immunocytochemical	 detection	 of	 rBAT	 protein	 was	 carried	 out	 on	 whole	 oocytes	
(Figure	5.16A-E).	 In	oocytes	 injected	with	 rBAT	cRNA,	bright	 fluorescence	was	observed	at	3	
and	 6	 days	 post-injection	 (Figure	 5.16B	 and	 D,	 respectively).	 A	weak	 signal	was	 detected	 in	
oocytes	 expressing	M465K,	 3	 days	 post-injection	 (Figure	 5.16C).	 By	 day	 6,	 the	 fluorescence	
associated	with	 the	mutant	 protein	 appeared	 to	 be	 brighter	 (Figure	 5.16E),	 correlating	with	
the	recovery	of	function	observed	in	the	uptake	studies.		
The	 data	 from	 whole	 oocyte	 imaging	 were	 supported	 by	 immunocytochemical	
detection	 of	 rBAT	 proteins	 in	 15μm	 oocyte	 sections	 (Figure	 5.16F).	 No	 fluorescence	 was	
detected	at	the	membrane	of	water-injected	control	oocytes	(Figure	5.16F,	left-hand	panel).	A	
bright	band	of	 fluorescence	representing	wild-type	rBAT	protein	was	observed	at	the	plasma	
membrane	 of	 oocytes	 injected	 with	 rBAT	 cRNA	 (Figure	 5.16F,	 middle	 panel).	 In	 oocytes	
expressing	 the	 mutant	 protein,	 no	 membrane	 fluorescence	 was	 identified.	 However,	 bright	
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intracellular	 staining	 was	 present,	 which	 could	 be	 masking	 any	 weak	 signal	 present	 at	 the	
membrane	(Figure	5.16F,	right-hand	panel).	These	data	complement	the	results	of	the	western	
blot	 immunodetection	 and	 functional	 studies.	Mutant	 rBAT	 protein,	M465K,	 is	 translated	 in	
the	oocyte,	but	trafficked	to	the	plasma	membrane	at	a	slower	rate	than	the	wild-type.	At	day	
6	post-injection	a	higher	level	of	the	mutant	protein	is	present	at	the	membrane	than	at	day	6,	
but	still	in	lower	quantities	than	the	wild-type	protein.		
From	these	data	we	can	conclude	that	M465K	is	translated	in	the	oocyte,	but	at	3	days	
post-injection	 is	 present	 in	 the	 membrane	 in	 lower	 amounts	 than	 the	 wild-type	 protein,	
resulting	in	a	decrease	in	the	Vmax	of	the	transport	system.	This	lag	in	trafficking	recovers	to	a	
certain	 extent	 over	 time	 post-injection,	 but	 not	 fully.	 Additionally	 it	 appears	 that	 the	 total	
amount	of	M465K	protein	in	the	oocyte	is	reduced,	compared	to	the	wild-type	protein	(Figure	
5.15).	 This	 suggests	 rapid	 degradation	 of	 the	 mutant	 protein	 by	 early	 quality-control	
checkpoints	in	the	ER.	
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Figure	 5.15:	 Immunodetection	 of	 rBAT	 and	 M465K	 in	 oocyte	 membranes	 by	 western	
blot.Western	 blot	 of	 total	 membrane	 protein	 samples	 from	 oocytes	 injected	 with	 water	
(control),	 rBAT	 or	 M465K	 cRNA	 (1-50ng),	 1-6	 days	 post-injection.	 Lanes	 represent	 samples	
taken	 from	oocytes	 injected	with:	a,	water;	b,	 rBAT	cRNA	 (1ng);	 c,	 rBAT	cRNA	 (5ng);	d,	 rBAT	
cRNA	 (50ng);	 e,	 M465K	 cRNA	 (1ng);	 f,	 M465K	 cRNA	 (5ng);	 g,	 M465K	 cRNA	 (50ng).	 Where	
doublet	bands	are	most	clearly	visible	they	are	indicated	by	*.	
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Figure	 5.16:	 Immunocytochemical	 detection	 of	 wild-type	 rBAT	 and	 novel	 mutant	 protein,	
M465K,	 in	 oocytes.	 Representative	 confocal	microscopy	 images	 (n=10-12)	 of	whole	 oocytes	
injected	with	water	(A),	or	50ng	cRNA	for	rBAT	(B)	or	M465K	(C)	3	days	post-injection;	or	rBAT	
(E)	or	M465K	(F)	cRNA	(50ng)	6	days	post-injection.	Scale	bar,	150µm;	a	white	arrow	indicates	
the	location	of	the	plasma	membrane	in	water-injected	oocytes;	F,	Representative	microscopy	
images	 (n=5)	 of	 sectioned	 oocytes	 (15μm)	 3	 days	 post-injection	 of	 water	 (left-hand	 panel),	
rBAT	(middle	panel),	or	M465K	(right-hand	panel)	cRNA	(50ng).	Scale	bar,	150μm.	 	
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5.3.4	Function	and	expression	of	the	novel	rBAT	mutant	N254T	
The	 novel	 pathogenic	 variant,	 N254T,	 was	 identified	 as	 a	 heterozygous	mutation	 in	
Patient	2	of	the	cohort	(see	Chapter	3).	This	previously	unreported	mutation	is	predicted	to	be	
located	 in	 loop-rich	 domain	 B	 of	 the	 rBAT	 extracellular	 domain	 (Figure	 5.1).	 The	 functional	
effect	 of	 N254T	 on	 rBAT	 was	 determined	 by	 [3H]arginine	 uptake	 in	 oocytes	 1-6	 days	 post-
injection	of	wild-type	rBAT	or	N254T	cRNA	(Figures	5.17-5.18).	[3H]Arginine	uptake	via	oocytes	
expressing	N254T	was	not	significantly	different	(p>0.05)	to	uptake	levels	in	equivalent	oocytes	
expressing	wild-type	protein	 on	 any	 day	 post-injection	 (Figure	 5.17).	 In	 the	 oocytes	 injected	
with	lower	amounts	of	cRNA	(1-5ng)	[3H]arginine	uptake	continued	to	increase	from	day	1-6	in	
both	 the	 wild-type	 and	mutant	 induced	 transport	 systems	 (Figure	 5.17A	 and	 B).	 In	 oocytes	
injected	with	50ng	wild-type	or	mutant	cRNA,	expressing	higher	levels	of	protein,	[3H]arginine	
uptake	reached	maximum	levels	by	day	2	(Figure	5.18).		
	 To	 identify	 any	 change	 in	 the	 kinetic	 parameters	 of	 System	 b0,+	transport	 by	 N254T,	
concentration-dependent	 (0.01-1mM)	 [3H]arginine	 uptake	 was	 performed,	 3	 days	 post-
injection	 of	 oocytes	 (Figure	 5.19).	 Following	 subtraction	 of	 water-injected	 control	 oocyte	
values,	 the	 data	 were	 plotted	 using	 the	Michaelis-Menten	 equation	 (Figure	 5.19A).	 The	 Km	
values	for	wild-type	rBAT	and	N254T-induced	[3H]arginine	transport	in	oocytes	were	calculated	
as	 96±17μM	and	 70±2μM,	 respectively	 (p=0.4).	 The	 capacity	 (Vmax)	 of	 the	 induced	 transport	
system	in	wild-type	rBAT-expressing	oocytes	was	310±17	pmol.oocyte-1.(60min)-1,	compared	to	
159±14pmol.oocyte-1.(60min)-1	in	those	expressing	N254T	(Figure	5.19B).	This	indicates	a	49%	
reduction	in	Vmax	caused	by	N254T	in	these	two	experiments	(p<0.001).	These	data	were	then	
transformed	 to	 the	Eadie-Hofstee	equation	 (Figure	5.19B).	The	 r2	value	of	 the	data	 following	
transformation	 to	 the	 linear	 equation	were	 0.91,	 indicating	 one-site	 binding	 kinetics	 (Figure	
5.19B).	 Although	 no	 reduction	 in	 [3H]arginine	 transport	was	 detected	 in	 the	 series	 of	 10μM	
uptake	experiments	presented	in	Figure	5.17,	the	significant	reduction	in	Vmax	measured	in	the	
concentration-dependent	uptakes	(Figure	5.19)	suggests	that	N254T	is	a	pathogenic	mutation.	
Additionally,	 the	evidence	that	 it	was	the	only	variant	discovered	 in	the	genotype	analysis	of	
Patient	2	of	our	cohort	(see	Chapter	3)	indicates	that	it	is	responsible,	at	least	in	part,	for	the	
phenotype	 of	 this	 patient.	 Saadi	 et	 al.	 (1998)	 reported	 no	 significant	 (p>0.05)	 reduction	 in	
uptake	of	[14C]cystine	in	oocytes	following	expression	of	rBAT	containing	the	SLC3A1	mutation	
S217R,	 24h	 post-injection	 of	 cRNA.	 However,	 when	 the	 experiment	 was	 repeated	 6h	 post-
injection	a	>50%	reduction	 in	 transport	was	observed	 (Saadi	et	al.,	1998).	This	 indicates	 that	
some	rBAT	mutants	show	a	shorter	delay	in	trafficking	than	others	when	expressed	in	oocytes.	
The	“milder”	effect	of	N254T	on	rBAT	function	than	other	mutations	is	also	evidenced	by	the	
fact	 that	 the	 reduction	 in	 Vmax	 (49%)	 is	 less	 than	 that	 observed	 in	 mutant	 proteins	 M467T	
(90%)	 and	 M465K	 (75%),	 both	 of	 which	 showed	 a	 significant	 (p<0.001)	 reduction	 in	 10μM	
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[3H]arginine	uptake	at	24h	post-injection	 (Figures	5.7	and	5.12,	 respectively).	To	confirm	this	
hypothesis,	 it	would	be	desirable	to	carry	out	uptake	experiments	in	N254T	6h	post-injection	
of	oocytes.	Additionally,	the	use	of	an	alternative	expression	system	such	as	a	mammalian	cell	
line	 could	 provide	 further	 insight	 into	 the	 effects	 of	 this	 mutation	 upon	 rBAT	 function.	
Unfortunately,	due	to	time	constraints	upon	this	investigation,	it	was	not	possible	to	carry	out	
these	experiments.		
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Figure	 5.17:	 [3H]Arginine	 uptake	 in	 oocytes	 following	 the	 expression	 of	 rBAT	 or	 the	 novel	
mutant,	N254T.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	injected	with	
water	 (controls),	 rBAT	 (1-50ng),	 or	 N254T	 (1-50ng)	 cRNA.	 A,	 [3H]Arginine	 uptake	 in	 water-
injected	(n=20),	rBAT-	(n=19-20),	or	N254T-injected	oocytes	(n=19-20),	1	day	post-injection;	B,	
[3H]Arginine	 uptake	 in	 water-injected	 (n=19),	 rBAT-	 (n=18-20),	 or	 N254T-injected	 oocytes	
(n=19-20),	2	days	post-injection;	C,	[3H]Arginine		uptake	in	water-injected	(n=18),	rBAT-	(n=18-
20),	 or	 N254T-injected	 oocytes	 (n=18-20),	 3	 days	 post-injection;	 D,	 [3H]Arginine	 	 uptake	 in	
water-injected	 (n=18),	 rBAT-	 (n=11-20),	 or	 N254T-injected	 oocytes	 (n=16-18),	 6	 days	 post-
injection.	Data	are	expressed	as	mean±SEM.	ns,	p>0.05	vs.	wild-type	rBAT-expressing	oocytes	
injected	with	the	same	amount	of	cRNA.		
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Figure	5.18:	Transporter-specific	[3H]arginine	uptake	induced	by	wild-type	rBAT	or	the	novel	
cystinuria	mutant,	N254T.	Data	(as	in	Figure	5.17)	are	shown	with	the	water-injected	control	
values	 subtracted.	 [3H]Arginine	 uptake	 (10μM,	 pH	7.4,	Na+-free,	 60min)	 via	oocytes	 injected	
with	rBAT	or	N254T	cRNA	(1-50ng).	A,	[3H]Arginine	uptake	in	oocytes	injected	with	rBAT	(black,	
n=19-20),	or	N254T	(red,	n=16-20)	cRNA	(1ng),	1-6	days	post-injection;	B,	[3H]Arginine	uptake	
in	oocytes	 injected	with	rBAT	(black,	n=16-20),	or	N254T	(red,	n=19-21)	cRNA	(5ng),	1-6	days	
post-injection;	C,	[3H]Arginine	uptake	in	oocytes	injected	with	rBAT	(black,	n=18-20),	or	N254T	
(red,	n=13-19)	cRNA	(50ng),	1-6	days	post-injection.	Data	are	expressed	as	mean±SEM.	
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Figure	 5.19:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 N254T-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-5mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	 injected	 with	 rBAT	 (black)	 or	 N254T	 (red)	 cRNA	 (50ng),	 3	 days	 post-injection	 of	
oocytes.	Data	are	mean±SEM	 (n=18-20,	 from	2	 separate	experiments).	A,	Data	 for	 rBAT	and	
N254T-mediated	uptakes	were	fitted	to	Michaelis-Menten	one-site	binding	kinetics	 following	
subtraction	of	water-injected	control	values	(r2=0.73	and	0.60,	respectively);	B,	Data	shown	in	
panel	A	were	transformed	to	the	linear	Eadie-Hofstee	equation	(r2=0.91).		
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	 Western	 blot	 analysis	 of	 total	 oocyte	 membrane	 proteins	 was	 carried	 out	 1-6	 days	
post-injection	of	wild-type	rBAT	or	N254T	cRNA	(Figure	5.20).	Doublet	bands	between	85	and	
90kDa	were	visible	1	day	post-injection	in	lanes	representing	oocytes	injected	with	both	rBAT	
and	 N254T	 cRNA	 (Figure	 5.20,	 Day	 1,	 lanes	 b-g).	 The	 bands	 representing	 N254T-injected	
oocytes	appeared	slightly	smaller	in	intensity	than	those	from	comparable	wild-type	samples,	
yet	 closer	 in	 intensity	 to	 the	 wild-type	 bands	 than	 was	 observed	 with	mutants	M467T	 and	
M465K	 (Figures	 5.10	 and	5.15,	 respectively).	 The	 lower	 intensity	 is	 particularly	 noticeable	 in	
oocytes	 injected	with	50ng	 cRNA.	However,	 the	 small	 size	of	 the	band	 in	 lane	 g	on	day	6	 is	
likely	a	blotting	error,	due	to	the	proximity	to	the	end	of	the	membrane.	Unfortunately,	due	to	
time	 constraints	 this	 is	 the	only	 available	blot	 for	N254T.	However,	 the	oocytes	used	 in	 this	
western	blot	were	from	the	same	batch	as	those	used	for	one	of	the	two	uptakes	presented	in	
Figure	5.17.	This	 indicates	 that,	despite	a	 lack	of	measured	difference	 in	 function	of	 the	 two	
proteins	(Figure	5.17),	there	is	less	N254T	protein	present	in	the	oocyte	compared	to	wild-type	
rBAT	(Figure	5.20).	This	could	be	due	to	the	mis-folded	mutant	being	degraded	at	a	more	rapid	
rate	than	the	native	protein,	or	a	slower	rate	of	translation.	These	data	support	the	results	of	
the	concentration-dependent	uptakes,	and	the	measured	49%	reduction	in	Vmax	(Figure	5.19).	
This	also	supports	the	hypothesis	that	some	“lag”	in	transport	via	N254T-expressing	oocytes	is	
a	possibility,	even	if	it	is	not	measurable	by	uptake	at	24h	post-injection.	Despite	this,	it	is	clear	
from	the	western	blot	that	both	the	mature	(90kDa	band)	and	core-	(85kDa	band)	glycosylated	
forms	 of	 the	 protein	 are	 detected	 in	wild-type	 and	N254T	 expressing	 oocytes	 (Figure	 5.20),	
indicating	processing	of	the	protein	by	the	Golgi	apparatus	(Bartoccioni	et	al.,	2008).		
	 The	 localisation	 of	 rBAT	 protein	 at	 the	 membrane	 of	 whole	 oocytes	 by	
immunofluorescent	detection	did	not	reveal	any	visible	difference	between	the	wild-type	and	
mutant	 protein	 (Figure	 5.21B-E).	 No	 fluorescence	 was	 visible	 at	 the	 plasma	 membrane	 of	
water-injected	control	oocytes	(Figure	5.21A).	A	strong	signal	was	present	in	oocytes	injected	
with	wild-type	rBAT	cRNA	3	and	6	days	post-injection	(Figure	5.21B	and	D,	respectively).	The	
fluorescence	appeared	slightly	more	diffuse	in	N254T-expressing	oocytes	than	that	of	the	wild-
type	3	days	post-injection	(Figure	5.21C).	However,	by	day	6,	no	difference	in	fluorescence	was	
visible	 in	 the	 N254T-expressing	 oocytes	 (Figure	 5.21E)	 than	 the	 wild-type	 controls	 (Figure	
5.21D).		
	 Immunocytochemical	 detection	 of	 these	 proteins	 was	 also	 carried	 out	 in	 oocyte	
sections,	 3	 days	 post-injection	 (Figure	 5.21F).	 Strong	 signals	 representative	 of	 plasma	
membrane	 protein	 were	 detected	 in	 oocytes	 expressing	 wild-type	 rBAT	 and	 N254T	 (Figure	
5.21F,	 middle	 panel	 and	 right-hand	 panel,	 respectively).	 However,	 the	 fluorescence	 in	 the	
oocytes	 expressing	mutant	 protein	 was	 lower	 at	 the	membrane,	 with	 a	 higher	 intracellular	
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signal	than	the	wild-type	(Figure	5.21F,	right-hand	panel).	These	data	suggest	that	perhaps	not	
all	N254T	protein	is	trafficked	to	the	membrane	by	day	3.	
	 The	N254T	mutant	protein	has	been	shown	to	function	in	a	broadly	similar	manner	to	
the	 wild-type	 protein,	 although	 with	 a	 reduced	 Vmax	 (Figure	 5.17-19).	 Less	 protein	 was	
detected	by	western	blot.	This	novel	mutation	was	 identified	 in	 the	genotype	of	a	cystinuric	
patient,	with	no	other	causal	variants	(Chapter	3).	To	date,	only	mutations	present	in	the	TIM	
barrel	 region	 of	 rBAT,	 along	 with	 one	 transmembrane	 domain	 mutation	 (L89P)	 have	 been	
characterised	 (Bartoccioni	 et	 al.,	 2010).	 The	 milder	 effect	 of	 this	 mutation	 on	 membrane	
localisation,	could	be	related	to	 its	putative	 location	 in	domain	B	of	rBAT	(Figure	5.1).	This	 is	
discussed	in	section	5.4.	We	hypothesise	that	this	mutation	has	a	milder	effect	upon	the	rBAT	
protein	than	some	other	mutations,	as	observed	by	Saadi	et	al.	(1998)	when	measuring	S217R	
expression	in	oocytes.		
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Figure	5.21:	Immunocytochemical	detection	of	rBAT	and	N254T	in	the	plasma	membranes	of	
oocytes.	A-E,	representative	confocal	microscopy	images	(n=6)	of	whole	oocytes	injected	with	
water	(A),	or	50ng	cRNA	for	rBAT	(B)	or	N254T	(C)	3	days	post-injection;	or	rBAT	(D)	or	N254T	
(E)	cRNA	(50ng)	6	days	post-injection.	Scale	bar,	150µm;	F,	Representative	microscopy	images	
(n=3)	of	sectioned	oocytes	(15μm)	injected	with	water	(left-hand	panel),	rBAT	(middle	panel),	
or	N254T	(right-hand	panel)	cRNA	(50ng).	Scale	bar,	150μm.	
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5.3.5	Function	and	expression	of	the	novel	rBAT	mutation,	L416P	
	 The	 novel	 cystinuria	mutation,	 L416P,	was	 identified	 in	 the	 compound	heterozygous	
genotype	of	Patient	26	of	our	cohort,	along	with	known	cystinuria	mutation	M467T	(Chapter	
3).	Based	on	the	predicted	structure	of	 the	rBAT	extracellular	domain,	 the	 leucine	residue	at	
position	416	putatively	sits	on	the	6th	α-helix	of	 the	TIM	barrel	structure	 (domain	A2)	 (Figure	
5.1).		
	 The	effect	of	the	L416P	mutation	on	the	expression	of	rBAT	was	measured	in	Xenopus	
oocytes.	[3H]Arginine	uptake	was	performed	in	oocytes	following	injection	of	water,	wild-type	
rBAT	or	L416P	cRNA	(1-50ng)	(Figure	5.22-5.23).	[3H]Arginine	uptake	via	oocytes	injected	with	
L416P	cRNA	was	not	significantly	different	(p>0.05)	to	that	in	oocytes	injected	with	wild-type	
rBAT	 cRNA	 at	 any	 time	 post-injection	 (Figure	 5.22).	 Following	 subtraction	 of	 background	
uptake	measurements,	 [3H]arginine	uptake	 levels	 rose	 from	10±2	pmol.oocyte-1.(60min)-1	 on	
day	1	to		32±5	pmol.oocyte-1.(60min)-1	by	day	6	in	oocytes	injected	with	50ng	wild-type	cRNA	
(Figure	 5.23C).	 Similarly,	 oocytes	 injected	 with	 50ng	 L416P	 cRNA	 showed	 uptake	 of	 4±1	
pmol.oocyte-1.(60min)-1	on	day	1	and	28±6	pmol.oocyte-1.(60min)-1	on	day	6	(Figure	5.23C).	A	
broadly	similar	effect	was	observed	in	oocytes	expressing	1-5ng	cRNA	(Figure	5.23A-B).		
	 Concentration-dependent	(0.01-1mM)	[3H]arginine	uptake	was	performed	3	days	post-
injection	 of	 oocytes	 with	 water,	 or	 wild-type	 rBAT	 or	 L416P	 cRNA	 (Figure	 5.24).	 Data	 were	
plotted	 to	 one-site	 binding	 Michaelis	 Menten	 kinetics	 following	 the	 subtraction	 of	 water-
injected	control	values	(Figure	5.24A).	The	Km	of	the	induced	wild-type	(96±17μM)	and	L416P	
(53±23μM)	 transport	 systems	 were	 not	 significantly	 different	 (p=0.17),	 despite	 a	 1.8-fold	
change.	However,	a	large	reduction	(64%)	in	Vmax	was	observed	(p<0.001).	The	fit	of	the	L416P	
data	 to	 the	 curve	 was	 poor	 (r2=0.19)	 (Figure	 5.24A).	 This	 was	 also	 observed	 following	
transformation	of	the	data	to	the	Eadie-Hofstee	equation	(r2=0.60,	Figure	5.24B).	The	affinities	
(Km),	 calculated	 by	 the	 gradients	 of	 the	 slopes	 in	 Figure	 5.24B,	 were	 significantly	 different	
following	 the	 linear	 transformation	 of	 the	 data	 (p=0.01)	 (Figure	 5.24B).	 This	 is	 further	
supported	by	 the	 fact	 that	 in	 the	concentration-dependent	experiment,	 the	10μM	uptake	 in	
oocytes	expressing	L416P	was	97%	of	those	measured	in	wild-type	expressing	oocytes	(Figure	
5.24A).	 This	 is	 consistent	 with	 the	 results	 of	 the	 time-dependent	 expression	 studies	
represented	in	Figure	5.22C,	where	[3H]arginine	uptake	in	L416P-expressing	oocytes	was	95%	
of	that	via	the	wild-type	transport	system.	However,	 in	the	concentration-dependent	uptake,	
the	 function	 of	 L416P	was	 only	 63%	of	 the	wild-type	 transport	 system	 at	 1mM	 [3H]arginine	
(Figure	 5.24A).	 These	 data,	 in	 addition	 to	 the	 significant	 reduction	 in	 Vmax	 measured	 in	 the	
concentration-dependent	uptakes	(Figure	5.24)	suggests	that	L416P	is	a	pathogenic	mutation.	
However,	 from	 these	 functional	 studies	 the	 effect	 of	 the	mutation	 on	 the	 transport	 system	
remains	unclear.	Although	it	seemed	unlikely,	it	appears	as	though	the	mutation	has	affected	
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the	affinity	of	the	transport	system.	This	could	occur	due	to	an	alteration	in	the	interaction	of	
rBAT	 with	 b0,+AT.	 This	 effect	 of	 mutations	 in	 rBAT	 has	 not	 been	 reported	 previously	 in	 the	
literature.	As	discussed	in	Chapter	1,	it	was	observed	that	CD98	can	induce	System	b0,+	activity	
when	 co-expressed	 with	 b0,+AT	 in	 HRPE	 cells	 (Rajan	 et	 al.,	 2000).	 However,	 the	 induced	
transport	system	had	a	significantly	lower	(p<0.05)	affinity	for	the	prototypical	substrates	than	
when	 transport	 was	 induced	 by	 rBAT	 and	 b0,+AT	 co-expression	 (Rajan	 et	 al.,	 2000).	
Additionally,	 the	 measurements	 of	 transport	 affinity	 in	 oocytes	 have	 varied	 following	 the	
expression	 of	 rBAT	 protein	 from	 different	 species	 (see	 Chapter	 1).	 This	 implies	 that	 small	
changes	 to	 the	 tertiary	 structure	 of	 the	 heavy	 chain	 used	 to	 traffic	 b0,+AT	 to	 the	membrane	
could	potentially	 influence	the	substrate	specificity	of	the	transport	system.	In	our	study,	the	
poor	fit	of	the	data	to	the	two	equations	makes	 it	 impossible	to	draw	a	definitive	conclusion	
from	 our	 findings.	 It	 would	 be	 desirable	 to	 repeat	 this	 experiment	 to	 confirm	 the	 results.	
Unfortunately,	due	to	time	constraints,	we	were	unable	to	investigate	this	further.		
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Figure	 5.22:	 [3H]Arginine	 uptake	 in	 oocytes	 expressing	 wild-type	 rBAT	 or	 the	 novel	 rBAT	
mutant,	L416P.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	injected	with	
water	 (controls),	 rBAT,	 or	 L416P	 cRNA	 (1-50ng).	 A,	 [3H]Arginine	 uptake	 in	 water-injected	
(n=10),	 rBAT-	 (n=9-10),	 and	 L416P-expressing	 oocytes	 (n=6-10),	 1	 day	 post-injection;	 B,	
[3H]Arginine	 uptake	 in	 water-injected	 (n=10),	 rBAT-	 (n=6-10),	 and	 L416P-expressing	 oocytes	
(n=8-10),	 2	 days	 post-injection;	 C,	 [3H]Arginine	 uptake	 in	water-injected	 (n=9),	 rBAT-	 (n=10),	
and	L416P-expressing	oocytes	(n=7-9),	3	days	post-injection;	D,	[3H]Arginine	uptake	in	water-
injected	control	 (n=10),	 rBAT-	 (n=9-10),	 and	L416P-expressing	oocytes	 (n=6-10),	6	days	post-
injection.	Data	are	expressed	as	mean±SEM.	ns,	p>0.05	vs.	wild-type	oocytes	injected	with	the	
same	amount	of	cRNA.	
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Figure	5.23:	Transporter-specific	[3H]arginine	uptake	induced	by	wild-type	rBAT	or	the	novel	
cystinuria	mutant,	L416P.	Data	(as	 in	Figure	5.22)	are	shown	with	the	water-injected	control	
values	subtracted.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	via	oocytes	injected	with	rBAT	
or	L416P	cRNA	(1-50ng).	A,	[3H]Arginine	uptake	in	oocytes	injected	with	rBAT	(black,	n=6-10),	
or	L416P	(red,	n=6-10)	cRNA	(1ng),	1-6	days	post-injection;	B,	 [3H]Arginine	uptake	 in	oocytes	
injected	with	rBAT	(black,	n=9-10),	or	L416P	(red,	n=9-10)	cRNA	(5ng),	1-6	days	post-injection;	
C,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	 rBAT	 (black,	 n=9-10),	 or	 L416P	 (red,	 n=9-10)	
cRNA	(50ng),	1-6	days	post-injection.	Data	are	expressed	as	mean±SEM	and	are	from	a	single	
experiment.	This	experiment	was	repeated	on	a	second	occasion	up	to	2	days	post-injection	of	
oocytes	and	a	broadly	similar	effect	was	observed.	
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Figure	 5.24:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 L416P-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-5mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	3	days	post-injection	of	oocytes	with	 rBAT	 (black)	or	N254T	 (red)	cRNA	 (50ng).	Data	
are	mean±SEM	(n=18-20,	from	2	separate	experiments).	A,	Data	for	rBAT	and	N254T-mediated	
uptakes	 were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	
water-injected	 control	 values	 (r2=0.73	 and	 0.19,	 respectively);	 B,	 Data	 from	 panel	 A	 was	
transformed	to	the	Eadie-Hofstee	equation	(r2=0.91	and	0.60,	respectively).		
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Immunodetection	of	wild-type	rBAT	and	L416P	protein	by	western	blotting	was	carried	
out	 in	 total	 membrane	 proteins	 from	 oocytes	 1-6	 days	 post-injection	 (Figure	 5.25).	 A	 non-
specific	band	was	observed	at	75kDa	 in	water-injected	control	oocytes	and	all	cRNA-injected	
oocyte	samples,	 related	to	a	new	batch	of	 the	M2	anti-FLAG	antibody	 (Figure	5.25).	A	single	
rBAT	 band	 at	 85kDa	was	 detected	with	 increasing	 intensity	 in	 oocytes	 injected	with	 1-50ng	
wild-type	cRNA	on	day	1	 (Figure	5.25,	 lanes	b-d).	At	days	3	and	6,	a	doublet	 rBAT	band	was	
detected	 in	 the	 lanes	 representing	 the	 wild-type	 protein	 sample.	 This	 is	 indicative	 of	 the	
mature	protein,	processed	by	the	Golgi	apparatus	(Chillarón	et	al.,	1997).	The	second	band	of	
higher	molecular	weight	(90kDa)	was	not	present	in	the	oocytes	expressing	the	mutant	protein	
L416P	(Figure	5.25,	lanes	e-g).	This	is	most	apparent	in	the	protein	samples	taken	6	days	post-
injection.	 It	 appeared	 from	 the	band	 intensity	 that	 less	 total	 L416P	protein	was	produced	 in	
the	oocytes	than	those	expressing	the	wild-type	protein,	at	day	1	post-injection.	However,	by	
day	6,	 the	band	observed	 in	50ng	 L416P-injected	oocytes	 appears	 closer	 in	 size	 to	 the	50ng	
rBAT-injected	oocytes	(Figure	5.25,	day	6,	lanes	d	and	g,	respectively).		
	 Fluorescent	 confocal	 imaging	of	whole	oocytes	 expressing	both	proteins	was	 carried	
out	to	detect	plasma	membrane	 localisation	(Figure	5.26A-E).	Bright	membrane	fluorescence	
was	 visible	 in	 oocytes	 injected	 with	 rBAT	 and	 L416P	 cRNA,	 3	 days	 (Figure	 5.26B	 and	 C,	
respectively)	 and	 6	 days	 (Figure	 5.26D	 and	 E,	 respectively)	 post-injection.		
Immunocytochemical	 detection	 of	 wild-type	 rBAT	 and	 L416P	 protein	 was	 carried	 out	 on	
sectioned	 oocytes	 injected	with	water	 (control),	 or	 50ng	 rBAT	 or	 L416P	 cRNA,	 3	 days	 post-
injection	(Figure	5.26F).	In	water-injected	control	oocytes	there	was	a	low	level	of	non-specific	
intracellular	fluorescence.	However,	no	specific	membrane	signal	was	detected	(Figure	5.26F,	
left-hand	 panel).	 In	 oocytes	 expressing	 the	 wild-type	 rBAT	 protein,	 bright	 membrane	
fluorescence	 was	 visible,	 along	 with	 a	 greater	 intracellular	 staining	 (Figure	 5.26F,	 middle	
panel).	 Similarly,	 oocytes	 expressing	 L416P	 showed	 fluorescence	 at	 the	 plasma	 membrane	
(Figure	 5.26F,	 right-hand	panel).	However,	 this	 appeared	more	diffuse	 that	 that	 recorded	 in	
the	wild-type	 expressing	 oocytes	 (Figure	 5.26F).	 This	 potentially	 indicated	 that	 although	 the	
function	of	the	L416P	mutant	was	not	significantly	lower	than	the	wild-type	(Figure	5.22C	and	
5.23C),	less	of	the	protein	was	present	at	the	membrane.	
	 The	results	of	the	functional	studies	of	the	novel	mutant,	L416P,	have	been	variable.	
As	 expected,	 a	 significant	 (p<0.001)	 reduction	 in	 Vmax	 was	 observed	 in	 the	 concentration	
dependent	 experiments	 (Figure	 5.24).	However,	 a	 reduction	 in	 Km	was	 also	observed,	which	
was	significant	 (p<0.001)	 following	transformation	of	 the	data	to	the	Eadie-Hofstee	equation	
(Figure	5.24B).	Although	these	values	may	not	be	accurate	due	to	a	poor	fit	of	the	data	to	the	
equations,	 it	 can	 be	 observed	 from	 the	 concentration-dependent	 uptake	 that	 the	 value	 at	
10μM	 is	 not	 significantly	 different	 to	 the	 wild-type	 (p>0.05).	 However,	 with	 increasing	
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concentration,	 a	 reduction	 in	 uptake	 in	 L416P-expressing	 oocytes,	 relative	 to	 the	 wild-type	
controls	 can	 be	 observed	 (Figure	 5.24A).	 This	 is	 consistent	 with	 a	 change	 in	 affinity	 of	 the	
transport	system.	No	difference	 in	membrane	expression	between	L416P	and	wild-type	rBAT	
was	 observed	 with	 immunocytochemistry,	 consistent	 with	 the	 results	 displayed	 in	 Figures	
3.22-3.23.	However,	a	slight	reduction	in	total	protein	was	detected	by	western	blot.	Overall,	
the	 results	 suggest	 that	 this	 mutation	 has	 a	 mild	 effect	 upon	 the	 expression	 of	 rBAT,	 as	
observed	with	N254T.	
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Figure	5.26:	Immunocytochemical	detection	of	rBAT	and	L416P	at	the	plasma	membrane	of	
oocytes.	A-E,	Representative	confocal	microscopy	images	(n=6)	of	whole	oocytes	injected	with	
water	(A),	or	50ng	cRNA	for	rBAT	(B)	or	L416P	(C)	3	days	post-injection;	or	rBAT	or	L416P	cRNA	
(50ng)	 6	 days	 post-injection.	 	 Scale	 bar,	 150µm;	 white	 arrows	 indicate	 the	 location	 of	 the	
plasma	membrane	in	water-injected	oocytes;	F,	Representative	microscopy	images	(n=3-4)	of	
sectioned	 oocytes	 (15μm)	 3	 days	 post-injection	 of	 water	 (left-hand	 panel),	 rBAT	 (middle	
panel),	or	L416P	(right-hand	panel)	cRNA	(50ng).	Scale	bar,	150μm.	
B"
C
D"
E"
F"
A
Water& rBAT& L416P&
Water&
rBAT&
L416P&
rBAT&
L416P&
Day"3"
Day"6"
	 290	
5.3.6	Function	and	expression	of	the	novel	rBAT	mutation,	Y579D	
The	 final	 rBAT	 mutation	 investigated	 in	 this	 study	 was	 the	 novel	 mutation	 Y579D,	
identified	 in	 two	 unrelated	 patients	 (6	 and	 20)	 of	 the	 current	 cohort	 (see	 Chapter	 3).	 The	
tyrosine	 residue	 at	 position	 579	 in	 the	 molecule	 is	 predicted	 to	 be	 located	 in	 the	 β	 sheet	
structure	 of	 rBAT	 extracellular	 domain	 C,	 based	 on	 the	model	 of	 rBAT	 created	 using	 the	B.	
cereus	oligo-1,6-glucosidase	crystal	structure	(Figure	5.1).		
	[3H]Arginine	uptake	was	measured	in	oocytes	1-6	days	post	injection	of	water,	or	wild-
type	 rBAT,	 or	 Y579D	 cRNA	 (1-50ng)	 (Figures	 5.27-5.28).	 At	 day	 1	 post-injection,	 [3H]arginine	
uptake	was	observed	in	oocytes	expressing	the	wild-type	protein.	However,	no	uptake	above	
background	 was	 observed	 in	 oocytes	 injected	 with	 any	 amount	 of	 Y579D	 cRNA.	 Over	 time	
post-injection,	 the	 levels	 of	 [3H]arginine	 uptake	 increased	 in	 all	 cRNA	 injected-oocytes.	 As	
observed	 in	M467T	 and	M465K	 rBAT	mutants,	 a	 recovery	 of	 Y579D	 function	was	measured	
over	time	post-injection	(Figure	5.27).	Following	subtraction	of	water-injected	control	values,	
[3H]arginine	uptake	in	oocytes	injected	with	Y579D	cRNA	(50ng)	was	not	significantly	different	
(p>0.05)	 to	 that	 in	oocytes	 injected	with	wild-type	cRNA	at	day	6	 (Figure	5.28C).	A	complete	
recovery	 of	 function	 was	 observed.	 However,	 in	 oocytes	 injected	 with	 1-5ng	 Y579D	 cRNA,	
function	only	recovered	to	46%	of	wild-type	uptake	levels	(Figure	5.28A	and	B).	This	indicates	
that	an	over-expression	of	the	mutant	protein	led	to	the	observed	recovery.		
Concentration	dependent	(0.01-1mM)	[3H]arginine	uptake	was	performed	3	days	post-
injection	 of	 oocytes	 with	 water,	 wild-type	 rBAT,	 or	 Y579D	 cRNA.	 Following	 subtraction	 of	
water-injected	control	values,	the	data	were	plotted	using	the	Michaelis-Menten	equation	to	
determine	 the	 transport	 kinetics	 of	 the	 induced	 transport	 system	 (Figure	 5.29A).	 The	 Km	 of	
arginine	 transport	 in	 wild-type	 rBAT-injected	 oocytes	 was	 92±15μM,	 and	 in	 Y579D-injected	
oocytes,	 53±30μM.	 These	 values	were	 not	 significantly	 different	 (p=0.25),	 despite	 a	 1.7-fold	
change.	 The	 calculated	 Vmax	 values	 for	wild-type	 and	 Y579D-induced	 transport	were	 300±17	
and	 16±3	 pmol.oocyte-1.(60min)-1,	 respectively.	 This	 19-fold	 reduction	 (p<0.001)	 in	 Vmax	 is	
associated	 with	 a	 lower	 amount	 of	 transport	 protein	 at	 the	 oocyte	 membrane.	 The	 mean	
10μM	 [3H]arginine	 uptake	 calculated	 in	 the	 Y579D	 concentration-dependent	 experiments	
(Figure	 5.29A)	 was	 10%	 of	 that	 measured	 in	 wild-type	 expressing	 oocytes	 (Figure	 5.29B).	
However,	in	two	previous	batches	of	oocytes,	the	mean	Y579D	function	was	53%	of	the	wild-
type	 at	 day	 3	 post-injection	 (Figure	 5.27C).	 This	 is	 reflective	 of	 poorer	 oocyte	 quality	 in	 the	
batches	used	to	perform	the	concentration-dependent	uptake	experiments	(Figure	5.29).	The	
lower	expression	levels	at	day	3	post-injection	in	Figure	5.29A,	provide	results	similar	to	those	
observed	 at	 day	 2	 in	 the	 experiments	 presented	 in	 Figure	 5.28C,	when	 Y579D	 function	was	
23%	of	the	wild-type.	This	provides	further	evidence	for	the	fluid	nature	of	rBAT	and	mutant	
expression	over	time,	and	an	increased	lag	in	the	expression	of	Y579D	when	the	oocytes	are	of	
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poorer	 quality.	 The	 levels	 of	 wild-type	 expression	 were	 also	 lower	 in	 Figure	 5.29A	 (22.6±3	
pmol.oocyte-1.(60min)-1)	than	the	mean	values	from	the	two	batches	used	in	the	experiments	
presented	in	Figure	5.28C	(40.3±9	pmol.oocyte-1.(60min)-1).	The	poor	expression	of	Y579D	at	3	
days	 post-injection	 of	 oocytes	 in	 Figure	 5.29A,	 led	 to	 a	 poor	 fit	 of	 the	 data	 to	 the	 curve	
(r2=0.12).	 Following	 transformation	 of	 the	 data	 to	 the	 Eadie-Hofstee	 equation,	 the	 data	
indicated	one-site	binding	kinetics	of	 [3H]arginine	 transport	 induced	by	both	proteins	 (Figure	
5.29B).	 Despite	 the	 52%	 reduction	 in	 the	 interpolated	 Km	 value	 from	 the	 Eadie-Hofstee	
equation,	 the	 gradients	 of	 the	 slopes	 were	 not	 significantly	 different	 (p=0.7),	 further	
demonstrating	a	lack	of	change	to	the	affinity	of	the	transport	system	by	novel	mutant	Y579D.	
Although	the	relative	function	of	Y579D-induced	transport	compared	to	the	wild-type	is	lower	
in	 Figure	 5.29	 than	 that	 demonstrated	 at	 day	 3	 in	 Figure	 5.27C,	 we	 hypothesise	 that	 the	
function	would	still	have	recovered	over	time.	We	have	observed	a	fluidity	of	rBAT	and	mutant	
protein	expression	in	oocytes	over	time.	The	data	presented	in	Figures	5.27	and	5.28	provide	a	
“snapshot”	 of	 this	 process	 at	 different	 time	 points.	 In	 Figure	 5.29,	 a	 “snapshot”	 is	 also	
presented,	 however,	 the	 poorer	 quality	 of	 these	 oocytes	 has	 led	 to	 a	 greater	 delay	 in	 the	
expression	 of	 the	 mutant	 protein.	 Amongst	 all	 experiments	 we	 have	 shown	 that	 Y579D	
function	 is	 consistently	 lower	 than	 that	 of	 the	wild-type	 protein	 at	 3	 days	 post-injection	 of	
50ng	cRNA.		
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Figure	 5.27:	 [3H]Arginine	 uptake	 in	 oocytes	 expressing	 wild-type	 rBAT	 or	 the	 novel	 rBAT	
mutant,	Y579D.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	injected	with	
water	(control),	rBAT	or	Y579D	cRNA	(1-50ng).	A,	[3H]Arginine	uptake	in	water-injected	(n=18),	
rBAT-	(n=19-20),	and	Y579D	cRNA-injected	oocytes	(n=20),	1	day	post-injection;	B,	[3H]Arginine	
uptake	in	water-injected	(n=20),	rBAT-	(n=19-20),	and	Y579D	cRNA-injected	oocytes	(n=20),	2	
days	 post-injection;	 C,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=19),	 rBAT-	 (n=19-20),	 and	
Y579D	cRNA-injected	oocytes	(n=18-20),	3	days	post-injection;	D,	[3H]Arginine	uptake	in	water-
injected	 (n=19),	 rBAT	 (n=19-20),	 and	 Y579D	 cRNA-injected	 oocytes	 (n=12-20),	 6	 days	 post-
injection.	 Data	 are	 expressed	 as	mean±SEM.	 **,	 p<0.001;	 *,	 p<0.01;	 ns,	 p>0.05	 vs.	 oocytes	
injected	with	the	same	amount	of	wild-type	rBAT	cRNA.	
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Figure	5.28:	Transporter-specific	[3H]arginine	uptake	induced	by	wild-type	rBAT	or	the	novel	
cystinuria	mutant,	Y579D.	Data	(as	in	Figure	5.22)	are	shown	with	the	water-injected	control	
values	 subtracted.	 A,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	 rBAT	 (black,	 n=19-20),	 or	
Y579D	 (red,	 n=12-20)	 cRNA	 (1ng),	 1-6	 days	 post-injection;	 B,	 [3H]Arginine	 uptake	 in	 oocytes	
injected	 with	 rBAT	 (black,	 n=19-20),	 or	 Y579D	 (red,	 n=18-20)	 cRNA	 (5ng),	 1-6	 days	 post-
injection;	C,	[3H]Arginine	uptake	in	oocytes	injected	with	rBAT	(black,	n=19-20),	or	Y579D	(red,	
n=19-20)	cRNA	(50ng),	1-6	days	post-injection.	Data	are	expressed	as	mean±SEM.	 	
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Figure	 5.29:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 Y579D-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-1mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	 at	 day	 3	 post-injection	 of	 rBAT	 (black)	 or	 Y579D	 (red)	 cRNA	 (50ng).	 Data	 are	
mean±SEM	 (n=19-20,	 from	 2	 separate	 experiments).	 A,	 Data	 for	 rBAT	 and	 Y579D-mediated	
uptakes	 were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	
water-injected	 control	 values	 (r2=0.68	 and	 0.12,	 respectively);	 B,	 Data	 from	 panel	 A	 were	
transformed	to	the	linear	Eadie-Hofstee	equation	(r2=0.88	and	0.73,	respectively).		
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Western	blot	detection	of	rBAT	and	Y579D	was	carried	out	in	samples	of	total	oocyte	
membranes	1-6	days	post-injection.	Two	western	blots	are	displayed	in	Figure	5.30.	In	the	blot	
displayed	in	Figure	5.30A,	no	clear	bands	were	visible	on	the	blot	after	day	1.	This	was	due	to	
incomplete	antibody	application.	Bands	specific	to	rBAT	protein	were	produced	in	mutant	and	
wild-type	 expressing	 oocytes,	 indicating	 a	 translation	 of	 mutant	 protein	 despite	 the	 lack	 of	
function	 at	 1	 day	 post-injection	 (Figure	 5.30A).	 Doublet	 bands	 were	 detected	 in	 lanes	
representing	 both	wild-type	 and	mutant	 samples,	 indicating	 the	 presence	 of	 both	 the	 core-	
and	mature-glycosylated	forms	of	rBAT.	It	can	be	noted	from	this	western	blot	image	that	the	
mature-glycosylated	 band	 (90kDa)	 in	 the	 wild-type	 samples	 is	 greater	 than	 the	 core-
glycosylated	band	 (85kDa).	However,	 in	 the	 lanes	 representing	Y579D-injected	oocytes,	both	
bands	are	of	an	equivalent	size.	A	broadly	similar	result	was	detected	by	Pineda	et	al.	(2004),	
following	R365W	expression	in	oocytes.	This	indicates	that	a	greater	amount	of	the	wild-type	
protein	has	been	processed	by	the	Golgi	apparatus	to	acquire	mature	N-linked	glycosylation,	
relative	 to	 the	mutant	 protein.	 In	 the	 bands	 representing	 oocytes	 injected	with	 5	 and	 50ng	
cRNA,	 the	mutant	 protein	 appeared	 to	 be	 produced	 in	 lower	 quantities	 than	 the	 wild-type	
(Figure	 5.30A	 lands	 c-d	 and	 f-g).	 A	 second	western	 blot	was	 carried	 out	 using	 protein	 from	
oocytes	 1-6	 days	 post-injection	 (Figure	 5.30B).	 As	 observed	 in	 the	 western	 blot	 of	 L416P	
protein	 (Figure	5.25)	 a	 non-specific	 band	was	detected	 at	 75	 kDa,	 associated	with	 the	 same	
batch	 of	 antibody.	 This	 band	was	 present	 in	 the	water-injected	 oocyte	 protein	 lane	 (Figure	
5.30B,	 lane	a).	 The	 lanes	 in	 this	 blot	were	 loaded	 in	 the	 reverse	order	 to	 the	previous	blots	
displayed	in	this	chapter,	and	the	bands	are	unclear,	making	it	difficult	to	detect	the	presence	
of	the	doublet	bands.	However,	from	this	blot	it	can	be	seen	that	less	total	Y579D	protein	was	
present	in	the	oocytes	than	in	equivalent	oocytes	injected	with	wild-type	cRNA.	This	effect	has	
not	been	previously	reported	in	the	literature.	However,	it	could	indicate	a	more	rapid	rate	of	
degradation	of	the	mutant	protein	in	the	oocyte	than	occurs	with	the	wild	type,	putatively	due	
to	ER-associated	degradation.	
Whole	 oocyte	 immunocytochemistry	 was	 carried	 out	 to	 support	 the	 data	 from	 the	
functional	 studies.	 At	 day	 3	 post-injection,	 membrane	 fluorescence	 in	 Y579D-expressing	
oocytes	 (Figure	 5.31C)	 was	 greater	 than	 water-injected	 controls	 (Figure	 5.31A),	 but	 visibly	
lower	than	wild-type	rBAT-expressing	oocytes	(Figure	5.31B).	However,	by	day	6,	the	detected	
membrane	 fluorescence	 of	 Y579D-expressing	 oocytes	 (Figure	 5.31E)	 appeared	 brighter.	 The	
apparent	 increase	 over	 time	 in	 the	 amount	 of	 mutant	 protein	 relative	 to	 the	 wild-type	
supports	 the	 observed	 recovery	 of	 Y579D	 function	 in	 the	 time-dependent	 uptake	 studies	
(Figure	5.27C	and	5.28C).	This	further	supports	the	hypothesis	that	the	particularly	low	levels	
of	uptake	observed	via	Y579D	in	Figure	5.29	were	due	to	oocytes	of	low	quality.		
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Immunocytochemical	detection	of	rBAT	was	performed	on	sections	of	oocytes	injected	
with	water,	 rBAT	 or	 Y579D	 cRNA	 (Figure	 5.31F).	 In	 oocytes	 injected	with	wild-type	 cRNA,	 a	
strong	 signal	 was	 detected	 at	 the	 plasma	 membrane,	 along	 with	 some	 intracellular	
fluorescence	(Figure	5.31F,	middle	panel).	This	intracellular	fluorescence	was	greater	than	the	
background	signal	visible	in	the	water-injected	control	oocytes	(Figure	5.31F,	left-hand	panel).	
No	 membrane	 fluorescence	 was	 visible	 in	 Y579D-expressing	 oocyte	 sections	 (Figure	 5.25G,	
right-hand	 panel),	 yet	 the	 intracellular	 fluorescence	 was	 visibly	 brighter	 than	 in	 the	 water-
injected	 controls.	 It	 is	 possible	 that	 fluorescence	was	 detected	 at	 the	membrane	 as	well	 as	
intracellularly,	 however	 in	 the	 absence	 of	 a	membrane-specific	 fluorescent	marker	 it	 is	 not	
possible	to	determine	this	from	these	images	alone.		
In	 conclusion,	 the	 data	 presented	 in	 this	 section	 indicate	 that	 Y579D	 protein	 is	
translated	 following	 injection	 into	 oocytes,	 and	 is	 present	 in	 the	 oocyte	 24h	 post-injection	
(Figure	 5.30),	 despite	 a	 lack	 of	 function	 (Figure	 5.27-5-28).	 Over	 time,	 the	 function	 of	 the	
protein	 was	 seen	 to	 recover	 (Figure	 5.28).	 This	 functional	 data	 was	 supported	 by	
immunocytochemical	detection	of	Y579D,	which	 indicated	that	 the	amount	of	protein	at	 the	
membrane	 increased	 over	 time	 (Figure	 5.31).	 The	 results	 of	 the	 concentration-dependent	
uptake	are	consistent	with	a	mutation	that	leads	to	a	trafficking	defect,	and	lack	of	protein	at	
the	membrane	 (Figure	5.29).	Although	some	decrease	 in	 the	affinity	of	 the	 transport	system	
was	 observed,	 the	 standard	 error	 values	 were	 large	 and	 the	 decrease	 was	 not	 significant	
(p>0.05).	The	observed	decrease	is	 likely	due	to	a	poor	fit	of	the	data	to	the	equation	due	to	
the	low	levels	of	uptake.	Despite	inconsistencies	with	the	levels	of	Y579D	expression	compared	
to	 the	wild-type	protein	between	experiments,	we	have	 shown	 that	 the	expression	of	 these	
proteins	 is	 a	 fluid	 process.	 Differences	 in	 oocyte	 quality	 can	 alter	 the	 relative	 rates	 of	
expression	of	the	two	proteins.	However,	we	have	shown	that	at	3	days	post-injection	of	50ng	
cRNA,	the	function	of	Y579D	is	consistently	lower	than	the	wild	type	through	functional	assays	
(Figures	5.27-5.29)	and	immunocytochemical	detection	(Figure	5.31).	
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Figure	 5.30:	 Immunodetection	 of	 wild-type	 rBAT	 and	 novel	 mutant	 protein,	 Y579D,	 by	
western	blot.	A,	Western	blot	of	total	membrane	protein	samples	from	oocytes	injected	with	
water	(control),	rBAT	or	Y579D	cRNA	(1-50ng),	1	day	post-injection.	Lanes	represent	samples	
taken	from	oocytes	injected	with:	a,	water	(control);	b,	rBAT	cRNA	(1ng);	c,	rBAT	cRNA	(5ng);	d,	
rBAT	 cRNA	 (50ng);	 e,	 Y579D	 cRNA	 (1ng);	 f,	 Y579D	 cRNA	 (5ng);	 g,	 Y579D	 cRNA	 (50ng).	 B,	
Western	blot	of	total	membrane	protein	samples	from	oocytes	 injected	with	water	(control),	
rBAT	or	Y579D	cRNA	(1-50ng),	1-6	days	post-injection.	Lanes	represent	samples	taken	from	a	
separate	batch	of	oocytes	to	those	displayed	in	panel	(A).	The	lanes	were	loaded	in	a	different	
order	 than	 the	other	examples	 in	 this	Chapter,	however	 they	are	 labelled	as	 in	panel	 (A)	 for	
consistency.		
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Figure	5.31:	Immunocytochemical	detection	of	rBAT	and	Y579D	in	the	plasma	membranes	of	
oocytes.	A-E,	Representative	confocal	microscopy	images	(n=6)	of	whole	oocytes	injected	with	
water	(A),	or	50ng	cRNA	for	rBAT	(B)	or	Y579D	(C)	3	days	post-injection;	or	rBAT	(D)	or	Y579D	
(E)	cRNA	(50ng)	6	days	post-injection.	Scale	bar,	150µm;	F,	Representative	microscopy	images	
(n=4)	 of	 sectioned	 oocytes	 (15μm)	 at	 day	 3	 post-injection	 of	 water	 (left-hand	 panel),	 rBAT	
(middle	panel),	or	Y579D	(right-hand	panel)	cRNA	(50ng).	Scale	bar,	150μm.	
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5.3.7	The	effect	of	genotype	on	the	phenotype	of	cystinuria	patients	
In	Chapter	3	of	this	study	we	reported	the	identification	of	four	novel	rBAT	mutations:	
M465K,	 N254T,	 L416P	 and	 Y579D.	 In	 this	 chapter,	 the	 effects	 of	 these	 mutations	 on	 the	
expression	of	 rBAT	have	been	measured	 in	Xenopus	oocytes.	Additionally,	 the	effects	of	 the	
common	 SNP	 M618I	 and	 the	 pathogenic	 mutation	 M467T	 upon	 rBAT	 expression	 were	
investigated.	 The	 time	and	 cRNA	concentration-dependent	expression	of	 System	b0,+	 protein	
and	function	following	injection	of	wild-type	rBAT	and	the	mutants	suggests	that	the	severity	
of	the	defect	is	likely	seen	in	the	following	order:	M465K	>	Y579D	=	M467T	>	N254T	=	L416P	>	
M618I	=	wild-type.	That	is,	with	M465K	causing	the	most	severe	defect	whereas	M618I	is	not	
distinguishable	 from	 wild-type.	 As	 expected,	 a	 reduction	 in	 Vmax	 occurs	 with	 most	 of	 the	
mutants	 although	 the	 absolute	 decrease	 in	 uptake	 is	 not	 easily	 comparable	 between	 the	
mutants	 as	 each	 mutant	 was	 compared	 with	 the	 control	 wild-type	 in	 distinct	 data	 sets.	
However,	 the	 time	 dependent	 expression	 gives	 a	 better	 indicator	 of	 the	mutation	 severity.	
Reduced	 activity	 was	 observed	 following	 injection	 with	 M465K,	 M467T	 and	 Y579D.	 A	 full	
recovery	was	observed	with	M467T	and	Y579D,	but	only	partial	recovery	with	M465K.	It	seems	
likely	 that	 a	 full	 recovery	would	 be	 observed	with	M465K	 if	 the	 incubation	 period	 could	 be	
extended	beyond	6	days.	 Similarly,	 it	 seems	equally	 likely	 that	 reduced	expression	would	be	
observed	with	N254T	and	 L416P	 if	 the	 incubation	period	was	 reduced	 to	 less	 than	one	day.	
Even	 a	 small	 time	 delay	 in	 expression	 would	 lead	 to	 a	 large	 decrease	 in	 transport	 capacity	
during	 the	 early	 days	 of	 incubation	 when	 the	 levels	 of	 protein	 expression	 in	 the	 oocyte	
membranes	are	yet	to	reach	equilibrium.	The	saturation	curves	support	this	idea.	Additionally,	
it	is	worth	noting	that	no	mutant	was	associated	with	an	increase	in	Vmax.	Thus,	it	seems	that	a	
time	 and	 cRNA-dependent	 over-expression	 is	 seen	with	 all	 of	 the	mutants	 to	 one	 extent	 or	
another.	This	is	possibly	the	best	indicator	of	the	severity	of	the	trafficking	defect.		
In	 a	 broad	 sense,	 the	 western	 blots	 and	 immunocytochemical	 data	 support	 these	
conclusions.	 The	 absolute	 levels	 of	 function	 are	 likely	 related	 to	 expression	 of	 the	 mature	
protein,	 thus	a	 second	 indicator	of	 the	 relative	severity	of	 the	mutants	could	be	 the	 ratio	of	
membrane	 expression	 of	 the	 two	 protein	 bands.	 We	 predict	 that	 a	 relatively	 high	 level	 of	
expression	 of	 the	 mature-glycosylated	 (90kDa)	 band	 would	 be	 observed	 in	 mild	 cases	 (as	
observed	with	N254T)	but	that	a	relatively	low	level	would	be	seen	in	more	severe	cases	(e.g.	
M465K).	 In	 several	 mutants,	 total	 protein	 levels	 were	 also	 reduced	 suggesting	 that	 the	
equilibrium	between	synthesis	and	degradation	was	slightly	turned	in	favour	of	the	latter.		
The	observations	that	were	not	particularly	consistent	with	all	of	the	above	were	the	
decreases	in	Km	observed	with	several	mutants.	The	decrease	in	Km,	and	associated	increase	in	
relative	affinity,	was	not	expected.	This	would	generally	 lead	to	an	 increase	 in	uptake	at	 low	
substrate	concentrations	as	opposed	to	the	dominant	decrease	in	Vmax	observed	in	each	of	the	
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five	(potential)	pathogenic	mutants.	Unfortunately,	in	several	of	those	saturation	experiments	
the	oocyte	quality	was	relatively	poor	and	the	absolute	levels	of	uptake	were	low	compared	to	
the	control	(water-injected)	oocytes.	These	low	levels	of	uptake	are	reflected	by	the	poor	data	
fits	and	the	low	r2	values	for	several	of	the	curves.	Thus	although	any	change	in	Km	would	be	of	
interest	it	seems	likely	that	in	these	mutants	the	observations	are	due	to	low	absolute	levels	of	
uptake.			 	
To	 extend	 these	 general	 observations	 some	 preliminary	 studies	 were	 performed	 to	
identify	 how	 these	 “Type	 A”	 (SLC3A1)	 mutations	 cause	 a	 phenotype	 in	 patients,	 but	 not	 in	
obligate	 heterozygote	 carriers,	 by	 co-expression	 of	wild-type	 and	mutant	 rBAT.	 [3H]Arginine	
uptake	was	measured	in	oocytes	injected	with	25-50ng	wild-type	cRNA,	3	days	post-injection	
of	oocytes	(Figure	5.32).	No	significant	difference	(p>0.05)	in	uptake	was	measured,	confirming	
our	 earlier	 findings	 that	 amounts	 of	 rBAT	 cRNA	 greater	 than	 10ng	 produce	maximal	 uptake	
levels	 in	 oocytes	 (Figure	 4.2).	 In	 oocytes	 injected	 with	 25-50ng	 M467T	 cRNA,	 [3H]arginine	
uptake	 was	 41%	 of	 that	 observed	 in	 oocytes	 expressing	 wild-type	 rBAT	 (p<0.001)	 (Figure	
5.32A).	This	is	consistent	with	the	results	displayed	in	Figure	5.7C,	where	M467T	function	was	
43%	of	the	wild-type,	3	days	post-injection	of	50ng	cRNA.	When	25ng	of	the	cRNAs	for	wild-
type	rBAT	and	M467T	were	co-injected,	[3H]arginine	uptake	levels	were	equivalent	to	those	in	
oocytes	injected	with	50ng	wild-type	cRNA	(Figure	6.1A).	This	indicates	that	in	the	presence	of	
a	wild-type	transporter,	expressed	at	levels	to	give	maximal	uptake,	the	expression	of	M467T	
is	not	sufficient	to	cause	a	reduction	in	transport.	
This	experiment	was	repeated	with	L416P	and	Y579D	(Figure	5.32B	and	C).	In	section	
5.3.4,	 it	 was	 reported	 that	 an	 effect	 on	 rBAT	 function	 by	 L416P	was	 not	 always	 detectable	
following	 expression	 in	 oocytes	 (Figures	 5.22-23).	 In	 Figure	 5.32B,	 no	 significant	 difference	
(p>0.05)	was	measured	in	oocytes	expressing	wild-type	rBAT,	L416P,	or	a	combination	of	both.	
However,	 the	 results	 from	 [3H]arginine	 uptake	 into	 Y579D-expressing	 oocytes	 were	 broadly	
similar	to	those	of	M467T	(Figure	5.32C).	[3H]Arginine	uptake	in	oocytes	injected	with	25-50ng	
Y579D	cRNA	was	significantly	lower	(p<0.001)	than	in	those	injected	with	50ng	cRNA	for	wild-
type	 rBAT	 (Figure	 5.32C).	 When	 Y579D	 cRNA	 (25ng)	 was	 co-injected	 with	 wild-type	 cRNA	
(25ng),	uptake	 levels	were	equivalent	 to	 those	 in	oocytes	 injected	with	50ng	wild-type	cRNA	
(Figure	 5.32C).	 These	 data	 indicate	 that	 one	mutated	 rBAT	 allele	would	 not	 be	 sufficient	 to	
cause	 a	 reduction	 in	 System	 b0,+	 activity	 in	 vivo.	 However,	 these	 experiments	 need	 to	 be	
repeated	at	lower	levels	of	cRNA,	where	an	effect	might	be	more	easily	observed.	
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	Figure	 5.32:	 System	 b0,+	 activity	 in	 oocytes	 co-expressing	 wild-type	 and	 mutant	 rBAT.	
[3H]Arginine	uptake	(10μM,	Na+-free,	pH7.4)	in	oocytes	injected	with	wild-type	rBAT	cRNA	(25-
50ng),	mutant	 cRNA	 (25-50ng)	 or	 a	 combination	 of	 both	 cRNAs	 (50ng	 total).	 A,	 [3H]Arginine	
uptake	 in	 oocytes	 injected	 with	 water	 (control,	 n=10),	 wild-type	 rBAT	 or	M467T	 cRNA	 (25-
50ng,	 n=10),	 or	 the	 cRNA	 for	 both	 constructs	 (25ng	 each,	 n=10);	 B,	 [3H]Arginine	 uptake	 in	
oocytes	injected	with	water	(control,	n=10),	wild-type	or	L416P	cRNA	(25-50ng,	n=10),	or	the	
cRNA	 for	both	 constructs	 (25ng	each,	 n=10);	 C,	 [3H]Arginine	uptake	 in	oocytes	 injected	with	
water	 (control,	 n=10),	 wild-type	 or	 Y579D	 cRNA	 (25-50ng,	 n=10),	 or	 the	 cRNA	 for	 both	
constructs	 (25ng	 each,	 n=10).	 Data	 are	mean±SEM.	 ***,	 p<0.001;	 ns,	 p>0.05	versus	oocytes	
injected	with	50ng	wild-type	rBAT	cRNA.	
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The	pathogenic	mutation	M467T	was	 identified	 in	9/84	alleles	 included	 in	 this	 study	
(Chapter	3).	 From	previous	 literature	 reports,	 this	mutation	 is	believed	 to	be	 recessive,	 thus	
conferring	no	phenotype	in	the	presence	of	one	wild-type	rBAT	allele	(Font-Llitjos	et	al.,	2005).	
Of	the	6	rBAT	mutants	produced	for	this	study,	M467T	was	identified	in	patient	genotypes	in	
combination	with	L416P	and	Y579D	(patients	26	and	20,	respectively).	[3H]Arginine	uptake	was	
measured	in	oocytes	that	had	been	co-injected	with	the	cRNAs	for	M467T	and	L416P	or	Y579D	
(Figure	 5.33).	 As	 indicated	 in	 Figure	 5.32,	 the	 co-injection	 of	M467T	 or	 Y579D	 cRNA	 (25ng)	
along	with	that	of	the	wild-type	protein	(25ng)	led	to	[3H]arginine	uptake	values	that	were	not	
significantly	different	 (p>0.05)	 to	 those	 in	oocytes	 injected	with	50ng	wild-type	cRNA	(Figure	
5.32A).	However,	co-injection	of	M467T	and	Y579D	led	to	a	significant	reduction	(p<0.001)	in	
uptake	of	 [3H]arginine	versus	wild-type	rBAT	(Figure	5.33A).	This	 indicates	that	both	of	 these	
mutations	are	pathogenic,	and	the	combination	of	the	two	in	the	genotype	of	a	patient	would	
cause	 a	 cystinuria	 phenotype.	 Unfortunately,	 we	 were	 unable	 to	 obtain	 any	 gDNA	 samples	
from	 relatives	 of	 Patient	 20	 (M467M/T	 and	 Y579Y/D).	 The	 novel	 mutation	 Y579D	 was	 also	
identified	 in	Patient	6	of	 the	 cohort,	 along	with	pathogenic	mutation	R452W	 (Figure	5.33B).	
The	sister	of	Patient	6	was	a	heterozygous	carrier	of	Y579D,	yet	had	no	cystinuria	phenotype.	
The	segregation	data	for	Patient	6	are	shown	here	to	complement	the	uptake	data,	indicating	
the	 recessive	 inheritance	 of	 Y579D	 (Figure	 5.33B).	 R452W	has	 also	 been	 proposed	 to	 be	 an	
autosomal	 recessive	 mutation	 (Font-Llitjos	 et	 al.,	 2005).	 Due	 to	 time	 limitations	 on	 these	
studies,	we	were	unable	to	produce	the	rBAT	mutant	R452W	to	investigate	the	co-expression	
of	R452W	and	Y579D,	reflective	of	the	genotype	of	Patient	6	(Figure	5.33B).	However,	together	
these	 data	 support	 the	 hypothesis	 that	 the	 novel	 mutation	 Y579D,	 and	 the	 known	 variant	
M467T,	are	a	pathogenic	missense	mutations,	with	recessive	modes	of	inheritance.	
	 [3H]Arginine	uptake	was	performed	in	oocytes	co-injected	with	the	cRNAs	for	M467T	
and	 L416P	 (Figure	 5.33C).	 This	 combination	of	mutations	was	 identified	 in	 Patient	 26	of	 the	
cohort	 (Figure	 5.33D).	 The	 expression	 of	 L416P	 in	 oocytes	 compared	 to	 wild-type	 rBAT	 has	
been	variable	in	the	experiments	presented	in	this	chapter	but	overall	appears	to	be	a	“mild”	
variant,	with	a	less	severe	effect	on	the	expression	of	rBAT,	than	some	others.	In	Figure	5.22,	
no	effect	of	L416P	on	rBAT	function	was	measured.	However,	a	significant	decrease	in	the	Vmax	
of	L416P-induced	transport	compared	to	wild-type	was	observed	in	two	separate	experiments	
(Figure	5.24).	 In	 this	 experiment,	uptake	of	 [3H]arginine	was	not	 significantly	 lower	 than	 the	
wild-type,	3	days	post-injection	of	50ng	cRNA	(Figure	5.33C).	Therefore,	the	co-injection	of	the	
cRNAs	for	L416P	and	M467T	led	to	uptake	levels	that	were	not	significantly	different	(p>0.05)	
from	those	measured	in	oocytes	expressing	the	wild-type	protein	(Figure	5.33C).		
	 These	data	 support	 the	hypothesis	 that	 co-expression	of	M467T	and	Y579D	mutants	
does	not	lead	to	successful	trafficking	of	System	b0,+	to	the	plasma	membrane.	This	provides	an	
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explanation	 for	 the	 cystinuria	 phenotype	 in	 Patient	 26	 of	 the	 cohort	 who	 had	 a	 compound	
heterozygous	genotype	for	these	two	mutations.	The	variability	in	a	reduction	of	[3H]arginine	
transport	 following	the	expression	of	L416P	creates	the	need	for	further	 investigation	of	this	
mutant	 protein.	 It	 would	 be	 desirable	 to	 repeat	 these	 experiments	 using	 lower	 amounts	 of	
cRNA,	 and	 at	 shorter	 time-points	 post-injection	 of	 cRNA.	 Additionally,	 an	 alternative	
expression	 system	 could	 be	 utilised	 to	 allow	 any	 changes	 to	 the	 protein	 expression	 to	 be	
measured.	One	such	example	would	be	the	mammalian	cell	line,	Caco-2.		
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Figure	 5.33:	 System	 b0,+	 activity	 in	 cystinuria	 patients	 with	 compound	 heterozygous	
genotypes.	 [3H]Arginine	uptake	(10μM,	Na+-free,	pH7.4)	in	oocytes	injected	with	water,	wild-
type	rBAT	cRNA	(25-50ng),	wild-type	rBAT	plus	mutant	cRNA	(50ng	total)	or	a	combination	of	
both	mutant	cRNAs	(50ng	total)	as	identified	in	patients	of	the	current	cohort.	A,	[3H]Arginine	
uptake	 in	 oocytes	 injected	with	water	 (control,	 n=10),	wild-type	 rBAT	 (25-50ng,	 n=10),	 rBAT	
plus	M467T	cRNA	(50ng	total,	n=10),	rBAT	plus	Y579D	(50ng	total,	n=10),	or	M467T	plus	Y579D	
cRNA	(50ng	total,	n=10);	B,	Pedigree	diagram	of	the	family	of	Patient	6	who	was	heterozygous	
for	 R452R/W	 and	 Y579Y/D;	 C,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	 (control,	
n=10),	wild-type	 rBAT	 (25-50ng,	n=10),	 rBAT	plus	M467T	 cRNA	 (50ng	 total,	 n=10),	 rBAT	plus	
Y579D	(50ng	total,	n=10),	or	M467T	plus	Y579D	cRNA	(50ng	total,	n=10);	D,	Pedigree	diagram	
of	 the	 family	 of	 Patient	 20,	 who	was	 heterozygous	 for	 L416L/P	 and	M467M/T;	 half-shaded	
symbols	represent	heterozygous	carriers.	Data	are	mean±SEM.	***,	p<0.001;	ns,	p>0.05	versus	
oocytes	 injected	with	 50ng	wild-type	 rBAT	 cRNA.	 The	 experiments	 were	 carried	 out	 3	 days	
post-injection.		
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5.4	Discussion	
Amino	 acid	 substitutions	 in	 a	 protein	 structure	 can	 arise	 when	missense	 mutations	
occur	 in	 the	 DNA	 sequence,	 altering	 the	 resultant	 codon.	 It	 has	 been	 identified	 that	 these	
amino	 acid	 substitutions	 in	 the	 nascent	 polypeptide	 chain	 can	 confer	 changes	 in	 protein	
stability,	 ligand	 binding,	 catalysis,	 allosteric	 regulation,	 and	 post-translational	 modifications	
(Wang	 &	 Moult,	 2001).	 The	 rBAT	 protein	 does	 not	 appear	 to	 have	 any	 enzymatic	 activity,	
despite	its	structural	homology	to	glucosidase	enzymes	(Wells	&	Hediger,	1992).	Additionally,	
it	 is	not	expected	 to	confer	 transport	 function	 to	System	b0,+.	Thus,	we	can	hypothesise	 that	
the	 most	 likely	 effects	 of	 SLC3A1	 missense	 mutations	 upon	 rBAT	 expression	 would	 be	 a	
decrease	 in	 protein	 stability,	 leading	 to	 early	 degradation	 in	 the	 endoplasmic	 reticulum.	
Indeed,	 this	 hypothesis	 appears	 to	 be	well-supported	by	 the	 evidence	of	 rapid	 ER-mediated	
degradation	and	lack	of	post-translational	modifications	in	rBAT	mutant	proteins	(Bartoccioni	
et	al.,	2008).		
5.4.1	rBAT	mutations	cause	“trafficking”	defects	in	oocytes	
To	date,	there	have	been	6	reports	on	the	characterisation	of	9	different	rBAT	mutant	
proteins	 in	Xenopus	oocytes	 (Calonge	 et	 al.,	 1994;	 Chillarón	 et	 al.,	 1997;	 Saadi	 et	 al.,	 1998;	
Ishihara	 et	 al.,	 2002;	 Pineda	 et	 al.,	 2004b;	 Bartoccioni	 et	 al.,	 2008).	 The	 majority	 of	 these	
studies	 report	 a	 decrease	 in	 function	 of	 mutant	 rBAT	 compared	 to	 the	 wild-type	 through	
uptake	 measurements	 of	 radiolabelled	 prototypical	 b0,+	 substrates.	 One	 report,	 in	 which	
[14C]cystine	 uptake	 was	 measured	 1-8	 days	 post-injection	 of	 cRNA,	 demonstrated	 a	 >90%	
recovery	 in	 function	of	M467T	compared	to	wild-type	rBAT,	by	day	7	(Chillarón	et	al.,	1997).	
The	expression	of	M467T	was	also	measured	as	part	of	the	current	study,	and	a	broadly	similar	
observation	was	made	 (Figure	 5.7).	 Additionally,	 Chillarón	et	 al.	 reported	 that	 following	 the	
substitution	of	hydrophobic	methionine	at	position	467	for	the	polar	amino	acid	lysine,	M467K	
function	 only	 reached	 20%	 of	 the	 wild-type	 protein	 by	 day	 7	 (Chillarón	 et	 al.,	 1997).	 This	
indicates	that	less	conservative	amino	acid	changes	in	the	molecule	confer	a	greater	effect	on	
protein	stability.		
From	 homology	models	 of	 the	 rBAT	 extracellular	 domain	we	 can	 predict	 how	 these	
mutations	 could	 affect	 the	 stability	 of	 the	 folded	 protein.	 A	model	 of	 the	 rBAT	 extracellular	
domain	was	created,	based	on	the	known	crystal	 structure	of	B.	cereus	oligo-1,6-glucosidase	
(PDB	 code	 1UOK,	 Figure	 5.34A).	 The	 methionine	 residue	 at	 position	 467	 in	 the	 rBAT	
extracellular	domain	 is	predicted	to	sit	on	the	7th	α-helix	of	 the	TIM	barrel	 (domain	A2),	with	
the	hydrophobic,	unreactive	side	chain	facing	outwards	towards	the	interface	with	the	β-sheet	
of	Domain	C	(Figure	5.34B).	Threonine	has	a	shorter	side	chain	than	methionine,	which	is	polar	
and	can	readily	form	hydrogen	bonds.	However,	based	upon	the	model,	the	hydroxyl	group	of	
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the	threonine	side-chain	is	predicted	to	be	located	6.2Å	from	the	nearest	amino	group,	that	of	
leucine	at	position	646.	This	 is	greater	than	the	distance	over	which	a	hydrogen	bond	can	be	
formed	 (≈4Å)	 (Figure	 5.34B).	 The	 substitution	 of	 methionine	 for	 lysine	 at	 position	 467	 is	
predicted	 to	 introduce	 a	 long,	 cationic	 side	 chain	 into	 the	 hydrophobic	 interior	 of	 the	 rBAT	
extracellular	 domain	 (Figure	 5.34D).	 This	 mutation	 has	 great	 potential	 for	 disrupting	 steric	
interactions	 within	 the	 molecule.	 From	 these	 in	 silico	 results,	 we	 can	 visualise	 how	 the	
introduction	of	a	lysine	residue	at	position	467	could	have	a	more	dramatic	effect	on	protein	
stability	than	threonine.	
Saadi	et	al.	(1998)	reported	a	novel	mutation,	S217R,	in	SLC3A1	of	a	cystinuric	patient.	
Through	 S217R	 expression	 in	 oocytes,	 they	 detected	 no	 change	 in	 [3H]arginine	 uptake	
compared	 to	 wild-type	 control	 oocytes,	 24h	 post-injection	 of	 cRNA.	 However,	 when	 this	
measurement	was	 repeated	 6h	 post-injection,	 the	 function	 of	 the	mutant	 protein	was	 only	
40%	of	the	wild-type	(Saadi	et	al.,	1998).	Similarly,	the	R452W	missense	mutation,	identified	in	
two	Italian	patients,	showed	a	“mild”	delay	in	expression	in	oocytes,	which	recovered	after	3	
days	 (Bartoccioni	 et	 al.,	 2008).	 Together,	 these	 reported	 data	 indicate	 that	 the	 extent	 of	
functional	 “recovery”	 of	 mutant	 proteins	 following	 expression	 in	 oocytes	 varies	 between	
mutations,	and	depends	on	the	severity	of	their	effect	on	protein	folding.	
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Figure	 5.34:	 A	 close-up	 view	 of	 the	 putative	 location	 of	 M467	 in	 the	 rBAT	 extracellular	
domain.	The	homology	model	was	created	based	on	the	known	crystal	structure	of	B.	cereus	
oligo-1,6-glucosidase	(PDB	code	1UOK).	A,	Side-view	of	the	rBAT	extracellular	domain	with	the	
residues	 in	 panels	 B-D	 indicated	 by	 the	 presence	 of	 a	 black	 box;	 B,	 Putative	 location	 of	
methionine	at	position	467	and	the	location	of	the	side	chain;	C,	Putative	location	of	M467T.	
The	predicted	distance	of	 the	 threonine	hydroxyl	 group	 from	 the	nearest	main	 chain	 amino	
group,	 in	 L646	 is	 6.2Å;	 D,	 the	 putative	 location	 of	 M467K.	 The	 predicted	 distance	 of	 the	
positively-charged	lysine	side	chain	from	the	nearest	main	chain	amino	group,	in	L646,	is	only	
1.8Å.		
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Of	 the	 four	 novel	mutations	 investigated	 in	 this	 study,	 two	mutant	 proteins,	M465K	
and	 Y579D,	 showed	 a	 broadly	 similar	 expression	 pattern	 to	 other	 mutant	 rBAT	 proteins	
reported	 in	 the	 literature.	 Our	 data	 correlated	 with	 the	 results	 of	 M467T	 and	 M467K	
expression	in	oocytes	where	a	recovery	in	function	was	observed	over	a	number	of	days	post-
injection	 (Chillarón	 et	 al.,	 1997).	 It	 is	 worthwhile	 noting	 that	 the	 expression	 of	M465K	 was	
more	similar	to	that	of	M467K	than	M467T.	In	the	current	study,	[3H]arginine	uptake	levels	in	
M465K-expressing	 oocytes	 were	 never	 equivalent	 to	 that	 of	 wild-type	 rBAT,	 remaining	
significantly	 lower	 (p<0.05)	even	by	day	6	 (Figure	5.12).	 In	oocytes	 injected	with	 the	highest	
amount	 of	 cRNA	 (50ng),	 [3H]arginine	 uptake	 only	 reached	 46%	 of	 the	 wild-type	 by	 day	 6	
(Figure	5.13).		
A	homology	model	of	rBAT	supports	the	hypothesis	that	the	M465K	mutation	leads	to	
protein	mis-folding	 and	 instability	 (Figure	 5.35A).	 The	methionine	 residue	 at	 position	 465	 is	
predicted	 to	 sit	 on	 the	 7th	 α-helix	 of	 the	 TIM	 barrel	 structure	 (Figure	 5.35Ai).	 The	 short,	
hydrophobic	side	chain	putatively	faces	into	the	centre	of	the	molecule	and	is	not	predicted	to	
contribute	 to	 intramolecular	bonding	 (Figure	5.35Aii).	When	 this	 residue	 is	mutated	 in	 silico,	
the	cationic	amino	group	on	the	long	side	chain	of	lysine	is	predicted	to	sit	2.0Å	from	the	main	
chain	 carboxyl	 group	 of	 neighbouring	 residue	 L453	 (Figure	 5.35Aiii).	 This	 is	 a	 comfortable	
distance	 over	 which	 polar	 interactions	 can	 occur	 (<4Å).	 Irrespective	 of	 this,	 introducing	 a	
charged	 residue	 into	an	 internal	hydrophobic	 region	of	a	protein	 creates	a	 rational	basis	 for	
suggesting	conferred	protein	instability.	
The	 second	 novel	 missense	 mutation	 that	 was	 shown	 to	 negatively	 affect	 rBAT	
expression	 was	 the	 tyrosine	 to	 aspartic	 acid	 substitution,	 Y579D.	 Putatively	 located	 on	 the	
second	strand	of	 the	β-sheet	of	domain	C,	 the	aromatic	 side	chain	of	 the	 tyrosine	 residue	 is	
predicted	 to	be	orientated	away	 from	 the	A2	domain	 (Figure	5.35Bi).	 The	orientation	of	 this	
side	 chain	 putatively	 allows	 polar	 interactions	 with	 residues	 of	 the	 loop	 (598-617),	 which	
connects	 strands	 3	 and	 4	 of	 the	β-sheet	 (Figure	 5.35Bii).	 The	mutagenesis	 of	 tyrosine	 (Y)	 to	
aspartic	 acid	 (D),	 a	 negatively-charged	 amino	 acid,	 provides	 scope	 for	 incorrect	 folding	 and	
assembly	 of	 the	 protein	 through	 altered	 interactions	 with	 domain	 C	 (Figure	 5.35Biii).	
Additionally,	 as	 the	 30	 amino	 acid	 “tail”	 of	 rBAT	 does	 not	 model	 to	 any	 known	 crystal	
structure,	 and	 is	 not	 included	 in	 the	 homology	model	 of	 the	 rBAT	 extracellular	 domain	 (see	
Chapter	1),	the	model	does	not	indicate	how	this	region	is	predicted	to	interact	with	residues	
in	 the	 C-terminal	 region	 of	 the	 protein.	 Deora	 et	 al.	 (1998)	 reported	 that	 progressive	 C-
terminal	 deletions	 of	 the	 rBAT	protein	 led	 to	 an	 abolition	of	 [3H]arginine	uptake	 in	 oocytes,	
indicating	 that	 this	 region	of	 the	 protein	 is	 essential	 for	 the	 function	 of	 rBAT	 	 (Deora	 et	 al.,	
1998).		
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Further	 investigation	 of	 the	 structure-function	 relationship	 in	 the	 rBAT	 protein	 is	
beyond	the	scope	of	this	investigation.	All	mutations	investigated	in	this	study	were	identified	
in	 the	 gDNA	 of	 cystinuric	 patients.	 However,	 separate	 studies	 investigating	more	 conserved	
substitutions	 of	 methionine	 at	 critical	 residues	 M465	 and	 M467,	 could	 prove	 highly	
informative.	In	the	absence	of	a	crystal	structure	of	rBAT,	and	due	to	the	predicted	differences	
in	 domain	 conservation	 between	 rBAT	 and	 CD98,	 these	 structure-function	 studies	 could	
provide	the	key	for	unlocking	the	function	of	the	System	b0,+	heavy	chain.	
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Figure	 5.35:	 A	 close-up	 view	 of	 the	 putative	 location	 of	 M465	 and	 Y579	 in	 the	 rBAT	
extracellular	domain.	The	homology	model	was	created	based	on	the	known	crystal	structure	
of	B.	cereus	oligo-1,6-glucosidase	(PDB	code	1UOK).	Ai,	Bottom-view	of	the	rBAT	extracellular	
domain	with	the	residues	in	panels	ii-iii	indicated	by	the	presence	of	a	black	box;	Aii,	Putative	
location	of	methionine	at	position	465	and	the	location	of	the	side	chain;	Aiii,	Putative	location	
of	M465K.	The	distance	of	the	positively-charged	lysine	side	chain	from	the	nearest	main	chain	
amino	 group,	 in	 L453,	 is	 only	 2.0Å;	 Bi,	 Side-view	 of	 the	 rBAT	 extracellular	 domain	with	 the	
residues	 in	 panels	 ii-iii	 indicated	 by	 the	 presence	 of	 a	 black	 box;	 Bii,	 Putative	 location	 of	
tyrosine	at	position	579	and	the	location	of	the	side	chain.	The	distances	of	the	hydroxyl	group	
of	the	tyrosine	side	chain	from	the	nearest	main	chain	amino	group	 in	L604,	and	main	chain	
carboxyl	 groups	 in	 S602	and	 L640,	 are	3.0,	 2.9,	 and	2.4Å,	 respectively.	 This	 is	 a	 comfortable	
distance	 over	 which	 stabilising	 polar	 interactions	 could	 occur;	 Biii,	 Putative	 location	 of	
negatively-charged	Y579D.		
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5.4.2	Limitations	of	Xenopus	oocytes	in	measuring	the	effects	of	trafficking	mutations	
In	the	current	study,	the	introduction	of	novel	mutations	N254T	and	L416P	to	the	rBAT	
sequence	led	to	variability	in	their	measured	effects	on	protein	function	following	expression	
in	 oocytes.	 The	 presence	 of	 these	 rare	 mutations	 in	 SLC3A1	 of	 cystinuric	 patients	 strongly	
suggests	that	they	are	pathogenic.	No	measurable	change	 in	protein	function	 in	oocytes	was	
detected	when	 10μM	 [3H]arginine	 uptake	was	 carried	 out	 at	 day	 3	 (Figures	 5.17,	 5.22,	 and	
5.32-33).	 However,	 when	 concentration-dependent	 uptake	 was	 measured,	 a	 significant	
(p<0.001)	reduction	in	Vmax	was	measured	with	both	mutant	proteins	(Figures	5.19	and	5.24).	
Additionally,	it	appeared	as	though	N254T	and	L416P	increased	the	affinity	(decreased	the	Km)	
of	the	transport	system,	putatively	through	an	altered	interaction	with	the	Xenopus	light	chain	
(Figure	 5.24).	 A	 change	 in	 the	 Km	has	 been	observed	 following	 the	 interaction	of	 CD98	with	
b0,+AT,	indicating	that	the	structure	of	the	heavy	chain	modulates	transport	via	System	b0,+	(see	
Chapter	 1,	 Rajan	 et	 al.,	 2000).	 	We	 hypothesise	 that	 these	mutations	 cause	 a	milder	 effect	
upon	 rBAT	 function	 than	M465K,	M467T,	 and	 Y579D.	We	 predict	 that	 these	 two	mutations	
would	lead	to	a	reduction	in	System	b0,+	function	if	uptake	experiments	were	carried	out	<24h	
post-injection	of	cRNA.	This	was	observed	by	Saadi	et	al.	(1998),	when	measuring	the	function	
of	 S217R	 in	 oocytes,	 6h	 post-injection.	 However,	 due	 to	 time	 restrictions	 on	 this	 study,	 we	
were	unable	to	perform	these	experiments.	
The	 inability	 to	 detect	 the	 effects	 of	 mutations	 on	 protein	 expression	 in	 oocytes	
following	the	 introduction	of	potentially	pathogenic	mutations	has	been	reported	previously.	
Leduc-Nadeau	 et	 al.	 (2010)	 reported	 a	 similar	 result	 in	 oocytes	 from	 their	 investigation	 of	
novel	aquaporin-2	(AQP2)	mutations	identified	in	patients	with	nephrogenic	diabetes	insipidus	
(NDI).	No	reduction	in	function	of	the	AQP2	channel	was	observed	following	the	incorporation	
of	 novel	 mutations	 K228E	 or	 V24A	 into	 the	 protein	 sequence	 (Leduc-Nadeau	 et	 al.,	 2010).	
Channel	function	was	measured	through	incubation	of	the	oocytes	in	a	hyposmotic	solution	to	
induce	 uptake	 of	 water	 and	 oocyte	 swelling	 (Leduc-Nadeau	 et	 al.,	 2010).	 Similarly,	 no	
reduction	 in	membrane	 localisation	was	detected	through	 immunocytochemical	detection	of	
FLAG-tagged	 AQP2	 mutants	 in	 oocyte	 sections	 or	 western	 blotting	 of	 oocyte	 plasma	
membrane	samples	(Leduc-Nadeau	et	al.,	2010).	However,	a	distinct	mutation	in	AQP2,	R187C,	
led	 to	 reduced	 functionality	of	 the	protein	 in	oocytes,	and	a	 reduction	 in	plasma	membrane	
localisation	 measured	 by	 immunocytochemistry	 and	 western	 blotting	 (Leduc-Nadeau	 et	 al.,	
2010).	 In	 the	 current	 study,	 we	 were	 unable	 to	 successfully	 use	 the	 plasma	 membrane	
preparation	 to	 detect	 mutant	 rBAT	 proteins	 by	 western	 blot.	 Despite	 this,	 the	 data	 from	
Leduc-Nadeau	 et	 al.	 demonstrate	 that	 the	 use	 of	 sectioned	 oocytes	 to	 identify	 plasma	
membrane	 localisation	 provides	 similar	 results	 as	 the	 western	 blot	 of	 oocyte	 plasma	
membranes.	In	mutant	AQP2	proteins	that	appear	to	function	in	the	same	manner	as	the	wild-
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type,	their	presence	at	the	plasma	membrane	in	oocytes	was	confirmed	through	both	western	
blotting	 and	 immunocytochemical	 detection	 (Leduc-Nadeau	 et	 al.,	 2010).	 Although,	 in	 the	
current	 study,	 the	 use	 of	 this	 technique	 was	 desirable	 to	 support	 the	 data	 from	
immunocytochemical	detection,	 it	 is	unlikely	 that	 it	would	have	provided	 further	 insight	 into	
the	function	of	mutant	proteins	L416P	and	N254T,	which	appear	to	localise	in	the	membrane.	
Leuduc-Nadeau	 et	 al.,	 also	 transfected	 a	 mouse	 inner	 medullary	 collecting	 duct	 cell	 line	
(mIMCD-3)	with	the	wild-type	and	mutant	AQP2	proteins	and	detected	membrane	localisation	
of	 the	 wild-type	 channel	 16-24h	 post-transfection.	 However,	 when	 all	 three	 AQP2	mutants	
(V24A,	 R187C,	 and	 K228E)	 were	 transfected	 in	 the	 cell	 line,	 no	membrane	 localisation	 was	
detected,	with	the	mutant	proteins	appearing	to	be	trapped	in	an	intracellular	compartment.	
These	 data	 support	 the	 hypothesis	 that	 L416P	 and	 N254T	 are	 pathogenic	 mutations,	 but	
perhaps	convey	a	less	severe	effect	on	the	protein,	rendering	it	 less	detectable	in	the	oocyte	
expression	 system,	 when	 high	 expression	 levels	 of	 the	 protein	 are	 achieved	 over	 long	
incubation	periods	(up	to	6	days).	
In	response	to	the	report	of	Leduc-Nadeau	et	al.	(2010),	the	use	of	Xenopus	oocytes	as	
a	useful	tool	for	detecting	trafficking	mutations	in	membrane	proteins	has	been	debated	in	the	
literature	(Moeller	&	Fenton,	2010).	Moeller	and	Fenton	(2010)	acknowledged	the	limitations	
on	protein	trafficking	measurements	reported	by	Leduc-Nadeau	et	al.	(2010).	It	was	concluded	
that	 the	measurements	made	 in	Xenopus	oocytes	 remain	 a	 robust	measurement	 of	 protein	
expression.	However,	 it	 is	 important	to	recognise	the	likelihood	of	protein	over-expression	in	
oocytes	(Moeller	&	Fenton,	2010).		
Another	 important	 factor	 to	 consider	 when	 using	 the	 Xenopus	 oocyte	 expression	
system	 is	 the	phenomenon	of	 temperature-dependent	protein	 release	 from	the	ER.	This	has	
been	 reported	 previously	 in	 studies	 of	 the	 Cystic	 Fibrosis	 Transmembrane	 Conductance	
Regulator	 protein	 (CFTR)	 (Denning	 et	 al.,	 1992).	 In	 a	 similar	 manner	 to	 rBAT,	 CFTR	 is	 a	
glycosylated	membrane	protein	 and,	 following	electrophoretic	 resolution,	 bands	of	 different	
molecular	weights	can	be	detected	(Denning	et	al.,	1992).	In	the	case	of	CFTR,	three	bands	are	
detected	in	the	wild-type	protein	expressed	in	cells	cultured	at	37°C:	unglycosylated	(band	A,	
120kDa),	 endoplasmic	 reticulum	 core-glycosylated	 (band	 B,	 140kDa),	 and	 Golgi-associated	
mature-glycosylated	 (band	 C,	 170kDa)	 protein	 (Cheng	 et	 al.,	 1990;	 Gregory	 et	 al.,	 1991;	
Denning	et	al.,	1992).	In	the	presence	of	a	phenylalanine	deletion	in	the	protein,	ΔF508,	found	
in	90%	of	cystic	fibrosis	patients,	band	C	is	not	detected	in	fibroblasts.	This	indicates	that	the	
mis-folded	 polypeptide	 does	 not	 leave	 the	 ER	 to	 be	 processed	 by	 the	Golgi	 (Denning	 et	 al.,	
1992).	 However,	 it	was	 discovered	 that	when	 the	 incubation	 temperature	 of	 the	 fibroblasts	
was	reduced	to	26°C,	a	reversible	recovery	of	 function	and	plasma	membrane	 localisation	of	
mature-glycosylated	protein	was	observed	 (Denning	 et	al.,	1992).	This	 temperature-sensitive	
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release	of	protein	from	the	endoplasmic	reticulum	explained	the	wild-type	function	of	ΔF508-
CFTR	 in	Xenopus	oocytes	when	cAMP-dependent	Cl-	 currents	were	measured	 (Drumm	 et	al.,	
1991).	 Temperature-dependence	 was	 shown	 to	 be	 a	 factor	 in	 the	 release	 of	 R365W	 rBAT	
mutant	 from	 the	 ER	 of	 HeLa	 cells	 transiently	 transfected	 with	 both	 subunits	 of	 System	 b0,+	
(Pineda	 et	 al.,	 2004b).	 The	 reduction	 in	 [14C]cystine	 transport	 and	 expression	 of	 R452W,	
compared	to	wild-type	rBAT,	was	more	pronounced	in	the	cell	line	than	in	oocytes	(Pineda	et	
al.,	 2004b).	 Additionally,	when	 the	 growth	 temperature	of	 the	HeLa	 cells	was	 reduced	 from	
37°C	to	33°C,	the	function	of	the	R352W	rBAT	mutant	was	not	significantly	different	(p>0.05)	
to	that	of	the	wild-type	protein	(Pineda	et	al.,	2004b).	
These	data	from	the	literature	indicate	that	some	rBAT,	AQP2	and	CFTR	mutants	may	
be	 released	 from	 the	 ER	 when	 expressed	 in	 cell	 systems	 that	 are	 incubated	 at	 lower	
temperatures	(below	26oC).	We	hypothesise	that	at	higher	temperatures,	we	would	observe	a	
reduced	 trafficking	 of	 rBAT	 mutants	 N254T	 and	 L416P.	 To	 confirm	 this	 hypothesis,	 the	
expression	of	FLAG-tagged	rBAT	in	a	mammalian	cell	line	is	desirable.	Successful	expression	of	
rBAT	 in	 a	 mammalian	 cell	 line	 would	 allow	 the	 effects	 of	 incubation	 temperature	 to	 be	
investigated.	 It	 is	 not	 possible	 to	 incubate	Xenopus	 ooyctes	 at	 temperatures	 above	 26°C	 for	
prolonged	periods	as	their	viability	would	rapidly	decline.	To	see	any	effect	of	temperature	on	
protein	 release	 from	 the	 ER,	 an	 expression	 system	 that	 can	 be	 incubated	 at	 temperatures	
exceeding	26°C,	for	longer	than	the	expected	turnover	rate	of	rBAT	protein,	is	necessary.		
The	 potential	 alteration	 on	 protein	 folding	 caused	 by	 N254T	 and	 L416P	 can	 be	
predicted	 by	 homology	modelling	 (Figure	 5.36).	 To	 date,	 no	 data	 has	 been	 reported	 in	 the	
literature	regarding	the	function	of	loop-rich	rBAT	extracellular	domain	B.	This	is	the	putative	
location	 of	 novel	 mutation	 N254T	 (Figure	 5.36Ai).	 In	 related	 glucosidase	 structures,	 this	
domain	 forms	 the	cleft	of	 the	enzyme	active	 site	 (see	Chapter	1).	This	domain	 is	 completely	
absent	in	the	only	other	member	of	the	mammalian	SLC3	family,	CD98	(SLC3A2).	However,	its	
importance	 in	 the	 function	 of	 rBAT	 is	 suggested	 by	 the	 location	 of	 11	 reported	 cystinuria	
mutations	falling	in	this	184-residue	domain	(Stenson	et	al.,	2014).	Notably,	mutations	N253K	
and	W255C	have	been	 reported	 in	 the	 literature,	which	 flank	 the	site	of	our	novel	mutation	
(Harnevik	et	al.,	2001;	Bisceglia	et	al.,	2007).	 In	silico	modelling	of	 rBAT	predicts	 interactions	
between	 the	 long,	 polar	 side	 chain	 of	 asparagine	 at	 position	 254	 and	 the	 side	 chain	 amide	
group	of	Q335,	 and	 the	main	 chain	 amino	 group	of	 E238	 (Figure	5.36Aii).	 Following	 in	 silico	
mutagenesis	of	this	residue	to	threonine	in	PyMol,	these	interactions	are	putatively	 lost,	due	
to	 an	 increased	distance	between	 the	 atoms	possibly	 decreasing	 the	 stability	 of	 the	 protein	
(Figure	5.36iii).	Additionally,	 a	 cystinuria	mutation	E328K	has	been	 reported	 (Bisceglia	 et	al.,	
2007),	which	would	also	affect	 the	 folding	of	 the	protein	 in	 this	 region.	These	data	highlight	
the	importance	of	the	correct	protein	assembly	in	this	region	of	the	rBAT	extracellular	domain.		
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	 The	 leucine	 residue	 at	 position	 416	 in	 the	 rBAT	 extracellular	 domain	 is	 putatively	
located	in	the	N-terminal	region	of	the	6th	α-helix	of	the	TIM	barrel	(Figure	5.36Bi).	This	α-helix	
is	 predicted	 to	 be	 non-continuous,	 due	 to	 the	 presence	 of	 a	 5-amino	 acid	 unwound	 region	
(D417-V421).	 The	 substitution	 of	 an	 amino	 acid	 located	 in	 an	 α-helix,	 for	 the	 imino	 acid	
proline,	can	lead	to	alterations	in	secondary	structure	stability	(Barlow	&	Thornton,	1988).	Due	
to	the	presence	of	the	imino	ring	within	the	proline	molecule,	this	amino	acid	is	unable	to	form	
a	hydrogen	bond	with	neighbouring	residues	and	stabilise	the	α-helix.	Therefore,	the	presence	
of	proline	in	an	alpha	helix	often	leads	to	a	kink	in	the	structure	(Barlow	&	Thornton,	1988).	In	
this	case,	a	change	in	the	angle	of	this	alpha	helix,	relative	to	the	rest	of	the	molecule,	could	
affect	protein	folding,	leading	to	decreased	stability	and	degradation	of	the	protein	by	the	ER.	
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Figure	 5.36:	 A	 close-up	 view	 of	 the	 putative	 location	 of	 N254	 and	 L416	 in	 the	 rBAT	
extracellular	domain.	A	homology	model	of	the	rBAT	extracellular	domain	was	created	based	
on	 the	 known	 crystal	 structure	 of	B.	 cereus	 oligo-1,6-glucosidase	 (PDB	 code	 1UOK).	Ai,	 Top-
view	 of	 the	 rBAT	 extracellular	 domain	 with	 the	 residues	 in	 panels	 ii-iii	 indicated	 by	 the	
presence	of	a	black	box;	Aii,	Putative	location	of	asparagine	at	position	254	and	the	location	of	
the	 polar	 side	 chain.	 The	 distances	 of	 the	 side	 chain	 amide	 group	 of	 asparagine	 from	 the	
nearest	 side	 chain	amide	group	of	Q335,	main	 chain	amino	group	of	E328,	 are	only	2.7	and	
3.2Å,	 respectively;	 Aiii,	 Putative	 location	 of	 N254T.	 The	 distance	 of	 the	 side	 chain	 hydroxyl	
group	of	the	threonine	residue	from	the	nearest	main	chain	amino	group,	in	E328,	is	4.2Å;	Bi,	
Side-view	of	 the	 rBAT	 extracellular	 domain	with	 the	 residues	 in	 panels	 ii-iii	 indicated	by	 the	
presence	of	a	black	box;	Bii,	Putative	location	of	leucine	at	position	416	and	the	location	of	the	
branched	hydrocarbon	side	chain.	The	distances	of	 the	main	chain	carboxyl	group	of	 leucine	
from	the	nearest	main	chain	amino	groups	 in	L414	and	Y412	are	3.2,	and	3.4Å,	 respectively;	
Biii,	Putative	location	of	L416P.	The	carboxyl	group	involved	in	the	imino	ring	is	unavailable	to	
form	polar	interactions,	adding	a	potential	kink	to	the	α-helix	structure.		
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5.4.3	Cellular	processing	of	rBAT	mutant	proteins	
In	 the	 current	 study,	 a	 reduction	 in	 the	 total	 amount	 of	 rBAT	 protein	 produced	 in	
oocytes	 following	 the	 introduction	of	 pathogenic	mutations	was	 observed.	 This	 reduction	 in	
total	protein	quantity	was	most	apparent	at	day	1	post-injection.	This	was	not	detected	in	the	
expression	of	rBAT	containing	the	common	SNP	M618I.	Leduc-Nadeau	et	al.,	(2010)	reported	a	
1:5	ratio	in	protein	expression	in	oocytes;	1ng	of	wild-type	cRNA	produced	a	protein	band	of	
equivalent	 intensity	 to	 that	 detected	 in	 oocytes	 injected	with	 5ng	mutant	 AQP2	 cRNA.	 Our	
data,	in	accordance	with	those	reported	by	Leduc-Nadeau,	support	the	hypothesis	that	mutant	
protein	is	being	retained	and	rapidly	degraded	by	the	ER.	This	could	account	for	an	observed	
reduction	 in	 total	 protein	 detection	 at	 the	 early	 time-points	 post-injection.	However,	 as	 the	
protein	 is	 over-expressed	 in	 the	 oocyte	 potential	 degradation	 pathways	 may	 become	
saturated	over	time,	with	the	rate	of	protein	translation	exceeding	the	rate	of	degradation.		
Substantial	 evidence	 for	 the	 co-translational	 assembly	 of	 rBAT	with	 b0,+AT	 has	 been	
reported	in	the	literature,	and	was	discussed	in	Chapter	1	of	this	thesis	(Bauch	&	Verrey,	2002;	
Reig	et	al.,	2002;	Pineda	et	al.,	2004b).	Through	co-transfection	of	both	System	b0,+	subunits	in	
MDCK	cells,	Bartoccioni	et	al.	(2008)	showed	that	the	association	of	rBAT	with	b0,+AT	occurred	
rapidly,	 preventing	 degradation	 of	 the	 heavy	 chain.	 Through	 co-expression	 of	 rBAT	 mutant	
proteins	 M467T,	 M467K,	 and	 T216M,	 Bartoccioni	 et	 al.	 identified	 a	 complete	 lack	 of	
[14C]cystine	 uptake.	 Additionally,	 all	 three	 mutant	 proteins	 did	 not	 acquire	 complex	 N-
glycosylation,	indicating	a	lack	of	processing	by	the	Golgi	apparatus	due	to	degradation	by	the	
Endoplasmic	Reticulum-Associated	Degradation	(ERAD)	pathway	(Bartoccioni	et	al.,	2008).	The	
lack	 of	 mature	 glycosylated	 form	 of	 R365W	 and	 M467T	 has	 also	 been	 reported	 following	
protein	expression	in	oocytes	(Chillarón	et	al.,	1997;	Pineda	et	al.,	2004b).	In	the	current	study,	
total	membrane	proteins	were	 isolated	 from	oocytes	 expressing	wild-type	 and	mutant	 rBAT	
proteins	and	used	for	western	blot	detection.	As	expected,	both	the	core	glycosylated	(85kDa)	
and	 mature	 glycosylated	 (90kDa)	 forms	 of	 rBAT	 were	 detected	 following	 expression	 of	 the	
common	variant,	M618I	(Figure	5.5A).	When	mutant	rBAT	proteins	M467T,	M465K	and	L416P	
were	 expressed	 in	 oocytes,	 only	 the	 core-glycosylated	 form	 (85kDa)	 of	 the	 protein	 was	
detected	by	western	 blot	 (Figures	 5.9A,	 5.13A,	 and	 5.21A,	 respectively).	 The	 absence	of	 the	
mature	glycosylated	form	of	L416P	in	oocytes	further	supports	the	potential	of	this	variant	as	a	
pathogenic	mutation.	 In	 the	 case	 of	 the	 Y579D	mutant	 protein,	 a	 doublet	 band	was	 visible,	
however	in	the	wild-type	sample,	the	ratio	of	the	mature	glycosylated	to	the	core	glycosylated	
form	was	higher	 (Figure	5.25A).	This	 is	 consistent	with	 the	 results	of	western	blotting	of	 the	
pathogenic	 mutant	 R365W	 expressed	 in	 oocytes	 by	 Pineda	 et	 al.	 (2004).	 However,	 when	
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R365W	was	 co-transfected	 with	 b0,+AT	 in	 HeLa	 cells,	 and	 incubated	 at	 37°C,	 only	 the	 core-
glycosylated	form	of	the	protein	was	detected	(Pineda	et	al.,	2004b).		
These	 data	 indicate	 that	 whilst	 the	 transfer	 of	 rBAT	 mutant	 proteins	 to	 the	 Golgi	
appears	to	be	eliminated	in	some	mutants,	the	extent	of	the	reduction	in	this	processing	step	
varies	 between	 mutants.	 Bartoccioni	 et	 al.	 (2008)	 found	 that	 transmembrane	 domain	
mutation	 L89P	 was	 present	 in	 both	 glycosylated	 forms	 following	 transfection	 in	 HeLa	 cells,	
whereas	all	TIM	barrel	mutants	investigated	(M467T,	M467K,	R352W,	and	T216M)	were	only	
detected	as	a	single	85kDa	band.	In	the	current	study,	both	the	core-	and	mature-glycosylated	
forms	of	novel	mutant	protein	N254T	were	identified	by	western	blot	(Figure	5.17A).	N254T	is	
not	a	TIM	barrel	mutant,	but	 is	predicted	to	be	 located	in	 loop-rich	domain	B	(Figure	5.28A).	
These	 data	 support	 the	 hypothesis	 that	 the	 location	 of	 mutations	 in	 the	 protein	 may	
contribute	to	the	variation	in	cellular	processing.	
In	 this	 Chapter	 we	 have	 utilised	 the	 range	 of	 techniques	 optimised	 in	 Chapter	 4	 to	
successfully	measure	 the	expression	of	wild-type	 rBAT	and	 rBAT	mutant	proteins	 in	oocytes.	
We	have	 reported	data	 that	 support	 the	hypothesis	 that	mutations	 in	 rBAT	can	 lead	 to	mis-
folding	of	the	protein,	causing	degradation	by	the	ER.	In	the	case	of	novel	mutant,	L416P,	some	
evidence	 was	 found	 to	 indicate	 that	 the	 rBAT	 mutation	 alters	 the	 affinity	 of	 the	 transport	
system	 for	 the	 prototypical	 b0,+	 substrate,	 arginine.	 However,	 this	 requires	 confirmation	
through	 further	 investigation.	 These	 data	 support	 the	 evidence	 that	 rBAT	 serves	 as	 a	
modulator	of	b0,+	transport,	and	does	not	form	the	substrate	binding	site.	In	this	chapter,	the	
data	present	the	“typical”	observed	pattern	of	mutant	rBAT	expression	in	oocytes.			
Based	 on	 these	 observations,	 the	 next	 stage	 of	 this	 investigation	 focussed	 on	 the	
modulation	 of	 rBAT	 expression	 through	 environmental	 modification	 of	 the	 oocytes.	 It	 was	
desirable	to	measure	the	effects	of	the	current	cystinuria	therapies	on	transporter	expression.	
Current	therapies	are	utilised	to	increase	the	solubility	of	cystine	and	prevent	stone	formation	
through	alkalinisation	of	the	renal	filtrate	or	conjugation	of	cystine	to	thiol	drugs	(see	Chapter	
1).	However,	no	effects	of	 these	 treatments	upon	the	 transport	 system	have	been	reported.	
Any	variation	 in	 the	 function	of	 the	different	mutant	proteins	 to	 incubation	with	 thiol	drugs	
could	 lead	 to	a	pharmacogenetic	approach	 to	cystinuria	 therapy.	These	data	are	 reported	 in	
Chapter	6.		
In	summary:	
• Using	the	techniques	established	in	Chapter	4	of	this	thesis	we	have	measured	
the	expression	of	rBAT	mutant	proteins	compared	to	the	wild-type.	
		
	
	
323	
• In	novel	mutants	M465K	and	Y579D,	a	delay	in	expression	compared	to	wild-
type	rBAT	was	observed,	which	began	to	recover	over	time.	
• Novel	 mutants	 N254T	 and	 L416P	 showed	 a	 much	 milder	 effect	 on	 rBAT	
expression.			
• Even	when	mutant	rBAT	proteins	reached	the	membrane	of	the	oocyte,	only	
the	 core	glycosylated	 from	was	detectable.	 This	 indicated	 that	processing	by	
the	Golgi	apparatus	remained	absent.		
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Chapter	6 :	Results	IV	
6.1	Introduction	
The	current	treatment	paradigm	for	patients	with	cystinuria	centres	on	increasing	the	
solubility	of	cystine	in	the	urine,	thereby	decreasing	precipitation	and	the	formation	of	stones.	
Patients	are	advised	to	limit	their	dietary	intake	of	sodium,	which	has	been	shown	to	increase	
urinary	 cystine	 excretion,	 and	 animal	 proteins,	 due	 to	 their	 high	 cystine	 and	 methionine	
content	 (Goldfarb	 et	 al.,	 2006).	 Cystine	 solubility	 in	 the	 urine	 is	 increased	 through	 a	
combination	of	hyperdiuresis	and	alkalinisation	of	the	renal	filtrate	(Chillarón	et	al.,	2010).	At	
pH	7	the	solubility	of	cystine	in	the	urine	is	<1mM.	However	at	pH	7.5,	this	increases	to	2mM	
(Dent	et	al.,	1965;	Chillarón	et	al.,	2010).	Potassium	citrate	is	the	preferred	alkalinising	agent	
due	 to	 the	 increased	 amount	 of	 cystine	 excretion	 associated	 with	 sodium	 bicarbonate	 or	
sodium	citrate	(Fjellstedt	et	al.,	2001).	If	treatment	of	patients	with	increased	fluid	intake	and	
urinary	 alkalisation	 fails	 to	 control	 their	 cystinuria,	 then	 they	 are	 treated	 with	 the	 cystine-
binding	thiol	drugs	(CBTD)	captopril,	tiopronin,	and	D-penicillamine	(Barbey	et	al.,	2000).	These	
drugs	 work	 by	 breaking	 down	 cystine	 into	 monomeric	 cysteine	 amino	 acids,	 through	
conjugation	 via	 disulphide	 bond	 formation.	 These	 cystine-drug	 conjugates	 have	 been	
estimated	to	increase	the	solubility	of	cystine	in	the	urine	by	50-fold	(Lotz	&	Bartter,	1965).	Of	
these	 three	 drugs,	 captopril	 is	 associated	 with	 the	 lowest	 incidence	 of	 adverse	 reactions.	
However,	 its	efficacy	 in	the	management	of	cystinuria	 is	uncertain	 (Goldfarb	et	al.,	2006).	To	
date,	 no	 reports	 have	 emerged	 on	 the	 investigation	 of	 the	 direct	 effects	 of	 these	 drug	
therapies	upon	System	b0,+.	 In	addition	to	their	conjugating	action	upon	cystine,	 it	 is	possible	
that	they	could	affect	the	function	or	expression	of	System	b0,+.	Many	of	the	SLC	transporter	
families	in	the	intestinal	and	renal	epithelium	have	become	targets	for	drug	delivery	or	therapy	
such	as	the	SLC5	glucose	transporters,	and	the	SLC10	intestinal	bile	acid	transporters	(Hediger	
et	al.,	2004).	If	these	drugs	are	transported	into	the	renal	epithelium,	they	could	influence	the	
expression	of	 the	 transport	 system.	Additionally,	 if	 they	 are	 substrates	 for	 System	b0,+,	 their	
presence	 in	 the	 renal	 filtrate	 could	 competitively	 inhibit	 the	 transport	 of	 cystine	 or	 dibasic	
amino	 acids.	 In	 this	 chapter,	 we	 consider	 the	 effect	 of	 short	 and	 long-term	 incubation	 of	
oocytes	and	Caco-2	cells	upon	the	function	of	System	b0,+.	
The	 Endoplasmic	 Reticulum	 Associated	 Degradation	 (ERAD)	 pathway	 in	 cells	 is	 a	
collection	 of	 processes	 that	 remove	mis-folded	 proteins	 from	 the	 ER	 into	 the	 cytoplasm	 for	
proteasomal	 degradation	 (Meusser	 et	 al.,	 2005;	 Molinari,	 2007).	 The	 pathways	 putatively	
involved	 in	 ERAD	 were	 outlined	 in	 Chapter	 1.	 It	 is	 believed	 that	 the	 ER	 mediates	 rapid	
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degradation	of	 rBAT	mutant	proteins	 following	 their	assembly	with	b0,+AT	 (Bartoccioni	 et	al.,	
2008).	The	kinetics	of	 rBAT	mutant	degradation	post-assembly	with	b0,+AT	were	 the	same	as	
those	of	unassembled,	wild-type	rBAT	expressed	in	the	absence	of	the	light	chain	(Bartoccioni	
et	 al.,	 2008).	 Using	 pulse-chase	 experiments	 in	 MDCK	 cells,	 Bartoccioni	 et	 al.	 (2008)	
demonstrated	 that	 use	 of	 the	 proteasome	 inhibitor	 MG132	 delayed	 the	 degradation	 of	
unassembled	rBAT.	In	the	current	chapter,	we	investigated	whether	the	incubation	of	oocytes	
with	MG132	would	allow	rBAT	mutants	to	exit	the	ER	during	the	degradation	“lag”	identified	
by	Bartoccioni	et	al.	(2008).		
Another	 process	 by	 which	 the	 ERAD	 pathway	 can	 be	 inhibited	 is	 through	 the	
incubation	 of	 cell	 lines	 at	 low	 temperatures.	 Denning	 et	 al.	 (1992)	 demonstrated	 that	
incubation	of	 fibroblasts	 at	 26°C	 restored	 the	 function	of	 ΔF508-CFTR,	which,	 at	 the	 normal	
incubation	 temperature	 of	 37°C,	 is	 degraded	 by	 the	 ERAD	 pathway.	 This	 phenomenon	 was	
confirmed	 by	 the	 Cl-	 channel	 function	 in	 Xenopus	 oocytes	 and	 Sf9	 insect	 cells	 expressing	
ΔF508-CFTR,	 which	 are	 routinely	 incubated	 at	 18°C	 and	 28°C,	 respectively	 (Denning	 et	 al.,	
1992).	Pineda	et	al.	(2004)	demonstrated	the	same	effect	with	the	expression	of	rBAT	mutant	
R365W	in	HeLa	cells.	Wild-type	and	R365W	rBAT	were	co-expressed	 in	HeLa	cells	along	with	
b0,+AT,	 and	 cultured	 at	 37°C.	 No	 uptake	 of	 [35S]cystine	 was	 measured,	 into	 cells	 expressing	
R365W	rBAT	(Pineda	et	al.,	2004).	However,	when	the	cells	were	cultured	at	33°C,	the	uptake	
of	[35S]cystine	via	R365W-medicated	transport	was	not	significantly	different	to	the	wild-type	
(Pineda	et	al.,	2004).	In	this	chapter	we	consider	the	effects	of	oocyte	incubation	temperature	
upon	the	release	of	rBAT	mutant	proteins	from	the	ER.		
Glycosylation	is	the	process	of	bonding	oligosaccharide	chains	to	intracellular	proteins	
through	N-	 or	O-	 glycosidic	 bonds.	 The	 oligosaccharides	 serve	 as	 universal	markers	 to	 allow	
essential	 Endoplasmic	 Reticulum	 (ER)	 functions	 to	 occur.	 This	 can	 include	 protein	 folding,	
transfer	to	the	Golgi,	and	intracellular	targeting	of	translated	proteins	(Helenius	&	Aebi,	2001).	
The	 oligosaccharyl	 transferase	 responsible	 for	 the	 addition	 of	 N-glycans	 in	 the	 ER	 lumen	
recognises	a	specific	motif	within	the	nascent	polypeptide	chain:	Asn-Xaa-Ser/Thr,	where	Xaa	
can	 be	 any	 amino	 acid	 except	 proline	 (Roitsch	 &	 Lehle,	 1989;	 Gavel	 &	 von	 Heijne,	 1990).	
Although	necessary,	this	motif	is	not	sufficient	for	glycosylation	to	occur	(Gavel	&	von	Heijne,	
1990).		
	 The	 fact	 that	 these	 modifications	 can	 occur	 co-translationally	 implies	 a	 putative	
influence	of	glycosylation	upon	protein	secondary	structure	and	subsequent	function	(Paulson,	
1989).	 Studies,	 however,	 have	 revealed	 a	 great	 deal	 of	 variability	 in	 the	 importance	 of	
glycosylation	 on	 protein	 folding.	 For	 example,	 the	 incubation	 of	 Opossum	 Kidney	 (OK)	 cells	
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expressing	an	organic	cation	transporter	with	tunicamycin,	an	inhibitor	of	glycosylation,	for	8-
48h	reduced	uptake	of	[14C]TEA	by	65%,	suggesting	a	lack	of	mature	protein	at	the	membrane	
(Ott	et	al.,	1992).	However,	inhibition	of	protein	glycosylation	by	treatment	of	rabbit	intestinal	
epithelial	 cells	 with	 peptide:N-glycosidase-F	 (PNG-F)	 was	 shown	 to	 have	 no	 effect	 on	 the	
uptake	 of	 glucose	 via	 a	 sodium-dependent	 transporter	 (Hediger	 et	 al.,	 1991;	 Hirayama	 &	
Wright,	1992).	This	indicated	that	the	absence	of	glycosylation	of	the	transporter	had	no	effect	
on	the	structure	and	function	of	the	protein.	
Site-directed	mutagenesis	has	been	used	for	the	addition	or	removal	of	 individual	N-
glycosylation	motifs	in	transport	proteins	(Dubé	et	al.,	1988;	Vagin	et	al.,	2009).	This	provides	
insight	 into	 the	 importance	 of	 specific	 glycan	 residues	 as	 opposed	 to	 glycosylation	 of	 the	
protein	as	a	whole.	Dubé	et	al.	 (1998)	demonstrated	 that	whilst	 there	 is	an	aggregation	and	
lack	of	trafficking	of	unglycosylated	Erythropoetin	produced	in	the	presence	of	TM,	only	two	of	
the	three	glycosylation	sites	affect	function	when	individually	mutated.		
	 Several	groups	have	 investigated	the	effect	of	N-glycosylation	on	apical	 trafficking	of	
epithelial	 transporters	 (Vagin	 et	 al.,	 2009).	 Vagin	et	 al.	 (2005)	 demonstrated	 that	 sequential	
addition	 of	 five	 extra	 N-glycosylation	 motifs	 to	 the	 beta	 subunit	 of	 Na-K-ATPase	 (normally	
basolaterally-located)	caused	the	protein	to	be	increasingly	distributed	in	the	apical	membrane	
of	HGT-1	cells,	when	expressed	in	vitro	(Vagin	et	al.,	2005).	A	comprehensive	review	by	Vagin	
et	 al.	 (2009)	 discussed	 the	 effects	 of	 N-oligosaccharides	 on	 apical	 targeting	 of	 membrane	
proteins.	 Fifteen	 different	membrane	 proteins	were	 considered	 that	 had	 been	 studied	 in	 in	
vitro	 polarised	 cell	 systems	 where	 glycosylation	 was	 inhibited	 either	 by	 tunicamycin	 or	
mutagenesis	 (Vagin	et	al.,	2009).	Apical	 localisation	of	 five	of	 these	proteins	was	unaffected,	
six	were	retained	in	the	Golgi	or	other	intracellular	compartments,	and	four	had	a	decrease	in	
apical:basolateral	distribution	(Vagin	et	al.,	2009).	
	 Results	 from	 studies	 investigating	 the	 role	 of	 N-glycosylation	 in	 protein	 folding	 and	
targeting	vary	greatly	between	different	molecules.	However,	there	is	a	strong	indication	that	
glycosylation	 is	 involved	 in	 the	 targeting	 of	 apical	 membrane	 proteins	 (Hayes	 et	 al.,	 1994;	
Olivares	 et	 al.,	 1995;	 Lee	 et	 al.,	 2003;	 Vagin	 et	 al.,	 2009).	 Despite	 the	 range	 of	 apical	
transporters	 considered,	no	work	has	 yet	been	published	on	 the	 role	of	 glycosylation	 in	 the	
folding	 and	 specific	membrane	 targeting	 of	 the	 heavy	 chains	 of	 heterodimeric	 transporters,	
rBAT	and	CD98.		
	 In	 this	 chapter	 we	 consider	 how	 the	 glycosylation	 of	 rBAT	 affects	 the	 plasma	
membrane	 localisation	 of	 the	 protein.	 Additionally,	 modifications	 that	 could	 affect	 rBAT	
mutant	 protein	 expression	 were	 investigated.	 This	 included:	 the	 temperature-dependent	
		
	
	
327	
escape	 of	 mis-folded	 protein	 from	 the	 ER,	 and	 the	 inhibition	 of	 proteasomal	 degradation	
through	 incubation	 with	 MG132.	 We	 investigated	 the	 effect	 of	 current	 pharmacological	
therapies	 used	 in	 cystinuria	 on	 the	 expression	 and	 function	 of	 System	 b0,+.	 Any	measurable	
differences	 in	 the	 way	 rBAT	 mutant	 proteins	 react	 to	 particular	 cystine-binding	 thiol	 drugs	
(CBTDs)	would	allow	exploitation	of	 the	effect,	and	a	pharmacogenetic	approach	to	 therapy.	
Through	 increased	understanding	of	 the	biogenesis	of	 rBAT	 in	vivo	 and	 the	effect	of	 specific	
mutations	upon	these	processes,	it	could	be	possible	to	tailor	novel	therapies	to	the	genotype	
of	individual	patients.	
6.2	Methods	
A	 homology	 model	 of	 the	 rBAT	 extracellular	 domain	 was	 created	 as	 described	 in	
Chapter	 2.	 To	 predict	 the	 sites	 of	 N-linked	 glycosylation	 and	 to	 add	 glycan	 residues	 to	 the	
appropriate	 residues,	 the	 rBAT	 PDB	 file	 was	 uploaded	 to	 the	 online	 tool	 Glyprot	
(www.glycosciences.de/modeling/glyprot/main.php).	 The	 resultant	 PDB	 file	was	 downloaded	
and	viewed	in	PyMol.		
Uptake	experiments	were	performed	 in	Caco-2	monolayers	 grown	on	polycarbonate	
Transwell	filters	as	described	in	Chapter	2.	For	transfection	of	cells,	and	confocal	imaging,	the	
cells	were	seeded	on	13mm	glass	coverslips	in	24-well	plates.		
6.3	Results	
6.3.1	The	ERAD	pathway	as	a	mechanism	of	rBAT	degradation	
	[3H]Arginine	 uptake	 was	 performed	 in	 oocytes	 expressing	 wild-type	 rBAT	 or	 the	
mutant	proteins	M467T,	M465K,	N254T,	L4616P,	and	Y579D	following	6h	pre-incubation	with	
MG132.	A	control	group	of	oocytes	was	also	incubated	in	0.1%	DMSO	to	measure	any	effect	of	
the	solvent	upon	protein	expression	or	function.	The	expression	patterns	of	rBAT	and	mutant	
proteins	in	non-incubated	oocytes	was	broadly	similar	to	those	reported	in	Chapter	5	(Figure	
6.1A).	Significant	 (p<0.001)	 [3H]arginine	uptake	was	measured	 in	oocytes	 injected	with	cRNA	
for	rBAT,	N254T,	and	L416P	(Figure	6.1A).	Uptake	into	oocytes	expressing	M467T,	M465K,	and	
Y579D	 was	 not	 significantly	 higher	 (p>0.05)	 than	 background	 uptake	 in	 water-injected	
controls.	 No	 significant	 difference	 (p>0.05)	 in	 [3H]arginine	 uptake	 was	 measured	 between	
control	oocytes,	those	incubated	with	DMSO	alone,	or	those	incubated	with	MG132	in	DMSO	
(Figure	 6.1A).	 This	 indicated	 that	 although	 MG132	 can	 cause	 a	 lag	 in	 degradation	 of	
unassembled	rBAT	 (Bartoccioni	et	al.,	2008),	 this	alone	does	not	allow	trafficking	of	 the	mis-
folded	protein	to	the	plasma	membrane	in	oocytes.	However,	to	fully	investigate	the	effect	of	
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this	 compound	 upon	 the	 expression	 of	 the	mutant	 proteins,	 further	 investigation	would	 be	
required.	 It	 may	 be	 necessary	 to	 incubate	 the	 oocytes	 at	 a	 different	 concentration	 at	 the	
compound	 for	 extended	 time	 periods	 in	 order	 to	 see	 an	 effect.	 Alternatively,	 co-incubation	
with	a	molecular	chaperone	may	aid	 the	escape	of	 the	molecule	 from	the	ER,	whilst	MG132	
inhibits	the	activation	of	the	ERAD	pathways.	
It	 was	 desirable	 to	 assess	 whether	 the	 routine	 incubation	 temperature	 of	 oocytes	
(18°C)	allowed	the	release	of	rBAT	mutant	protein	from	the	ER.	It	has	been	demonstrated	that	
incubation	temperatures	below	26°C	can	allow	the	release	of	mis-folded	proteins	from	the	ER	
(Denning	et	al.,	1992).	At	37°C,	these	mis-folded	proteins	are	degraded	by	the	ERAD	pathway	
(Denning	 et	 al.,	 1992).	 However,	 it	 is	 not	 possible	 to	 incubate	 oocytes	 at	 temperatures	
exceeding	 26°C	 for	 prolonged	 periods.	 Therefore,	 to	 investigate	 the	 effect	 of	 short-term	
incubation	at	higher	 temperatures,	 [3H]arginine	uptake	was	performed	at	 room	temperature	
(22°C)	and	at	30°C	(Figure	6.1B).	At	higher	temperatures,	we	would	hypothesise	that	a	greater	
reduction	 in	 [3H]arginine	 uptake	 would	 be	 observed	 via	 the	 mutant	 proteins.	 However,	
following	uptake	over	60min	at	30°C,	no	significant	change	(p>0.05)	in	[3H]arginine	uptake	was	
observed	in	the	wild-type	or	mutant	proteins	(Figure	6.1B).	It	is	likely	that	incubation	at	higher	
temperatures	for	longer	periods	of	time	would	be	required	to	observe	any	effect.	To	measure	
an	 effect	 by	 our	 proposed	 mechanism,	 oocytes	 would	 need	 to	 be	 incubated	 at	 high	
temperatures	for	longer	than	the	half-life	of	rBAT	protein	at	the	plasma	membrane,	reported	
to	be	>8h	by	Bartoccioni	et	al.	(2008).	In	order	to	investigate	this	effect	further,	expression	of	
rBAT	and	mutant	rBAT	proteins	in	a	mammalian	cell	line	is	desirable.		 	
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Figure	 6.1:	 The	 effect	 of	 proteasomal	 inhibition	 and	 high	 temperatures	 on	 ER-mediated	
degradation	 of	 rBAT	 mutant	 proteins.	 [3H]Arginine	 uptake	 (10μM,	 Na+-free,	 pH7.4)	 3	 days	
post-injection	 of	 oocytes	 with	 water,	 rBAT	 (50ng),	 or	 mutant	 rBAT	 cRNA.	 A,	 [3H]Arginine	
uptake	 in	 oocytes	 injected	 with	 water	 (n=10),	 or	 50ng	 cRNA	 for	 wild-type	 rBAT	 (n=8-10),	
M467T	 (n=9-10),	 M465K	 (n=10),	 N254T	 (n=8-10),	 L416P	 (n=8-9),	 or	 Y579D	 (n=10).	 Oocytes	
were	 pre-incubated	 for	 6h	 in	 MBS	 alone	 (open	 bars),	 or	 MBS	 containing	 0.1%	 (v/v)	 DMSO	
(black	 bars),	 or	 0.1%	 (v/v)	 DMSO	 and	 10μM	 MG132	 (grey	 bars);	 B,	 [3H]Arginine	 uptake	 in	
oocytes	injected	with	water	(n=10),	or	50ng	cRNA	for	wild-type	rBAT	(n=10),	M467T	(n=9-10),	
M465K	 (n=10),	N254T	 (n=8-10),	 L416P	 (n=8-10),	 or	 Y579D	 (n=10).	Uptake	was	 performed	 at	
22°C	 (open	 bars)	 or	 30°C	 (black	 bars)	 over	 60min.	 Data	 are	 mean±SEM;	 ***,	 p<0.001;	 ns,	
p>0.05	versus	non-incubated	water-injected	oocytes	at	22°C.	
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6.3.2	The	effect	of	alkalinisation	on	System	b0,+	activity	in	oocytes	
The	mainstay	of	current	cystinuria	therapy	is	the	solubilisation	of	cystine	 in	the	renal	
filtrate	and	urine	(Barbey	et	al.,	2000;	Thomas	et	al.,	2014).	First-line	therapy	in	cystine	stone-
forming	 patients	 is	 long-term	hyperdiuresis	 and	 urinary	 alkalinisation	 (Goldfarb	 et	 al.,	 2006;	
Chillarón	 et	 al.,	 2010;	 Thomas	 et	 al.,	 2014).	 The	 first	 report	 of	 System	 b0,+	 activity	 by	 Van	
Winkle	 et	 al.	 (1988)	 noted	 that	 there	 was	 no	 effect	 of	 pH	 in	 the	 range	 6.3-8.0	 in	 mouse	
blastocysts.	The	“normal”	pH	of	 the	 renal	 filtrate	 is	around	6.7	 (Rector	 et	al.,	1965;	Vieira	&	
Malnic,	1968;	Malnic	et	al.,	1972;	Yoshitomi	&	Fromter,	1984;	Jaramillo-Juarez	et	al.,	1990).	At	
pH	6.7,	the	solubility	of	cystine	is	estimated	to	be	1-2mM	(250-500mg.l-1),	which	increases	2-
fold	at	pH	7.5	(Pak,	1969;	Nakagawa	et	al.,	2000;	Goldfarb	et	al.,	2006;	Chillarón	et	al.,	2010).	
Following	 an	 intravenous	 infusion	 of	 sodium	 bicarbonate,	 the	 pH	 of	 the	 proximal	 tubular	
filtrate	in	rats	has	been	shown	to	reach	≈pH	7.6	(Rector	et	al.,	1965).	We	investigated	whether	
long-term	 incubation	of	oocytes	at	a	 range	of	pH	values	can	affect	 the	expression	of	System	
b0,+.	
[3H]Arginine	uptake	was	performed	in	oocytes	injected	with	water	or	rBAT	cRNA	at	a	
pH	range	of	6.0-8.0	(Figure	6.2).	No	significant	difference	(p>0.05)	 in	[3H]arginine	uptake	was	
observed	 in	 rBAT-injected	 oocytes	 measured	 at	 any	 of	 the	 pH	 values	 (Figure	 6.2).	 This	
supported	 the	 findings	of	Van	Winkle	et	al.	 (1988).	We	 then	 investigated	 the	effect	of	 long-
term	incubation	of	oocytes	at	different	pH	values	to	detect	any	alteration	in	the	expression	or	
function	of	System	b0,+.	Oocytes	injected	with	water	or	rBAT	cRNA	were	pre-incubated	for	6h	
at	 pH	 6.7,	 7.4,	 or	 7.7.	 [3H]Arginine	 uptake	was	 then	 performed	over	 60min	 at	 pH	 6.7-7.7	 in	
oocytes	 that	 had	 been	 pre-incubated	 at	 all	 3	 pH	 values	 (Figure	 6.3).	 No	 significant	 change	
(p>0.05)	 in	 uptake	was	 observed	 following	 pre-incubation	 at	 pH	 6.7-7.7.	 This	 indicated	 that	
alkalinisation	of	the	renal	filtrate	likely	has	no	effect	upon	the	expression	of	System	b0,+.	The	in	
vivo	 decrease	 in	 cystine	 stone	 formation	 in	 patients	 treated	 with	 sodium	 bicarbonate	 or	
potassium	citrate	can	thus	be	attributed	to	an	increase	in	cystine	solubility.			
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Figure	6.2:	System	b0,+	activity	in	oocytes	at	pH	6-8.	[3H]Arginine	uptake	(10μM,	Na+-free,	pH	
6-9)	 in	 oocytes	 injected	 with	 water	 (control),	 or	 rBAT	 cRNA	 (50ng),	 3	 days	 post-injection.	
Oocytes	were	incubated	at	pH	7.5	until	the	start	of	the	uptake	measurement	when	they	were	
placed	 in	 the	uptake	solution	at	pH	6.0-8.0	 (n=8-10).	Data	are	mean±SEM.	ns,	p>0.05	versus	
uptake	at	pH	7.5.	
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Figure	 6.3:	 The	 effect	 of	 pre-incubation	 pH	 on	 measurements	 of	 System	 b0,+	 activity	 in	
oocytes.	[3H]Arginine	uptake	(10μM,	pH	6.7-7.7,	60min)	in	oocytes	injected	with	water	or	rBAT	
cRNA	 (50ng),	 following	 6h	 pre-incubation	 at	 pH	 6.7-7.7.	 A,	 [3H]Arginine	 uptake	 in	 oocytes	
injected	with	water	(control)	or	rBAT	cRNA	(50ng)	at	pH	6.7-7.7	following	pre-incubation	(5h)	
at	pH	6.7	(n=10);	B,	[3H]Arginine	uptake	in	oocytes	injected	with	water	(control)	or	rBAT	cRNA	
(50ng)	at	pH	6.7-7.7	following	pre-incubation	(6h)	at	pH	7.4	(n=10);	C,	 [3H]Arginine	uptake	 in	
oocytes	 injected	 with	 water	 (control)	 or	 rBAT	 cRNA	 (50ng)	 at	 pH	 6.7-7.7	 following	 pre-
incubation	(6h)	at	pH	7.7	(n=10).	 	Data	are	mean±SEM.	ns,	p>0.05	versus	uptake	at	pH	7.4	in	
rBAT-expressing	oocytes	pre-incubated	at	pH	7.4.	
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6.3.3	The	effects	of	current	pharmacological	therapies	for	cystinuria	on	the	function	of	
System	b0,+	
Cystine-binding	 thiol	 drugs	 are	 used	 in	 an	 estimated	 30%	of	 patients	with	 cystinuria	
(Thomas	 et	 al.,	 2014).	 Their	 use	 can	 lead	 to	 a	 50-fold	 increase	 in	 the	 solubility	 of	 cystine	
through	 formation	 of	 a	 drug-cysteine	 conjugate	 (Thomas	 et	 al.,	 2014).	 The	 low	 incidence	 of	
their	use	is	mainly	attributed	to	a	side	effect	profile	including	rashes,	nausea	leucopenia,	and	
proteinuria.	The	Angiotensin	Converting	Enzyme	inhibitor	(ACEi)	Captopril	 is	better	tolerated,	
although	reports	of	its	clinical	efficacy	in	cystinuria	have	varied	(Sloand	&	Izzo,	1987;	Cohen	et	
al.,	1995).	A	lower	efficacy	of	captopril	in	cystinuria	has	been	attributed	to	relatively	low	peak	
urinary	 concentrations	 (Goldfarb	 et	 al.,	 2006).	Despite	 the	 investigations	 into	 the	efficacy	of	
these	 drugs	 in	 increasing	 cystine	 solubility,	 no	 data	 has	 been	 published	 which	 reports	 any	
direct	 interaction	 with	 the	 transport	 system.	 To	 estimate	 concentrations	 of	 the	 CBTD	 that	
would	 be	 deemed	 “physiological”	 in	 the	 renal	 filtrate,	 peak	 plasma	 concentration	 data	was	
taken	from	the	literature	(Table	6.1).	As	all	of	these	drugs	had	a	molecular	weight	<5kDa	they	
were	considered	to	be	freely	filtered	from	the	glomerulus.		
[3H]Arginine	 uptake	 was	 performed	 in	 oocytes	 injected	 with	 water	 or	 rBAT	 cRNA	
following	 24h	 pre-incubation	 with	 captopril	 (3.7μM).	 Uptake	 was	 also	 performed	 in	 the	
presence	of	3.7μM	captopril	in	the	uptake	solution.	Pre-incubation	of	rBAT-expressing	oocytes	
with	captopril	did	not	affect	[3H]arginine	uptake	levels,	compared	to	the	control	uptake	values	
in	oocytes	that	had	not	been	pre-incubated	(Figure	6.4A).	Similarly,	the	presence	of	captopril	
in	 the	 uptake	 solution	 did	 not	 significantly	 change	 (p>0.05)	 the	 binding	 or	 translocation	 of	
[3H]arginine	 by	 the	 transport	 system	 in	 oocytes.	 No	 significant	 difference	 (p>0.05)	 in	
[3H]arginine	uptake	was	observed	 in	oocytes	 following	pre-incubation	with	 captopril	 nor	 the	
introduction	of	captopril	into	the	uptake	solution	at	physiological	concentrations	(Figure	6.4A).	
A	 similar	 effect	 was	 observed	 when	 the	 experiment	 was	 repeated	 with	 tiopronin	 (24	 μM)	
(Figure	6.4B)	and	D-penicillamine	(134nM)	(Figure	6.4C).		
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Figure	6.4:	System	b0,+	function	in	oocytes	following	pre-incubation	with	cystine	binding	thiol	
drugs	 at	 physiological	 concentrations.	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	
(control)	or	 rBAT	cRNA	 (50ng)	 in	 the	presence	 (+)	or	absence	 (-)	of	 thiol	drugs	used	 to	 treat	
cystinuria,	 with	 (+)	 or	 without	 (-)	 pre-incubation	 (24h).	 A,	 [3H]Arginine	 uptake	 in	 oocytes	
injected	 with	 water	 (control,	 n=18-20)	 or	 rBAT	 cRNA	 (50ng,	 n=19-20)	 in	 the	 presence	 or	
absence	 of	 3.7μM	 captopril;	 B,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	water	 (control,	
n=20)	 or	 rBAT	 cRNA	 (50ng,	 n=18-20)	 in	 the	 presence	 or	 absence	 of	 24μM	 tiopronin;	 C,	
[3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	 (control,	 n=19-20)	 or	 rBAT	 cRNA	 (50ng,	
n=19-20)	in	the	presence	or	absence	of	134nM	D-penicillamine.	-/-,	no	drug	pre-incubation	or	
in	 the	uptake	solution;	+/-,	pre-incubation	with	drug,	no	drug	 in	 the	uptake	solution;	 -/+,	no	
drug	pre-incubation,	drug	in	the	uptake	solution;	+/+	pre-incubation	with	the	drug	and	drug	in	
the	uptake	solution.	Data	are	mean	±SEM.	ns,	p>0.05	versus	uptake	in	rBAT-injected	oocytes	in	
the	absence	of	drug	pre-incubation	or	in	the	uptake	solution	(-/-).	
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It	was	desirable	to	investigate	whether	the	current	cystinuria	therapies	would	lead	to	a	
difference	 in	 patient	 response	 based	 upon	 their	 genotype.	 Potentially,	 this	 could	 lead	 to	
personalised	 therapies	 for	 patients	 with	 cystinuria	 and	 improved	 treatment	 outcomes.	 The	
24h	pre-incubation	of	oocytes	with	the	CBTD	was	repeated	in	oocytes	expressing	the	wild-type	
rBAT	 or	 the	mutant	 proteins.	 It	 had	 been	 established	 that	 the	 presence	 of	 the	 CBTD	 in	 the	
uptake	 solution	 at	 physiological	 concentrations	 did	 not	 compete	 for	 transport	 with	
[3H]arginine	(Figure	6.4).		
[3H]Arginine	uptake	was	performed	in	oocytes	injected	with	water,	rBAT	cRNA	or	the	
cRNA	 for	 rBAT	 mutants	 M467T,	 M456K,	 N254T,	 L416P,	 or	 Y579D	 (Figure	 6.5).	 In	 oocytes	
expressing	 rBAT,	 [3H]arginine	 uptake	 was	 17-fold	 greater	 than	 in	 water-injected	 control	
oocytes	 (Figure	 6.5).	 Following	 pre-incubation	 with	 tiopronin	 (24μM)	 or	 D-penicillamine,	
uptake	via	wild-type	expressing	oocytes	was	not	significantly	different	(p>0.05)	to	the	control	
group	(Figure	6.5).	However,	pre-incubation	with	captopril	(3.7μM)	led	to	a	2-fold	decrease	in	
[3H]arginine	uptake	 (p>0.05).	 This	was	 likely	due	 to	deterioration	 in	quality	of	 this	particular	
group	 of	 oocytes	 during	 pre-incubation	with	 the	 thiol	 drug.	 In	 oocytes	 expressing	 the	 rBAT	
mutant	proteins	M467T,	M465K,	and	Y579D,	the	control	uptake	was	significantly	lower	than	in	
oocytes	 expressing	 the	wild-type	protein	 (p<0.001)	 (Figure	 6.5A,	 B,	 and	 E,	 respectively).	 The	
uptake	levels	of	all	mutant	proteins	following	24h	incubation	with	the	CBTDs	were	unaltered.		
When	[3H]arginine	uptake	was	carried	out	in	oocytes	expressing	rBAT	mutants	N254T	
and	 L416P,	 the	 levels	 of	 uptake	 were	 significantly	 lower	 than	 the	 wild-type	 uptake	 values	
(Figure	 6.5C	 and	 D).	 This	 is	 consistent	 with	 the	 reduction	 in	 Vmax	 observed	 following	
concentration-dependent	uptake	of	[3H]arginine	 in	Chapter	5	(Figures	5.19	and	5.24),	 further	
evidencing	that	these	mutations	are	pathogenic.	However,	as	observed	with	the	other	mutant	
rBAT	 proteins,	 [3H]arginine	 uptake	 via	 N254T	 and	 L416P-mediated	 transport	 following	 pre-
incubation	 with	 the	 drugs	 was	 unaffected	 by	 pre-incubation	 with	 any	 of	 the	 3	 CBTDs	 at	
physiological	concentrations	(Figure	6.5C	and	D).		 	
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Figure	6.5:	System	b0,+	 function	 in	oocytes	expressing	wild-type	and	mutant	rBAT	following	
pre-incubation	 with	 thiol	 drugs	 at	 physiological	 concentrations.	 [3H]Arginine	 uptake	 in	
oocytes	injected	with	water,	or	wild-type	or	mutant	rBAT	cRNA	(50ng,	day	3)	in	the	presence	
of	thiol	drugs	used	to	treat	cystinuria,	following	24h	pre-incubation.	Where	captopril	(3.7μM),	
tiopronin	(24μM),	or	d-penicillamine	(124nM)	was	present	in	the	uptake	solution,	oocytes	had	
been	 pre-incubated	 in	 the	 drugs	 for	 24h	 at	 these	 concentrations.	 A,	 [3H]Arginine	 uptake	 in	
oocytes	 injected	 with	 water	 (control,	 n=10)	 ,	 wild-type	 rBAT	 cRNA	 (50ng,	 n=10),	 or	 M467T	
cRNA	(n=10);	B,	[3H]Arginine	uptake	in	oocytes	injected	with	water	(control,	n=10)	,	wild-type	
rBAT	 cRNA	 (50ng,	 n=10),	 or	M465K	 cRNA	 (n=10);	 C,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	
with	 water	 (control,	 n=10)	 ,	 wild-type	 rBAT	 cRNA	 (50ng,	 n=10),	 or	 N254T	 cRNA	 (n=10);	 D,	
[3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	 (control,	 n=10)	 ,	 wild-type	 rBAT	 cRNA	
(50ng,	 n=10),	 or	 L416P	 cRNA	 (n=10);	 E,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	
(control,	 n=10)	 ,	 wild-type	 rBAT	 cRNA	 (50ng,	 n=10),	 or	 Y579D	 cRNA	 (n=10);	 Data	 are	mean	
±SEM.	Cap,	captopril;	Tio,	tiopronin;	Pen,	D-penicillamine.	ns,	p>0.05	versus	uptake	in	control	
oocytes	injected	with	the	same	cRNA.	
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The	mammalian	epithelial	 cell	 line,	Caco-2,	endogenously	expresses	both	subunits	of	
System	 b0,+,	 mediating	 Na+-independent	 uptake	 of	 dibasic	 amino	 acids	 across	 the	 apical	
membrane	 (Thwaites	 et	 al.,	 1996;	 Anderson	 et	 al.,	 2004).	 To	 demonstrate	 this,	 [3H]arginine	
uptake	 was	 carried	 out	 across	 the	 apical	 membrane	 of	 Caco-2	 monolayers	 in	 the	 absence	
(control)	or	presence	of	5mM	competitor	compounds	lysine,	leucine,	and	proline	(Figure	6.6).	
[3H]Arginine	uptake	was	 inhibited	 in	 the	order:	arginine>	 lysine>	 leucine>>proline.	Uptake	 in	
the	presence	of	5mM	proline	was	not	significantly	different	 (p>0.05)	 than	 in	control	oocytes	
(Figure	6.6).		
	 [3H]Arginine	uptake	was	carried	out	 in	Caco-2	cells	following	24h	pre-incubation	with	
captopril	(3.7μM),	tiopronin	(24μM),	or	D-penicillamine	(134nM)	in	the	presence	or	absence	of	
the	 same	 drug	 in	 the	 uptake	 solution	 (Figure	 6.7).	 No	 significant	 difference	 (p>0.05)	 in	
[3H]arginine	 uptake	was	measured	 following	 pre-incubation	with	 any	 of	 the	 three	 CBTDs	 at	
physiological	concentrations	(Figure	6.7).	This	measurement	was	then	repeated	with	all	three	
drugs	 at	 1mM	 concentration	 to	 identify	 if	 any	 drug-induced	 effects	 would	 occur	 at	 higher	
concentrations	 (Figure	 6.8).	 No	 effect	 on	 System	 b0,+	 function	 was	 observed	 following	
incubation	 with	 captopril	 or	 tiopronin	 (Figure	 6.8A	 and	 B,	 respectively).	 Cell	 monolayers	
exposed	 to	1mM	D-penicillamine	 show	a	 reduced	uptake	of	 [3H]arginine,	which	 increased	 in	
monolayers	that	had	been	exposed	to	the	drug	for	24h	(Figure	6.8C).	We	hypothesise	that	this	
is	due	to	a	toxic	effect	on	the	cells	following	incubation	with	this	thiol	drug	at	a	concentration	
7.5x103	-fold	higher	than	the	estimated	physiological	concentration.	
	 In	 conclusion,	 these	 data	 present	 no	 evidence	 for	 any	 direct	 effect	 of	 current	
pharmacological	therapies	on	the	transport	system.	Such	evidence	could	have	provided	scope	
for	 a	 pharmacogenetic	 approach	 to	 cystinuria	 therapy	 in	 the	 case	 of	 mutant	 proteins	
responding	differently	 to	 therapy.	However,	 it	 is	 likely	 that	 the	 focus	of	 novel	 therapies	will	
target	the	underlying	genetic	cause	of	the	disease.		
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Figure	6.6:	System	b0,+	substrate	specificity	in	Caco-2	monolayers	determined	by	competitive	
inhibition	 of	 [3H]arginine	 uptake.	 [3H]Arginine	 uptake	 (10μM,	 Na+-free,	 pH	 7.4)	 in	 Caco-2	
monolayers.	Uptake	was	performed	over	5min	 in	 the	absence	 (control)	or	presence	of	5mM	
competitor	compounds	arginine	(n=10),	 lysine	(n=10),	 leucine	(n=10),	and	proline	(n=8).	Data	
are	mean±SEM.			
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Figure	 6.7:	 The	 effect	 of	 cystine-binding	 thiol	 drugs	 at	 physiological	 concentrations	 on	 the	
function	of	System	b0,+	in	Caco-2	cells.	[3H]Arginine	uptake	(10μM,	Na+-free,	pH	7.4)	in	Caco-2	
monolayers.	Uptake	was	performed	without	pre-incubation	of	cells	over	5min	in	the	presence	
(-/+)	of	CBTD	at	physiological	 concentrations.	Uptake	was	also	performed	 following	24h	pre-
incubation	of	monolayers	with:	A,	captopril	(3.7μM);	B,	tiopronin	(24μM)	C,	or	d-penicillamine	
(134nM)	 in	 the	 presence	 (+/+)	 of	 CBTD	 at	 the	 same	 physiological	 concentrations.	 Data	 are	
mean±SEM	(n=8).		ns,	p>0.05	versus	uptake	in	monolayers	without	exposure	to	CBTD	(-/-).	
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Figure	6.8:	 The	effect	 of	 1mM	cystine-binding	 thiol	 drugs	on	 the	 function	of	 System	b0,+	in	
Caco-2	cells.	 [3H]Arginine	uptake	(10μM,	Na+-free,	pH	7.4)	in	Caco-2	monolayers.	Uptake	was	
performed	 without	 pre-incubation	 of	 cells	 over	 5min	 in	 the	 presence	 (-/+)	 of	 1mM	 CBTD.	
Uptake	 was	 also	 performed	 following	 24h	 pre-incubation	 of	 monolayers	 with:	 A,	 1mM	
captopril;	 B,	 tiopronin,	 or;	 C,	 D-penicillamine	 in	 the	 presence	 (+/+)	 of	 1mM	 CBTD.	 Data	 are	
mean±SEM	(n=4-5).		ns,	p>0.05	versus	uptake	in	monolayers	without	exposure	to	CBTD	(-/-).	
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6.3.4	The	transient	expression	of	rBAT3F	in	Caco-2	cell	monolayers	
As	 part	 of	 this	 investigation,	 it	 was	 desirable	 to	 express	 exogenous	 rBAT3F	 in	 a	
mammalian	cell	 line.	This	would	enable	the	FLAG-tagged	construct	to	be	expressed,	allowing	
immunodetection	 of	 the	 transiently	 expressed	 protein.	 Following	 the	 optimisation	 of	 rBAT3F	
expression	 in	Caco-2	 cells,	we	would	be	able	 to	express	 rBAT	mutant	proteins	of	 interest	 to	
detect	their	expression	in	the	cell	line.	As	we	have	demonstrated	in	section	6.3.3,	Caco-2	cells	
endogenously	express	both	subunits	of	System	b0,+	(Thwaites	et	al.,	1996).	Thus,	 this	cell	 line	
was	selected	for	transfection	of	rBAT	cDNA	due	to	the	increased	likelihood	of	correct	protein	
processing	and	targeting	to	the	apical	membrane.	
To	optimise	the	transient	transfection	of	Caco-2	cells,	they	were	seeded	at	a	range	of	
densities	 (1x104-2.5x105.cm-2)	on	13mm	glass	 cover	 slips	and	grown	 for	24h	 (see	Chapter	2).	
The	cells	were	then	visualised	under	a	light	microscope	to	assess	monolayer	confluency	at	24h	
(Figure	6.9).	In	order	for	successful	transfection	with	Lipofectamine,	cells	needed	to	be	50-80%	
confluent	(Hawley-Nelson	et	al.,	2008).	At	24h	post-seeding,	Caco-2	cells	seeded	at	the	three	
highest	 densities	 appeared	 at	 optimum	 confluency	 for	 transfection	 (Figure	 6.9).	 Cells	 were	
transfected	as	described	in	Chapter	2	using	the	plasmid	vector	pEGFP-N2,	which	contains	the	
open	 reading	 frame	 for	 enhanced	 green	 fluorescent	 protein	 (EGFP).	 This	 allowed	 successful	
transfection	to	be	visualised	by	fluorescent	microscopy	following	excitation	at	452-500nm.	The	
highest	number	of	cells	expressing	EGFP	was	observed	in	cells	seeded	at	1.5x105.cm-2	(Figure	
6.10C).	 This	 indicated	 that	 transfection	 of	 Caco-2	 cells	 24h	 post-seeding	was	 optimal	 at	 this	
density.	 In	 cells	 seeded	 at	 0.5-1x105.cm-2,	 less	 fluorescence	 was	 observed	 (Figure	 6.10A).	 It	
appeared	as	though	the	confluence	of	cells	seeded	at	a	density	of	2.5x105.cm-2	was	too	high	
for	 transfection	 of	 the	 cDNA.	 No	 fluorescence	 was	 visualised	 in	 these	 cells	 24h	 post-
transfection,	indicating	an	absence	of	EGFP	expression	(Figure	6.10D).	Subsequent	transfection	
of	 Caco-2	 cells	 using	 the	 pCMV.SPORT6	 vector	 containing	 rBAT3F	 was	 carried	 out	 24h	 post-
seeding	of	cells	at	a	density	of	at	1-1.5x105.cm-2.	
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Figure	6.10:	Transient	expression	of	EGFP	in	Caco-2	monolayers	24h	post-transfection.	Caco-
2	 cells	were	 seeded	 at	 a	 range	 of	 densities	 and	 transfected	with	 cDNA	 for	 EGFP.	 24h	 post-
transfection,	 cells	 were	 visualised	 by	 light	 and	 fluorescent	 microscopy	 (488-509nm,	 x20	
magnification).	Scale	bar,	50μm.	
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Caco-2	 cells	 were	 transfected	 with	 cDNA	 for	 rBAT3F	 as	 described	 in	 Chapter	 2.	 To	
maximise	 the	 amount	 of	 rBAT3F	 successfully	 targeted	 to	 the	 Caco-2	 apical	 membrane,	
monolayers	 were	 fixed	 72h	 post-transfection.	 Immunocytochemical	 detection	 of	 rBAT	 using	
the	M2	anti-FLAG	antibody	was	performed	as	described	in	Chapter	2.	Additionally,	monolayers	
were	 incubated	 with	 an	 antibody	 raised	 against	 ezrin,	 used	 here	 as	 an	 apical	 membrane	
marker.	Ezrin	is	a	cytoskeletal	protein	located	in	the	apical	membranes	of	polarised	epithelial	
tissues	(Bretscher	et	al.,	1997).	Co-localisation	of	ezrin	and	rBAT	would	identify	the	presence	of	
the	transiently	expressed	rBAT	at	the	apical	membrane.	Unfortunately,	when	imaging	the	cells,	
it	was	discovered	that	there	was	some	crosstalk	between	detection	of	FITC	(rBAT,	emission	at	
525nm)	 and	 TRITC	 (ezrin,	 emission	 at	 570nm)	 (Figure	 6.11Aii	 and	 Bii).	 This	 meant	 that	 the	
fluorescence	 visible	 from	 rBAT	 was	 also	 visible	 when	 detecting	 ezrin,	 making	 it	 appear	
intracellular.	However,	the	ezrin-associated	fluorescence	was	not	detected	as	rBAT.	This	meant	
that	 although	 some	 intracellular	 “ezrin”	 fluorescence	 was	 visible,	 only	 rBAT-associated	 FITC	
fluorescence	was	a	true	measurement	of	its	location.		
At	 72h	post-transfection,	 it	 did	 appear	 as	 though	 some	 rBAT	protein	was	present	 at	
the	apical	membrane	of	Caco-2	monolayers,	co-localising	with	the	ezrin	protein	(Figure	6.11Aiii	
and	 Biii).	 However,	much	 of	 the	 protein	 remained	 intracellular	 (Figure	 6.11).	 Unfortunately,	
due	 to	 time	restrictions	on	 this	 study,	we	were	unable	 to	 transfect	Caco-2	cells	with	mutant	
rBAT	 cDNA	 to	 identify	 differences	 in	 mutant	 protein	 expression	 patterns.	 McCloy	 (2002)	
identified	 that	 there	 is	 a	 delay	 in	 the	 apical	 membrane	 localisation	 of	 rBAT	 relative	 to	 the	
polarisation	of	the	epithelium	in	Caco-2	cells.	Caco-2	cell	monolayers	are	routinely	grown	for	
14-21	 days	 to	 ensure	 full	 differentiation	 although	 are	 polarised	 within	 1-2	 days	 following	
seeding	 at	 high	 density	 (2.5x105cells.cm-2).	 This	 would	 not	 be	 possible	 with	 transiently	
transfected	Caco-2	cell	monolayers	but	future	experiments	would	be	designed	to	increase	the	
incubation	 period	 beyond	 72h	 to	 maximise	 apical	 membrane	 expression	 of	 wild-type	 rBAT	
protein	and	to	allow	comparison	with		mutated	rBAT	proteins.		
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Figure	6.11:	Sub-cellular	localisation	of	rBAT3F	72h	post-transfection	of	Caco-2	monolayers.	X-
Z	 section	 fluorescent	 confocal	microscopy	 images	 of	 Caco-2	monolayers	 (x63	magnification)	
transiently	 transfected	 with	 rBAT3F	 in	 pCMV-SPORT6.	 White	 arrows	 indicate	 co-localisation	
(yellow)	of	ezrin	(red)	and	rBAT	(green).	Scale	bar,	10μm;	*,	cross-talk	fluorescence	from	FITC	
fluorophore	detected	at	570nm.			
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6.3.5	The	effect	of	genistein	on	the	function	of	System	b0,+	in	oocytes	and	Caco-2	monolayers	
Genistein	 is	 an	 isoflavone	 compound	 that	 has	 been	 shown	 to	 inhibit	 tyrosine	 kinase	
activity	 in	mammalian	cells	 (Akiyama	et	al.,	1987).	Many	studies	have	reported	the	ability	of	
genistein	 to	activate	 the	epithelial	 cAMP-activated	Cl-	 channel,	CFTR,	 in	 transfected	cell	 lines	
(Sears	 et	 al.,	 1995;	 Illek	 et	 al.,	 1996;	 Reenstra	 et	 al.,	 1996;	 Yang	 et	 al.,	 1997)	 and	 those	
endogenously	expressing	the	protein	(Illek	et	al.,	1995;	Sears	et	al.,	1995).	The	mechanism	of	
this	 is	believed	to	be	the	prevention	of	 the	phosphorylation	of	Nucleotide	Binding	Domain	2	
(NBD2)	in	the	channel,	which	leads	to	a	prolonged	burst	duration	of	the	channel	(French	et	al.,	
1997).	 However,	 when	 the	 effects	 of	 genistein	 were	 investigated	 in	 epithelial	 transporters	
GLUT-1	 (Vera	 et	 al.,	 1996)	 and	 MDR1	 (Versantvoort	 et	 al.,	 1993),	 an	 inhibitory	 effect	 was	
observed.	In	2001,	Mizoguchi	et	al.	reported	a	stimulation	of	System	b0,+	activity	in	COS-7	cells	
transiently	expressing	rBAT	and	b0,+AT	following	a	20min	pre-incubation	with	2-50μM	genistein	
(Mizoguchi	 et	 al.,	 2001).	 The	 authors	 attributed	 this	 increase	 in	 [14C]cystine	 uptake	 in	 the	
presence	 of	 genistein	 to	 be	 due	 to	 an	 increased	 rate	 of	 transport.	 It	was	 hypothesised	 that	
PKA-dependent	 tyrosine	 phosphorylation	 of	 b0,+AT	 could	 negatively	 regulate	 transport	
function,	 leading	 to	a	decrease	 in	 [14C]cystine	 transport	 (Mizoguchi	 et	 al.,	 2001).	 If	 genistein	
was	 confirmed	 to	 stimulate	 System	 b0,+	 activity,	 it	 could	 have	 therapeutic	 potential	 in	
cystinuria	 patients.	 A	 similar	 application	 of	 genistein	 has	 been	 proposed	 in	 Cystic	 Fibrosis	
(French	et	al.,	1997).	
In	the	current	study,	the	effect	of	genistein	on	System	b0,+	 function	was	measured	 in	
oocytes.	 [3H]Arginine	uptake	was	performed	 in	oocytes	 injected	with	water	 (control)	or	rBAT	
cRNA	 following	 20min	 pre-incubation	 with	 0-50μM	 genistein	 (Figure	 6.12).	 No	 significant	
difference	(p>0.05)	in	uptake	was	measured	following	treatment	of	the	oocytes	with	genistein	
at	 10-50μM	 (Figure	 6.12).	 The	 experiment	 was	 repeated	 using	 Caco-2	 cells	 (Figure	 6.13).	
[3H]Arginine	uptake	was	carried	out	in	Caco-2	cell	monolayers	following	20min	pre-incubation	
with	genistein	(2-50μM).	Genistein	was	dissolved	in	DSMO,	therefore,	to	control	for	any	effect	
of	the	solvent,	[3H]arginine	uptake	was	also	performed	in	the	presence	of	0.1%	DMSO	(Figure	
6.13).	 No	 significant	 difference	 in	 [3H]arginine	 uptake	 was	 observed	 in	 monolayers	 pre-
incubated	with	genistein	at	any	concentration	(Figure	6.13).	The	pre-incubation	of	monolayers	
with	 0.1%	DMSO	did	 not	 have	 any	 significant	 (p>0.05)	 effect	 on	 System	b0,+	function	 (Figure	
6.13).		
These	data	do	not	support	the	results	from	the	literature	that	show	genistein	to	be	a	
stimulator	 of	 System	 b0,+	 transport	 (Mizoguchi	 et	 al.,	 2001).	 No	 further	 data	 is	 available	 to	
inform	the	effects	of	genistein	on	the	function	of	organic	solute	transporters.	Therefore,	 it	 is	
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not	 currently	 possible	 to	 conclude	whether	 the	 potential	 phosphorylation	 of	 the	 light	 chain	
could	be	targeted	in	novel	cystinuria	therapies,	and	further	investigation	is	required.	
In	summary:	
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Figure	 6.12:	 The	 effect	 of	 genistein	 on	 System	b0,+	function	 in	 oocytes.	 [3H]Arginine	uptake	
(10μM,	pH	7.4,	60min)	in	oocytes	injected	with	water	(control)	or	rBAT	cRNA	(50ng),	following	
30min	pre-incubation	with	10-50μM	genistein	(n=10).	Data	are	mean±SEM.	ns,	p>0.05	versus	
uptake	in	rBAT-expressing	oocytes	without	genistein	pre-incubation.	
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Figure	6.13:	The	effect	of	genistein	on	System	b0,+	function	in	Caco-2	cells.	Apical	[3H]arginine	
uptake	 (10μM,	 pH	 7.4,	 5min)	 in	 Caco-2	monolayers	 following	 30min	 pre-incubation	 with	 0-
50μM	 genistein	 (n=8).	 Open	 bars,	 control	 cell	 monolayers;	 black	 bars,	 monolayers	 pre-
incubated	 with	 0.1%	 DMSO.	 Data	 are	 mean±SEM.	 ns,	 p>0.05	 versus	 uptake	 in	 control	
monolayers	(open	bars).	
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6.3.6	The	effect	of	N-linked	glycosylation	on	rBAT	expression	
To	 investigate	 the	 effect	 of	 glycosylation	 on	 the	 expression	of	 rBAT,	 the	 putative	N-
linked	glycosylation	sites	were	identified.	In	proteins,	the	glycosylation	consensus	sequence	is	
N-X-S/T,	were	X	is	any	amino	acid,	apart	from	proline	(Gavel	&	von	Heijne,	1990).	In	rBAT,	this	
sequence	 is	 present	 at	 6	 locations	 in	 the	 protein	 (Table	 6.2).	 All	 six	 of	 the	 putative	 N-
glycosylation	sites	were	conserved	to	some	extent	in	other	mammalian	species	of	rBAT	(Figure	
6.16).	However,	N495	was	not	present	 in	the	amino	acid	sequence	of	pig	rBAT	(Figure	6.16),	
and	N513	was	only	conserved	in	human	and	rabbit	sequences	(Figure	6.16).	This	is	consistent	
with	reports	that	C-terminal	N-glycosylation	motifs	are	 less	 likely	to	be	glycosylated	(Gavel	&	
von	Heijne,	1990).		
Of	 the	 6	 putative	 glycosylation	 sites	 in	 rBAT,	 only	 one	 has	 been	 investigated	 in	 the	
literature	(Bartoccioni	et	al.,	2008).	This	is	due	to	the	presence	of	cystinuria	mutation	T216M,	
which	 removes	 the	consensus	 sequence	N214-H215-T216.	T216M	was	characterised	 in	1998	
by	 Saadi	 et	 al.	 (1998)	 as	 an	 rBAT	 trafficking	mutation,	 shown	 to	 cause	 an	 80%	 decrease	 in	
[14C]cystine	uptake	compared	to	wild-type	function	when	expressed	in	oocytes.	Bartoccioni	et	
al.	 (2008)	 identified	 an	 absence	 in	 band	 shift	 following	 electrophoretic	 resolution	 of	 T216M	
compared	to	the	wild-type	protein.	This	indicates	that	the	removal	of	the	consensus	site	does	
not	 remove	 a	 glycan	 residue	 from	 the	 protein,	 and	 that	 N214	 is	 not	 glycosylated	 in	 vivo.	
Additionally,	 this	 glycosylation	 motif	 appears	 to	 be	 in	 a	 cleft	 on	 the	 model	 of	 the	 rBAT	
extracellular	domain	(Figure	6.17).	Based	on	this	finding,	online	tool	GlyProt,	which	was	used	
to	 add	 oligosaccharide	 residues	 to	 the	 structure,	 ruled	 this	 out	 as	 a	 candidate	 site	 for	
glycosylation	 (Figure	 6.18).	Homology	modelling	was	 used	 to	 add	oligosaccharide	 chains	 the	
five	 remaining	 putative	 sites	 of	 N-glycosylation	 (Figure	 6.18).	 From	 this	 model	 it	 can	 be	
observed	 that	 these	 residues	 sit	 on	 the	 outer	 edge	 of	 the	 molecule	 (Figure	 6.19A)	 on	 the	
surface	predicted	to	face	away	from	the	cell	membrane	(Figure	6.19B).	This	provided	a	sound	
rationale	for	N-linked	glycosylation	of	rBAT	at	these	sites.		
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Table	6.2:	The	positions	of	the	N-glycosylation	consensus	sequence	 in	rBAT.	The	estimation	
of	 percentage	 conservation	of	 the	motifs	 is	 based	upon	 the	multiple	 sequence	 alignment	of	
human	 (NM_000341.3),	 mouse	 (NM_009205.2),	 rat	 (NM_017216.1),	 rabbit	
(NM_001082242.1),	pig	(NM_001123042.1),	and	cow	(NM_001034633.2)	rBAT	in	Figure	5.16.	
The	Asn	residue	number	in	the	human	sequence	is	given.		
	
	  
Asn	Residue	Number	 Motif	 Conserved	 Mutation	
214	 NHT	 100%	 T216M	
261	 NSS	 100%	 --	
332	 NKT	 100%	 --	
495	 NES	 66%	 --	
513	 NSS	 100%	 --	
575	 NDS	 33%	 --	
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Mouse         KEIDPIFGTMKDFENLVAAIHDKGLKLIIDFIPNHTSDKHPWFQSSRTRSGKYTDYYIWH 239 
Rat           KEIDPIFGTMKDFENLVAAVHDKGLKLIIDFIPNHTSDKHPWFQSSRTRSGKYTDYYIWH 237 
Rabbit        REIDPIFGTMEDFENLLAAIHDKGLKLIIDFIPNHTSDKHAWFQLSRTRTGKYTDYYIWH 232 
Human         REVDPIFGTMEDFENLVAAIHDKGLKLIIDFIPNHTSDKHIWFQLSRTRTGKYTDYYIWH 240 
Pig           REIDPIFGTMKDFENLVAAIHDKGLKLIIDFIPNHTSDKHAWFQLSRTRTGKYTDYYIWH 23 
Cow           REIDPIFGTMKDFENLVAAIHDKGLKLIIDFIPNHTSDKHAWFQWSRNQTGKYTDYYIWH 240 
              :*:*******:*****:**:******************** *** **.::********** 
 
Mouse         NCTHVNGVTTPPNNWLSVYGNSSWHFDEVRKQCYFHQFLKEQPDLNFRNPAVQEEIKEII 299 
Rat           NCTHANGVTTPPNNWLSVYGNSSWQFDEERKQCYFHQFLKEQPDLNFRNPAVQEEIKEII 297 
Rabbit        DCAHENGITTPPNNWLSVYGNSSWHFDEVRNQCYFHQFLKEQPDLNFRNPDVQEEIKEIM 292 
Human         DCTHENGKTIPPNNWLSVYGNSSWHFDEVRNQCYFHQFMKEQPDLNFRNPDVQEEIKEIL 300 
Pig           DCTQEDGITIPPNNWLSVYGNSSWHFDEIRNQCYFHQFLKEQPDLNFRNPDVQEEIKEII 297 
Cow           DCNRENGTTIPPNNWLSVYGNSSWHFDEVRKQCYFHQFMKEQPDLNFRNPDVQEEIKEII 300 
              :* : :* * **************:*** *:*******:*********** ********: 
 
Mouse         TFWLSKGVDGFSFDAVKFLLEAKDLRNEIQVNTSQIPDTVTHYSELYHDFTTTQVGMHDI 359 
Rat           KFWLSKGVDGFSFDAVKFLLEAKDLRNEIQVNTSQIPDTVTRYSELYHDFTTTQVGMHDL 357 
Rabbit        QFWLTKGVDGFSFNAVKFLLEAMHLRNEIQVNASQIPDTVTRYSELYHDFTTTQEGMHDL 352 
Human         RFWLTKGVDGFSLDAVKFLLEAKHLRDEIQVNKTQIPDTVTQYSELYHDFTTTQVGMHDI 360 
Pig           QFWLSKGVDGFSFDAVQFLLEAKHLRDETQVNKTQIPATITHYSELYHDFTTTQVGMHDI 357 
Cow           QFWLSKGVDGFSFDALPFLLEAKHLRDEAQVNKTQIPDMVTHYSQLHHDFTTTQVGMHDI 360 
              ***:*******::*: ***** .**:* *** :***  :*:**:*:******* ****: 
 
Mouse         VRDFRQTMNQYSREPGRYRFMGAEASAESIERTMMYYGLPFIQEADFPFNKYFTTIGTLS 419 
Rat           VRDFRQTMNQFSREPGRYRFMGTEVSAESTERTMVYYGLSFIQEADFPFNKYLATLDTLS 417 
Rabbit        VRSFRQTMDKYSREPGRYRFLGTEAYAESIDRTMRYYGLSFIQEADFPFNNYFTTLDTLS 412 
Human         VRSFRQTMDQYSTEPGRYRFMGTEAYAESIDRTVMYYGLPFIQEADFPFNNYLSMLDTVS 420 
Pig           VRSFRQMMDQYSREPGRYRFMGTEAQGESIAGTMMYYGLPFIQEADFPFNSYFGQLDSPS 417 
Cow           VRSFRQTMNQYSREPGRYRFMGTEAHGESITKTMVYYGLPFIQEADFPFNSYLSKLDKPS 420 
              **.*** *:::* *******:*:*. .**   *: ****.**********.*:  :.. * 
 
Mouse         GHTVYEVITSWMENMPEGKWPNWMTGGPETPRLTSRVGSEYVNAMHMLLFTLPGTPITYY 479 
Rat           GHTVYEAITSWMENMPEGKWPNWMIGGPETSRLTSRVGSEYVNAMNMLLFTLPGTPITYY 477 
Rabbit        GNTVYEVITAWMENMPEGKWPNWMTGGPDITRLTSRLGNQYVNIMNMLLFTLPGTPITYY 472 
Human         GNSVYEVITSWMENMPEGKWPNWMIGGPDSSRLTSRLGNQYVNVMNMLLFTLPGTPITYY 480 
Pig           GDSVAEVILSWMENMPEGKWPNWMTCGPDNARLTSRLGEEYVNVMNMLIFTLPGTPITYY 477 
Cow           GNSVSEIITSWMENMPEGKWPNWMTGGPDSVRLTSRLGEKYVNIMNMLVFTLPGTPITYY 480 
              *.:* * * :**************  **:  *****:*.:*** *:**:*********** 
 
Mouse         GEEIGMGDISVTNFNESYDSTTLVSKSPMQWDNSSNAGFTEANHTWLPTNSDYHTVNVDV 539 
Rat           GEEIGMGDISITNLNERYDTNALLSKSPMQWDNSSNAGFTEANHTWLPTNSDYHTVNVDV 537 
Rabbit        GEEIGMGNILATNLNESYDVNTLLSKSPMQWDNSSNAGFSEGNHTWLPTSSDYHTVNVDV 532 
Human         GEEIGMGNIVAANLNESYDINTLRSKSPMQWDNSSNAGFSEASNTWLPTNSDYHTVNVDV 540 
Pig           GEEIGMRNILATSLYETYDADTLLSKSPMQWDNSSNAGFSEGSHTWLPTRSDYPTVNGDV 537 
Cow           GEEIGMRNILAANLNETYDAGTLFSKSPMQWDNSSNAGFSEGNHTWLPTSSDYHTVNVDV 540 
              ****** :*  :.: * **  :* ***************:*..:***** *** *** ** 
 
Mouse         QKTQPSSALRLYQDLSLLHATELVLSRGWFCLLRDDSHSVVYTRELDGIDNVFLVVLNFG 599 
Rat           QKTQPSSALRLYQDLSLLHARELLLSRGWFCLLRDDNHSVVYTRELDGIDKVFLVVLNFG 597 
Rabbit        QKTQPTSALKLYQALSLLHANELLLSRGWFCLLRNDSRVLVYTRELDGIDRVFIVVLNFG 592 
Human         QKTQPRSALKLYQDLSLLHANELLLNRGWFCHLRNDSHYVVYTRELDGIDRIFIVVLNFG 600 
Pig           QKTQPKSALKLYQELSLLHANELLLSRGWFCYLRNDNYSVVYTRELNGIDRVLLMVLNFG 597 
Cow           QKTQPRSALKLYQELSLLHANELLLGRGWFCFLGNYNHSIMYTRELDGINRIFLMVLNFG 600 
              ***** ***:*** ****** **:*.***** * : .  ::*****:**:.::::***** 
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Figure	6.14:	The	positions	of	the	N-glycosylation	consensus	sequence	in	a	multiple	sequence	
alignment	 of	 rBAT.	 Multiple	 sequence	 alignment	 of	 human	 (NM_000341.3),	 mouse	
(NM_009205.2),	 rat	 (NM_017216.1),	 rabbit	 (NM_001082242.1),	 pig	 (NM_001123042.1),	 and	
cow	 (NM_001034633.2)	 rBAT.	 Consensus	 symbols	 are	 displayed	 below	 aligned	 residues.	 *,	
fully	 conserved	 residues;	 :,	 conservation	 between	 groups	 with	 strongly	 similar	 properties	
(scoring	 >0.5	 in	 the	 Gonnet	 PAM	 250	matrix);	 .,	 conservation	 between	 groups	 with	 weakly	
similar	 properties	 (scoring	 ≤0.5	 in	 the	 Gonnet	 PAM	 250	 matrix);	 red,	 fully-conserved	 N-
glycosylation	motifs;	blue,	the	location	of	cystinuria	mutations	that	fall	in	glycosylation	motifs.		
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Figure	6.15:	The	putative	location	of	N214	in	the	rBAT	extracellular	domain.	Side	view	of	the	
rBAT	extracellular	domain	model	based	on	oligo-1,6-glucoside	from	B.	cereus	(PDB	code	1UOK)	
to	 show	 the	 putative	 location	 of	N214,	 located	 internally	 in	 the	 hydrophobic	 interior	 of	 the	
model,	 denoted	 by	 a	 black	 circle.	 Domains	 are	 labelled	 in	 the	 same	 colour	 as	 shown	 in	 the	
protein	 structure	 with	 amino	 acid	 residue	 numbers	 in	 brackets.	 Red,	 domain	 A1;	 yellow,	
domain	B;	green,	domain	A2;	blue,	domain	C.	The	transmembrane	domain	and	30	amino	acid	
“tail”	of	the	protein	do	not	model	to	any	known	crystal	structure	and	their	positions	at	the	N-	
and	C-termini	of	the	molecule,	respectively,	are	labelled.		
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Figure	6.16:	Potential	sites	of	N-glycosylation	in	the	rBAT	extracellular	domain.	A,	Top	view	
of	the	rBAT	extracellular	domain	model	based	on	oligo-1,6-glucoside	from	B.	cereus	(PDB	code	
1UOK)	to	show	the	putative	location	of	N-linked	oligosaccharide	residues.	The	Asn	(N)	residue	
in	the	protein	to	which	the	glycans	are	predicted	to	be	covalently	bonded	are	numbered	next	
to	 their	 respective	 glycan	 chains	 (purple);	 *,	 the	 Asn	 residues	 individually	 mutated	 by	 site-
directed	mutagenesis	in	this	investigation;	B,	side-view	of	the	rBAT	extracellular	domain	model	
based	on	oligo-1,6-glucoside	from	B.	cereus	(PDB	code	1UOK)	to	show	the	putative	location	of	
N-linked	oligosaccharide	residues.	The	putative	location	of	the	apical	cell	membrane	in	relation	
to	 the	protein	 is	 indicated.	Domains	are	 labelled	 in	 the	same	colour	as	shown	 in	 the	protein	
structure	 with	 amino	 acid	 residue	 numbers	 in	 brackets.	 Red,	 domain	 A1;	 yellow,	 domain	 B;	
green,	domain	A2;	blue,	domain	C.	The	transmembrane	domain	and	30	amino	acid	“tail”	of	the	
protein	 do	 not	 model	 to	 any	 known	 crystal	 structure	 and	 their	 positions	 at	 the	 N-	 and	 C-
termini	of	the	molecule,	respectively,	are	labelled.	
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Of	 the	 five	 candidate	 glycosylation	 sites	 in	 rBAT,	 three	 are	 fully	 conserved	 in	 the	
multiple	 alignment	 of	 mammalian	 rBAT	 sequences	 (Figure	 6.14).	 These	 residues	 are	 N261,	
N332,	and	N513,	highlighted	in	Figure	6.16A.	In	this	study,	site	directed	mutagenesis	was	used	
to	mutate	these	three	residues	to	aspartic	acid	(D),	thereby	removing	the	consensus	sequence.	
Mutant	 cDNA	 sequences	 created	 single,	 double,	 and	 triple	 mutants.	 The	 following	 mutant	
rBAT	 sequences	 were	 created:	 N261D,	 N332D,	 N513D,	 N261D/N332D,	 N261D/N513D,	
N261D/N332D/N513D.		
[3H]Arginine	uptake	was	measured	in	oocytes	injected	with	water	or	the	cRNA	for	wild-
type	 rBAT,	 or	 each	 of	 the	 glycosylation	 mutants	 (Figure	 6.17A).	 No	 significant	 difference	
(p>0.05)	 was	 measured	 in	 uptake	 between	 wild-type	 rBAT	 expressing	 oocytes	 or	 those	
expressing	 the	mutant	 proteins	 N332D,	 N513D,	 N261D/N332D,	 N332D/N513D,	 or	 the	 triple	
mutant	 N261D/N332D/N513D	 (Figure	 6.17A).	 Oocytes	 expressing	 N213D	 showed	 no	
significant	uptake	(p>0.05)	above	that	measured	 in	water-injected	controls,	which	 is	 thought	
to	be	due	 to	non-functional	 cRNA	 (Figure	6.17A).	 This	was	 confirmed	by	 the	absence	of	any	
translated	protein	in	western	blotting	of	total	membrane	proteins	from	oocytes	injected	with	
N261D	 cRNA	 (Figure	 6.17B,	 lane	 C).	 Uptake	 in	 oocytes	 expressing	 the	 double	 mutant	
N261D/N513D	was	significantly	greater	 (p<0.001)	 than	 in	oocytes	expressing	wild-type	 rBAT.	
These	are	the	results	of	a	single	experiment	(n=10),	which,	due	to	time	restrictions,	could	not	
be	 repeated.	 To	 confirm	 the	 reproducibility	 of	 this	 observation,	 further	 investigation	 is	
required.	 Although	 improbable,	 it	 is	 not	 impossible	 that	 the	 selective	 removal	 of	 N-
glycosylation	at	these	two	sites	can	increase	expression.	Dubé	et	al.,	demonstrated	that	whilst	
there	is	an	aggregation	and	lack	of	trafficking	of	unglycosylated	Erythropoetin	produced	in	the	
presence	 of	 tunicamycin,	 only	 two	 of	 the	 three	 glycosylation	 sites	 affect	 function	 when	
individually	mutated	(Dubé	et	al.,	1988).	
Western	 blotting	 was	 used	 to	 detect	 the	 size	 of	 rBAT	 proteins	 containing	 the	
glycosylation	 mutations	 (Figure	 6.18).	 As	 demonstrated	 previously,	 wild-type	 rBAT	 protein	
produces	a	doublet	band	at	85	and	90kDa	(Figure	6.18A,	lanes	b	and	j).	With	the	exception	of	
N231D,	 in	 which	 no	 protein	 was	 translated,	 all	 mutant	 proteins	 investigated	 led	 to	 the	
detection	of	doublet	bands	by	western	blot	 (Figure	6.18A,	 lanes	d-i).	 	This	 indicated	 that	we	
had	not	removed	all	sites	of	N-glycosylation	in	the	rBAT	triple	mutant,	and	that	at	least	one	of	
the	 two	other	putative	 sites	 (N495	and	N575)	 is	 glycosylated	 in	 vitro.	Despite	 this,	 a	 shift	 in	
band	 size	 was	 observed	 compared	 to	 wild-type	 rBAT	 (Figure	 5.18B).	 In	 lanes	 d	 and	 e,	
representing	 single	mutant	proteins	N332D	and	N513D,	 respectively,	bands	between	75	and	
88	 kDa	were	 observed.	 A	 further	 shift	 in	 band	 size	 was	 observed	 in	 lanes	 representing	 the	
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double	 mutants	 (lanes	 f-h)	 and	 the	 triple	 mutant	 (lane	 j).	 Despite	 the	 increase	 in	 uptake	
identified	 in	 Figure	 6.17,	 no	 increase	 in	 band	 intensity	 was	 identified	 in	 the	 western	 blot	
(Figure	6.18).	This	indicates	that	there	has	been	no	increase	in	protein	translation.	The	larger	
band	identified	in	lane	h,	representative	of	N332D/N513D	protein	is	likely	due	to	smearing	of	
the	band.	To	confirm	whether	N261	is	a	site	of	N-glycosylation,	and	whether	the	larger	band	
size	detected	 in	 lane	h	 is	an	anomaly,	 this	experiment	needs	 to	be	 repeated	with	 functional	
cRNA.		
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Figure	 6.17:	 The	 effect	 of	 N-linked	 glycosylation	 on	 the	 function	 of	 rBAT	 in	 oocytes.		
[3H]Arginine	 uptake	 (10μM,	 pH	 7.4,	 60min)	 3	 days	 post-injection	 of	 oocytes	 with	 water	
(control)	or	the	cRNA	for	rBAT	or	the	glycosylation	knock-out	mutants:	N261D,	N332D,	N513D,	
N261D/N332D,	 N261D/N513D,	 N332D/N513D,	 or	 N261D/N332D/N513D	 (50ng)	 (n=10).	 Data	
are	mean±SEM.	***,	p<0.001;	*,	p<0.05;	ns,	p>0.05	versus	uptake	in	wild-type	rBAT-expressing	
oocytes.	
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Figure	6.18:	 The	effect	of	N-linked	glycosylation	on	 the	 function	and	 cellular	processing	of	
rBAT	in	oocytes.	A,	Western	blot	of	total	oocyte	membranes	taken	from	the	same	batches	of	
oocytes	used	for	the	uptake	experiment	in	panel	(A).	Lanes	a-j	represent	oocytes	injected	with:	
a,	 water	 (control);	 b,	 wild-type	 rBAT;	 c,	 N261D;	 d,	 N332D;	 e,	 N513D;	 f,	 N261D/N332D;	 g,	
N261D/N513D;	 h,	 N332D/N513D;	 i,	 N261D/N332D/N513D;	 j,	 wild-type	 rBAT;	 B,	 the	 same	
western	 blot	 image	 is	 shown	 as	 in	 panel	 (A)	 with	 dotted	 lines	 representing	 the	 two	 bands	
identified	 in	wild-type	protein	 in	 lanes	a	and	 j.	 From	 this	 the	band	 shift	 can	be	more	clearly	
observed.		
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To	 determine	 whether	 a	 complete	 absence	 of	 N-glycosylation	 in	 rBAT	 affected	
function,	 [3H]arginine	 uptake	was	 carried	 out	 in	 oocytes	 co-injected	with	water	 (control)	 or	
rBAT	 cRNA	 and	 tunicamycin.	 No	 significant	 difference	 (p>0.05)	 in	 uptake	 was	 observed	 via	
rBAT-expressing	oocytes	that	had	been	co-injected	with	tunicamycin,	compared	to	those	that	
had	not	(Figure	6.19A).	[3H]Arginine	uptake	was	also	carried	out	in	Caco-2	cells	following	24h	
pre-incubation	with	tunicamycin.	Similarly,	no	significant	difference	(p>0.05)	was	observed	in	
cells	 that	 had	been	pre-incubated	with	 TM,	 compared	 to	 those	 that	 had	not	 (Figure	 6.19B).	
These	 data	 indicate	 that	 the	 N-glycosylation	 of	 rBAT	 is	 not	 essential	 for	 localisation	 of	 the	
transport	system	to	the	apical	membrane	in	polarised	cell	systems.		
Total	membrane	proteins	were	taken	from	oocytes	that	had	been	injected	with	water	
(control),	water	and	tunicamycin,	rBAT	cRNA,	or	rBAT	cRNA	and	tunicamycin.	Western	blotting	
was	used	to	detect	the	size	of	the	translated	rBAT	protein	in	oocytes	(Figure	6.19C).	In	lane	b,	
representing	 oocytes	 injected	 with	 rBAT	 cRNA,	 a	 band	 was	 observed	 at	 around	 90kDa.	
However,	in	lane	d,	representing	oocytes	co-injected	with	rBAT	and	tunicamycin,	the	majority	
of	the	translated	protein	had	shifted	in	weight	to	around	70kDa	(Figure	6.19C).	These	data	are	
supported	by	the	published	findings	of	Bertran	et	al.	(1993)	who	reported	a	shift	in	band	size	
from	 90kDa	 to	 72kDa	 following	 injection	 of	 oocytes	 with	 rBAT	 cRNA	 and	 tunicamycin.	 The	
results	 indicate	 that	 the	membrane	 localisation	 of	 rBAT	 is	 not	mediated	 by	 N-glycosylation.	
The	lack	of	conservation	of	N495	and	N575	in	some	species,	and	their	apparent	glycosylation	
in	 the	 human	 form	 indicate	 that	 glycans	 at	 these	 residues	 would	 not	 be	 essential	 for	
membrane	localisation.			 	
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Figure	6.19:	The	effect	of	tunicamycin	on	the	function	of	System	b0,+	 in	oocytes	and	Caco-2	
cells.	A,	[3H]Arginine	uptake	(10μM,	pH	7.4,	60min)	in	oocytes	injected	with	water	(control)	or	
rBAT	 cRNA	 (50ng),	 with	 or	 without	 co-injection	 of	 20ng	 tunicamycin	 (n=25-30).	 Data	 are	
mean±SEM.	 ns,	 p>0.05	 versus	 uptake	 in	 rBAT-expressing	 oocytes	 without	 tunicamycin;	 B,	
[3H]Arginine	uptake	(10μM,	pH	7.4,	5min)	across	the	apical	membrane	of	Caco-2	monolayers	
following	24h	pre-incubation	with	DMEM	(control),	DMEM	plus	0.01%	DMSO,	or	DMEM	plus	
1μM	 tunicamycin	 in	 0.01%	DMSO	 (n=8-9).	Data	 are	mean±SEM.	 ns,	 p>0.05	versus	uptake	 in	
control	monolayers;	C,	Western	blot	of	total	oocyte	membranes	taken	from	the	same	batches	
of	oocytes	used	for	the	uptake	experiment	in	panel	(A).	Lanes	a-d	represent	oocytes	injected	
with:	a,	water	(control);	b,	rBAT	cRNA	(50ng);	c,	water	plus	tunicamycin	(20ng);	d,	rBAT	cRNA	
(50ng)	plus	tunicamycin	(20ng).	
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6.4	Discussion	
In	 this	 chapter	 we	 have	 investigated	 how	 modifications	 to	 the	 rBAT	 protein	 can	
potentially	effect	the	expression	or	function	of	the	transport	system.	The	ultimate	aim	of	these	
modifications	 was	 to	 try	 to	 identify	 ways	 in	 which	 current	 cystinuria	 therapies	 could	 be	
optimised	 for	 individual	 patients	 based	 upon	 their	 genotype,	 or	 to	 suggest	 the	 potential	 of	
other	compounds	for	a	pharmacological	purpose	in	the	treatment	of	cystinuria.		
6.4.1	A	pharmacogenetic	approach	to	cystinuria	
Following	 the	 completion	 of	 the	 Human	 Genome	 Project	 in	 2000,	 the	 field	 of	
pharmacogenetics	 appeared	 highly	 promising	 (Roses,	 2000).	 The	 ability	 to	 use	 the	 genetic	
information	 of	 a	 patient	 to	 tailor	 their	 response	 to	 therapy	 and	 provide	 a	 personalised	
treatment	moving	away	from	the	“one	drug	fits	all”	paradigm	appeared	 imminent.	However,	
more	 than	 a	 decade	 on,	 the	 results	 in	 clinical	 practice	 have	 fallen	 somewhat	 short	 of	 this	
promise	 (Crews	 et	 al.,	 2012).	 Despite	 this,	 some	 advances	 have	 been	 made.	 The	 best-
established	 use	 of	 pharmacogenetic	 testing	 in	 clinical	 practice	 is	 the	 genotyping	 of	 the	
thiopurine	 methyltransferase	 gene	 TMPT,	 which	 occurs	 prior	 to	 prescription	 of	 the	
immunomodulating	 thiopurine	 drug,	 azathioprine	 (McLeod	 et	 al.,	 2000;	Holme	 et	 al.,	 2002).	
This	prevents	 severe	myelosuppression	 in	around	11%	of	 the	population	who	are	carriers	of	
the	 TMPT	 polymorphisms	 and	 require	 a	 reduced	 dosage	 of	 the	 drug	 (McLeod	 et	 al.,	 2000).	
Despite	the	 lack	of	progress	 in	this	field,	the	potential	 for	personalised	treatments	 in	genetic	
disease,	through	identification	of	new	therapeutic	targets,	remains	great.		
In	 this	 chapter	 we	 investigated	 whether	 the	 current	 cystinuria	 therapies	 used	 to	
increase	 the	 solubility	 of	 cystine	 had	 any	 effect	 upon	 the	 transporter	 (Figure	 6.4-6.6).	 No	
change	in	[3H]arginine	uptake	was	observed	following	alkalinisation	of	the	incubation	medium	
and	 uptake	 solution	 of	 oocytes	 expressing	 rBAT	 (Figures	 6.4-6.5).	 We	 also	 investigated	
whether	pre-incubation	of	 rBAT-expressing	oocytes	with	CBTDs	 captopril,	 D-penicillamine,	or	
tiopronin	would	affect	the	protein	expression.	Similarly,	no	change	 in	function	was	detected,	
nor	 did	 any	 of	 the	 investigated	 rBAT	 mutant	 proteins	 (M467T,	 M465K,	 N254T,	 L416P,	 or	
Y579D)	respond	differently	to	treatment	with	the	CBTD	(Figures	6.7-6.8).	This	experiment	was	
also	carried	out	in	Caco-2	cells	with	the	drugs	at	estimated	physiological	concentrations,	and	at	
a	 1mM	 concentration	 (Figures	 6.9	 and	 6.10,	 respectively).	 The	 experimental	 data	 obtained	
using	the	mammalian	cell	line	confirmed	that	the	drugs	had	no	direct	effect	upon	the	transport	
system	 expression	 (following	 24h	 pre-incubation)	 or	 function	 (when	 present	 in	 the	 uptake	
solution).	
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From	 these	 data	 we	 can	 conclude	 that	 there	 is	 no	 scope	 for	 a	 pharmacogenetic	
approach	to	cystinuria	therapy	using	established	treatments.	However,	the	knowledge	of	the	
underlying	 genetic	 cause	 of	 the	 disease	 has	 great	 potential	 for	 providing	 personalised	
therapies	in	cystinuria.	To	date,	91	pathogenic	missense	mutations	have	been	reported	in	rBAT	
(SLC3A1),	and	53	in	b0,+AT	(SLC7A9)	(Stenson	et	al.,	2014).	Very	few	reports	have	emerged	on	
the	 function	of	b0,+AT	mutant	proteins	 (Feliubadalo	et	al.,	1999;	Font	et	al.,	2001).	However,	
following	 co-expression	 of	 rBAT	 and	 b0,+AT	 in	 COS-7	 and	HeLa	 cells,	 a	 complete	 abolition	 in	
[34S]cystine	 uptake	 was	 observed	 following	 the	 introduction	 of	 the	 following	 SLC7A9	
mutations:	A70V,	G105R,	V170M,	and	R333W	(Feliubadalo	et	al.,	1999;	Font	et	al.,	2001).	The	
SLC7A9	mutations	A182T	and	A354T	caused	a	20-40%	in	transport	activity	following	expression	
in	HeLa	 cells,	 compared	 to	 those	expressing	wild-type	b0,+AT	 (Font	et	al.,	2001).	Despite	 the	
lack	of	data	collected	on	 the	effect	of	SLC7A9	mutations	on	 the	 function	of	System	b0,+,	 it	 is	
predicted	 that	 mutations	 in	 the	 12-transmembrane	 domain	 transport	 pore	 would	 affect	
substrate	 binding,	 or	 translocation	 across	 the	 membrane.	 As	 a	 result	 of	 this,	 it	 could	 be	
possible	 to	 design	 novel	 therapies	 for	 cystinuria	 treatment	 based	upon	 the	 genotype	of	 the	
patient.	 Patients	 with	 an	 AA	 or	 AB	 genotype	 could	 potentially	 be	 treated	 by	 the	 use	 of	
molecular	chaperones,	which	would	enable	stabilisation	of	mis-folded	rBAT,	and	trafficking	of	
the	transport	pore	to	the	plasma	membrane.		
Bartoccioni	et	al.	(2008)	demonstrated	that	rBAT	mutations	located	in	the	TIM	barrel	
domain	 (A1	 and	A2)	 of	 the	 translated	polypeptide	 caused	 a	 rapid	degradation	of	 the	protein	
following	its	assembly	with	b0,+AT	in	HeLa	cells.	However,	rBAT	mutation	L89P,	located	in	the	
putative	 transmembrane	 domain	 of	 the	 protein,	 led	 to	 a	 lack	 of	 assembly	 with	 b0,+AT	
(Bartoccioni	 et	 al,	 2008).	 No	 L89P	 protein	 could	 be	 co-precipitated	 with	 an	 anti-b0,+AT	
antibody,	unlike	 the	other	 translated	mutant	proteins	 (Bartoccioni	et	al.,	2008).	 The	authors	
suggested	 that	 TIM	 barrel	 mutants	 are	 folding-defective,	 whilst	 the	 L89P	 transmembrane	
domain	mutation	is	assembly-defective.	This	suggests	that	from	genetic	testing	of	patients	we	
could	not	only	target	therapies	based	upon	which	protein	subunit	is	affected,	but	also	by	the	
location	in	which	rBAT	mutations	fall.			
Chemical	chaperones	are	small	molecules	that	facilitate	the	folding	of	proteins	in	the	
ER	by	modifying	the	luminal	environment,	or	directly	binding	to	polypeptide	chains	(Molinari,	
2007).	 	 An	 alternative	 mechanism	 of	 molecular	 chaperone	 function	 is	 the	 inhibition	 of	 ER	
stress,	 which	 allows	 the	 maturation	 of	 polypeptides	 (Molinari,	 2007).	 For	 example,	 4-
phenylbutyrate	 (PBA)	 has	 been	 shown	 to	 allow	 the	 exit	 of	 ΔF508	 CFTR	 from	 the	 ER,	 and	
restore	 function	 in	 nasal	 epithelia	 in	 a	 cohort	 of	 adult	 patients	 orally	 dosed	 with	 the	 drug	
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(Zeitlin	et	al.,	2002).	Other	compounds	have	been	considered	that	target	heat	shock	protein,	
hsp90,	and	heat	shock	cognate	protein,	hsc70,	to	facilitate	folding	of	ΔF508	CFTR	and	increase	
its	presence	at	the	membrane	(Chanoux	&	Rubenstein,	2012).	The	biogenesis	of	CFTR	has	been	
studied	 in	 detail,	 enabling	 the	 identification	 of	 many	 potential	 targets	 for	 these	 chemical	
correctors	 (Wang	 et	 al.,	 2006).	 In	 order	 to	 discover	 potential	 targets	 for	 rBAT	mutant	 mis-
folding	 in	 the	ER	and	prevention	of	 degradation	by	 the	ERAD	pathway,	 further	 investigation	
into	the	biogenesis	of	the	System	b0,+	heavy	chain	is	required.		
In	this	investigation	we	studied	the	effects	of	genistein	on	the	function	of	System	b0,+	
(Figure	6.14-6.15).	This	was	based	upon	a	report	by	Mizoguchi	et	al.	(2001),	which	measured	
an	 increase	 in	 [14C]cystine	 uptake	 in	 COS-7	 cells	 transfected	with	 both	 System	b0,+	 subunits,	
following	incubation	with	2-50μM	genistein.	The	authors	hypothesised	that	this	increase	could	
be	 due	 to	 the	 PKA-dependent	 phosphorylation	 of	 b0,+AT	 negatively	 regulating	 the	 rate	 of	
transport.	 It	was	demonstrated	that	PKA	activator,	db-cAMP,	also	decreased	uptake	 levels	 in	
COS-7	cells,	the	effect	of	which	was	abolished	in	the	presence	of	the	inhibitor	compound	H-89	
(Mizoguchi	 et	 al.,	 2001).	 Despite	 this	 observation	 by	 Mizoguchi	 et	 al.	 (2001),	 no	 effect	 of	
genistein	 on	 the	 function	 of	 System	 b0,+	 was	 observed	 in	 the	 current	 study.	 The	 effect	 of	
genistein	pre-incubation	was	investigated	in	both	oocytes	(Figure	6.14)	and	Caco-2	cells	(Figure	
6.15),	but	no	significant	difference	(p>0.05)	in	[3H]arginine	uptake	was	observed.	This	requires	
further	investigation.	The	observations	made	by	Mizoguchi	et	al.	(2001)	could	potentially	lead	
to	 tailored	 therapies	 for	 patients	 with	 type	 B	 cystinuria.	 If	 selective	 treatment	 with	 PKA-
inhibition	 of	 b0,+AT	 phosphorylation	 could	 increase	 the	 rate	 of	 reaction,	 it	 could	 potentially	
overcome	an	effect	of	altered	substrate	affinity	in	vivo	and	increase	the	rate	of	dibasic	amino	
acid	reabsorption	from	the	proximal	tubule.	Currently,	little	is	known	about	this	effect.	
6.4.2	Transient	expression	of	rBAT	in	a	mammalian	cell	line	
In	this	chapter	the	transient	expression	of	rBAT	in	the	mammalian	cell	line	Caco-2	was	
investigated	 (Figures	 6.11-6.13).	 Caco-2	 cells	 endogenously	 express	 both	 subunits	 of	 System	
b0,+,	which	was	demonstrated	in	the	current	study	through	apical	Na+-independent	uptake	of	
the	 dibasic	 amino	 acid	 [3H]arginine,	 and	 its	 selective	 inhibition	 through	 competition	 with	
excess	 (5mM)	amino	acids	 (Figure	6.10).	The	aim	of	 transfection	 in	 the	current	study	was	 to	
express	 a	 FLAG-tagged	 rBAT	 protein	 (rBAT3F),	 which	 could	 be	 detected	 by	
immunocytochemical	methods.	Due	to	the	difficulties	 in	 transfecting	confluent	cells,	and	the	
presence	 of	 the	 endogenous	 rBAT,	 functional	 studies	 of	 exogenously	 expressed	 rBAT	 were	
outside	of	the	scope	of	this	investigation.	However,	expression	studies	of	a	FLAG-tagged	rBAT	
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would	allow	comparison	of	the	sub-cellular	localisation	of	the	wild-type	and	mutant	proteins	in	
vitro.	In	this	study,	we	demonstrated	that	at	72h	post-transfection,	the	transfected	cDNA	had	
been	 translated	 and	 rBAT3F	 was	 expressed	 (Figure	 6.13).	 Through	 co-localisation	 with	 the	
apical	 membrane	 protein	 ezrin,	 it	 appeared	 as	 though	 some	 rBAT3F	 was	 present	 at	 the	
membrane.	 However,	 the	majority	 of	 the	 protein	 was	 intracellular	 (Figure	 6.13).	 As	 Caco-2	
cells	endogenously	express	 rBAT,	we	would	expect	 that,	over	 time,	 the	majority	of	 the	wild-
type	 protein	 would	 traffic	 to	 the	 apical	 membrane.	 Despite	 this,	 at	 72h	 post-transfection,	
there	is	no	clear	indication	that	this	has	happened	sufficiently	to	allow	comparison	of	wild-type	
and	mutant	 rBAT.	 Unfortunately,	 due	 to	 time	 restrictions	 on	 this	 study,	we	were	 unable	 to	
transfect	Caco-2	cells	with	the	mutant	proteins	to	compare	the	expression	patterns.	In	future	
studies,	 this	 would	 be	 desirable	 for	 detection	 of	 the	 sub-cellular	 localisation	 of	 the	 rBAT	
mutants.	 Additionally,	 this	 would	 allow	 experiments	 to	 be	 carried	 out	 to	 detect	 any	
temperature-sensitive	 release	 of	 rBAT	mutant	 proteins	 from	 the	 endoplasmic	 reticulum.	 As	
discussed	in	Chapter	5,	it	has	previously	been	demonstrated	that	incubation	of	mammalian	cell	
lines	below	26°C	allow	the	release	of	ΔF508	CFTR	from	the	ER,	when	normally	it	is	degraded	by	
the	ERAD	pathway	(Denning	et	al.,	1992).	The	optimisation	of	rBAT	expression	in	a	mammalian	
cell	line	would	allow	this	effect	to	be	measured	on	rBAT	mutants.		
In	 the	 current	 study,	oocytes	were	 incubated	at	 30°C	during	a	60min	uptake	 (Figure	
6.3B).	 No	 effect	 of	 increased	 temperature	 on	 System	b0,+	function	was	measured	 in	 oocytes	
expressing	wild-type	rBAT,	or	any	of	the	mutant	proteins	(Figure	6.3B).	We	hypothesise	that	if	
rBAT	mutant	protein	can	be	released	from	the	ER	in	a	temperature-sensitive	manner	a	greater	
effect	of	the	mutations	would	be	measured	in	a	mammalian	cell	line	(incubated	at	37°C)	than	
in	oocytes.	This	result	was	observed	by	Pineda	et	al.	(2004),	following	the	transfection	of	HeLa	
cells	with	rBAT	and	b0,+AT.	The	reduction	in	[35S]cystine	uptake	caused	by	rBAT	mutant	R365W	
was	 greater	 following	 protein	 expression	 in	 HeLa	 cells,	 than	 in	 oocytes.	 The	 effect	 of	 this	
reduction	 in	 transport	was	 also	 shown	 to	 be	 temperature	 sensitive:	 at	 37°C	 no	 uptake	was	
measured	in	HeLa	cells	expressing	R365W.	When	the	incubation	temperature	was	reduced	to	
33°C,	[35S]cystine	uptake	was	not	significantly	lower	(p>0.05)	than	in	HeLa	cells	expressing	the	
wild-type	rBAT	protein	(Pineda	et	al.,	2004b).	This	 technique	would	be	particularly	useful	 for	
confirming	the	role	of	novel	mutants	N254T	and	L416P	in	the	pathogenesis	of	cystinuria	(see	
Chapter	5).	However,	 to	detect	 this	 in	oocytes,	 they	would	need	to	be	 incubated	at	30°C	 for	
longer	 than	 the	 turnover	 time	of	 the	protein	 the	membrane.	This	 is	not	possible	 in	oocytes,	
which	rapidly	degrade	in	quality	at	higher	temperatures.		
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Several	research	groups	have	reported	the	expression	of	System	b0,+	in	mammalian	cell	
lines,	COS-1,	COS-7,	HeLa	and	MDCK	(Feliubadalo	et	al.,	1999;	Font	et	al.,	2001;	Mizoguchi	et	
al.,	2001;	Pineda	et	al.,	2004b;	Bartoccioni	et	al.,	2008).	In	these	cell	lines,	System	b0,+	function	
has	been	measured,	 indicating	 the	correct	cellular	processing	and	trafficking	of	 the	proteins.	
Additionally,	Feliubadalo	et	al.	(1999)	used	immunocytochemical	detection	to	show	that	when	
rBAT	 was	 transfected	 in	 COS-1	 cells	 alone,	 it	 localised	 to	 an	 intracellular	 compartment.	
However,	when	both	System	b0,+	subunits	were	co-transfected	in	the	cell	line,	fluorescence	was	
detected	at	the	plasma	membrane	(Feliubadalo	et	al.,	1999).	These	results,	along	with	the	data	
presented	 in	 the	 current	 study	 appear	 promising	 for	 the	 optimisation	 of	 rBAT	 expression	 in	
Caco-2	 cells.	 However,	 further	 optimisation	 of	 this	 technique	 is	 required.	 The	 successful	
expression	of	 rBAT	and	mutant	proteins	 in	 the	cell	 line	would	also	provide	scope	 for	 further	
research	 into	 the	biogenesis	of	 rBAT,	 and	 treatment	of	 the	 cells	with	 chemical	 correctors	of	
mis-folded	rBAT,	as	discussed	in	section	6.4.1.	
6.4.3	N-glycosylation	of	rBAT		
The	 high	 affinity	 glycine	 transporter,	 GLYT1,	 has	 four	 potential	 glycosylation	 sites	
(Olivares	et	al.,	1995).	Olivares	et	al.	(1995)	transfected	COS-7	cells	with	both	wild-type	protein	
and	mutated	GLYT1	to	measure	the	effect	of	N-glycosylation	on	apical	targeting	and	activity	of	
the	 transporter.	 In	 the	 mutated	 protein,	 the	 asparagine	 (Asn)	 residues	 of	 the	 motif	 were	
substituted	 for	 glutamine	 (Gln).	When	 cells	 transfected	with	wild-type	 protein	were	 treated	
with	 tunicamycin,	 there	 was	 a	 30%	 inhibition	 in	 [3H]glycine	 uptake	 (Olivares	 et	 al.,	 1995).	
Mutated	 protein	 had	 either	 two,	 three,	 or	 four	 of	 the	 potential	 glycosylation	 motifs	
substituted	 and	 the	 removal	 of	 oligosaccharide	 residues	 was	 shown	 to	 have	 a	 cumulative	
effect	on	uptake	inhibition	(Olivares	et	al.,	1995).	
In	 2003	 Lee	 et	 al.,	 demonstrated	 that	 complete	 inhibition	 of	 N-glycosylation	 of	 the	
organic	anion	transporter	Oatp1	 (SLC21A1)	when	expressed	 in	 tunicamycin	 -treated	Xenopus	
oocytes	 reduced	uptake	of	 [3H]taurocholate	by	over	70%	 (Lee	 et	al.,	 2003).	 The	 same	group	
also	 used	 site-directed	 mutagenesis	 to	 individually	 substitute	 the	 Asn	 residues	 of	 the	 four	
glycosylation	motifs.	Whilst	western	 blotting	 showed	 a	molecule	 of	 lower	molecular	weight	
compared	to	the	native	protein,	there	was	no	effect	on	function	in	single	mutants	(Lee	et	al.,	
2003).	 However,	 when	 double	 and	 triple	mutants	 were	made,	 an	 additive	 effect	 was	 seen,	
with	 immunocytochemical	 detection	 confirming	 lower	 amounts	 of	 protein	 in	 the	 oocyte	
membrane	(Lee	et	al.,	2003).		
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Another	apical	proximal	tubule	transporter	that	has	had	the	effects	of	N-glycosylation	
studied	 is	the	Na+-dependent	 inorganic	phosphate	transporter,	NaPi-II.	NaPi-II	was	expressed	
in	 Xenopus	 oocytes	 and	 treated	 with	 both	 PNG-F	 and	 Endo-H	 for	 total	 inhibition	 of	 N-
glycosylation	 (Hayes	 et	 al.,	 1994).	NaPi-II	 has	 two	putative	 extracellular	N-glycosylation	 sites	
that	were	additionally	removed	through	Asn	mutation	both	individually	and	a	doubly-mutated	
protein	(Hayes	et	al.,	1994).	As	expected,	when	treated	with	PNG-F	and	Endo-H,	a	reduction	in	
protein	size	was	observed	following	electrophoretic	resolution	of	oocyte	homogenates	on	SDS	
gels	 (Hayes	 et	 al.,	 1994).	 Immunocytochemical	 detection	 techniques	 in	 sections	 of	 oocytes	
expressing	 NaPi-II	 showed	 presence	 of	 both	 the	 mutant	 and	 wild-type	 protein	 in	 the	
membrane.	 However,	 in	 the	 double	 mutant,	 diffuse	 staining	 was	 also	 observed	 inside	 the	
oocyte,	 implying	 incomplete	 trafficking	 of	 the	 protein	 (Hayes	 et	 al.,	 1994).	 Radiolabelled	
phosphate	uptake	into	oocytes	expressing	the	double	mutant	was	reduced	by	50%	compared	
to	the	wild-type	protein	(Hayes	et	al.,	1994).	
In	 the	 current	 study,	we	 investigated	 the	 role	of	N-linked	glycans	on	 the	 function	of	
rBAT	 (Section	 6.3.4).	 Of	 the	 six	 N-linked	 glycosylation	 consensus	 sites	 present	 in	 the	 rBAT	
amino	 acid	 sequence	 (N-X-S/T),	 we	 predict	 five	 of	 these	 to	 be	 glycosylated	 based	 upon	 a	
homology	model	of	 the	extracellular	domain	 (Figure	6.16).	 Individual	mutation	of	 two	of	 the	
five	potential	glycosylation	sites	(N332	and	N513)	to	aspartic	acid	(D)	residues	did	not	lead	to	a	
reduced	function	in	System	b0,+	measured	by	[3H]arginine	uptake	(Figure	6.17A).	To	determine	
whether	 N261D	 affects	 the	 function	 of	 rBAT,	 the	 experiment	 requires	 repeating	 with	
functional	cRNA.	One	combination	of	glycosylation	mutations	(N261D/N513D)	lead	to	a	2-fold	
increase	 in	 uptake	 compared	 to	 wild-type	 rBAT.	 However,	 these	 results	 are	 of	 a	 single	
experiment	 and	 would	 require	 repeating	 before	 conclusion	 could	 be	 made	 about	 this	
anomalous	 result.	 Despite	 this,	 a	 reduction	 in	 rBAT	 band	 weight	 was	 observed	 following	
mutation	of	the	asparagine	residues,	indicating	that	these	three	sites	would	be	glycosylated	in	
vivo	(Figure	6.18).	In	double	and	triple	mutant	protein	samples,	the	decrease	in	protein	weight	
appeared	to	shift	further.	However,	the	treatment	of	oocytes	with	tunicamycin	led	to	a	greater	
decrease	in	the	weight	of	the	detected	band,	to	around	70kDa	(Figure	6.19C).	This	could	mean	
that	the	remaining	2	consensus	sites	at	N495	and	N575	are	also	glycosylated	in	vivo	in	human	
rBAT.	Following	the	 inhibition	of	N-glycosylation	 in	rBAT,	no	significant	change	 in	System	b0,+	
function	was	measured	in	oocytes	or	Caco-2	cells	following	the	tunicamycin	treatment	(Figure	
6.19).	 In	a	 similar	manner,	 the	elimination	of	N-glycosylation	appeared	 to	have	no	effect	on	
the	function	or	expression	of	the	apical	membrane	protein	CFTR	(O'Riordan	et	al.,	2000).	From	
these	 data,	we	 can	 conclude	 that	 glycosylation	 of	 rBAT	 is	 not	 essential	 for	 apical	 sorting	 or	
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function.	However,	the	anomalous	result	from	the	N261D/N513D	uptake	experiment	requires	
further	investigation.		
In	conclusion,	the	data	presented	in	this	chapter	demonstrate	a	variety	ways	in	which	
the	 nature	 of	mutations	 in	 the	 proteins	 of	 System	 b0,+	 could	 be	 exploited	 to	 provide	 novel	
therapeutic	targets	for	cystinuria.	Despite	the	lack	of	results	indicating	any	selective	response	
of	particular	mutations	to	therapy,	our	increasing	knowledge	of	the	effect	of	these	individual	
mutations	 on	 the	 transport	 system	 provides	 scope	 for	 personalised	 therapies	 in	 the	 future.	
Only	by	further	 increasing	our	knowledge	on	the	biogenesis	of	both	wild-type	rBAT	and	how	
this	is	affected	by	the	presence	of	mutations	in	the	distinct	subunits	will	we	be	able	to	identify	
novel,	effective	therapies	for	cystinuria.		
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Chapter	7 :	General	Discussion	
The	re-absorption	of	amino	acids	from	the	renal	filtrate	into	the	bloodstream	requires	
the	 transport	 of	 these	 small,	 zwitterionic	 molecules	 across	 the	 phospholipid	 bilayer	 of	 the	
apical	 and	 basolateral	 membranes	 of	 the	 epithelium.	 To	mediate	 this,	 a	 range	 of	 transport	
systems	with	distinct	substrate	specificities	and	ion-coupling	mechanisms,	is	present	along	the	
length	 of	 the	 proximal	 tubule	 (Bröer,	 2008).	 Mutations	 in	 the	 genes	 that	 encode	 these	
transport	 systems	 can	 confer	 changes	 to	 the	 structural	 conformation	 of	 the	 translated	
proteins,	 preventing	 the	 efficient	 reabsorption	 of	 their	 native	 substrates	 (Bröer,	 2008).	 This	
can	 lead	 to	 inherited	 renal	 transport	 defects	 such	 as	 Hartnup	 disorder	 (B0AT1),	 Lysinuric	
Protein	Intolerance	(y+LAT1),	and	cystinuria	(rBAT	and	b0,+AT)	(Palacin	et	al.,	2004;	Bröer,	2009;	
Chillarón	et	al.,	2010).		
This	study	focussed	on	the	 inherited	renal	disease,	cystinuria.	Cystinuria	 is	caused	by	
mutations	in	SLC3A1	and	SLC7A9,	encoding	the	two	protein	subunits	of	System	b0,+	(Pras	et	al.,	
1994;	 Yan	 et	 al.,	 1994).	 Mutations	 in	 either	 of	 these	 two	 genes	 prevent	 the	 successful	
reabsorption	of	the	dibasic	amino	acids	arginine,	ornithine,	and	lysine,	causing	a	benign	dibasic	
aminoaciduria	 (Harris	 et	 al.,	 1955).	 However,	 System	b0,+	 is	 the	 only	 known	 apical	 transport	
system	 capable	 of	 re-absorbing	 cystine	 from	 the	 proximal	 tubule,	 where	 >90%	 of	 cystine	
reabsorption	 occurs	 (Volkl	 &	 Silbernagl,	 1982).	 Cystine	 is	 poorly	 soluble	 in	 the	 renal	 filtrate	
(<1mM)	and	a	reduction	in	the	reabsorption	leads	to	precipitation	of	the	cysteine	dimer,	and	
the	formation	of	renal	calculi	(Goldfarb	et	al.,	2006).	The	phenotype	of	patients	with	cystinuria	
varies	greatly,	and	current	 therapies	are	not	 curative.	 In	 fact,	 the	cystine	binding	 thiol	drugs	
used	 in	 the	 treatment	 of	 cystinuria	 are	 poorly	 tolerated	 by	 many	 patients	 (Goldfarb	 et	 al.,	
2006;	 Thomas	 et	 al.,	 2014).	 For	 this	 reason,	 research	 has	 turned	 to	 the	 investigation	 of	 the	
structure	and	biogenesis	of	rBAT	and	b0,+AT	(Bartoccioni	et	al.,	2008).	This	will	enable	further	
understanding	 of	 the	 effect	 that	 cystinuria	 mutations	 have	 on	 these	 two	 proteins,	 and	
ultimately	 lead	 to	 the	 identification	 of	 novel	 therapeutic	 targets.	 To	 date,	 only	 9	 of	 the	 91	
reported	 SLC3A1	 missense	 mutations	 have	 been	 characterised	 functionally	 (Calonge	 et	 al.,	
1994;	 Chillarón	 et	 al.,	 1997;	 Saadi	 et	 al.,	 1998;	 Ishihara	 et	 al.,	 2002;	 Pineda	 et	 al.,	 2004b;	
Bartoccioni	 et	 al.,	 2008).	 Through	 the	 investigations	 included	 in	 this	 study,	 we	 aimed	 to	
contribute	to	this	body	of	knowledge,	by	identifying	the	effects	that	novel	rBAT	mutations	had	
upon	the	System	b0,+	transport	heterodimer.		
The	 primary	 aim	 of	 this	 investigation	 was	 to	 identify	 causal	 variants	 in	 SLC3A1	 and	
SLC7A9	in	a	cohort	of	cystinuric	patients	(Chapter	3).	A	range	of	mutation	detection	techniques	
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was	employed,	including	the	quantitative	detection	technique	MLPA	in	Patients	2-5,	11,	14,	15,	
18,	19,	21	and	22,	which	allowed	the	detection	of	 large	genomic	rearrangements	(Table	3.6).	
We	identified	causal	variants	in	98%	of	the	cohort,	and	solved	the	genotype	of	83%	(Table	3.6,	
and	 section	 3.4.1).	 Eggermann	 et	 al.	 (2012)	 reported	 an	 average	mutation	detection	 rate	 of	
85%	amongst	 cystinuria	 cohorts	worldwide.	 The	 consistency	of	 this	 value	with	our	mutation	
detection	 rate	 validated	 the	 efficacy	 of	 our	 detection	 protocols.	 Patients	 were	 classified	 as	
genetically	“solved”	following	the	identification	of	two	SLC3A1	mutations,	(Type	AA;	26%),	the	
presence	of	 the	heterozygous	SLC3A1	duplication	of	 exons	5-9	 (Type	A;	 5%),	or	 at	 least	one	
SLC7A9	mutation	 (Type	B	or	BB;	31%	and	21%,	respectively).	No	patients	 in	our	cohort	were	
found	 to	 have	 Type	 AB	 cystinuria	 (Table	 3.6),	 consistent	 with	 reports	 in	 the	 literature.	 This	
genotype	has	been	reported	with	an	average	rate	of	2.7%	in	cohort	studies	(Font-Llitjos	et	al.,	
2005;	Rhodes	et	al.,	2015;	Wong	et	al.,	2015).	However,	it	has	not	been	explained	why,	when	
Type	 A	 and	 Type	 B	 mutations	 are	 equally	 common,	 patients	 rarely	 present	 with	 Type	 AB	
cystinuria	(Dello	Strologo	et	al.,	2002).			
	 It	 has	 not	 been	 possible	 to	 explain	 the	 missing	 heredity	 in	 cystinuria	 through	 the	
involvement	of	a	third	gene	(Leclerc	et	al.,	2001;	Pineda	et	al.,	2004a;	Schmidt	et	al.,	2004b;	
Brauers	et	al.,	2005;	Chatzikyriakidou	et	al.,	2005),	and	 linkage	analysis	 in	cystinuric	patients	
only	maps	the	 locations	of	gene	 involvement	to	2p21	and	19q13.11,	 the	 locations	of	SLC3A1	
and	SLC7A9,	respectively	(Yan	et	al.,	1994).	In	Chapter	3,	we	reported	the	screening	of	patients	
32-44	through	next	generation	sequencing	(Table	3.5).	These	patients	were	investigated	in	30	
genes	 known	 to	 be	 involved	 in	 nephrolithiasis	 or	 nephrocalcinosis,	 including	 SLC3A1	 and	
SLC7A9	 (Halbritter	et	al.,	2014).	No	causal	variants	were	 identified	 in	any	of	 the	other	genes	
screened	 in	 the	 cystinuria	 patients,	 eliminating	 their	 putative	 role	 in	 the	 phenotype	 of	 the	
unsolved	patients	 (35	and	38,	Table	3.5).	 In	 the	course	of	 these	 investigations,	we	 identified	
four	 novel	 missense	 mutations	 in	 the	 System	 b0,+	 heavy	 chain	 protein	 rBAT.	 These	 were:	
M465K,	N254T,	L416P	and	Y579D	(Table	3.6,	Figure	3.12).		
In	 Chapter	 4	 we	 reported	 the	 optimisation	 of	 a	 range	 of	 techniques	 that	 allowed	
detection	of	 rBAT	 function	and	expression	 in	Xenopus	oocytes,	 following	 its	association	with	
the	 endogenous	 light	 chain,	 homologous	 to	 b0,+AT.	 It	 was	 essential	 that	 we	 established	
accurate	methods	of	measuring	the	expression	of	rBAT	to	enable	the	subsequent	comparison	
of	the	wild-type	protein	and	the	novel	mutants	identified	in	Chapter	3.	In	Chapter	5,	we	used	
these	 techniques	 to	 identify	 the	 effects	 of	 our	 four	 novel	 mutations,	 in	 addition	 to	 the	
common	SNP	M618I,	and	the	common	cystinuria	variant,	M467T.		
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Of	 the	 four	 novel	mutations	 investigated	 in	 this	 study,	 two	mutant	 proteins,	M465K	
and	 Y579D,	 showed	 a	 broadly	 similar	 expression	 pattern	 to	 other	 mutant	 rBAT	 proteins	
reported	 in	 the	 literature,	 in	 which	 a	 significant	 reduction	 of	 [3H]arginine	 uptake	 was	
measured,	 which	 recovered	 over	 time.	 Our	 data	 correlated	 with	 the	 results	 of	 M467T	 and	
M467K	 expression	 in	 oocytes	where	 a	 recovery	 in	 function	was	 observed	 over	 a	 number	 of	
days	post-injection	(Chillarón	et	al.,	1997).	In	concentration-dependent	(0.01-1mM)	uptakes,	a	
significant	 (p<0.001)	 reduction	 in	 the	capacity	 (Vmax)	of	 the	 transport	 system	 for	 [3H]arginine	
was	measured.	The	investigation	of	novel	mutations	N254T	and	L416P	led	to	some	variability	
in	 their	 measured	 effects	 on	 protein	 function	 following	 expression	 in	 oocytes.	 When	
[3H]arginine	uptake	(10μM)	was	conducted	at	day	3,	no	reduction	 in	uptake	was	observed	 in	
the	mutant	proteins	(Figures	5.17	and	5.22).	However,	when	concentration-dependent	uptake	
was	 measured,	 a	 significant	 (p<0.001)	 reduction	 in	 Vmax	 was	 measured	 with	 both	 mutant	
proteins	 (Figures	 5.19	 and	 5.24).	 Overall,	 these	mutations	 cause	 a	milder	 effect	 upon	 rBAT	
function	 than	 M465K,	 M467T,	 and	 Y579D.	 The	 functional	 data	 were	 broadly	 supported	 by	
western	blots	and	immunocytochemical	data.	From	these	data	we	conclude	that	the	severity	
of	 defect	 conveyed	 upon	 rBAT	 by	 the	 different	 mutations	 was	 M465K	 >	 M467T=Y579D	 >	
N254T	 =	 L416P	 >M618I	 =	 wild-type.	 The	 novel	 mutant	 M465K	 caused	 the	 most	 “severe”	
defect,	as	the	recovery	of	function	observed	6	days	post-injection	of	oocytes	was	incomplete.	
Common	 SNP	M618I	was	 the	mildest	 defect,	 conveying	 no	 significant	 change	 to	 the	 kinetic	
parameters	of	[3H]arginine	transport	by	System	b0,+.	
To	date,	91	missense	mutations	have	been	reported	in	rBAT,	at	75	different	residues	
(Stenson	et	al.,	2014).	Of	these	75	residues,	68	putatively	fall	into	the	extracellular	domain	of	
rBAT,	with	3	 in	the	transmembrane	domain,	and	4	 in	the	30	amino	acid	“tail”	of	the	protein,	
based	upon	the	homology	model	with	oligo-1,6-glucosidase	 from	B.	cereus	 (PDB	code	1UOK,	
Watanabe	el	al.	1997).	When	 these	mutated	 residues	are	mapped	 to	 the	multiple	 sequence	
alignment	 of	 rBAT	with	 CD98	 and	B.	 cereus	 oligo-1,6-glucosidase,	 as	 displayed	 in	 Chapter	 1,	
along	 with	 the	 four	 novel	 mutations	 identified	 in	 this	 study,	 36	 residues	 (50%)	 were	 fully-
conserved	 between	 rBAT	 and	 the	 prokaryotic	 enzyme,	 whilst	 only	 16	 (22%)	 were	 fully	
conserved	with	CD98.	Only	10	residues	identified	as	mutations	in	cystinuria	patients	were	fully	
conserved	 in	all	 three	proteins.	From	mapping	the	mutated	residues	 in	cystinuric	patients	 to	
the	multiple	sequence	alignment,	several	regions	of	interest	can	be	identified.		
The	first	of	these	regions	is	Trp117-Tyr151	in	rBAT,	which	corresponds	to	Trp5-Tyr39	in	
the	 glucosidase	 enzyme,	 and	 Trp117-Tyr149	 in	 CD98	 (Figure	 7.1A).	 Over	 this	 region	 of	 35	
amino	 acid	 residues,	 rBAT	 shares	 69%	 sequence	 identity	 with	 1UOK	 (Figure	 7.1A),	 which	
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corresponds	to	β1/α1	of	domain	A1	(Figure	7.1B).	The	high	level	of	conservation	of	this	region	
of	the	extracellular	domain,	and	the	fact	that	11	reported	missense	mutations	lie	in	this	region	
is	 striking,	 and	 highlights	 the	 importance	 of	 its	 structural	 integrity.	 To	 date,	 no	 further	
information	 is	 available	 about	 the	 function	of	 residues	 in	 this	 region	of	 proteins	 structurally	
related	 to	 rBAT.	 Therefore,	 we	 cannot	 infer	 any	 further	 hypotheses	 as	 to	 why	 so	 many	
cystinuria	mutations	fall	in	this	region.	
In	 Chapter	 3,	 we	 reported	 the	 discovery	 of	 a	 novel	 cystinuria	 mutation,	 M465K,	
identified	homozygously	in	Patient	25	of	the	cohort	(Table	3.6).	This	mutation	was	of	particular	
interest.	 In	addition	to	being	a	novel	variant,	 it	 is	situated	only	two	amino	acids	upstream	of	
common	cystinuria	mutation	M467T,	and	sister	mutation	M467K	(Figure	7.2A).	Additionally,	a	
number	of	cystinuria	mutations	have	been	reported	that	are	predicted	to	form	a	dense	cluster	
in	the	same	hydrophobic	region	(α7)	of	the	molecular	structure	as	M465K	(Figure	7.2A).	These	
mutations	 include:	 R452W,	 R452Q,	 S455L,	 R456H,	 R456C,	 G458E,	 Y461H,	 and	 Y461X	 (Figure	
7.2B).	With	no	data	available	on	the	structures	related	to	rBAT,	it	is	difficult	to	hypothesise	the	
importance	of	 this	region	of	 the	TIM	barrel	 to	the	function	of	rBAT.	 In	general,	 this	region	 is	
less	conserved	(44%	identity)	than	β1/α1	(Figure	7.1A).	Furthermore,	the	glucosidase	enzyme	
has	an	additional	sequence	of	6	amino	acids	in	this	region,	which	are	absent	in	rBAT	and	CD98	
(Figure	 7.2A).	 However,	 the	 unwound	 structure	 of	 α7	 in	 the	 homology	 model	 of	 rBAT	 is	
present	in	the	crystal	structures	of	1UOK	and	CD98	(Watanabe	et	al.,	1997;	Fort	et	al.,	2007).		
Despite	the	fact	that	little	information	is	available	on	the	function	of	specific	residues	
of	 TIM	 barrel	 domains	 in	 structures	 related	 to	 rBAT,	 we	 can	 use	 an	 in	 silico	 approach	 to	
identify	 conserved	 residues	 between	 proteins.	 Residues	 that	 remain	 fully	 conserved	
throughout	the	evolution	of	the	different	proteins,	amongst	different	domains	of	life	are	likely	
to	be	more	important	to	the	structure	or	function	of	the	molecule	(Gabrisko	&	Janecek,	2009).	
To	date,	little	is	known	about	the	function	of	the	rBAT	protein,	beyond	its	ability	to	traffic	the	
light	chain	of	System	b0,+	to	the	apical	membrane	of	epithelial	cells	in	the	kidney	and	intestine	
(Chillarón	et	al.,	2010).	Despite	this,	it	retains	many	of	the	structural	features	of	the	GH-H	clan	
of	 enzymes	 that	 have	 been	 lost	 in	 the	 evolution	 of	 CD98	 (Gabrisko	 &	 Janecek,	 2009).	 In	
addition	to	the	catalytic	triad,	rBAT	also	retains	one	of	the	two	histidine	residues	(His215)	from	
oligo-1,6-glucosidase	 (His103),	 that	 is	 involved	 in	 substrate	 binding	 (Watanabe	et	 al.,	1997).	
These	 residues	 are	 not	 conserved	 in	 CD98,	 nor	 are	 the	 three	 residues	 of	 the	 catalytic	 triad	
(Fort	et	al.,	2007;	Gabrisko	&	Janecek,	2009).		
Despite	 the	 lack	of	 enzymatic	 activity	detected	 in	 rBAT	 (Wells	&	Hediger,	 1991),	 the	
strict	 conservation	 of	 these	 structural	 features	 suggests	 that	 the	 large,	 glycosylated	
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ectodomain	 of	 the	 protein,	 possesses	 a	 function	 as	 yet	 undetermined	 (Fort	 et	 al.,	 2007).	
Members	of	the	SLC6	family	of	membrane	transport	proteins,	including	B0AT1,	involved	in	the	
pathophysiology	of	Hartnup	disease,	along	with	SIT1,	XT2,	and	EAATC1,	have	been	shown	to	
require	 co-localisation	 with	 an	 accessory	 protein	 to	 function	 (Danilczyk	 et	 al.,	 2006).	 In	 the	
intestine,	this	protein	is	Angiotensin	Converting	Enzyme	2	(ACE2)	a	carboxypeptidase	enzyme	
involved	 in	the	renin-angiotensin	system	(Camargo	et	al.,	2009).	 In	the	kidney,	however,	 this	
protein	 is	 collectrin,	 a	 homologue	 of	 ACE2,	 which	 shares	 48%	 sequence	 identity	 with	 the	
cytoplasmic,	 transmembrane,	 and	 extracellular	 domains	 of	 ACE2,	 but	 lacks	 the	 dipeptidyl	
carboxypeptidase	 catalytic	 domain	 (Zhang	 et	 al.,	 2001).	 Studies	 of	 collectrin	 knockout	 mice	
have	shown	a	lack	of	B0AT1	activity	in	kidney	brush-border	membrane	vesicles,	leading	to	loss	
of	 amino	 acids	 in	 the	 urine	 (Danilczyk	 et	 al.,	 2006).	 These	 data	 were	 further	 supported	 by	
immunoblotting	of	total	kidney	membranes,	which	showed	a	lack	of	B0AT1	localisation	at	the	
apical	membranes	 of	 the	 proximal	 tubule	 (Danilczyk	 et	 al.,	 2006).	 Na+-dependent	 uptake	 of	
leucine	 in	Xenopus	oocytes	 is	only	observed	following	co-expression	of	collectrin	with	B0AT1,	
and	 not	 following	 the	 expression	 of	 either	 protein	 in	 isolation	 (Danilczyk	 et	 al.,	 2006).	
Collectrin,	like	rBAT	and	CD98,	is	a	Type-II	membrane	glycoprotein,	passing	only	once	through	
the	 plasma	 membrane.	 However,	 unlike	 the	 SLC3	 and	 SLC7	 families	 of	 heterodimeric	
transporters,	 collectrin	 and	 ACE2	 do	 not	 appear	 to	 associate	 covalently	with	 the	 light	 chain	
subunits	(Danilczyk	et	al.,	2006).	It	has	been	hypothesised	that	the	physiological	significance	of	
the	association	of	ACE2	with	the	SLC6	transporters	in	the	intestine	could	be	that	the	release	of	
the	 neutral	 and	 cationic	 terminal	 amino	 acids	 that	 are	 cleaved	 from	 angiotensinogen,	 are	
substrates	 for	 the	 transport	 system	 (Singer	 &	 Camargo,	 2011).	 To	 date,	 no	 evidence	 for	 a	
similar	role	of	rBAT	has	been	 identified.	However,	the	strict	evolutionary	conservation	of	the	
domains	and	catalytic	residues	of	the	GH-H	clan	of	enzymes	is	implicit	of	a	secondary	role	for	
the	System	b0,+	heavy	chain.			
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Figure	 7.1:	 The	 conservation	of	 rBAT	domain	A1	with	 oligo-1,6-glucosidase	 from	B.	 cereus.	
The	 conservation	 of	 residues	 117-151	 in	 rBAT,	 which	 putatively	 lie	 in	 the	 β1/α1	 region	 of	
extracellular	 domain	 A1.	 A,	 Multiple	 sequence	 alignment	 of	 human	 rBAT	 (NM_000341.3)	
residues	 117-151	 with	 human	 CD98	 (NM_0001013251.2),	 and	 oligo-1,6-glucosidase	 from	 B.	
cereus	(GI:	4558191).	Grey	boxes	indicate	residues	conserved	with	rBAT.	X,	mutated	residues	
identified	in	the	genotype	of	cystinuria	patients	(Stenson	et	al.,	2014);	B,	Homology	model	of	
rBAT	based	upon	the	crystal	structure	of	oligo-1,6-glucosidase	from	B.	cereus	(PDB	code	1UOK,	
Watanabe	et	al.,	1997).	Residues	117-151	are	highlighted.	The	putative	 location	of	 identified	
cystinuria	missense	and	nonsense	mutations	are	 identified	with	black	arrows	 (Stenson	et	al.,	
2014).
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Figure	 7.2:	 The	 conservation	 of	 rBAT	domain	A2	with	 oligo-1,6-glucosidase	 from	B.	 cereus.	
The	 conservation	 of	 residues	 452-467	 in	 rBAT,	 which	 putatively	 lie	 in	 the	 α7	 region	 of	
extracellular	 domain	 A2.	 A,	 Multiple	 sequence	 alignment	 of	 human	 rBAT	 (NM_000341.3)	
residues	 452-467	 with	 human	 CD98	 (NM_0001013251.2),	 and	 oligo-1,6-glucosidase	 from	 B.	
cereus	(GI:	4558191).	Grey	boxes	indicate	residues	conserved	with	rBAT.	X,	mutated	residues	
identified	 in	 the	 genotype	 of	 cystinuria	 patients	 (Stenson	 et	 al.,	 2014);	 *,	 novel	 mutations	
identified	in	this	study;	B,	Homology	model	of	rBAT	based	upon	the	crystal	structure	of	oligo-
1,6-glucosidase	from	B.	cereus	(PDB	code	1UOK,	Watanabe	et	al.,	1997).	Residues	452-467	are	
highlighted.	 The	 putative	 location	 of	 identified	 cystinuria	missense	 and	 nonsense	mutations	
are	identified	with	black	arrows	(Stenson	et	al.,	2014).	
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The	 final	 aims	 of	 this	 study	 were	 to	 determine	 how	 rBAT	 expression	 in	 Xenopus	
oocytes	and	Caco-2	cells	could	be	modified	through	incubation	with	different	compounds	that	
would	 differentially	 affect	 the	 biogenesis	 of	 the	 native	 and	mutant	 protein	 (Chapter	 6).	 The	
global	aim	of	these	modifications	was	to	identify	novel	therapeutic	strategies	that	would	allow	
targeted	 treatments	 for	 individual	 patients	 based	 upon	 their	 genotype.	 A	 pharmacogenetic	
approach	to	disease	treatment	allows	more	effective	therapies,	potentially	with	a	lower	risk	of	
adverse	effects.		
We	reported	that	the	current	therapies	used	in	cystinuria	to	increase	the	solubility	of	
cystine,	 including	 alkalinisation	 and	 incubation	with	 the	 CBTDs	 captopril,	 D-penicillamine,	 or	
tiopronin	had	no	effect	upon	the	protein	expression	(Figures	6.2-6.4,	and	6.7-6.8).	Similarly,	no	
change	 in	 function	 was	 detected	 in	 the	 wild-type	 or	 rBAT	mutant	 proteins	M467T,	M465K,	
N254T,	 L416P,	 or	 Y579D	 (Figure	 6.5).	 These	 data	 indicate	 that	 there	 is	 no	 scope	 for	 a	
pharmacogenetic	approach	to	cystinuria	therapy	using	established	treatments.		
Following	 this,	 we	 investigated	 the	 biogenesis	 of	 rBAT	 in	 the	 ER	 by	 considering	
whether	the	proteasomal	inhibitor	MG132	would	allow	the	localisation	of	mutant	proteins	to	
the	 plasma	 membrane.	 No	 increase	 in	 function	 of	 rBAT	 mutant	 proteins	 was	 measured	
following	 incubation	of	oocytes	with	MG132	 (Figure	6.1A).	However,	 these	were	preliminary	
studies,	and	 it	would	be	desirable	 to	repeat	 these	at	a	 range	of	 incubation	conditions.	Using	
pulse-chase	experiments	in	MDCK	cells,	Bartoccioni	et	al.	(2008)	demonstrated	that	use	of	the	
proteasome	inhibitor	MG132	delayed	the	degradation	of	unassembled	rBAT.	However,	it	was	
not	 demonstrated	 that	 this	 “lag”	 in	 degradation,	 measured	 by	 immunoblotting	 of	 rBAT	
proteins,	caused	an	increase	in	trafficking	of	the	protein	to	the	plasma	membrane	(Bartoccioni	
et	 al.,	 2008).	 It	 would	 be	 interesting	 to	 investigate	 the	 use	 of	 the	 proteasomal	 inhibitor	
MG132,	 in	 combination	with	 a	molecular	 chaperone	 such	 as	 4-phenylbutyrate	 (PBA),	 which	
has	been	 shown	 to	 allow	 the	exit	 of	ΔF508	CFTR	 from	 the	ER,	 and	 restore	 function	 in	nasal	
epithelia	in	a	cohort	of	adult	patients	(Zeitlin	et	al.,	2002).		
Xenopus	 oocytes	 are	 a	 robust	 expression	 system	 for	 the	 functional	 expression	 of	
membrane	 transport	 proteins,	 and	 are	widely	 reported	 in	 the	 literature	 (Moeller	&	 Fenton,	
2010).	 However,	 in	 mutant	 proteins	 that	 cause	 trafficking	 defects	 due	 to	 ER-associated	
degradation,	 it	 has	 been	 shown	 that	 the	 low	 incubation	 temperatures	 can	 allow	 release	 of	
mutant	 proteins	 from	 the	 ER,	 which	 would	 not	 occur	 in	 vivo	 (Denning	 et	 al.,	 1992;	 Leduc-
Nadeau	 et	 al.,	 2010).	This	 is	due	 to	 temperature-dependent	 inhibition	of	 the	ERAD	pathway	
(Denning	 et	 al.,	 1992).	 No	 effect	 of	 increasing	 the	 oocyte	 incubation	 temperature	 on	 the	
function	 of	 System	 b0,+	 function	 was	 measured	 in	 this	 study	 (Figure	 6.1B).	 However,	 we	
hypothesised	 that	 if	 rBAT	 mutant	 protein	 can	 be	 released	 from	 the	 ER	 in	 a	 temperature-
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sensitive	manner	a	greater	effect	of	 the	mutations	would	be	measured	 in	a	mammalian	 cell	
line	 (incubated	at	37°C)	 than	 in	oocytes,	 as	observed	by	Pineda	et	al.	 (2004).	 Therefore,	 the	
transient	 expression	 of	 rBAT	 in	 the	 mammalian	 cell	 line	 Caco-2	 was	 investigated.	 Through	
preliminary	investigations	it	appeared	as	though	some	wild-type	rBAT	protein	was	present	at	
the	apical	membrane	 (Figure	6.11).	Unfortunately,	due	 to	 time	restrictions	on	 this	 study,	we	
were	 unable	 to	 transfect	 Caco-2	 cells	 with	 the	mutant	 proteins	 to	 compare	 the	 expression	
patterns.	In	future	studies,	this	would	be	desirable	for	detection	of	the	sub-cellular	localisation	
of	the	rBAT	mutants.	Additionally,	this	would	allow	experiments	to	be	carried	out	to	detect	any	
temperature-sensitive	 release	of	 rBAT	mutant	proteins	 from	the	endoplasmic	 reticulum.	The	
expression	 of	 wild-type	 rBAT	 and	 mutant	 proteins	 in	 a	 cell	 line	 would	 also	 enable	 the	
determination	 of	 the	 cellular	 localisation	 of	 any	 protein	 not	 trafficked	 to	 the	 plasma	
membrane	through	the	use	of	immunofluorescent	markers.		
Finally,	 the	effect	of	N-glycosylation	on	 the	apical	 targeting	of	 rBAT	was	 investigated	
following	expression	of	the	protein	in	oocytes,	and	using	the	Caco-2	cell	line	(Figure	6.17-6.18).	
Using	a	combination	of	site-directed	mutagenesis	to	remove	individual	glycosylation	motifs	(at	
positions	261,	332,	and	513),	along	with	incubation	with	tunicamycin,	a	shift	in	band	size	was	
observed,	indicating	a	reduction	in	the	weight	of	the	protein	(Figure	6.18).	However,	no	effect	
on	the	function	of	System	b0,+	was	observed	in	either	of	these	systems	(Figures	6.17-6.18).		
In	 conclusion,	 we	 have	 identified	 four	 novel	 mutations	 in	 SLC3A1,	 one	 of	 the	 two	
genes	known	 to	contribute	 to	 the	pathophysiology	of	 cystinuria	 (Chapter	3)	 (Chillarón	 et	al.,	
2010).	We	have	established	a	series	of	techniques	to	allow	the	accurate	measurement	of	rBAT	
expression	and	function	in	Xenopus	oocytes	(Chapter	4).	These	techniques	were	then	utilised	
to	 identify	 key	 changes	 in	 rBAT	 function	 and	 expression	 compared	 to	 the	wild-type	 protein	
(Chapter	5).	As	observed	with	other	rBAT	mutant	proteins	(Chillarón	et	al.,	1997;	Bartoccioni	et	
al.,	 2008)	 it	 appeared	 as	 though	 the	 mutations	 led	 to	 trafficking	 defects,	 resulting	 in	 a	
reduction	 in	 Vmax	 in	 concentration-dependent	 uptakes.	 Following	 on	 from	 this,	 a	 series	 of	
modifications	 to	 the	 incubation	 conditions	 of	 rBAT	 were	 attempted	 to	 determine	 how	 the	
biogenesis	of	the	protein	could	be	influenced	(Chapter	6).		
Further	 investigations	 into	 the	 effect	 of	 cystinuria	mutations	 upon	 the	 biogenesis	 of	
rBAT,	 coupled	 with	 studies	 into	 the	 use	 of	 molecular	 chaperones	 that	 enable	 successful	
targeting	of	the	protein	to	the	membrane,	are	required.	This	will	allow	novel	therapies	to	be	
identified,	 through	 a	 pharmacogenetic	 approach	 to	 the	 disease.	 If	 the	 specific	 effects	 upon	
rBAT	and	b0,+AT	conveyed	by	individual	mutations	can	be	determined,	future	therapies	can	be	
tailored	to	the	specific	genotype	of	individual	patients.		
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